<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1403221847
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ENTYVIO 300 mg powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VEDOLIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7019.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            TAKEDA PHARMA A/S
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA33  
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Entyvio contains the active substance vedolizumab. Vedolizumab belongs to a group of biological medicines called monoclonal antibodies (MAbs). Vedolizumab blocks a protein on the surface of white blood cells that cause the inflammation in ulcerative colitis and Crohn&rsquo;s disease, and so the amount of inflammation is reduced.</p><p>Entyvio is used to treat the signs and symptoms in adults of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderately to severely active ulcerative colitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderately to severely active Crohn&rsquo;s disease.</p><p>.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;moderately to severely active chronic pouchitis.</p><p><strong>Ulcerative colitis</strong></p><p>Ulcerative colitis is an inflammatory disease of the large bowel. If you have ulcerative colitis, you will first be given other medicines. If you do not respond well enough or are intolerant to these medicines, your doctor may give you Entyvio to reduce the signs and symptoms of your disease.</p><p><strong>Crohn&rsquo;s disease</strong></p><p>Crohn&rsquo;s disease is an inflammatory disease of the gastrointestinal tract. If you have Crohn&rsquo;s disease you will first be given other medicines. If you do not respond well enough or are intolerant to these medicines, your doctor may give you Entyvio to reduce the signs and symptoms of your disease.</p><p><strong>Pouchitis</strong></p><p>Pouchitis is a disease that causes inflammation of the lining of the pouch, which was created during surgery to treat ulcerative colitis. If you have pouchitis, you may first be given antibiotics. If you do not respond well enough to the antibiotics, your doctor may give you Entyvio to reduce the signs and symptoms of your disease.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Entyvio if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to vedolizumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an active severe infection, for example, tuberculosis, blood poisoning, severe gastroenteritis, nervous system infection</p><p><strong>Warnings and precautions</strong></p><p>When you first receive this medicine and during the course of the treatment, also between doses, <strong>tell your doctor or nurse immediately</strong> if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a <strong>serious and potentially fatal brain condition </strong>known as progressive multifocal leukoencephalopathy (<strong>PML</strong>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an <strong>infection</strong>, or think you have an infection, if you develop chills, shivering, persistent cough or a high fever. Some infections may become serious and possibly even life-threatening if left untreated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience signs of <strong>an allergic reaction or other</strong> <strong>reaction</strong> <strong>to the</strong> <strong>infusion </strong>such as wheezing, difficulty breathing, hives, itching, swelling or dizziness. These could occur during or after the infusion. For more detailed information, see infusion and allergic reactions in section 4.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have a tiredness, loss of appetite, pain on the right side of your stomach (abdomen), dark urine or yellowing of the skin and eyes (jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are<strong> </strong>going to receive any <strong>vaccination</strong> or have recently had a vaccination.<strong> </strong>Entyvio may affect the way you respond to a vaccination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have cancer, tell your doctor. Your doctor will have to decide if you can still be given Entyvio.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are not feeling any better as vedolizumab may take up to 14&nbsp;weeks to work in some patients with very active Crohn&rsquo;s disease.</p><p><strong>Children and adolescents</strong></p><p>Entyvio is not recommended for use in children or adolescents (under 18 years of age) due to the lack of information regarding the use of this medicine in this age group.</p><p><strong>Other medicines and Entyvio</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken or might start taking any other medicines.</p><p>Entyvio should not be given with other biologic medicines that suppress your immune system as the effect of this is not known.</p><p>If you have previously taken natalizumab (a medicine used to treat multiple sclerosis) or rituximab (a medicine used to treat certain types of cancer and rheumatoid arthritis), tell your doctor, who will decide if you can be given Entyvio.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, discuss this with your doctor before starting treatment with Entyvio.</p><p>The effects of Entyvio in pregnant women are not known. Therefore, this medicine is not recommended for use during pregnancy unless you and your doctor decide that the benefit to you clearly outweighs the potential risk to yourself and your baby.</p><p>If you are a woman of childbearing potential, you are advised to avoid becoming pregnant while using Entyvio. You should use adequate contraception during treatment and for at least 4.5 months after the last treatment.</p><p>Tell your doctor if you are breast-feeding or planning to breast-feed. Entyvio passes into breast milk. There is insufficient information on what effect this may have on your baby. A decision must be made whether to discontinue breast--feeding or to discontinue/abstain from Entyvio therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><strong>Driving and using machines</strong></p><p>This medicine may have a minor influence on your ability to drive or use tools or machines. A small number of patients have felt dizzy after receiving Entyvio. If you feel dizzy, do not drive or use tools or machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The infusion will be given to you, by your doctor or nurse, through a drip in one of the veins in your arm (intravenous infusion) over about 30 minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For your first 2 infusions, your doctor or nurse will monitor you closely during the infusion and for approximately 2 hours after you have completed the infusion. For all subsequent infusions (after the first two), you will be monitored during the infusion and for approximately 1 hour after you have completed the infusion.</p><p><strong>Dose and frequency</strong></p><p>Treatment with Entyvio is the same for ulcerative colitis and Crohn&rsquo;s disease.</p><p>The recommended dose is 300&nbsp;mg of Entyvio given as follows (see table below):</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Treatment (infusion) number</p></td><td style="vertical-align:top"><p>Timing of treatment (infusion)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment 1</p></td><td style="vertical-align:top"><p>0 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Treatment 2</p></td><td style="vertical-align:top"><p>2 weeks after Treatment 1</p></td></tr><tr><td style="vertical-align:top"><p>Treatment 3</p></td><td style="vertical-align:top"><p>6 weeks after Treatment 1</p></td></tr><tr><td style="vertical-align:top"><p>Further treatments</p></td><td style="vertical-align:top"><p>Every 8 weeks</p></td></tr></tbody></table><p>&nbsp;</p><p>Your doctor may decide to alter this treatment schedule depending on how well Entyvio works for you.</p><p><strong>If you forget or miss your Entyvio infusion</strong></p><p>If you forget or miss an appointment to receive the infusion, make another appointment as soon as possible.</p><p><strong>If you stop using Entyvio</strong></p><p>You should not stop using Entyvio without talking with your doctor first.</p><p>If you have any questions on this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them.</p><p>Possible serious side effects include infusion reactions or allergic reactions (may affect up to 1 in 100 people) and infections (may affect up to 1 in 10 people).</p><p>Tell your doctor <strong>immediately</strong> if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid heart rate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the infusion site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills or shivering</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high fever or rash</p><p>Other side effects that you may experience while taking Entyvio are listed below. Tell your doctor <strong>as soon as possible</strong> if you notice any of the following:</p><p><strong>Very common side effects (may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; common cold</p><p>&middot;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp; headache</p><p><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp; chest infection</p><p>&middot;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp; flu (influenza)</p><p>&middot;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp; throat pain</p><p>&middot;&nbsp;&nbsp;&nbsp; sinus infection</p><p>&middot;&nbsp;&nbsp;&nbsp; itching / itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp; rash and redness</p><p>&middot;&nbsp;&nbsp;&nbsp; pain in the limb</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp; throat infection</p><p>&middot;&nbsp;&nbsp;&nbsp; stomach flu</p><p>&middot;&nbsp;&nbsp;&nbsp; anal infection</p><p>&middot;&nbsp;&nbsp;&nbsp; anal sore</p><p>&middot;&nbsp;&nbsp;&nbsp; hard faeces</p><p>&middot;&nbsp;&nbsp;&nbsp; bloated stomach</p><p>&middot;&nbsp;&nbsp;&nbsp; passing gas</p><p>&middot;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp; prickling or tingling</p><p>&middot;&nbsp;&nbsp;&nbsp; heart burn</p><p>&middot;&nbsp;&nbsp;&nbsp; haemorrhoids</p><p>&middot;&nbsp;&nbsp;&nbsp; blocked nose</p><p>&middot;&nbsp;&nbsp;&nbsp; eczema</p><p>&middot;&nbsp;&nbsp;&nbsp; night sweats</p><p>&middot;&nbsp;&nbsp;&nbsp; acne (pimples)</p><p>-&nbsp;&nbsp; &nbsp;rectal bleeding<br />-&nbsp;&nbsp; &nbsp;chest discomfort</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; redness and tenderness of hair follicle</p><p>&middot;&nbsp;&nbsp;&nbsp; throat and mouth yeast infection</p><p>&middot;&nbsp;&nbsp;&nbsp; vaginal infection</p><p>&middot;&nbsp;&nbsp;&nbsp; shingles (herpes zoster)</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp; blurred vision (loss of sharpness of eyesight)</p><p>&middot;&nbsp;&nbsp;&nbsp; sudden, severe allergic reaction which can cause breathing difficulty, swelling, fast heartbeat, sweating, drop in blood pressure, light-headedness, loss of consciousness and collapse (anaphylactic reaction and anaphylactic shock)</p><p>Not known (frequency cannot be estimated from the available data)&nbsp;<br />.&nbsp; &nbsp; lung disease causing shortness of breath (interstitial lung disease)</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) &nbsp;Reporting hot-line: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><p>&nbsp;Other GCC States:</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Entyvio is given by a doctor or nurse and patients should not need to store or handle Entyvio.</p><p>Entyvio is for single-use only.</p><p><strong>Unopened vial:</strong> Store in a refrigerator (2&deg;C‑8&deg;C). Keep the vial in the original carton in order to protect from light.</p><p><strong>Reconstituted and diluted solutions:</strong> Use immediately. If this is not possible, reconstituted solution in the vial can be stored for up to 8 hours at 2&deg;C-8&deg;C. Diluted solution in 0.9% sodium chloride solution can be stored up to 12&nbsp;hours at a room temperature of not above 25&deg;C, or up to 24&nbsp;hours in a refrigerator (2&deg;C‑8&deg;C), or for up to 12&nbsp;hours at room temperature and in a refrigerator (2&deg;C‑8&deg;C), &nbsp;up to a combined total of 24 hours. A 24 hour period may include up to 8 hours at 2&deg;C-8&deg;C for reconstituted solution in the vial and up to 12 hours at 20&deg;C - 25&deg;C for diluted solution in the infusion bag but the infusion bag must be stored in the refrigerator (2&deg;C-8&deg;C) for the rest of the 24 hour period Any time that the reconstituted solution was held in the vial should be subtracted from the time the solution may be held in the infusion bag.</p><p>Do not freeze.</p><p>Do not use this medicine if you notice any particles in the liquid or discolouration prior to administration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The <strong>active substance</strong> is vedolizumab. Each vial contains 300&nbsp;mg of vedolizumab.</p><p>The <strong>other ingredients</strong> are L‑histidine, L‑histidine monohydrochloride, L‑arginine hydrochloride, sucrose, and polysorbate&nbsp;80.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Entyvio is a white to off white powder for concentrate for solution for infusion provided in a glass vial with a rubber stopper and a plastic cap.

Each pack of Entyvio consists of one vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Takeda Pharma A/S &nbsp;<br />Delta Park 45<br />2665 Vallensbaek Strand<br />Denmark<br /><strong>Manufacturer and primary packaging site:</strong><br />Hospira Inc.,<br />1776 North Centennial Drive McPherson,<br />67460, Kansas USA<br /><strong>Additional Manufacturer and primary packaging site: </strong></p><p>Takeda Pharmaceutical Company LTD, Hikari Plant.&nbsp;<br />4720, Takeda Mitsui, Hikari, Yamaguchi, Japan &nbsp;<br />743-8502</p><p><strong>Secondary Packaging and Final Batch Release site: </strong></p><p>Takeda Austria GmbH,&nbsp;<br />St. Peter-Stra&szlig;e 25, &nbsp;<br />4020 Linz, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 29/03/2022

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="ltr">يحتوي دواء إنتيفيو على المادة الفعالة فيدوليزوماب التي تنتمي إلى مجموعة من الأدوية الحيوية تدعى<br />يقوم الفيدوليزماب بتعطيل عمل البروتين الموجود على خلايا ،)MAbs( الأجسام المضادة وحيدة النسيلة<br />الدم البيضاء الذي يسبب حدوث التهاب في حالة مرض التهاب القولون التقرحي ومرض كرون، وذلك بدوره<br />يؤدي إلى خفض حدة الالتهاب.<br />يستخدم إنتيفيو للمرضى البالغين لعلاج العلامات والأعراض المصاحبة ل:</p><ul><li>الحالات المتوسطة إلى الشديدة من التهاب القولون التقرحي&nbsp;</li><li>الحالات المتوسطة إلى الشديدة من مرض كرون</li><li>&nbsp;اﻟﺗﮭﺎب اﻟﺟﯾب اﻟﻣزﻣن ذو اﻟﻧﺷﺎط اﻟﻣﻌﺗدل إﻟﻰ اﻟﺷدﯾد&nbsp;</li><li><strong>التهاب القولون التقرحي</strong></li><li>يعتبر التهاب القولون التقرحي واحد ا من أمراض الالتهاب التي تصيب الأمعاء الغليظة، وإذا كنت تعاني من التهاب القولون التقرحي ففي البداية سيقوم الطبيب بإعطائك بعض الأدوية الأخرى، وفي حال لم تحدث&nbsp;استجابة جيدة لتلك الأدوية أو لم تستطع تحملها، فمن الممكن أن يصف لك الطبيب إنتيفيو لتقليل العلامات والأعراض المصاحبة للمرض.</li><li><strong>مرض كرون</strong><br />يعتبر مرض كرون واحد ا من أمراض الالتهاب التي تصيب القناة الهضمية، وإذا كنت تعاني من مرض<br />كرون، ففي البداية سيقوم الطبيب بإعطائك بعض الأدوية الأخرى، وفي حال لم تحدث استجابة جيدة لتلك<br />الأدوية أو لم تستطع تحملها، فمن الممكن أن يصف لك الطبيب دواء إنتيفيو لتقليل العلامات والأعراض<br />المصاحبة للمرض.</li><li><strong>اﻟﺗﮭﺎب اﻟﺟﯾب&nbsp;</strong></li><li>اﻟﺗﮭﺎب اﻟﺟﯾب ھو ﻣرض ﯾﺳﺑب اﻟﺗﮭﺎب ﺑطﺎﻧﺔ اﻟﺟﯾب اﻟذي &nbsp;أُﻧﺷﺊ ﺟراﺣﯾًﺎ ﻟﻌﻼج اﻟﺗﮭﺎب اﻟﻘوﻟون اﻟﺗﻘرﺣﻲ. إن ﻛﻧت ﻣﺻﺎﺑًﺎ ﺑﺎﻟﺗﮭﺎب اﻟﺟﯾب، ﻓﻘد ﺗُﻌطﻰ&nbsp; &nbsp;اﻟﻣﺿﺎدات اﻟﺣﯾوﯾﺔ أوﻻً. إن ﻟم ﺗﻛن اﺳﺗﺟﺎﺑﺗك ﻟﮭﺎ ﺟﯾدة ﺑﻣﺎ ﯾﻛﻔﻲ، ﻓﻘد ﯾﻌطﯾك طﺑﯾﺑك إﻧﺗﯾﻔﯾو ﻟﺗﻘﻠﯾل ﻋﻼﻣﺎت ﻣرﺿك وأﻋراﺿﮫ.&nbsp;</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب الامتناع عن استعمال إنتيفيو في حال:</strong></p><ul><li>كنت تعاني من حساسية تجاه مادة الفيدوليزوماب، أو أي من المكونات الأخرى )المدرجة في الفقرة&nbsp;رقم 6</li><li>كنت مصابا بالعدوى، كما في حال مرض السل، أو تسمم الدم، أو التهاب المعدة والأمعاء الشديد، أو&nbsp;عدوى الجهاز العصبي</li><li>التحذيرات والاحتياطات<br />عند بدء استعمال الدواء، وخلال فترة العلاج، وبين الجرعات أيضا، راجع طبيبك أو الممرض على الفور في حال:</li><li>عانيت من عدم وضوح الرؤية، أو فقدان أو ازدواجية الرؤية، أو ضعف الذراع، أو القدم، أو تغير&nbsp; طلريقة المشي، أو تعرضت لمشاكل في التوازن، أو الإحساس بالتنميل المستمر، أو انخفاض الإحساس، أو فقدانه، أو فقدان الذاكرة، أو التشوش، فمن الممكن أن تكون جميعا أعراض لمرض<br />.)PML( دماغي خطير يدعى اعتلال بيضاء الدماغ المتعدد البؤر المترقي</li><li>إذا كنت تعاني من العدوى، أو تظن أنك تعاني منها، وفي حال أصبت بالقشعريرة، أو الارتعاش، أو&nbsp;الكحة المستمرة، أو الحمى الشديدة، فقد تصبح بعض العدوى خطيرة، وقد تؤدي إلى الوفاة إذا لمتعالج.</li><li>إذا عانيت من العلامات المصاحبة للحساسية، أو أية تفاعلات أخرى تجاه التنقيط، مثل صوت أزيز&nbsp; الصدر، أو صعوبة التنفس، أو حساسية الجلد، أو الحكة، أو التورم، أو الدوخة، ويمكن أن تصاب بأي من هذه الأعراض خلال أو بعد التنقيط، ولمعرفة المزيد من المعلومات المفصلة، يرجى&nbsp;&nbsp;الاطللاع على موضوع التنقيط وما يمكن أن يصاحبه من حساسية في القفرة رقم 4</li><li>إذا ما أصبت بالتعب، أو فقدان الشهية، أو شعرت بألم في الناحية اليمنى من المعدة )البطن(، أو في&nbsp;حال البول الداكن، أو اصفرار الجلد والعينين )اليرقان(.</li><li>إذا ما كان عليك أخذ أية تطعيمات، أو أخذت تطعيما منذ فترة قصيرة، فقد يؤثر إنتيفيو على استجابة&nbsp; جسمك لهذا التطعيم.</li><li>إذا كنت مصابا بالسرطلان، راجع طلبيبك، ومن ثم سيقرر هل ستستمر في استعمال إنتيفيو أم لا.&nbsp;</li><li>إذا لم تشعر بأي تحسن، وقد يستغرق ظهور تأثير الفيدولزوماب فترة، قد تصل إلى 14 أسبوع ا في&nbsp;بعض المرضى الذين يعانون من تفاقم مرض كرون</li><li><strong>الأطفال والمراهقون</strong><br />لا ينصح باستعمال إنتيفيو للأطلفال والمراهقين )من هم دون سن 18 عام ا ( نظرا لقلة لمعلومات المتوفرة حول تأثير الدواء على هذه الفئة العمرية.<br /><strong>تناول أدوية أخرى</strong><br />استشر طلبيبك أو الممرض إن كنت تتناول، أو تناولت حديثا، أو بدأت بتناول أي أدوية أخرى.<br />يحظر استعمال إنتيفيو مع الأدوية الحيوية )البيولوجية( الأخرى التي تثبط المناعة، فإن تأثير الجمع بينهما غير معروف.<br />إن سبق لك تناول دواء نيتاليزيوماب ) وهو دواء يستخدم في علاج التصلب المتعدد(، أو ريتوكسيماب )وهو دواء يستخدم لعلاج أنواع محددة من السرطلان والتهاب المفاصل الروماتيزمي(، بادر إلى استشارة الطبيب، فهو من يقرر إن كنت تستطيع استعمال إنتيفيو أم لا.<br /><strong>الحمل والرضاعة</strong><br />إذا ما كنت حاملا ، أو تعتقدين ذلك، أو تعتزمين الحمل، فعليك استشارة طلبيبك قبل البدء باستخدام إنتيفيو.<br />أن تأثير إنتيفيو على المرأة الحامل غير معروف، وبناء عليه لا ينصح استخدامه خلال فترة الحمل، إلا في حال قررت أنت والطبيب أن الفوائد تفوق المخاطلر المحتملة عليك وعلى الجنين.<br />وإذا كنت في مرحلة تتيح لك الإنجاب، ينصح بعدم الحمل أثناء استخدام إنتيفيو، ولذا يتعيّن استخدام مانع حمل مناسب خلال فترة العلاج، وبعدها بمدة لا تقل عن 4 أو 5 أشهر.</li><li>يرجى استشارة الطبيب في حالة الرضاعة الطبيعية، أو التخطيط لها، فإمكانية مرور الدواء إلى لبن الأم غير معروفة.</li><li><strong>القيادة واستخدام الآلات</strong><br />قد يكون لهذا الدواء تأثيرا بسيط ا على قدرتك على القيادة، أو استخدام المعدات، أو الآلات، فقد شعر عدد قليل من المرضى بالدوار عقب استعمال إنتيفيو، وعلى ذلك إذا شعرت بالدوار فلا تقود، ولا تستخدم المعدات، أو الآلات</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم إعطاء المستحضر من قبل الطبيب أو الممرض، من خلال الحقن في أحد أوردة الذراع )عن&nbsp;طلريق التنقيط الوريدي(، إلى ما يقرب النصف ساعة.<br />ستخضع لمراقبة الطبيب أو الممرض خلال المرة الأولى والثانية من التنقيط الوريدي لحوالي&nbsp;ساعتين بعد الانتهاء من التنقيط، ولجميع إجراءات التنقيط الوريدي التالية )بعد المرتين الأولى والثانية(، ستتم المراقبة خلال الإجراء وخلال ساعة بعد الانتهاء منه.<br /><strong>الجرعة والتكرار</strong><br />تتشابه الجرعة وطلريقة العلاج باستخدام إنتيفيو في كل من مرض التهاب القولون التقرحي، ومرض كرون.<br />الجرعة الموصي بها 300 ملغم و تُعطى كالتالي ) طلالع الجدول أدناه(:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:310px">عدد مرات العلاج )بالتنقيط الوريدي(</td><td style="width:187px">&nbsp;توقيت العلاج )بالتنقيط الوريدي(</td></tr><tr><td style="width:310px">العلاج 1</td><td style="width:187px">بداية تناول العلاج</td></tr><tr><td style="width:310px">العلاج 2</td><td style="width:187px">بعد أسبوعين من العلاج الأول</td></tr><tr><td style="width:310px">&nbsp;العلاج 3</td><td style="width:187px">بعد ستة أسابيع من العلاج الأول</td></tr><tr><td style="width:310px">العلاجات التالية الأخرى</td><td style="width:187px">كل ثمانية أسابيع</td></tr></tbody></table><p>يمكن أن يعدل الطبيب الجدول السابق وفقا لتأثير إنتيفيو على حالتك الصحية.<br /><strong>في حال نسيان أو تفويت موعد التنقيط الوريدي</strong><br />إذا ما نسيت أو فاتك موعد إجراء التنقيط الوريدي للدواء، فعليك حجز موعد أخر بأسرع وقت ممكن.<br /><strong>في حال التوقف عن استعمال إنتيفيو</strong><br />ينبغي استشارة الطبيب أولا قبل التوقف عن استعمال إنتيفيو.<br />إذا كانت لديك أية تساؤلات حول الدواء، اسأل الطبيب أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية، قد ينتج عن استعمال هذا الدواء تأثيرات جانبية، وعلى الرغم من ذلك لاتظهر في جميع المرضى.<br />تشمل التأثيرات الجانبية الخطيرة المحتملة، حدوث ردود فعل تجاه التنقيط الوريدي، أو حساسية من الدواء<br />)قد يصاب بها 1 بين 100 آخرين( أو الإصابة بالعدوى )قد يصاب بها 1 بين 10 آخرين(.</p><p>أبلغ ط<strong>لبيبك على الفور </strong>عند ملاحظة ظهور أي من الأعراض التالية:<br />صوت أزيز في الصدر أو صعوبة التنفس&nbsp;<br />الشرى / حساسية الجلد&nbsp;<br />حكة في الجلد&nbsp;<br />التورم&nbsp;<br />تسارع نبض القلب&nbsp;<br />الشعور بالتعب&nbsp;<br />ألم في مكان الحقن&nbsp;<br />احمرار الجلد&nbsp;<br />القشعريرة والارتجاف&nbsp;<br />الحمى الشديدة أو الطفح الجلدي</p><p>أدرجنا أدناه التأثيرات الجانبية الأخرى التي يمكن الإصابة بها، استشر طلبيبك بأسرع وقت ممكن إذا لاحظت ظهور أي من الأعراض التالية:<br /><strong>التأثيرات الجانبية الأكثر شيوعا ) قد ي صاب بها أكثر من 1 بين 10 آخرين(</strong><br />الإصابة بالبرد&nbsp;<br />ألم المفاصل&nbsp;<br />الصداع</p><p><strong>التأثيرات الجانبية الشائعة ) قد ي صاب بها 1 بين 10 آخرين(</strong><br />الحمى&nbsp;<br />العدوى الرئوية&nbsp;<br />التعب&nbsp;<br />الكحة&nbsp;<br />الإنفلونزا&nbsp;<br />ألم الظهر&nbsp;<br />ألم الحلق&nbsp;<br />عدوى الجيوب&nbsp;<br />الحكة&nbsp;<br />الطفح الجلدي واحمرار الجلد&nbsp;<br />ألم في الأطلراف&nbsp;<br />تشنج العضلات&nbsp;<br />ضعف العضلات&nbsp;<br />عدوى الحلق&nbsp;<br />إنفلونزا المعدة&nbsp;<br />العدوى الشرجية&nbsp;<br />ألم عند فتحة الشرج</p><p>تصلب البراز&nbsp;<br />انتفاخ المعدة&nbsp;<br />الغازات&nbsp;<br />ارتفاع ضغط الدم&nbsp;<br />الإحساس بالوخز واللسع.&nbsp;<br />حرقة المعدة&nbsp;<br />البواسير&nbsp;<br />انسداد الأنف&nbsp;<br />الإكزيما&nbsp;<br />التعرق الليلي&nbsp;<br />حب الشباب )البثور</p><p>&nbsp;اﻟﻧزف اﻟﻣﺳﺗﻘﯾﻣﻲ&nbsp;</p><p>&nbsp;أﻟم اﻟﺻدر&nbsp;</p><p><strong>التأثيرات الجانبية الأقل شيوعا )قد ي صاب بها 1 بين 100 آخرين(</strong><br />احمرار وألم في بصيلة الشعر&nbsp;<br />عدوى الخمائر في الفم والحلق )داء المبيضات(.&nbsp;<br />العدوى المهبلية&nbsp;<br /><strong>الآثار الجانبية النادرة جدا )قد يصاب بها 1 بين 10.000 أخرين(</strong><br />الالتهاب الرئوي&nbsp;<br />عدم وضوح الرؤية ) فقدان حدة البصر(&nbsp;<br />آثار جانبية نادرة ج دا: فجائية، تفاعلات حساسية شديدة قد تتسبب في صعوبة التنفس، تورم، تسارع&nbsp;<br />نبضات القلب، تعرق، هبوطل ضغط الدم، دوار، فقد الوعي وهبوطل )تفاعل التأقي والصدمة التأقية(.</p><p>ﻏﯾر ﻣﻌروﻓﺔ )ﻻ ﯾﻣﻛن ﺗﻘدﯾر ﺷﯾوﻋﮭﺎ ﺑﻧﺎء ﻋﻠﻰ اﻟﺑﯾﺎﻧﺎت &nbsp;اﻟﻣﺗﺎﺣﺔ(</p><p>&nbsp;ﻣرض اﻟرﺋﺔ اﻟﻣﺳﺑب ﻟﺿﯾﻖ اﻟﺗﻧﻔس )ﻣرض اﻟرﺋﺔ اﻟﺧﻼﻟﻲ(</p><p><strong>الإبلاغ عن التأثيرات الجانبية</strong><br />راجع طلبيبك عند الإصابة بأي من التأثيرات الجانبية، ويشمل هذا أي ا من التأثيرات الجانبية المحتملة غير المدرجة في هذه النشرة، فمن خلال إبلاغك عن التأثيرات الجانبية ستسهم في كشف المزيد من المعلومات المتعلقة بأمن وسلامة هذا الدواء.</p><p>ﻟﻺﺑﻼغ ﻋن أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ &nbsp;اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ:&nbsp;</p><p>اﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ اﻟدواﺋﻲ وﺳﻼﻣﺔ اﻷدوﯾﺔ )NPC(</p><p>اﻹﺑﻼغ ﻋﺑر اﻟﺧط اﻟﺳﺎﺧن: 19999&nbsp;<br />اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ: npc.drug@sfda.gov.sa</p><p>اﻟﻣوﻗﻊ اﻹﻟﻛﺗروﻧﻲ: www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيد ا عن نظر ومتناول الأطلفال.<br />ويشير تاريخ الصلاحية إلى ،&ldquo;EXP&rdquo; لا تستعمل الدواء بعد انتهاء تاريخ الصلاحية المدون على العلبة بعد اليوم الأخير من نفس الشهر.<br />يعطى المريض إنتيفيو من قبل الطبيب أو الممرض، لذا لا حاجة للمريض بأخذ أو الاحتفاظ بالدواء.<br />تستخدم العبوة مرة واحدة فقط</p><p dir="ltr"><strong>القارورة غير المفتوحة: تُحفظ في الثلاجة ) 2</strong><br />لحمايتها من الضوء.<br />ا<strong>لمحلول المذاب والمحلول المخفف</strong>: يجب أن يستعمل على الفور. وفي حال لم يكن ذلك ممكن ا ، يمكن حفظ<br />5 درجة مئوية، كما يمكن الاحتفاظ - المحلول المذاب في القارورة لمدة 8 ساعات، في درجة حرارة من 2<br />بالمحلول المخفف في 0.9 % من المحلول الملحي لمدة 12 ساعة في درجة حرارة الغرفة بحيث لا تتجاوز 5 درجة مئوية(، أو لمدة 12 ساعة في درجة حرارة - 25 درجة مئوية، أو لمدة 24 ساعة في الثلاجة ) 2 5 درجة مئوية(، بحيث يكون المجموع الكلي 24 ساعة، وتشتمل ال 24 ساعة على - الغرفة أو في الثلاجة ) 2<br />5 درجة مئوية، للمحلول المذاب في القارورة، و لمدة 12 ساعة في درجة - 8 ساعات في درجة حرارة من 2 25 درجة مئوية للمحلول المخفف في كيس التنقيط الوريدي، ولكن ينبغي حفظ كيس التنقيط - حرارة من 20 5 درجة مئوية(، وللمتبقي من مدة ال 24 ساعة فيجب طلرح الفترة التي حُ فظ فيه المحلول - في الثلاجة ) 2 المذاب في القارورة من الفترة الذي حُ فظ فيها المحلول في كيس التنقيط.<br />لا يُجمد المحلول.<br />لا تستعمل الدواء إذا لاحظت وجود أية جزئيات في السائل، أو تغير في اللون قبل إعطائه.<br />لا تلقي أي دواء في مجاري الصرف أو الفضلات المنزلية، واستشر الصيدلي حول كيفية إلقاء الأدوية التي لم تعد قيد الاستخدام، فمن خلال اتباعك هذه الإجراءات ستسهم في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة الفعالة</strong> هي فيدوليزوماب، وتحتوي كل قارورة على 300 ملغم من فيدوليذوماب.<br />(L-histidine ( هيستدين أحادي الهيدروكلوريد ،)L-histidine(</p><p>المكونات الأخرى: الهستداين<br />سكروز، بولي ،)L-Arginine hydrochloride( أرجنين هيدروكلوريد - ،monohydrochoride<br />. سوربات 80<br /><strong>ما هو الشكل الدوائي لإنتيفيو وما هي محتويات العبوة</strong><br />دواء إنتيفيو عبارة عن مسحوق لونه أبيض أو مائل إلى الصفرة، مركّ ز لتحضير محلول منه صالح للتنقيط الوريدي، يأتي في قارورة لها سدادة من المطاطل وغطاء بلاستيكي.<br />تحتوي العبوة على قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;Takeda Pharma A/S &nbsp;Delta Park 45 Vallensbaek Strand 2665 &nbsp; اﻟدﻧﻣﺎرك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>اﻟﺷرﻛﺔ اﻟﻣﺻﻧﻌﺔ وﻣوﻗﻊ اﻟﺗﻐﻠﯾف اﻷﺳﺎﺳﻲ</strong></p><p>شركة هوسبيرا<br />1776 شمال سنتننيال دريف<br />ماكفرسون<br />67460 ، كنساس<br />الولايات المتحدة الأمريكية</p><p><strong>اﻟﺷرﻛﺔ اﻟﻣﺻﻧﻌﺔ اﻹﺿﺎﻓﯾﺔ وﻣوﻗﻊ اﻟﺗﻐﻠﯾف اﻷﺳﺎﺳﻲ: &nbsp;</strong></p><p>&nbsp;Takeda Pharmaceutical Company LTD &nbsp;Hikari Plant.<br />&nbsp;اﻟﯾﺎﺑﺎن ،Takeda Mitsui, Hikari, Yamaguchi ,4720</p><p><strong>ﻣوﻗﻊ اﻟﺗﻐﻠﯾف اﻟﺛﺎﻧوي &nbsp;وإﺻدار اﻟدُﻓﻌﺎت اﻟﻧﮭﺎﺋﯾﺔ </strong></p><p>,Takeda Austria GmbH&nbsp;<br />St. Peter-Stra&szlig;e 25,&nbsp;<br />4020 ﻟﯾﻧز، اﻟﻧﻣﺳﺎ &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آﺧر ﻣراﺟﻌﺔ ﻟﮭذه اﻟﻧﺷرة ﻓﻲ 2022/03/29
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Entyvio 300 mg powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 300 mg of vedolizumab.
After reconstitution, each ml contains 60 mg of vedolizumab.
Vedolizumab is a humanised IgG1 monoclonal antibody that binds to the human α4β7 integrin and is produced in Chinese hamster ovary (CHO) cells.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.
White to off-white lyophilised cake or powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Ulcerative Colitis</strong></u><br />Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF&alpha;) antagonist.</p><p><u><strong>Crohn&rsquo;s Disease</strong></u><br />Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn&rsquo;s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF&alpha;) antagonist.</p><p><u><strong>Pouchitis&nbsp;</strong></u><br />Entyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with, or lost response to antibiotic therapy.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis, Crohn&rsquo;s disease or pouchitis (see section 4.4). Patients should be given the package leaflet and the Patient Alert Card.&nbsp;</p><p><strong><u>Posology</u></strong><br /><em><u>Ulcerative Colitis</u></em><br />The recommended dose regimen of Entyvio is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.</p><p>Therapy for patients with ulcerative colitis should be discontinued if no evidence of therapeutic benefit is observed by Week 10 (see section 5.1).<br />Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.<br />In patients who have responded to treatment with Entyvio, corticosteroids may be reduced and/or discontinued in accordance with standard of care.</p><p><em>Retreatment</em><br />If therapy is interrupted and there is a need to restart treatment with Entyvio, dosing at every four weeks may be considered (see section 5.1). The treatment interruption period in clinical trials extended up to one year. Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with vedolizumab (see section 4.8).<br /><em><u><strong>Crohn&rsquo;s disease</strong></u></em><br />The recommended dose regimen of Entyvio is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.<br />Patients with Crohn&rsquo;s disease, who have not shown a response may benefit from a dose of Entyvio at Week 10 (see section 4.4). Continue therapy every eight weeks from Week 14 in responding patients. Therapy for patients with Crohn&rsquo;s disease should be discontinued if no evidence of therapeutic benefit is observed by Week 14 (see section 5.1).<br />Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.</p><p>In patients who have responded to treatment with Entyvio, corticosteroids may be reduced and/or discontinued in accordance with standard of care.</p><p><em>Retreatment</em><br />If therapy is interrupted and there is a need to restart treatment with Entyvio, dosing at every four weeks may be considered (see section 5.1). The treatment interruption period in clinical trials extended up to one year. Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with vedolizumab (see section 4.8).</p><p>Pouchitis&nbsp;<br />The recommended dose regimen of intravenous vedolizumab is 300 mg administered by intravenous infusion at 0, 2 and 6 weeks and then every 8 weeks thereafter. &nbsp;<br />Treatment with vedolizumab should be initiated in parallel with standard of care antibiotic (e.g., four-week of ciprofloxacin) (see section 5.1).&nbsp;<br />Discontinuation of treatment should be considered if no evidence of therapeutic benefit is observed by 14 weeks of treatment with vedolizumab.&nbsp;<br /><em>Retreatment&nbsp;</em><br />There are no retreatment data available in patients with pouchitis.&nbsp;</p><p><u><em>Special populations&nbsp;<br />Elderly patients&nbsp;</em></u><br />No dose adjustment is required in elderly patients. Population pharmacokinetic analyses showed no effect of age (see section 5.2).&nbsp;<br /><u><em>Patients with renal or hepatic impairment&nbsp;</em></u><br />Vedolizumab has not been studied in these patient populations. No dose recommendations can be made.&nbsp;<br /><u><em>Paediatric population&nbsp;</em></u><br />The safety and efficacy of vedolizumab in children aged 0 to 17 years old have not been established. No data are available.&nbsp;<br /><u><em>Method of administration&nbsp;</em></u><br />Entyvio 300 mg powder for concentrate for solution for infusion is for intravenous use only. It is to be reconstituted and further diluted prior to intravenous administration, for instructions see section 6.6.&nbsp;<br />Entyvio 300 mg powder for concentrate for solution for infusion is administered as an intravenous infusion over 30 minutes. Patients should be monitored during and after infusion (see section 4.4).&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML) (see section 4.4).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vedolizumab should be administered in a healthcare setting equipped to allow management of acute hypersensitivity reactions including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering vedolizumab. All patients should be observed continuously during each infusion. For the first two infusions, they should also be observed for approximately two hours following completion of the infusion for signs and symptoms of acute hypersensitivity reactions. For all subsequent infusions, patients should be observed for approximately one hour following completion of the infusion.</p><p><strong><u>Infusion-related reactions</u></strong></p><p>In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity (see section 4.8).<br />If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of Entyvio must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines) (see section 4.3).<br />If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated. Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks (see section 4.8).</p><p><u><strong>Infections</strong></u><br />Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity (see section 5.1).<br />Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier (see section 4.8). Entyvio treatment is not to be initiated in patients with active, severe infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with Entyvio. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Entyvio is contraindicated in patients with active tuberculosis (see section 4.3). Before starting treatment with vedolizumab, patients must be screened for tuberculosis according to the local practice. If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis treatment in accordance with local recommendations, before beginning vedolizumab. In patients diagnosed with TB whilst receiving vedolizumab therapy, then vedolizumab therapy should be discontinued until the TB infection has been resolved.<br />Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the &alpha;4&beta;7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect specific to the gut. Although no systemic immunosuppressive effect was noted in healthy subjects the effects on systemic immune system function in patients with Inflammatory Bowel Disease patients is not known.<br />healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms as outlined in physician education materials and consider neurological referral if they occur. The patient is to be given a Patient Alert Card (see section 4.2). If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued.</p><p><u><strong>Malignancies</strong></u><br />The risk of malignancy is increased in patients with ulcerative colitis and Crohn&rsquo;s disease. Immunomodulatory medicinal products may increase the risk of malignancy (see section 4.8).<br /><strong><u>Prior and concurrent use of biological products</u></strong><br />No vedolizumab clinical trial data are available for patients previously treated with natalizumab or rituximab. Caution should be exercised when considering the use of Entyvio in these patients.<br />Patients previously exposed to natalizumab should normally wait a minimum of 12 weeks prior to initiating therapy with Entyvio, unless otherwise indicated by the patient&rsquo;s clinical condition.<br />No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of Entyvio in such patients is not recommended.</p><p><u><strong>Liver Injury</strong></u><br />There have been reports of elevations of transaminase and/or bilirubin in patients receiving vedolizumab. In general, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant in some patients. Vedolizumab should be discontinued in patients with jaundice or other evidence of significant liver injury<br /><strong><u>Live and oral vaccines</u></strong><br />In a placebo-controlled study of healthy volunteers, a single 750 mg dose of vedolizumab did not lower rates of protective immunity to hepatitis B virus in subjects who were vaccinated intramuscularly with three doses of recombinant hepatitis B surface antigen. Vedolizumab-exposed subjects had lower seroconversion rates after receiving a killed, oral cholera vaccine. The impact on other oral and nasal vaccines is unknown. It is recommended that all patients be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Entyvio therapy. Patients receiving vedolizumab treatment may continue to receive non-live vaccines. There are no data on the secondary transmission of infection by live vaccines in patients receiving vedolizumab. Administration of the influenza vaccine should be by injection in line with routine clinical practice. Other live vaccines may be administered concurrently with vedolizumab only if the benefits clearly outweigh the risks.</p><p><u><strong>Induction of remission in Crohn&rsquo;s disease</strong></u></p><p>Induction of remission in Crohn&rsquo;s disease may take up to 14 weeks in some patients. The reasons for this are not fully known and are possibly related to the mechanism of action. This should be taken into consideration, particularly in patients with severe active disease at baseline not previously treated with TNF&alpha; antagonists. (See also section 5.1.)<br />Exploratory subgroup analyses from the clinical trials in Crohn&rsquo;s disease suggested that vedolizumab administered in patients without concomitant corticosteroid treatment may be less effective for induction of remission in Crohn&rsquo;s disease than in those patients already receiving concomitant corticosteroids (regardless of use of concomitant immunomodulators; see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.<br />Vedolizumab has been studied in adult ulcerative colitis and Crohn&rsquo;s disease patients with concomitant administration of corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), and aminosalicylates. Population pharmacokinetic analyses suggest that co-administration of such agents did not have a clinically meaningful effect on vedolizumab pharmacokinetics.&nbsp;<br />In adult patients with pouchitis, vedolizumab has been co-administered with antibiotics (see section 5.1). The pharmacokinetics of vedolizumab in patients with pouchitis has not been studied (see section 5.2). &nbsp;<br />The effect of vedolizumab on the pharmacokinetics of commonly co-administered medicinal compounds has not been studied.&nbsp;</p><p><u><strong>Vaccinations</strong></u><br />Live vaccines, in particular live oral vaccines, should be used with caution concurrently with Entyvio (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Women of childbearing potential</strong></u><br />Women of childbearing potential are strongly recommended to use adequate contraception to prevent pregnancy and to continue its use for at least 18 weeks after the last treatment with Entyvio.<br /><strong><u>Pregnancy</u></strong><br />There are limited amount of data from the use of vedolizumab in pregnant women.<br />Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).<br />Entyvio is to be used during pregnancy only if the benefits clearly outweigh any potential risk to both the mother and foetus.</p><p><u><strong>Breast-feeding</strong></u><br />Vedolizumab has been detected in human milk. The effect of vedolizumab on breast-fed infants and te effect on milk production &nbsp;are unknown. In a milk-only lactation study assessing the concentration of vedolizumab in breast milk of lactating women with active ulcerative colitis or Crohn&rsquo;s disease receiving vedolizumab, the concentration of vedolizumab in human breast milk was approximately 0.4% to 2.2% of the maternal serum concentration obtained from historical studies of vedolizumab. The estimated average daily dose of vedolizumab ingested by the infant was 0.02 mg/kg/day, which is approximately 21% of the body weight-adjusted average maternal daily dose).&nbsp;</p><p>The use of vedolizumab in lactating women should take into account the benefit of therapy to the mother and potential risks to the infant.&nbsp;<br /><br /><u><strong>Fertility</strong></u><br />There are no data on the effects of vedolizumab on human fertility. Effects on male and female fertility have not been formally evaluated in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Entyvio may have a minor influence on the ability to drive or operate machines, as dizziness has been reported in a small number of patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Summary of safety profile</strong></u><br />Vedolizumab has been studied in three placebo-controlled clinical trials in patients with ulcerative colitis (GEMINI I) or Crohn&rsquo;s disease (GEMINI II and III). In two controlled studies (GEMINI I and II) involving 1,434 patients receiving vedolizumab 300 mg at Week 0, Week 2 and then every eight weeks or every four weeks from Week 6 for up to 52 weeks, and 297 patients receiving placebo for up to 52 weeks, adverse events were reported in 84% of vedolizumab-treated patients and 78% of placebo-treated patients. Over 52 weeks, 19% of vedolizumab-treated patients experienced serious adverse events compared to 13% of placebo-treated patients. Similar rates of adverse events were seen in the every eight week and every four week dosing groups in the Phase 3 clinical trials. The proportion of patients who discontinued treatment due to adverse events was 9% for vedolizumab-treated patients and 10% for placebo-treated patients. In the combined studies of GEMINI I and II the adverse reactions that occurred in &ge;5% were nausea, nasopharyngitis, upper respiratory tract infection, arthralgia, pyrexia, fatigue, headache, cough. Infusion-related reactions were reported in 4% of patients receiving vedolizumab.</p><p>In the shorter (10 week) placebo controlled induction trial, GEMINI III, the types of adverse reactions reported were similar but occurred at lower frequency than the longer 52 week trials.<br />A further 279 patients were treated with vedolizumab at Week 0 and Week 2 and then with placebo for up to 52 weeks. Of these patients, 84% experienced adverse events and 15% experienced serious adverse events.<br />Patients (n=1,822) previously enrolled in Phase 2 or 3 vedolizumab studies were eligible to enrol in an ongoing open-label study and received vedolizumab 300 mg every four weeks.</p><p><u><strong>Tabulated list of adverse reactions</strong></u><br />The following listing of adverse reactions is based on clinical trial and post marketing experience and is displayed by system organ class. Within the system organ classes, adverse reactions are listed under headings of the following frequency categories: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100) and very rare (&lt; 1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p><strong>Table 1. Adverse Reactions</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:875px"><tbody><tr><td style="width:242px"><strong>System Organ Class</strong></td><td style="width:130px">&nbsp; &nbsp; &nbsp;&nbsp;<strong>Frequency</strong></td><td style="width:521px"><strong>&nbsp; &nbsp;Adverse Reaction(s)</strong></td></tr><tr><td rowspan="4" style="width:242px">&nbsp;Infection and infestation</td><td style="width:130px">&nbsp;Very Common</td><td style="width:521px">&nbsp;Nasopharyngitis</td></tr><tr><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Bronchitis, Gastroenteritis, Upper respiratory tract infection, Influenza, Sinusitis, Pharyngitis</td></tr><tr><td style="width:130px">&nbsp;Uncommon</td><td style="width:521px">&nbsp;Respiratory tract infection, Vulvovaginal candidiasis, Oral Candidiasis, Herpes zoster</td></tr><tr><td style="width:130px">&nbsp;Very rare</td><td style="width:521px">&nbsp;Pneumonia</td></tr><tr><td style="width:242px">&nbsp;Immune system disorders</td><td style="width:130px">&nbsp;Very rare</td><td style="width:521px">&nbsp;Anaphylactic reaction, anaphylactic shock</td></tr><tr><td rowspan="2" style="width:242px">&nbsp;Nervous system disorders</td><td style="width:130px">&nbsp;Very Common</td><td style="width:521px">&nbsp;Headache</td></tr><tr><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Paraesthesia</td></tr><tr><td style="width:242px">&nbsp;Eye disorders&nbsp;</td><td style="width:130px">&nbsp;Very rare</td><td style="width:521px">&nbsp;Blurred vision</td></tr><tr><td style="width:242px">&nbsp;Vascular disorders</td><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Hypertension</td></tr><tr><td style="width:242px">&nbsp;Respiratory, thoracic and mediastinal disorders</td><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Oropharyngeal pain, Nasal congestion, Cough</td></tr><tr><td style="width:242px">&nbsp;Gastrointestinal disorders</td><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Anal Abscess, Anal fissure, Nausea, Dyspepsia, Constipation, Abdominal distension, Flatulence, Haemorrhoids,&nbsp;Rectal haemorrhage*&nbsp;</td></tr><tr><td rowspan="2" style="width:242px">&nbsp;Skin and subcutaneous tissue disorders</td><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Rash, Pruritus, Eczema, Erythema, Night sweats, Acne</td></tr><tr><td style="width:130px">&nbsp;Uncommon</td><td style="width:521px">&nbsp;Folliculitis</td></tr><tr><td rowspan="2" style="width:242px">&nbsp;Musculoskeletal and connective tissue disorders</td><td style="width:130px">&nbsp;&nbsp;Very Common</td><td style="width:521px">&nbsp;Arthralgia</td></tr><tr><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Muscle spasms, Back pain, Muscular weakness, Fatigue, Pain in the extremity</td></tr><tr><td rowspan="2" style="width:242px">&nbsp;General disorders and administration site conditions</td><td style="width:130px">&nbsp;Common</td><td style="width:521px">&nbsp;Pyrexia,&nbsp;Infusion related reaction* (asthenia and chest discomfort)&nbsp;</td></tr><tr><td style="width:130px">&nbsp;Uncommon</td><td style="width:521px">&nbsp;Infusion site reaction (including: Infusion site pain and Infusion site irritation), Infusion related reaction Chills, Feeling cold</td></tr></tbody></table><p>*Reported in the EARNEST pouchitis study</p><p><strong><u>Description of selected adverse reactions</u></strong><br /><em><u>Infusion-related reactions</u></em><br />In GEMINI I and &nbsp;2 controlled studies (ulcerative colitis and Crohn&rsquo;s disease), 4% of vedolizumab-treated patients and 3% of placebo-treated patients experienced an adverse event defined by the investigator as infusion-related reaction (IRR) (see section 4.4). No individual Preferred Term reported as an IRR occurred at a rate above 1%. The majority of IRRs were mild or moderate in intensity and &lt;1% resulted in discontinuation of study treatment. Observed IRRs generally resolved with no or minimal intervention following the infusion. Most infusion related reactions occurred within the first 2 hours. Of those patients who had infusion related reactions, those dosed with vedolizumab had more infusion related reactions with in the first two hours as compared to placebo patients with infusion related reactions. Most infusion related reactions were not serious and occurred during the infusion or within the first hour after infusion is completed.</p><p>One serious adverse event of IRR was reported in a Crohn&rsquo;s disease patient during the second infusion (symptoms reported were dyspnoea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate) and was successfully managed with discontinuation of infusion and treatment with antihistamine and intravenous hydrocortisone. In patients who received vedolizumab at Weeks 0 and 2 followed by placebo, no increase in the rate of IRR was seen upon retreatment with vedolizumab after loss of response.</p><p>In EARNEST controlled study (pouchitis) with intravenous vedolizumab, hypersensitivity reactions, including IRRs, were reported in 3 out of 51 subjects (5.9%) in the vedolizumab group and 2 out of 51 subjects (3.9%) in the placebo group. The individual Preferred Terms included mouth ulceration, swelling, oedema peripheral, chest discomfort, asthenia, acute kidney injury, obstructive airway disorder and flushing. All events were reported as mild to moderate in intensity, none were considered serious and none resulted in study discontinuation.&nbsp;<br /><em><u>Infections</u></em><br />In GEMINI I and II controlled studies, the rate of infections was 0.85 per patient-year in the vedolizumab-treated patients and 0.70 per patient-year in the placebo-treated patients. The infections consisted primarily of nasopharyngitis, upper respiratory tract infection, sinusitis, and urinary tract infections. Most patients continued on vedolizumab after the infection resolved.<br />In GEMINI I and II controlled studies, the rate of serious infections was 0.07 per patient year in vedolizumab-treated patients and 0.06 per patient year in placebo-treated patients. Over time, there was no significant increase in the rate of serious infections.</p><p>In the EARNEST controlled study (pouchitis) with intravenous vedolizumab, only 1 out of 51 subjects (2.0%) in the vedolizumab group experienced a serious infection of gastroenteritis. The subject was hospitalized for observation, recovered from the event and completed the study.&nbsp;<br />In controlled and open-label studies in adults with vedolizumab, serious infections have been reported, which include tuberculosis, sepsis (some fatal), salmonella sepsis, listeria meningitis, and cytomegaloviral colitis.</p><p><u><em>Malignancy</em></u><br />Overall, results from the clinical program to date do not suggest an increased risk for malignancy with vedolizumab treatment; however, the number of malignancies was small and long-term exposure was limited. Long-term safety evaluations are ongoing.</p><p><strong><u>Reporting of suspected adverse reactions</u></strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via<br />The National Pharmacovigilance and Drug Safety Centre (NPC):</p><table border="1" cellspacing="1" cellpadding="1" style="width:652px"><tbody><tr><td style="width:649px">Reporting hotline: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>For other GCC States:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&nbsp;Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Doses up to 10 mg/kg (approximately 2.5 times the recommended dose) have been administered in clinical trials. No dose-limiting toxicity was seen in clinical trials.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immunosuppressants, selective immunosuppressants, ATC code: L04AA33</p><p><u><strong>5.1 Pharmacodynamic properties</strong></u></p><p>Vedolizumab is a gut-selective immunosuppressive biologic. It is a humanized monoclonal antibody that binds specifically to the &alpha;4&beta;7 integrin, which is preferentially expressed on gut homing T helper lymphocytes. By binding to &alpha;4&beta;7 on certain lymphocytes, vedolizumab inhibits adhesion of these cells to mucosal addressing cell adhesion molecule-1 (MAdCAM-1), but not to vascular cell adhesion molecule-1 (VCAM-1). MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T lymphocytes to tissues within the gastrointestinal tract. Vedolizumab does not bind to, nor inhibit function of, the &alpha;4&beta;1 and &alpha;E&beta;7 integrins.&nbsp;<br />The &alpha;4&beta;7 integrin is expressed on a discrete subset of memory T helper lymphocytes which preferentially migrate into the gastrointestinal (GI) tract and cause inflammation that is characteristic of ulcerative colitis and Crohn&rsquo;s disease, both of which are chronic inflammatory immunologically mediated conditions of the GI tract. Vedolizumab reduces gastrointestinal inflammation in UC, and CD and pouchitis patients. Inhibiting the interaction of &alpha;4&beta;7 with MAdCAM-1 with vedolizumab prevents transmigration of gut-homing memory T helper lymphocytes across the vascular endothelium into parenchymal tissue in nonhuman primates and induced a reversible 3-fold elevation of these cells in peripheral blood. The murine precursor of vedolizumab alleviated gastrointestinal inflammation in colitic cotton-top tamarins, a model of ulcerative colitis.&nbsp;<br />In healthy subjects, ulcerative colitis patients, or Crohn&rsquo;s disease patients, vedolizumab does not elevate neutrophils, basophils, eosinophils, B-helper and cytotoxic T lymphocytes, total memory T helper lymphocytes, monocytes or natural killer cells, in the peripheral blood with no leukocytosis observed.&nbsp;<br />Vedolizumab did not affect immune surveillance and inflammation of the central nervous system in Experimental Autoimmune Encephalomyelitis in non-human primates, a model of multiple sclerosis. Vedolizumab did not affect immune responses to antigenic challenge in the dermis and muscle (see section 4.4). In contrast, vedolizumab inhibited an immune response to a gastrointestinal antigenic challenge in healthy human volunteers (see section 4.4).&nbsp;</p><p><u>Immunogenicity</u><br />Antibodies to vedolizumab may develop during vedolizumab treatment most of which are neutralising. The formation of anti--vedolizumab antibodies is associated with increased clearance of vedolizumab and lower rates of clinical remission.<br />Infusion related reactions after vedolizumab infusion are reported in subjects with anti--vedolizumab antibodies.</p><p><u><strong>Pharmacodynamic effects</strong></u><br />In clinical trials with vedolizumab at doses ranging from 2 to 10 mg/kg, &gt;95% saturation of &alpha;4&beta;7 receptors on subsets of circulating lymphocytes involved in gut immune surveillance was observed in patients.<br />Vedolizumab did not affect CD4+ and CD8+ trafficking into the CNS as evidenced by the lack of change in the ratio of CD4+/CD8+ in cerebrospinal fluid pre- and post-vedolizumab administration in healthy human volunteers. These data are consistent with investigations in nonhuman primates which did not detect effects on immune surveillance of the CNS.<br /><u>Clinical efficacy</u><br /><em>Ulcerative Colitis</em><br />The efficacy and safety of vedolizumab for the treatment of adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12 with endoscopic sub score &ge;2) was demonstrated in a randomised, double-blind, placebo-controlled study evaluating efficacy endpoints at Week 6 and Week 52 (GEMINI I). Enrolled patients had failed at least one conventional therapy, including corticosteroids, immunomodulators, and/or the TNF&alpha; antagonist infliximab (including primary non-responders). Concomitant stable doses of oral aminosalicylates, corticosteroids and/or immunomodulators were permitted.</p><p>For the evaluation of the Week 6 endpoints, 374 patients were randomised in a double-blind fashion (3:2) to receive vedolizumab 300 mg or placebo at Week 0 and Week 2. Primary endpoint was the proportion of patients with clinical response (defined as reduction in complete Mayo score of 3 points and 30% from baseline with an accompanying decrease in rectal bleeding subscore of 1 point or absolute rectal bleeding subscore of &le;1 point) at Week 6. Table 2 shows the results from the primary and secondary endpoints evaluated.</p><p><strong>Table 2. Week 6 Efficacy Results of GEMINI I</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center">&nbsp;Endpoint</td><td style="text-align:center; width:136px">Placebo N=149</td><td style="text-align:center; width:165px">Vedolizumab N=225</td></tr><tr><td style="text-align:center">&nbsp;Clinical response</td><td style="text-align:center; width:136px">&nbsp;26%</td><td style="text-align:center; width:165px">&nbsp;47%*</td></tr><tr><td style="text-align:center">&nbsp;Clinical remission&sect;</td><td style="text-align:center; width:136px">&nbsp;&nbsp;5%</td><td style="text-align:center; width:165px">&nbsp;17%&dagger;</td></tr><tr><td style="text-align:center">&nbsp;Mucosal healing&para;</td><td style="text-align:center; width:136px">&nbsp;25%</td><td style="text-align:center; width:165px">41%&Dagger;</td></tr></tbody></table><p><sup>*p&lt;0.0001<br />&dagger;p&le;0.001<br />&Dagger;p&lt;0.05<br />&sect;Clinical remission: Complete Mayo score of &le;2 points and no individual subscore &gt;1 point<br />&para;Mucosal healing: Mayo endoscopic subscore of &le;1 point</sup></p><p>The beneficial effect of vedolizumab on clinical response, remission and mucosal healing was observed both in patients with no prior TNF antagonist exposure as well as in those who had failed prior TNF antagonist therapy.<br />In GEMINI I, two cohorts of patients received vedolizumab at Week 0 and Week 2: cohort 1 patients were randomised to receive either vedolizumab 300 mg or placebo in a double-blind fashion, and cohort 2 patients were treated with open-label vedolizumab 300 mg. To evaluate efficacy at Week 52, 373 patients from cohort 1 and 2 who were treated with vedolizumab and had achieved clinical response at Week 6 were randomised in a double-blind fashion (1:1:1) to one of the following regimens beginning at Week 6: vedolizumab 300 mg every eight weeks, vedolizumab 300 mg every four weeks, or placebo every four weeks. Beginning at Week 6, patients who had achieved clinical response and were receiving corticosteroids were required to begin a corticosteroid-tapering regimen. Primary endpoint was the proportion of patients in clinical remission at Week 52. Table 3 shows the results from the primary and secondary endpoints evaluated</p><p>&nbsp;</p><p><strong>Table 3. Week 52 Efficacy Results of GEMINI I </strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:899px"><tbody><tr><td style="text-align:center; width:246px">Endpoint</td><td style="text-align:center; width:148px">Placebo N = 126*</td><td style="text-align:center; width:267px">&nbsp;Vedolizumab Every 8 Weeks N = 122</td><td style="text-align:center; width:235px">Vedolizumab Every 4 Weeks N = 125</td></tr><tr><td style="text-align:center; width:246px">&nbsp;Clinical remission</td><td style="text-align:center; width:148px">&nbsp;16%</td><td style="text-align:center; width:267px">&nbsp;42%&dagger;</td><td style="text-align:center; width:235px">&nbsp;45%&dagger;</td></tr><tr><td style="text-align:center; width:246px">Durable clinical response&para;</td><td style="text-align:center; width:148px">24%&nbsp;</td><td style="text-align:center; width:267px">&nbsp;57%&dagger;</td><td style="text-align:center; width:235px">52%&dagger;</td></tr><tr><td style="text-align:center; width:246px">Mucosal healing</td><td style="text-align:center; width:148px">20%</td><td style="text-align:center; width:267px">52%&dagger;</td><td style="text-align:center; width:235px">56%&dagger;</td></tr><tr><td style="text-align:center; width:246px">Durable clinical remission#</td><td style="text-align:center; width:148px">9%</td><td style="text-align:center; width:267px">20%&sect;</td><td style="text-align:center; width:235px">24%&Dagger;</td></tr><tr><td style="text-align:center; width:246px">Corticosteroid-free clinical remission&spades;</td><td style="text-align:center; width:148px">14%</td><td style="text-align:center; width:267px">31%&sect;</td><td style="text-align:center; width:235px">45%&dagger;</td></tr></tbody></table><p><sup>*The placebo group includes those subjects who received vedolizumab at Week 0 and Week 2, and were randomised to receive placebo from Week 6 through Week 52. </sup></p><p><sup>&dagger;p&lt;0.0001 </sup></p><p><sup>&Dagger;p&lt;0.001 </sup></p><p><sup>&sect;p&lt;0.05</sup></p><p><sup>&para;Durable clinical response: Clinical response at Weeks 6 and 52 </sup></p><p><sup>#Durable clinical remission: Clinical remission at Weeks 6 and 52</sup></p><p><sup>&spades;Corticosteroid-free clinical remission: Patients using oral corticosteroids at baseline who had discontinued corticosteroids beginning at Week 6 and were in clinical remission at Week 52. Patient numbers were n=72 for placebo, n=70 for vedolizumab every eight weeks, and n=73 for vedolizumab every four weeks</sup></p><p>Exploratory analyses provide additional data on key subpopulations studied. Approximately one-third of patients had failed prior TNF antagonist therapy. Among these patients, 37% receiving vedolizumab every eight weeks, 35% receiving vedolizumab every four weeks, and 5% receiving placebo achieved clinical remission at Week 52. Improvements in durable clinical response (47%, 43%, 16%), mucosal healing (42%, 48%, 8%), durable clinical remission (21%, 13%, 3%) and corticosteroid-free clinical remission (23%, 32%, 4%) were seen in the prior TNF&alpha; antagonist failure population treated with vedolizumab every eight weeks, vedolizumab every four weeks and placebo, respectively.<br />Patients who failed to demonstrate response at Week 6 remained in the study and received vedolizumab every four weeks. Clinical response using partial Mayo scores was achieved at Week 10 and Week 14 by greater proportions of vedolizumab patients (32% and 39%, respectively) compared with placebo patients (15% and 21%, respectively).<br />Patients who lost response to vedolizumab when treated every eight weeks were allowed to enter an open-label extension study and receive vedolizumab every four weeks. In these patients, clinical remission was achieved in 25% of patients at Week 28 and Week 52.</p><p>Patients who achieved a clinical response after receiving vedolizumab at Week 0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open-label extension study and receive vedolizumab every four weeks. In these patients, clinical remission was achieved in 45% of patients by 28 weeks and 36% of patients by 52 weeks.<br />In this open-label extension study, the benefits of vedolizumab treatment as assessed by partial Mayo score, clinical remission, and clinical response were shown for up to 196 weeks.<br />Health-related quality of life (HRQOL) was assessed by Inflammatory Bowel Disease Questionnaire (IBDQ), a disease specific instrument, and SF-36 and EQ-5D, which are general measures. Exploratory analysis show clinically meaningful improvements were observed for vedolizumab groups, and the improvements were significantly greater as compared with the placebo group at Week 6 and Week 52 on EQ-5D and EQ-5D VAS scores, all subscales of IBDQ (bowel symptoms, systemic function, emotional function and social function), and all subscales of SF-36 including the Physical Component Summary (PCS) and Mental Component Summary (MCS).</p><p><u>Crohn&rsquo;s Disease</u><br />The efficacy and safety of vedolizumab for the treatment of adult patients with moderately to severely active Crohn&rsquo;s Disease (Crohn&rsquo;s Disease Activity Index [CDAI] score of 220 to 450) were evaluated in two studies (GEMINI II and III). Enrolled patients have failed at least one conventional therapy, including corticosteroids, immunomodulators, and/or TNF&alpha; antagonists (including primary non-responders). Concomitant stable doses of oral corticosteroids, immunomodulators, and antibiotics were permitted.<br />The GEMINI II Study was a randomised, double-blind, placebo-controlled study evaluating efficacy endpoints at Week 6 and Week 52. Patients (n=368) were randomised in a double-blind fashion (3:2) to receive two doses of vedolizumab 300 mg or placebo at Week 0 and Week 2. The two primary endpoints were the proportion of patients in clinical remission (defined as CDAI score &le;150 points) at Week 6 and the proportion of patients with enhanced clinical response (defined as a &ge;100-point decrease in CDAI score from baseline) at Week 6 (see Table 4).<br />GEMINI II contained two cohorts of patients that received vedolizumab at Weeks 0 and 2: Cohort 1 patients were randomised to receive either vedolizumab 300 mg or placebo in a double-blind fashion, and Cohort 2 patients were treated with open-label vedolizumab 300 mg. To evaluate efficacy at Week 52, 461 patients from Cohorts 1 and 2, who were treated with vedolizumab and had achieved clinical response (defined as a &ge;70-point decrease in CDAI score from baseline) at Week 6, were randomised in a double-blind fashion (1:1:1) to one of the following regimens beginning at Week 6: vedolizumab 300 mg every eight weeks, vedolizumab 300 mg every four weeks, or placebo every four weeks. Patients showing clinical response at Week 6 were required to begin corticosteroid tapering. Primary endpoint was the proportion of patients in clinical remission at Week 52 (see Table 5).<br />The GEMINI III Study was a second randomised, double-blind, placebo-controlled study that evaluated efficacy at Week 6 and Week 10 in the subgroup of patients defined as having failed at least one conventional therapy and failed TNF antagonist therapy (including primary non-responders) as well as the overall population, which also included patients who failed at least one conventional therapy and were na&iuml;ve to TNF antagonist therapy. Patients (n=416), which included approximately 75% TNF antagonist failures patients, were randomised in a double-blind fashion (1:1) to receive either vedolizumab 300 mg or placebo at Weeks 0, 2, and 6. The primary endpoint was the proportion of patients in clinical remission at Week 6 in the TNF antagonist failure subpopulation. As noted in Table 4, although the primary endpoint was not met, exploratory analyses show that clinically meaningful results were observed.</p><table border="0" cellspacing="0" cellpadding="0" style="width:518px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="7" style="vertical-align:bottom"><p><strong>Table&nbsp;4. Efficacy Results for GEMINI&nbsp;II and III Studies at Week&nbsp;6 and Week&nbsp;10</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>Study</p><p>Endpoint</p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Vedolizumab</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>GEMINI&nbsp;II Study</strong></p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Clinical remission, Week&nbsp;6</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Overall</p></td><td colspan="3" style="vertical-align:top"><p>7% (n = 148)</p></td><td colspan="2" style="vertical-align:top"><p>15%* (n = 220)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Failure</p></td><td colspan="2" style="vertical-align:top"><p>4% (n = 70)</p></td><td colspan="2" style="vertical-align:top"><p>11% (n = 105)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Na&iuml;ve</p></td><td colspan="2" style="vertical-align:top"><p>9% (n = 76)</p></td><td colspan="2" style="vertical-align:top"><p>17% (n = 109)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Enhanced clinical response, Week&nbsp;6</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Overall</p></td><td colspan="3" style="vertical-align:top"><p>26% (n = 148)</p></td><td colspan="2" style="vertical-align:top"><p>31%<sup>&dagger;</sup> (n = 220)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Failure</p></td><td colspan="2" style="vertical-align:top"><p>23% (n = 70)</p></td><td colspan="2" style="vertical-align:top"><p>24% (n = 105)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Na&iuml;ve</p></td><td colspan="2" style="vertical-align:top"><p>30% (n = 76)</p></td><td colspan="2" style="vertical-align:top"><p>42% (n = 109)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Serum CRP change from baseline to Week&nbsp;6, median (mcg/mL)</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Overall<sup>&Dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>-0.5 (n = 147)</p></td><td colspan="2" style="vertical-align:top"><p>-0.9 (n = 220)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>GEMINI&nbsp;III Study</strong></p></td><td colspan="3" style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Clinical remission, Week&nbsp;6</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Overall<sup>&Dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>12% (n = 207)</p></td><td colspan="2" style="vertical-align:top"><p>19% (n = 209)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Failure<sup>&para;</sup></p></td><td colspan="3" style="vertical-align:top"><p>12% (n = 157)</p></td><td colspan="2" style="vertical-align:top"><p>15%<sup>&sect;</sup> (n = 158)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Na&iuml;ve</p></td><td colspan="3" style="vertical-align:top"><p>12% (n = 50)</p></td><td colspan="2" style="vertical-align:top"><p>31% (n = 51)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Clinical remission, Week&nbsp;10</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Overall</p></td><td colspan="3" style="vertical-align:top"><p>13% (n = 207)</p></td><td colspan="2" style="vertical-align:top"><p>29% (n = 209)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Failure<sup>&para;,&Dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>12% (n = 157)</p></td><td colspan="2" style="vertical-align:top"><p>27% (n = 158)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Na&iuml;ve</p></td><td colspan="3" style="vertical-align:top"><p>16% (n = 50)</p></td><td colspan="2" style="vertical-align:top"><p>35% (n = 51)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Sustained clinical remission<sup>#,</sup><sup>&para;</sup></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Overall</p></td><td colspan="3" style="vertical-align:top"><p>8% (n = 207)</p></td><td colspan="2" style="vertical-align:top"><p>15% (n = 209)</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Failure<sup>&para;,&Dagger;</sup></p></td><td colspan="3" style="vertical-align:top"><p>8% (n = 157)</p></td><td colspan="2" style="vertical-align:top"><p>12% (n = 158)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Na&iuml;ve</p></td><td colspan="3" style="vertical-align:top"><p>8% (n = 50)</p></td><td style="vertical-align:top"><p>26% (n = 51)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Enhanced clinical response, Week&nbsp;6<sup> </sup></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Overall^</p></td><td colspan="2" style="vertical-align:top"><p>23% (n = 207)</p></td><td colspan="3" style="vertical-align:top"><p>39% (n = 209)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Failure<sup>&Dagger;</sup></p></td><td colspan="2" style="vertical-align:top"><p>22% (n = 157)</p></td><td colspan="3" style="vertical-align:top"><p>39% (n = 158)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>TNF&alpha; Antagonist(s) Na&iuml;ve^</p></td><td colspan="2" style="vertical-align:top"><p>24% (n = 50)</p></td><td colspan="3" style="vertical-align:top"><p>39% (n = 51)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="7" style="vertical-align:top"><p>*p&lt;0.05</p><p><sup>&dagger;</sup>not statistically significant</p><p><sup>&Dagger;</sup>secondary endpoint to be viewed as exploratory by pre-specified statistical testing procedure</p><p><sup>&sect;</sup>not statistically significant, the other endpoints were therefore not tested statistically</p><p><sup>&para;</sup>n=157 for placebo and n=158 for vedolizumab</p><p><sup>#</sup>Sustained clinical remission: clinical remission at Weeks&nbsp;6 and&nbsp;10</p><p>^Exploratory Endpoint</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="4" style="vertical-align:top"><p>Table&nbsp;5. Efficacy Results for GEMINI&nbsp;II at Week&nbsp;52</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p>Placebo<br />N=153*</p></td><td rowspan="2" style="vertical-align:bottom"><p>Vedolizumab<br />Every 8 Weeks<br />N=154</p></td><td rowspan="2" style="vertical-align:bottom"><p>Vedolizumab<br />Every 4 Weeks<br />N=154</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Clinical remission</p></td><td><p>22%</p></td><td style="vertical-align:bottom"><p>39%<sup>&dagger;</sup></p></td><td style="vertical-align:bottom"><p>36%<sup>&Dagger;</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Enhanced clinical response</p></td><td><p>30%</p></td><td style="vertical-align:top"><p>44%<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>45%<sup>&Dagger;</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroid-free clinical remission<sup>&sect;</sup></p></td><td><p>16%</p></td><td style="vertical-align:bottom"><p>32%<sup>&Dagger;</sup></p></td><td style="vertical-align:bottom"><p>29%<sup>&Dagger;</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Durable clinical remission<sup>&para;</sup></p></td><td><p>14%</p></td><td style="vertical-align:bottom"><p>21%</p></td><td style="vertical-align:bottom"><p>16%</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*The placebo group includes those subjects who received vedolizumab at Week&nbsp;0 and Week&nbsp;2, and were randomised to receive placebo from Week&nbsp;6 through Week&nbsp;52.</p><p><sup>&dagger;</sup>p&lt;0.001</p><p><sup>&Dagger;</sup>p&lt;0.05</p><p><sup>&sect;</sup>Corticosteroid‑free clinical remission: Patients using oral corticosteroids at baseline who had discontinued corticosteroids beginning at Week&nbsp;6 and were in clinical remission at Week&nbsp;52. Patient numbers were n=82 for placebo, n=82 for vedolizumab every eight weeks, and n=80 for vedolizumab every four weeks</p><p><sup>&para;</sup>Durable clinical remission: Clinical remission at &ge;80% of study visits including final visit (Week&nbsp;52)</p><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>Exploratory analyses examined the effects of concomitant corticosteroids and immunomodulators on induction of remission with vedolizumab. Combination treatment, most notably with concomitant corticosteroids, appeared to be more effective in inducing remission in Crohn&rsquo;s disease than vedolizumab alone or with concomitant immunomodulators, which showed a smaller difference from placebo in the rate of remission. Clinical remission rate in GEMINI&nbsp;II at Week&nbsp;6 was 10% (difference from placebo 2%, 95% CI: -6, 10) when administered without corticosteroids compared to 20% (difference from placebo 14%, 95% CI: -1, 29) when administered with concomitant corticosteroids. In GEMINI&nbsp;III at Week&nbsp;6 and 10 the respective clinical remission rates were 18% (difference from placebo 3%, 95% CI: -7, 13) and 22% (difference from placebo 8%, 95% CI: -3, 19) when administered without corticosteroids compared to 20% (difference from placebo 11%, 95% CI: 2, 20) and 35% (difference from placebo 23%, 95% CI: 12, 33) respectively when administered with concomitant corticosteroids. These effects were seen whether or not immunomodulators were also concomitantly administered.</p><p>Exploratory analyses provide additional data on key subpopulations studied. In GEMINI&nbsp;II, approximately half of patients had previously failed TNF&alpha; antagonist therapy. Among these patients, 28% receiving vedolizumab every eight weeks, 27% receiving vedolizumab every four weeks, and 13% receiving placebo achieved clinical remission at Week&nbsp;52. Enhanced clinical response was achieved in 29%, 38%, 21%, respectively, and corticosteriod‑free clinical remission was achieved in 24%, 16%, 0%, respectively.</p><p>Patients who failed to demonstrate response at Week&nbsp;6 in GEMINI&nbsp;II were retained in the study and received vedolizumab every four weeks. Enhanced clinical response was observed at Week&nbsp;10 and Week&nbsp;14 for greater proportions of vedolizumab patients 16% and 22%, respectively, compared with placebo patients 7% and 12%, respectively. There was no clinically meaningful difference in clinical remission between treatment groups at these time points. Analyses of Week 52 clinical remission in patients who were non-responders at Week&nbsp;6 but achieved response at Week&nbsp;10 or Week&nbsp;14 indicate that non-responder CD patients may benefit from a dose of vedolizumab at Week&nbsp;10.</p><p>Patients who lost response to vedolizumab when treated every eight weeks in GEMINI&nbsp;II were allowed to enter an open‑label extension study and received vedolizumab every four weeks. In these patients, clinical remission was achieved in 23% of patients at Week&nbsp;28 and 32% of patients at Week&nbsp;52.</p><p>Patients who achieved a clinical response after receiving vedolizumab at Week&nbsp;0 and 2 and were then randomised to placebo (for 6 to 52 weeks) and lost response were allowed to enter the open‑label extension study and receive vedolizumab every four weeks. In these patients, clinical remission was achieved in 46% of patients by 28&nbsp;weeks and 41% of patients by 52&nbsp;weeks.</p><p>In this open-label extension study, clinical remission and clinical response were observed in patients for up to 196 weeks.</p><p>Exploratory analysis showed clinically meaningful improvements were observed for the vedolizumab every four weeks and every eight weeks groups in GEMINI&nbsp;II and the improvements were significantly greater as compared with the placebo group from baseline to Week&nbsp;52 on EQ‑5D and EQ‑5D VAS scores, total IBDQ score, and IBDQ subscales of bowel symptoms and systemic function.</p><p>Pouchitis&nbsp;<br />The efficacy and safety of intravenous vedolizumab for the treatment of adult patients with chronic pouchitis were demonstrated in a randomised, double-blind, placebo-controlled study evaluating efficacy at week 14 and week 34 (EARNEST). Enrolled patients had undergone proctocolectomy and ileal pouch anal anastomosis (IPAA) for ulcerative colitis at least one year prior to randomisation and had developed active chronic pouchitis (defined as antibiotic-dependent (recurrent) or antibiotic-refractory), with a baseline modified Pouchitis Disease Activity Index (mPDAI) score &ge; 5 and endoscopic subscore &ge; 2. All patients received concomitant antibiotic treatment with ciprofloxacin 500 mg twice daily from the start of treatment through week 4. Patients received additional courses of antibiotics during the study as needed, including for pouchitis flares.&nbsp;<br />Patients (n=102) were randomised (1:1) to receive either intravenous vedolizumab 300 mg or intravenous placebo at 0, 2 and 6 weeks, and every 8 weeks thereafter, until week 30. The primary endpoint was clinical remission (defined as an mPDAI score &lt; 5 and a reduction in total mPDAI score of &ge; 2 points from baseline) at week 14. Table 6 shows the results from the primary and secondary endpoints at week 14 and Table 7 shows the results from secondary endpoints at week 34.&nbsp;</p><p>Approximately two-thirds of patients had received prior (for UC or pouchitis) TNF &alpha; antagonist therapy (33 in vedolizumab and 31 in placebo treatment groups). Among these patients, 33.3% in the vedolizumab group achieved clinical remission at W14 compared with 9.7% in the placebo group.&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with vedolizumab in one or more subsets of the paediatric population in ulcerative colitis, Crohn&rsquo;s disease and Pouchitis disease (see section&nbsp;4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The single and multiple dose pharmacokinetics of vedolizumab have been studied in healthy subjects and in patients with moderate to severely active ulcerative colitis or Crohn&rsquo;s disease.&nbsp;The pharmacokinetics of vedolizumab has not been studied in patients with pouchitis but is expected to be similar to that in patients with moderate to severely active ulcerative colitis or Crohn&rsquo;s disease.&nbsp;</p><p>In patients administered 300&nbsp;mg vedolizumab as a 30&nbsp;minute intravenous infusion on Weeks&nbsp;0 and 2, mean serum trough concentrations at Week&nbsp;6 were 27.9&nbsp;mcg/ml (SD&nbsp;&plusmn;&nbsp;15.51) in ulcerative colitis and 26.8&nbsp;mcg/ml (SD&nbsp;&plusmn;&nbsp;17.45) in Crohn&rsquo;s disease. Starting at Week&nbsp;6, patients received 300&nbsp;mg vedolizumab every eight or four weeks. In patients with ulcerative colitis, mean steady‑state serum trough concentrations were 11.2&nbsp;mcg/ml (SD&nbsp;&plusmn;&nbsp;7.24) and 38.3&nbsp;mcg/ml (SD&nbsp;&plusmn;&nbsp;24.43), respectively. In patients with Crohn&#39;s disease mean steady‑state serum trough concentrations were 13.0&nbsp;mcg/ml (SD&nbsp;&plusmn;&nbsp;9.08) and 34.8&nbsp;mcg/ml (SD&nbsp;&plusmn;&nbsp;22.55), respectively.</p><p><u>&nbsp;Distribution</u></p><p>Population pharmacokinetic analyses indicate that the distribution volume of vedolizumab is approximately 5&nbsp;litres. The plasma protein binding of vedolizumab has not been evaluated. Vedolizumab is a therapeutic monoclonal antibody and is not expected to bind to plasma proteins.</p><p>Vedolizumab does not pass the blood brain barrier after intravenous administration. Vedolizumab 450&nbsp;mg administered intravenously was not detected in the cerebrospinal fluid of healthy subjects.</p><p><u>Elimination</u><br />Population pharmacokinetic analyses based on intravenous and subcutaneous data indicate that the clearance of vedolizumab &nbsp;is approximately 0. 162 L/day (through linear elimination pathway) and the serum half-life &nbsp;is &nbsp;26 days. The exact elimination route of vedolizumab is not known. Population pharmacokinetic analyses suggest that while low albumin, higher body weight and prior treatment with anti-TNF drugs may increase vedolizumab clearance, the magnitude of their effects is not considered to be clinically relevant.&nbsp;<br /><u>Linearity</u></p><p>Vedolizumab exhibited linear pharmacokinetics at serum concentrations greater than 1&nbsp;mcg/ml.</p><p><u>Special populations</u></p><p>Age does not impact the vedolizumab clearance in ulcerative colitis and Crohn&rsquo;s disease patients based on the population pharmacokinetic analyses. Age is not expected to impact the vedolizumab clearance in patients with pouchitis. No formal studies have been conducted to examine the effects of either renal or hepatic impairment on the pharmacokinetics of vedolizumab.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, as well as reproductive and development toxicology studies.</p><p>Long‑term animal studies with vedolizumab to assess its carcinogenic potential have not been conducted because pharmacologically responsive models to monoclonal antibodies do not exist. In a pharmacologically responsive species (cynomolgus monkeys), there was no evidence of cellular hyperplasia or systemic immunomodulation that could potentially be associated with oncogenesis in 13‑ and 26‑week toxicology studies. Furthermore, no effects were found of vedolizumab on the proliferative rate or cytotoxicity of a human tumour cell line expressing the &alpha;<sub>4</sub>&beta;<sub>7</sub> integrin in vitro.</p><p>No specific fertility studies in animals have been performed with vedolizumab. No definitive conclusion can be drawn on the male reproductive organs in cynomolgus monkey repeated dose toxicity study, but given the lack of binding of vedolizumab to male reproductive tissue in monkey and human, and the intact male fertility observed in &beta;7 integrin‑knockout mice, it is not expected that vedolizumab will affect male fertility.</p><p>Administration of vedolizumab to pregnant cynomolgus monkeys during most of gestation resulted in no evidence of effects on teratogenicity, prenatal or postnatal development in infants up to 6&nbsp;months of age. Low levels (&lt;300&nbsp;mcg/L) of vedolizumab were detected on post‑partum Day&nbsp;28 in the milk of 3 of 11&nbsp;cynomolgus monkeys treated 100&nbsp;mg/kg of vedolizumab dosed every 2&nbsp;weeks and not in any animals that received 10&nbsp;mg/kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L‑histidine</p><p>L‑histidine monohydrochloride</p><p>L‑arginine hydrochloride</p><p>sucrose</p><p>polysorbate 80</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
In-use stability of the reconstituted solution in the vial has been demonstrated for 8 hours at 2°C-8°C.
In-use stability of the diluted solution in 0.9% sodium chloride solution in infusion bag has been demonstrated for 12 hours at 20°C-25°C or 24 hours at 2°C-8°C. 
The combined in-use stability of Entyvio in the vial and infusion bag with 0.9% sodium chloride is a total of 12 hours at 20°C-25°C or 24 hours at 2°C-8°C. A 24 hour period may include up to 8 hours at 2°C-8°C for reconstituted solution in the vial and up to 12 hours at 20°C-25°C for diluted solution in the infusion bag but the infusion bag must be stored in the refrigerator (2°C-8°C) for the rest of the 24 hour period.
Do not freeze the reconstituted solution in the vial or the diluted solution in the infusion bag.

	Storage Condition
	Refrigerator (2°C- 8°C)	20°C-25°C
Reconstituted solution in the vial	8 hours	Do not hold1
Diluted solution in 0.9% sodium chloride solution	24	hours2,3	12 hours2
1 Up to 30 minutes are allowed for reconstitution
2 This time assumes the reconstituted solution is immediately diluted in the 0.9% sodium chloride solution and held in the infusion bag only. Any time that the reconstituted solution was held in the vial should be subtracted from the time the solution may be held in the infusion bag.
3 This period may include up to 12 hours at 20°C-25°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C‑8&deg;C). Keep the vial in the outer carton in order to protect from light.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Entyvio 300&nbsp;mg powder for concentrate for solution for infusion in Type&nbsp;1&nbsp;glass vial (20&nbsp;ml) fitted with rubber stopper and aluminium crimp protected by a plastic cap.</p><p>Each pack contains 1&nbsp;vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Instructions for reconstitution and infusion</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use aseptic technique when preparing Entyvio solution for intravenous infusion.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove flip‑off cap from the vial and wipe with alcohol swab. Reconstitute vedolizumab with 4.8&nbsp;ml of sterile water for injection at room temperature (20&deg;C - 25&deg;C), using a syringe with a 21‑25&nbsp;gauge needle.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the needle into the vial through the centre of the stopper and direct the stream of liquid to the wall of the vial to avoid excessive foaming.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the vial for at least 15&nbsp;seconds. Do not vigorously shake or invert.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Let the vial sit for up to 20&nbsp;minutes at room temperature (20&deg;C - 25&deg;C), to allow for reconstitution and for any foam to settle; the vial can be swirled and inspected for dissolution during this time. If not fully dissolved after 20&nbsp;minutes, allow another 10&nbsp;minutes for dissolution.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the reconstituted solution visually for particulate matter and discoloration prior to dilution. Solution should be clear or opalescent, colourless to light yellow and free of visible particulates. Reconstituted solution with uncharacteristic colour or containing particulates must not be administered.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once dissolved, gently invert vial 3&nbsp;times.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immediately withdraw 5&nbsp;ml (300&nbsp;mg) of reconstituted Entyvio using a syringe with a 21‑25&nbsp;gauge needle.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add the 5&nbsp;ml (300&nbsp;mg) of reconstituted Entyvio to 250&nbsp;ml of sterile 0.9% sodium chloride solution, and gently mix the infusion bag (5&nbsp;ml of 0.9% sodium chloride solution does not have to be withdrawn from the infusion bag prior to adding Entyvio). Do not add other medicinal products to the prepared infusion solution or intravenous infusion set. Administer the infusion solution over 30&nbsp;minutes (see section 4.2).</p><p>Once reconstituted, the infusion solution should be used as soon as possible.</p><p>Do not store any unused portion of the reconstituted solution or infusion solution for reuse.</p><p>Each vial is for single-use only.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Takeda Pharma A/S 
Delta Park 45 
2665 Vallensbaek Strand 
Denmark 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/jpg; base64,/9j/4QAYRXhpZgAASUkqAAgAAAAAAAAAAAAAAP/sABFEdWNreQABAAQAAABkAAD/4QOPaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLwA8P3hwYWNrZXQgYmVnaW49Iu&#x2B;7vyIgaWQ9Ilc1TTBNcENlaGlIenJlU3pOVGN6a2M5ZCI/PiA8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIiB4OnhtcHRrPSJBZG9iZSBYTVAgQ29yZSA1LjYtYzExMSA3OS4xNTgzMjUsIDIwMTUvMDkvMTAtMDE6MTA6MjAgICAgICAgICI&#x2B;IDxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI&#x2B;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&#x2B;IDwvcmRmOkRlc2NyaXB0aW9uPiA8L3JkZjpSREY&#x2B;IDwveDp4bXBtZXRhPiA8P3hwYWNrZXQgZW5kPSJyIj8&#x2B;/&#x2B;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&#x2B;GBIJCMBORRE/ghC4Fack0NEFj4ZfKJGJLJzRAQz/MQ&#x2B;IxIN&#x2B;SlCE&#x2B;EUhnxjlww2olw3N1KCK8F&#x2B;yxwJ11dD05rnmg1SPEYlaIecEGXM/wAMSfKLqkCRH5RyQZxxos5dHSQVCfifsgwWoUt5eapIKkdCnmUOJnspwJclRboY5cVjlHz44tOan4XVdAWGcR8MT8Vl2q6LpSPyy&#x2B;AguJwbpZxVV0k8o5&#x2B;J5ariBbxV5Qa1UhiwVDnxh8kwOs3NEXQOWefP44nOi0ATZSAeMF45ZcBh15LLGyrojqkV&#x2B;HmRnibTVJJo6np5fjrD78CBUc0XTwH4ZeIxJZrsyjpGoX7QGpEfnhChSqkNOSfDWC54EBndT05cMz&#x2B;XjiWrk/6lQYVHj92emLxU4BY8FIYmafeDwgmFDm2qktB&#x2B;y/wwKY6Kug6Jrw&#x2B;UOGFig0U9AMfxgnkMaYe9lr/abIw3xgMxl/LFqBUFBFHU9PxzyiRyOiYGYMoCnuVBhUZZZaD8sTEeKbCnFT0mGSnL7Bc0xMwrZBDU1UdEOHH5&#x2B;ZhiYe37lcwi6F&#x2B;UR/HRMZU5odFQZmFAOQGv2TEl&#x2B;anpGaaQGsFXkuJI1dT0nUhfDmdEiuJVBZT0CHyJjriQbuo6UiB4cPuJzwrINeSosB8NUh98EwJFDzUtaicctILlyU4lHgSpLNczE6cFhDEFoEimilAdE&#x2B;2aRw11VXqPAIujh4qnPjDEp2LaqejiFJUZ5cwkcSDy0VBnhrnwPiIHEtF&#x2B;mqMNC&#x2B;P8tMSqlgia2JICxjkMvgY4vktVR9OWmfiMk8UTEpMDQeQhDMnhmsMSyx6nVFsRyj8BHkvDPEtOhLDHMQTyX&#x2B;OJVkJZygPIk&#x2B;f4YkMAX1KFAQhh8eOeJjdBe4dAWQECeev5YlCXxZQ0ZgRRMxwyTjxxKD6okIUZiPAgRywK5sgew5kAnwU&#x2B;S64fmpxYullnihQ/dpniUGDl6KOhv/5PA8U&#x2B;CeeF1dQVsTkRw/kI64tW0XEobmc1/gc/hjRiPepz7kSJBclTx/nivdIZWkwQ4BEKfd8MDfEoNVauZ9XgRx1yQLjJsFckwNTzAPHMKNEJywJqaaJrWxiMsxwTJTiUxApZPa0kL8D5cF54rKcg1Uhp4Q&#x2B;fjrCGG5bVbApS4UdBzgi&#x2B;A/PF0qcVAuyro5ZDh9x8DhJDUWSeKAtz5JA/kRkDg8EkF30U9Omfn9hnhDXlZQI&#x2B;lV05hOenD4YD&#x2B;Ki4UBsSsCYHMIE18cFW5KkXAUkefwj&#x2B;ZGFUWYqSEX7vhwzxX5KqwACnpiIjmOH54QGokmmqLoH8eCZcf1YSCBVZeiroihXNPHly&#x2B;7GeZUKFiq6eAT&#x2B;H54GZJ4m6noACcIY0&#x2B;tEit2ZR0qdS3jl/PB4oFAxRhoB5aef5ADEWdZJB0qi6YCCrEjPEA9EgCxsq6cynD71/HAyDwUFpBgIgEAc/xBwmtleKoNJAgoP2Kchh6TdNi5uqSCmEeeY1TFQ0ZJFWCIBDnDjxP8caiHLqNQ5CLpUJ8efD4YCC/NZdioDDrnE8vmscFeFE9Qr7FQGmIQmGR4w0VVC40KjnwWyWDhMa06oifzBwgE3ZYPCrqUblADSCx8OWMm9NFWuiAWI8AiDPL44TKrioCg7shIggC/isYw0wG3ArTUawUgBPhEr/AD0xmuqyQWRdOqwgPsnDAs3VEBAhVfxy&#x2B;OHwWjdmVIF4J&#x2B;esYEJgWgDEtxRNimWupXnww2WqAOpTM5&#x2B;P8o4FmTdNLKoAIkU8Tp95w81dNHN1Gp0AVfDJAmBYvxdShK8PjHCtdPvUoMtQmiZ4ltmqFPDLTw5w1KYvFZNC4UhvDLPz/GOL5KLNxKlEKeP8kyxURfxKoNB/T8M/sScSWL19vemBiISvPLOH54taKr9UdUQAXiSUT5csJtzWm0KY0KB9vimWBNUXSAYKCi8FHHhjXTWlkIw3XkeGfPRMBYeKgh6QijxVNTGOBKFwMeAz&#x2B;EIRyxO6AUstUKcvtriRy0SXAiEclMVIIzOixwswdJ&#x2B;aKW3ywKFkbpYy&#x2B;fiqQy/niP4KdAQePkkeBTFoghLcIZFYjPX8Ya4kEUrZ0PS7jovzz&#x2B;GJwjyLHFPOHh5LrjVrrHzVNi4nKOXx0wlSMpDz&#x2B;44n4KZirV/3/HRTjJOilbhv1Kcvly4knEemzVUG1TWtyh4/NMslwM11JzWAwBKKpA&#x2B;7nhNCtAtRPDYJkE1gfPBT3q/FSWxy4jXnlAYg&#x2B;l0gH8FBb8E8PkmEhjSrqIaTaqiOWmWhX48MQAH1Iua8Utoift5L44aMkuQxZnRdOUB9vywAF2QzKulMsz8kEEHDGUX9ygDwKwJ5fD4Y0LM9FCvuU9EVTIJ4Z/PAz&#x2B;C0DpopIKwTx4cE88NDRAoFKLAjx&#x2B;GY8cQDmlksWdEByhkmS58shhkoj4qumBEMlziU/PEIuHKTSpFVSLlAr/NEGUcTBuSSxQOexpi9rVJAJIAJ4Bc8BNGWRE6qjMly2lz3sa1o6nPcWhrQIkklyAAYCVsir6q0l3S2zgXya6lmta7ocZc5kwB6A9KtUKhGNHpsLI&#x2B;3KJ8wYn3J4rKUh0wT5XSxS5/UA0DUkmAAxl9XWTE2CGVX0k&#x2B;X6smpkzpRLgJkp7ZjCRmA5qgplgBBCTAj6ndBIuVDUvnMkVcie&#x2B;nPTPbKmte6U7g9rT1McgiDiSccosZBgUmRfLTUzJrKe4U090g9M5suY13pOBTpehIa6BhhFKqOCcWMwwNk&#x2B;pudvpJYm1dVJkSs/VnuEuWerIdTkbHTFrRUYTJ6YA&#x2B;6qCVd7ZOcGyKyTOc5OlslwmuJORRioE1w9XT71v7c4/UGU1F4tlHNlyamslSHziGyxNWW17jkxj3AMc7kCuF604LH2pyDxFkbLtbps0yZVU2fNCNLJDXT&#x2B;g//AJ0ymuEokHVMDh2L&#x2B;9X2yGcIJN4ts&#x2B;sqaGTP9SrpWddTKbLmOEoDjMDfTBC5Kq4uoXWjjlGIkX6ZGnNLk3&#x2B;0TvU9Kq6zJf6cz/amt6XAElqOZ9ScoYXYIMJAqW321zagUkqbNmVJb1mUynnud0nmGdMRzxl09JHmI8qvmVkl6gS5wQIr5MyWB49YbFcFX5LIiRQEoZtwppP0vMxYJ0SXvLTzDASAV8MbDNzV0glBLulLNnvkj9w2bLb1kPppzGFuX0zXsEtzjwBwW4VWekMol3akmF7Wiob0PLXNm0s6Q4lurBNa0vYdHCBwFgbhQiVTLpSTBPez904U0ZhNFUNVIkSAWD9z/wDw&#x2B;qOIPTmmIIPJUy60j2h4E8Ne0OAmU02VMTL6pcxrZjXciFxMxbgljfVMpblIqpfrSpdVLYXOY0VNLNpJhLShLZdQyW8sOjkQjI4rLRAN1P8AcpP7oUnp1Pr&#x2B;kZytppxkdAKJ&#x2B;56PQMz/AKerq5YHGtFmttEP90kGodSenVie2WJp/wDhz/R6CU&#x2B;mqLP273r/AEhxIGmJxco6Xv7kDbpTddRLDarro5bZk5rqOoYrHDqa6Q50sNqimYll2LR6MVEV8VaN3LbDLExv7x7To2gqusxQgSjLExR4QxrpKW11WTp7hT1UsTpDnTWOzUdJaYfQ4H6muBEQYjASx6SwKQ&#x2B;tuKuBUMKwLQqDy1WOeBxxCfmrgOBQgA6cAo15YVggmipYDkiH8zgQGc2dkwHNAnyBPIj7QxCiovZEqxhEeaZromNMwfVaA6QynhEQWP3Ya6UUTpqjDRDT8Cfxy44hXgl9NU3KBWEDy&#x2B;OX5YgwNUqk5pDgYwj9uGFg1boVZ5D&#x2B;JRcycoYhfqKeSAgcD9Xz4HPjgLEor70JBiNEgqDxwEcVH8UsjMqFKkkRHIYhbmVWPUbMql5gJ9hHxxM6kwjgIkxXLzxV1UOCEgEQMFAOhHhgt4KseSQ5uvHLmOXE4W4XRfxCrp8P0/jnidL&#x2B;CxBSPyMFgEGh5YVxNqiloCSip888TBkKVWJEE5w0jh0UUh480XTGb60TogACpxjwhoFJwAEoTgzIn&#x2B;eacNTiLJNDRNYFgQYnhD5JDD9RYMmJIPJXIaEH28BomNSagQHBpdUAugU5fBfywOb6pIAYFR0nyKw4KYwzj8MXm9ygQDzUFsUPh/DIwwUdkE1pZT0DIcOa80VVOCQZCHoTLy8fuxoFrarUiCgLSV/hzgqoMZSKiijoQLDnE&#x2B;PKOBTkeClozgUy&#x2B;ZzHI4jVBckcWUoiLyRMtYCPPCQqV2F1JEVSP2XzTCJEUFlB7hUiDhlwPEeOEdJFTVaBJKqJBIUBNOHOEPjiMqcktSt0twJ5BM/x&#x2B;OOGU/8ATdKW2Q96kMeQF6nS2OcGoFiW5HxhjIlL6gyloL3bkuj/AN1V7Zq22&#x2B;XUvoWbel1tiutRWSnTOll8ucupoG09FTsAVsqVUT3gRIJhhqZNVr/50stCUol4kg8iQmMpLpJm1YlWer/a0VumzaSSDt8yLhW&#x2B;qTKt8hsq2U06lexv0h7nCUAYsLo4jIjihybuT8VlJFpuM&#x2B;gpJNRUT7dPfNl1dRIZLtFY57XtV9qqJZs1PTTKeUcnsYJrj/WmMCUj4Py/ch9VaUlFuSXXVXqUd0bRtkl9HK/f2f0ZhpmvdLlNp6awyaiifXuIa4erNawfUDmMa6mGvT7ck34qyZRbsqKFsqTQVdHWXGtlG4CRd7PJmWOlmTOqpmUtbSbSfLuE&#x2B;lYjWsm0zXzAYzWn6sZBYU&#x2B;f&#x2B;CEqrot9CXf6qRaKNwk3Cjt&#x2B;26GZfzSMrrQzoZW3&#x2B;7XB216t9Jc3q57KRvqtcWoZzVUJkQOoe3t7FRLq5n2651d3mSZ9JIqbNTbc6KORcb5KL7hf/We9ja2xSLbMfKkhgYHVjqqYjXI2QE6jqMpX4JEpCsSQeSsKqh3vc9q26nZIsdu3G2422ZcaPb24rtarPSUsuetfLl3GgpZ90rJUuR&#x2B;mR00vrug6YwYeqUhQeZRJlUuZLLVNr3YJ99fT04p6YtlyrEH3m5z5dQxtOQaiueaOjfZHvqT0lofcHBiP9Qn6MBcRMvy&#x2B;3tqjxsgpbXu6XW7ZFeKemoaeyVEq&#x2B;lu4b5cHOvM2a0yZVFTupLYL3KZLX/5VS&#x2B;W9kA2XmcIJJHDWqR4LL0ttv9bRtkbiZLttfLuU6bTDbFddOiptcl7f2TqqbUypNQ6onMU1EkB0tpgHOwvKrg30QsJOse&#x2B;506/9VbaHy5ddInbRoJE3cludMp2SpYmf8rrpNbNmP6prpjhIp5QkuAasY4y5Z&#x2B;fs6vBXbLLuCdXNDp0kWyqoptPfW0lz3K2ukTejqkTLEyTcZdJa53rD66jp9csyOIE6Ake9CuLJaLwJNJUX6okTbjTSqyldJsdTuD&#x2B;0mmmzOilfO/uVzq5lfXNpGtL501peJpc5hAOIEuHP7vmnVY2qtd6s7r9WOuNppLJTWj1NvVN9uN9E2junpuFbVbmuVTdJTHWdj3D0zLmSpksf1goQOWMhfh&#x2B;99PekP7lZ7dkvrm7Xudl3Pty/Wj/e/vlVQbivd&#x2B;bWVDZLgW7brhui5U9WJdaR1y641aS4QchwRbq0b4v4FyEaqJW0N2ssG4LdWXm2zrvVX6fdNvT5v/KpVDQ0BrpNVSUlymStw024Jk0SWvY9lPWSqQEgCT6YdLIaUNC/NSy0qwXtm4514Y6z0lHXWgyLrTtn3utrJ97kS/SoKylM6vk2eht0uXCbLl0YnzDEzlwAkSdSxUvam6pFgutplV9hl1MyicbJXibuia&#x2B;VdjUOqQ&#x2B;8Tp18mXOptXW5PTl1LXBqtBDUbic9JjxUrl20Lk&#x2B;fWS5xtFTZrxaKOkvNGajcbK2bc6cD1qmkqZ95rKKjoHuAMttPT09S0hXznnJLNS7IoLJY2puSfRWORV3GwfubVfDNq3UsvdlNTzNtiX6TaKkZL3T/ALt&#x2B;ZLT/AOTW/uqYkL6AMQF2A9v8/j4Jaq2Kx2a5WmrusqbVW&#x2B;fZJ0yTOs8qVKuv93pphYRXC6Vddda&#x2B;iq5cyY0GSKeRShgUODz9WKo1qqq2VIfcCRDjyUYvBTKgwZmK&#x2B;IKrlFIHhisGFEIuhSron8PHOCYmctxSqEuEPM/dmDjVGarfJVdU5jejLMGIghHAHzxyAuH0VdPHS5CD9y8EhjT/AAWDSSgcGlc&#x2B;A1hEJFcaDqD9TJgcVAT8IJFc1xFmA1SxI96YCh0KQ458NMIJiWN1G4CIInIl34HLQDGVoo2mGcUjnGHljTjpbUJUw&#x2B;334WfxRX3Kua/f9lxRiD7kupKJlEhc/nictQUKPmlmKaLogOSckGMlKUSU6ctf5E4HPuWCA9bKWfq5xJjyEOGEckj8E9IxWMM1yyxpgB4pSzBQBqqFc&#x2B;K4yeGieaW9CM8xoMvv4YjZYcvQIPq4f0r55piZapyWFP6c8xEpx08vnhNKlcN1TDwGakcox&#x2B;OIngrxTSV8gBBBqvmQmGpNSSlKME8HQ1EYQ0xh1aKWAjgmniQv88aiWKSHtdNDVzguekVQfPARwRWxT2gqg8Tyyy0hiF1CxTSFUAZ6fDPxTG78qqA4nRTADgPsq6qUxl46u6pckHTHgFAPM6oMsRkS3JTlEVGreHGKGHFPuxO3iyECZJE8I4zqnkVBj4FRHljRL2oGUwZ9VRCCGX3Z/djJFaWTGtFCIsP5jTzGERN2sk83dV9j8FhripqGCyGdlHl&#x2B;eJn8Fq9HDKoJ845wzjiaLAupulUGk8Q0AqkSp4c8RZaArd0XQQMoZkqq&#x2B;HPHEZRJYGq0&#x2B;ijpACJBPEEnPPAY6/mUV4Z3k7KP7rP2xcLZv7dnbvcO1bgyqpLvtmpIkV9G2c2odbbtb3uFPVyvXYrXkFzQ5wyOOPyvV2CH0Cv5faiovU81ncre1/36&#x2B;VOlTqGxtZK2zs2gmyA4yKl23rO6VLu9bLnH1PWqnE9RQACGNEghjX8B7lPRa3aOy&#x2B;8bZV3SouPfLf265NwcDS0l6NJb5FjkAzEpbXLszJbWyCyYAOoKOluM0dySQjwV5eOyV0rtmzNp2bvP3d2rU1V1F0rdyUO55l5vE0NlmX/aaSpvEt8y1WRx&#x2B;p0iSgcTE4pMR0wlKJ8Umq13fvtxd3D2bbdkXDuZuuw2ykdT/wB1r9tU1FS3vc0qnYGFl5uk6Z&#x2B;4cKiYsyZ0ITNIOgxAuwkSyNGWz13Y2jn1mzxa9&#x2B;b3sm2NmWyitdHsGRWSa7Z11l2&#x2B;QZEmpvtFV/8AyrjVzifUmPdM&#x2B;qYOrERGXFxpp4pZX9N2aopO/Lfv9&#x2B;895Sau0ymyaXbFirxtvZtWWqhvlmoHOZeypiJ2YCZYQIkubvYMAmy1Pantq2vtC&#x2B;9zt20W8N9V&#x2B;8&#x2B;6lJX0N13Xcro2dcLBTXKZNm1I2xS9RobdNc57Gtf0rLZKlgfpwgRcyrUezLNOavNte3&#x2B;k2Z28k9vNqdwN50NM671l3u247tKtu5Ny3aorIBrq269Yt4pP/pOkAEYWiPICw4sHT0gBuHNZXYnYjbuwrw2/U1&#x2B;3DuG6kTDPrtzTm3K4TZ8yU6Ualla&#x2B;cX0bml/UGy29IITLGItG34qH4rC7R9vNLsGo3rM2v3T7my5W/DPdd2X&#x2B;40m6aqhdUNnte6wXK7ddVaOgVDugy/0lDmBjUBCId5VvZVPerCh9ruzqHtVuTtJI3p3MNp3XdW3a77lmbpqXbwdMY9j20dJdjML6SgJaVYwheo4R0wDRJMX8UU1V9uT2xdvNzbL2vsV9331YKPano/tL/trdNfat13QypDqdxvd6lzjOrmz2zC5wOb0OgxFpB2YXpdLD3K&#x2B;3j7dNjbzvOxr1U3je&#x2B;36nYX7YW6RtXc1daKW8tpnS3SzuWXLmgXWY700c58SCeOMERNZP1Czft4qdgstuPslaNz7wqt5XHe/ckzqqWJI2z/yefM2bRsDQ0G3WFxZIpnCJDlXqJOuAsS5fw0&#x2B;Cgz1stb2l7Yu3Oz9r9w9n0l57i3ezdzpD6bc7Nw7zuV1qKaS/1Opm3ZtRMmGyh3qGEtAgHDDoY6LRHA0SbD7V&#x2B;1&#x2B;2&#x2B;3B7S2at3hTbFc2pY&#x2B;kN8mOvJl1jg6pbL3I1zLnTumEfqYQ5umIdMY9AB6eCzyXr&#x2B;wNhbb7Z7Wt&#x2B;ztqMucux2t099K28Xeuvtwa6oe180zbjcZk6rmt6mjpBcQ0ZYiQ9LK8VuaqYa8c&#x2B;aL/LAyFSmHwiAOHnz88SlMcl8tRzXPEG96fBQ2JiQqouiH7zjRMealIQZoiII8k154y9XQphHLTM/DFR62SFMIIghnp9jjQY1Jqqio5wT9I1X48MaeJFqBT8UbTBOfLLM5&#x2B;GONiG4qsmAj8hDiv3Y5A9gyq6qHDoIgCHfAO481TG4S6hyVdEOScSuh58scg/BFBR0WRivkRprHCQxfRLsKJgcDoRkYHMEajRMF2QBqbo2nxjnw8fDELqajIgTqug5pqTyxNUapOnBGqxHDJVSGXww0N0l1QOp8&#x2B;emEM3NBVEgAZklQBoMRlxFFVQkwgIiHL7Qxm48FNVyUojOMOKccoajEwNAi/ipYCDlqVXwz88aZgynF04xyjl9vLEQl/ihITMiIgPvzxkhqKBcsEkpzRQf4eBwV96NVEf9On8OnLLC3yQ3Pl/isFEqvH58cJquOwRMMUOcctBp4YuSb&#x2B;KM5wKAFdYhIk4qkM9VHioIUgIsI&#x2B;PPAwZWlUxoGhHx84CAjhAHt8kXTGhU5cFQJFIxRcRrU2WiLFPYgyXjBYZiONM1XYKMXDm6MLEaLCAEPLFIG/FBDKiNEgfPWECeJxkM/SbKobqCgjkhQRPmOGAEjmyEJ5iKkFPjrqpwyDBzcqYqCqacIRKfMjPljLEB1C6g8OH2jxIxX8FIV&#x2B;B5fhywtroq4VLqsPD79cQHwUUJchIXy0&#x2B;7A9HC04A5qi5ATn4cNclwg60QGetkIUwHmv888BmwrZcotVGD0hBBuXimpzxwmbsnxRF3H7lB8c1wAgEh6lQQ9XDJfyWBSC4iQKXU2mqDrVfuCx5HTBWS108VRJgsBw&#x2B;ekYYys&#x2B;UFqoS7XSK6kjVcSBXxVL4afbliZTaaqF4ZL8eGeeI0oov70ILooeOScIaArio/JVlOZ5nROETiurRkKlUWJ1SPhrhqRyClHXHJQMwE4cUMMJs5t&#x2B;KtHVF5GiA/njKtEJcefEEcvgnliSAbhMimSR45LlkBiQCoU6x5p/IQOJykB7KVd9ssvji0QykF2R8ANSYeJSAxK8bKC7NSsY6RXyhiSPxVdRiDp4/eiA4izqZ2RAoi6Q&#x2B;KrCBjiuplHUcuMUHL4AHE&#x2B;irBSsDpA5p&#x2B;OuJVPcq6inEIIeaZ5YkNVlQPDw8cRVyU9UMx&#x2B;Xjyxaq1VFx5xECAIFfkOOLkhSDqvLkIIvjDEUo2mBgRwOaL8FjiQiB/npDPE73SXRtPMlQg&#x2B;yHGnkzaJejInEOBBMECqDpqDmI45YF4q0UMcqtcnU0ofwOeoxyCyCNRdNB4xH5ZjM8cBDHmsl2Y8UQcAVyBgBqU4Kc440T/poy1X3pzSDyPHL7HA4V80SqF4LHhxSGg1wClFAF&#x2B;SYDAHmc/LGh&#x2B;Ci7qk01j8sIH5bq&#x2B;SAldAUUcdR4HGTdWipeklfAGMfhBcQpQoLm9ktxJMTDiAfhwxpifAI1cBS1ARD7Za6LhLBINEwqTHJERU0GmZzxgpoqRQpKopVQfDI4Wo6jwGqUSMhFTpD56ffi1YoVR&#x2B;X2OXDD7e1FOFgtPGJ5BUwariVMzgVzhz4ZYm1KTzVEqRD7HniJLNoiiPyKBAoiPMJhALUupnTGpDXLRScaYGouFAkJwOWUcvhgLkJNS4dMCtAgq/pQofPlhZrVom4oUYzgEKHUlF0&#x2B;OMGkhxQ3zVE5qMh9&#x2B;acsTm5U6FxCcD/T&#x2B;a88VDXUoajqEzHAfjxgqDFISsLKQxHI6cPziMZsEjp1QrHNQdefzwgfJGtFWvFRwhr&#x2B;eNANLVlICcgkVgFJSPAgYL04oUEICfDXXgMYWqA1QHhkV&#x2B;7M/AY07eK1EVrZErWqAh6lJTUpqmOsZGV1ti7aqi7kEB/UvyGq4FuvJD1BSFgOQRfE6nEx96yXCnqgggnPzUDxwJAJLlQqmJ/hyw/NQAs6pIeH3ZfCOJ/gsvobIYRiOYh881OBCoOAOnPwPFcRdKgOCkk/ip8cSFPVFMjid1IS4ZjMiOgh554vFNFQQmPmT4/HI4nUtO7gdxdr9tLGL/uiuZRUU2eaOlBE4vqqsMMxsqW2npqqY1oaFe/oRgicdTf9w23btuM&#x2B;5JGMlg2p4ar2f0l6Q71627qe09jx9e4jDrkSwEYOxJ6pRHgHcrmQe&#x2B;btTMtk&#x2B;5Utj3jcP272S6qkt9qrKipD/VcybLpwbfLl1DhIaZ0vqMv1ZeSHHrn/AHr2wxJGLOTE1AFfC3v0dfZZ/wBtHrLHuY7fNve244TrCcsgAIa5HWSPMeggdXTLiti237str7pn7aZZ9m7mNJumppqC21NZUU1LNbXVM57WU1TSftXuldNLLM4u6&#x2B;npgI41g9Y7Hc5Ywx4MsessCSL8Gb3vwXT7t/b933sW13W43nctlLJs4HJOMIyI6AB5oyMg/mPQzO9WZdT/AL5gLh0OcihQ4ISFUiBUY9hG9xs4iSviX9NymspAcks3BiRkOJJJPS8fFC1SYDGZb&#x2B;IvCXxC5I9smT9cR7ks3WSyLqachOfU1Y/&#x2B;3GJd1xRNcch8Fyx7Nnn9OSD&#x2B;9WtZuSioaOtr58ucynoKOprp/wBTOr0KSS&#x2B;onIoA6hLllMccu77WIJImwBK5cPpze7nPj22OUPu5ckYRveZER&#x2B;JC5su/vJ7R2GVbam627fEiReGzX211LtybXPqGyJTZtQ18uQ8Pp6mS49JlvQnMFMeKyese04gOuOcdVmi/ysy&#x2B;t7X&#x2B;3X17vZ5cW1z9rlLD9fVuOgBywYyDSiRUEeDOqpfel2CqH0Mibf7rRV9dMkgUFVZ6uRUU7ag/TNq3VMqklyZcpkZkSBk0uONR9Y9jMhjlLIJnTpNH4mltV1s39vH6m48eTLiw7XJt8YPmjmiRIj8sBEyJJNI/iwXSdn3BZtzW2lvW37jIutqrWl1LXU3qCTODHFry31GscC0wMPjj2LDmw7nEM&#x2B;CQlilY/wCa&#x2B;O927P3LsW/ydr7xhnt&#x2B;44iOuEmeLhxYkV8VlARAJHjp545V48U1opJCgmIK65CHCOJ0OqULnDzPjE5xCYuSqk80QCDhn5DzyxJtSiqB8xkTlHhgRzKorCPDxPFePywoVKRrDWOkADz44EhED/I5&#x2B;KYeaTS91QPDlrx14jLFdOjujDtSAhhmh0J5gDFyQQHomBwICJ8vsmIFllQpbMDoI/6T4/0lcc2ORBa4TcMVcAoVz&#x2B;HxipyxyLLFuBRHNUQ6nPLImGoxVSKfUaqWkqmY8NT/ABxLScCRDX7owMV44X&#x2B;Ck0IVQkJxyI5LmMWjC6KhSRqq8V8vnh6dNWU5KHJIjxHL7kxUtoo25ICSAAkB96r5QOJw3SbJZLfFQhJTlBI4NaLDVcGilpEIr8ea8cacNWskkMmqkeH8Eh4YzrVKhwRAOcIR1zwszVU1XCW4ocoEov2GEEDxWA3gVK/b8PHF5/wTXmsEBBdfjFQqYA7sFx6Khrx/jH5YvmoIlCjTpAiRx/AYDdLDVGIaeAPj8Fjh6m0Q2uiaPBPDIA/djXmOjBQrRMGkIp5n4RzwNKPgtDqN7I2qqoDkp5ZY0TqLqkQzA0Rkj846r/DGPqqHdBre6hQ45kQKafZcZ8bqshUDLyXTn4rhBOiEK5/E84rDBrVPTZtVBTP466wT44ReiKhASBDQZ&#x2B;JWCeOEeU8kuXfVV1LAQ5nh8xiejmqi5qocumhz1/BPxxmj0QOaAlBx1X8tfHFrRaEXKMAAKQI8T4a&#x2B;OOCciS2i5ADbVCiearA/zjjC5X4XCEwjp4jzwrFX8FCAkIE84LnlpitXVa0YokKRgmfHhrwOJZ6mNFXSBEiAhn9uGKnvSS4YXUOaQOA&#x2B;OueeeDVZFTS6HpIPHIxCeJ&#x2B;eJBsyrp&#x2B;4pwXw0TEed1KEIhBR9yeCHF4oQ9JQALxzBJhqVyXApCQR&#x2B;ChIeAwqRta7MlUU9SZ80jkPni1Tdcb&#x2B;5y5bmuV0s22tp1O2aK60kkuoZ&#x2B;6pdfIktqa6WHVVRa66TT1FFWOkyQk6Q4KGZkY9P9T5s08sNrgljhMVBlxOo0Pgv0l&#x2B;iXbu17Ptu6753jFvM21yTacduYHyQLRjkiSJxBP0zjR&#x2B;K47ucru239nSv7lbL2nu18wTq2kt9gdMp7jSI&#x2B;nlGla0l1dQClY6ZImNlkyj9L3Bcejbg9yi0TucWPcu5AjcftDW4FfozZY/SOTFLJg7Rvt32cBhPJmD45OJSFWOOfURGYJHVeIXqXtwsTd275k3P&#x2B;&#x2B;OvtLRSHX&#x2B;vuUulNrfU1tsnTbTbWy7ZL9Skt9NMfKmlzJZV6Awx2OyYDu9z94S6ojzGTNagpYe5erfq53T/t30se2fZGDdZJDDCHUMgjDIBlyE5D5pyDxAJFKhd4bh3RNslw2/Z6Wj/e3Xc9wmUVCyZN9CkpWSZL6msrq6YA6Y2np5LCUY1ziYJj3DNup7ecccA85lvDiSvzB2rsWPue03fcc&#x2B;T7ew2WETmQOqciT0whAWMpEi5AAquddw7431S7grbjtTu7bJ723iktVPsXc/b6vnbUqKmfN/by7dI3NZ3VVyoTUTA7/5foTGsMXNABx4fJ3LdwzmWPNGXmbolAiPBuoOfey&#x2B;nbD0l2PcdqxbbuXY8uIfYlllvMG8h/MiER1GZ2&#x2B;XphLpDfw&#x2B;oE6EronZ&#x2B;8H7iNXar7ZJ21922qXKfdbBUT5dZKdKmfS242S4yeqReLPOd&#x2B;mawq3J4a6GPO7fdR3ETjyR6M4vE194Oo5r5X3z0&#x2B;e0/b33b9wN72PMSMWeMTEuP/LzYzXFlGsTQ3iSFhO8042/ttuoUx6Ku6W6bY6Fx6hLFZeGupGGc5gc6XKaxzi52gx1e6g4tlklD6zFh4mnwXmP08xHe&#x2B;r9lDJ/0cWUZp2foxeYsDc2Yar5rUtJvOrttRctibk29TTqm8XG8V913lKqJdJSSKANtdTQWihZKnzHdaIx7g0Oazq1THpW3huZA5NvOIJJk838Cw4L9f8AdM/ZtvmhsO&#x2B;7PPlhHDjxRxbdjKXX/EjLJJwAdSHLORorhx7yS6v1LjtHtdeLMZkv9xcW1zqG67krJFG9wbSTL1bxVU0j03DpWU1kw/8AbBzx3Se5D6o4Jx4uxlTmH/BeGxj0PkAjhz92wb1iIwAE8eAGYDkY59JIN/MZD83BfSnsX657VbRdU2KZtuomUk586zT&#x2B;gzKKY6oeOgvlveyY1wAIcCOoFUBhj6T2Tr/peL7kTCZjUcPbivxt&#x2B;qxxf9&#x2B;9wjg3I3eKOQAZQfrHSK8q3GnEr10KmqHh&#x2B;WPK8l85RICIH5ImvDJcCkPSUy8OPgRqv34VrwCKJEIcY5QimZAxIVJrwXiAcz5piUp11KfblE4kKoqYQh8h5BBgukFlKR1CJ95PgmFQUdMc4ErD8cSTTxRQhw1TMeGIclVvqmNTWEM/z4jEoABS4dTSASDnpAj6gnAKMRe6iGuny39YDtUQoYg8CNEIx2QaDgsmg4Jo&#x2B;9cxwEIcMPyWZVqEQb/UpzyGF&#x2B;C2&#x2B;iaCFUp1EIpy5BcHNHVc6JoIgIFYGH2SJwk0ZNTVTAqPsv2GNAh66K&#x2B;SFBn5JHTkhz&#x2B;7AG6XKgVGkYxzhlHxzXGXSluAIULzTVOPjjQoOpcfURKtioECDDlwyTIeOHwSK3TdOA118U0iuBpDwW1BaSQeaw5JEcFGCwpZSUQQYqvA5AfYjzws/isgi6pfD7HPD1SS6wpyQGEBqpzMcUXZiuBQBxikT4fhh6QpFmR8Si65JoMZp1UWhzTBnHVPAa/DCBUKfgmCJXQDLMj8V&#x2B;WNMx5IY3TACnmn2MM0xkl4vxTY1sjEWoMkhEDzGnxwMWoql0QCFNPtkkVxdTUKTUObqOlFROSxXQaYGACBzsoJ5g&#x2B;X3eOJnrRHhZDGP2y5BUxlSgwHgPw&#x2B;7CpLzzyI&#x2B;J&#x2B;GF3SWaio6rA6eIGXAppgL2QhJMVy&#x2B;0QOOEAs6erhdSxqqSiDT4/BMcU5N4rkADPqicQRxQlOGeeOElaJ0QlDzJzPjoAQeOJLl3QrABEH28YYqe9VCXkha9hnCn9RgnvaXtldQ9RzMi8MzLBrhDHxTR30Cu/QcNDmPBfAcsb&#x2B;2Sg1qoMpyIhTVQqarwwdBdh9Syygy3rqOEQfNOeARN0ingoMtxzHLzU6aAJhOMpbXRD6ZMRloi/PF9uQWWUdBCwMM/vh44BElSWWgePicvxGMtqbIHFUWE8fhpyhDE2uiVDnSqeVMnz1bJp5cyonEgnpkyGOmzXEAFUYwww&#x2B;URMyWiA59y3CE8s44cf8A1JkRA5yLD8SvjT3o3Z2P3xvG/VG7N83qrn1lwfW0srb1/wBw1lroqls0yJDKmwyayZKpaihlNV/pt6CP0dBx8Z7zuu077uGSefLOU5F2EpkBqWdg3&#x2B;S/o36C7F&#x2B;oXpn01s9r2jY7XDjw4hCQy48EMsokdUpDN0dUozJp1F3u4XlEq89kjeKSt2hYN3T94Uc9lLabxbqa/wByop5ly2yKFwortPdNkUNfUE&#x2B;oZ5DpRi17hjw2WfahkH8rjmNwDSQEi&#x2B;n5iSxN3tovdtvsfW0cM/6xvdnLsuWH8XHOWOEogl5jqxgRM4CxjSWsQV9H/axZ5NIzed//AGBpDdqi3UpLPQNJTzqSR1V9FQukM6TKlVsx7nkOcC9xx7p6bAiMuQihI8BSoB8V&#x2B;Wv103QyZu3dthkEzghklqJSEpfw5zeoJgABQUAXrG56mmG97leJzwJGxe390rg55IZLrr4RTSi76XI4Uxdkpx5jcdEt0cpLDFhJ8DKi&#x2B;e9lw7gencXb8YPX3PuuOFLmGHzH/wATaryv287VlTX3m/SalzR6slj2S5lvqpQ/eepXzaJ0idZ6G82uV6k/1WtmumOc5yiY5uPE9n2gmZZQWANQGIrVrAjjV/Fe8/qt32UBt&#x2B;2Th1FiXkJxl5GhGQIyzxZC0ekmIAAoYgr3W507J&#x2B;89utpWl1dZaO4VVfOlhRS0FdLEuTSVDwpaauYOpks5/qTHk8&#x2B;L/wBTD7Y88A5bQHj4r5vsc0sfpzeHOQNtucmOMIn804FzOI/2ihl7l5p7kK8M7ZvoKma&#x2B;TJuV&#x2B;tMqpmMc&#x2B;XNFJRPmXKp9OYzpc1wZSxSJENcdPu&#x2B;b/wBCceRwDIPxYVPyXt36Q7R/WQ3mGIlPBtcsogsR1TAxxcG9ZU5r5b7g/wDDFVVbe3x3HlVG3q/dkqRMt8gVVysTZ92oJzZMq7VtPImh0mU6jLJkmeZfTLcCWkux6RA9vySG53YMZZAKVjUH6mFgRUFl&#x2B;vz/AN2YMeXsnp3LDLi2uQgykI5fJKL/AGg9JSEnjKJNjUMtvo9sdva66Tq3bPe/eH9/qKSvm00mg3tLNstFO1jTT1LKzdNLc7hcqmc1QSH1FQ4FGCW2I8jjxbLJkJw7qZysT9dI&#x2B;&#x2B;Qc/iV4LN3D1Tg20cPdexbP&#x2B;mCUBLq2wOTKSXI6NuYRgBzEIC5Mivr/ANs6ORSdvdn09NXOukptloybk5znOr5pas&#x2B;qJe57wZs4k9PVDRMsfWe2Qjj7fhjCXVEQvx4lfz&#x2B;9dZ8u59X9xzZsQw5juZfwwAOgC0WDCgYWqt6DDAJArCOniBjvMV6oRqUXQV/SsI5fE6FMQ4rKkSzwMVU5Yb2FFOdFQlnQHKK/yAji6Szq8VXpu/0lYlVivJcDG&#x2B;iipEt2QaePh44WIuptVRlTIkMdAxPSo4jTExZCn0ngdRBKCP8AFAmvliH4JHFLcIAwIORBUeUekr44OSTdgoCZFQEVYfLzOJ1O1BZEoEFA4wz5KiKcSH0NlHWV14g56QxLkEYko5MwCY5uXX9Q5kAKIaY5cZ0XEXNBdXqhAIRB&#x2B;PLnjlWRfWiIEQ4Ar4g8v44nISCXITQUC8OEfJOGKhT9QZH1COfnCK/jiU1GCkFESH4wK55/hiuUkP4KiV0hFAnMa/YYqlQDKDEJ5lSpPHlrjQD0R1D3JboKCuf25fjiDvWyy4odELSOYByj92NFgOSn1T1XKMBl8OR144wTotRUOWA156Djrni8U/JLcSggSnwgv4Y09muFjpr7lC8jl/BM8VOavb/FYXNAvjlxQDxwdXBYYshOSA6ZpE&#x2B;WFwzK8EbYZLkBw&#x2B;peeB9fzJKbmPhiYq14o2/6stTEnmcapUWKCT7k4E/bT&#x2B;OMMW5JYX1ZE0QPLLTikMNOmhLpABFLos/gFOqrrqMAAIawCCGKjTMeQgh/lgUA9kLgTEaIPsTBBiFCwsoVohMTnx/HLxOHXy3Q9G0QmEUzOXHl4riP7VDihWJ46pp5mMPvwPfgpR5JBRHgDFfLELiqkiYpa4KWq0gOXIkFHHh0GOEyUFxv3Y9wtf2jrP2dZvTbV4nhz3Ot7LVUzainkgnpZUz5TDKM0Aj9MYY9d3u/ls5mJyQkToxf3rzW02cd1EHolHm9yvIJX&#x2B;QqzyFZWSLJMDGxmspLnJc5xAI/&#x2B;kgaMdSHfHvGJHJ135dhl9Tyb3FX8r/ITtQhvXR2iI6lZ/cunpAVOoy8zjl/rQP5Q/Cq4z2bIzx6vwWdk&#x2B;/PaM6SKlrLC6S2Lmy59Y2YuQY1j5fVMK5kDGv6zib8r&#x2B;Kx/R84pUPyC2LYfu8sfci/3Wm21STKpllp6enudRKo6yTQS6uq/wBxtHTVs&#x2B;U39zPlsi8Mg3HNt&#x2B;4jcSIAcBvZ1xZ&#x2B;3ZMDCTgmzsvdpPca5TkEmkmgkhQ502BKQgOHxx3/AL0mB0XTGEN5rpx31uMORlGCCqdPqqE4lIL88aGZg9ij7IVDfm51/wDtWNJUDq9R2qIQAuflh&#x2B;7Ih6UR9mFir&#x2B;n3vuKcWsfIlB/6Qzrc0PMCQHFqCHzxn&#x2B;Yla6vsh2eiyFTurcNJ6ZqLYZPW1ZZLw4PP/SRw542MuUXdZ&#x2B;3EuQaKyfvq8AJ&#x2B;1aHCLR1E8YOgiri&#x2B;9I1V9mtCqbv66hOuj6i6C9QAHBqERQ4fulqWR9rRQe4F0y/ZtIEIJHUpBMsByvQmqOh2itR353Jn0O0NwOrZ0u1yKm11FG6vaGum0TqweiybKlzCyVNmtc&#x2B;DHEB2Rx0O47uOLZ5MkyIDpIfg&#x2B;vtde1ejO0Zu5&#x2B;qNjt9tiO4yjcRn9qo&#x2B;4IeYxJDkAtUiouvlDd/cn2ts10u9lut42fbN5bUrptTUXllRJZb5DqOk67VUSZNFIdKuEq8ZVdLQu6WuPTM1x8fz&#x2B;ou04DLDmniG8hIsdCdCwFerUR8Cv6J7P9JvXO/xYe5bPa7vJ6b3eGIlikGyRjKX8WJOSTxli/8AKy5qkB4rSrj7rpu6dq7W3btWikSaC97ttWyak2m3UVv9P154qLkaSRTy/Tp6abMBcXA9cuWmpOPG5u&#x2B;Zt9jhn28el5CBDAcyw5/Jef236Zds9O9w3fb&#x2B;4ZP5n7W2ybjGZZJZOph0w65E1MBf8spWovqR7fN21UvtHtaqFG2WLoytubAJAYHCtrJ01rukCHUwquPd&#x2B;zZ8uHt2MgN1Am3Er8Z/qhtNruvXe&#x2B;h1mX2ZQx3f6IAN8VqXcTfFZQTO6lPuWuo9r2HelutEq3byukgTdu26gtsmZLrKG8zFAo3gvUdf0zGnHV3ncM2KWeGciOLKA0yPKBqPa69i9Kdl2e7w9k3HacWTedx7blzHLtMcunPOeQgwyYh&#x2B;aNGLVivGO3Huet9yutX299vDdr939&#x2B;GfMZfO4llpqlnbLttZyyTKlf3y7THD&#x2B;8XGUxpfTUEtSXI39GOv2/vU4ZP5XtcYZ92TWbeSA/3P9TcPdZe2erP066dpD1P&#x2B;pGTddm9NCP8AD2UpQnvt9mBJIxQjTDCRIE8stHN13jtWum7dtTaWdUPu10q3Crvl9rGg1l5ukxv&#x2B;9WVCf9uWqtlSwjZUsADHt&#x2B;3yHDiuZZTWR1J/dwX5t7znj3XfnNHHHBsoeXDhgWhhxi0Y8TrKRrKTlcn&#x2B;73unc7RabHSU1skV5pae9bloqV1Oag1lxtNG/wBOS6UCJf7aTKmPmTOuBaMeq&#x2B;qd/nxwh0AGIBkzPUD5Vqvvn9vXprt/cd/vNxucssMicW3lLq6RHHllUvcSJAjFtSuFdme5LtZdKuno5F721ure26qm1TJFRfqqZRW2VMp6JzrsynlXGW4WKitzgBLt83/Zq5oQZ49V7d37t7/blOE95kkKzpG1Wf6QNImhX6O9T/pZ6ujjO6O3z7b03s8eUdOADLlLy/hv0H&#x2B;LOderNHz441NlslRQdsd00c6gptu7Zm32okT7nuTdt8slNYqTbTzc2Spd5ujLM&#x2B;fXWOurGO6bZKYDRznAEgAnHlhh7duv4eGEJ5yHlIgR6a3LVi/5RYr1fHu/VfaMn9Q3ebeYdjGUcW32&#x2B;LLLNk3A&#x2B;2ScOP7gEM0IGu4kWywDgGi&#x2B;s&#x2B;0u4L7fY7TabfLNVRW23UdBS1LhKE6ok01NKlS57&#x2B;holF08DqJaACScfYNjOMNrCEagRDe3Ffzu7/HLn7xutxnpmyZ5ykA/lJkSRWrC1arZv/JF0A/&#x2B;wahEAHBSUXpjBRrjt/dJDrw32tSk/wDki7kRppa5FitPT58ScX3C9Lq&#x2B;yNCku7mXdpLRSsVSg6jDJcghC4PuEe9AwHiod3Luar&#x2B;0bLgjgZkF4tT&#x2B;lNMEsrUWhhDUqyj/AMmXAdS0oBKgJNQKIh0Y6&#x2B;GD78jJjdX2ddFbu7l3fp&#x2B;mVJUwJe8tdny5Y192ZF6I&#x2B;yWqlP7n3RpBdLktAMT6zypCQiYZ&#x2B;GMfdqwsj7LHxVpP7wGkaDUZ5RmgMLnZAAEByY45bgAFajgqeC8PpffH2so5l027Ivm371uDb1yraO92aVfrfS3211DXNf6dbaZ05tVKldLlY4NIcIg46E&#x2B;6wxAiUeoDULuDts8vmiSPcfmsfUe/ztpSvIqZVDLe0foF8oy4lTn9StKY4D3/AG7/AE08QuY9kzCkj&#x2B;BViP8AIX2yeemTbpE18UDL1Sq5In6epTzwnvu34U8Vn&#x2B;ibhnengrqi9&#x2B;W2LpNEm37bkTXvcjeq7yQDH6VcXdIccYHf8RPTCFfELmPZMmNhklXw&#x2B;K6E7Y90N09ybhJny9s2&#x2B;02KnPqVNc68U1TUODmFJcimlOMyYS4xOSY8vs9zk3MhIRAj4rxe722PAGjIymeTLoPqdEc8/mRxH448roukA4CYCAFPDwhkDiSBQcU1rkzi3kOSQ0zxEOhnCa1wEcxp&#x2B;GJaKJUiQFPPUcOAxeKy51U9QRCCPCPnjRNKIDkuahLJSJ8SkIQ&#x2B;eAqYswQElEJVYn46rquNaAg0CKBQ0xOWY100TzxU96TzsnjIZ8tE/jjJFVEnppdUCNRAfgq4XYMaj8UF2dKdy48dIfEnDQWNWSx96FR&#x2B;Pkv540hliCOGqxQ&#x2B;SxyPyxxtVli6iBJXihXyXPC9CpHmYZAJx84anBdiLq5lGumvPLh54T73SL1KY1Qi6eCecRHEDUnVRL&#x2B;CaMkB48/AJxxHjooDUpgI6QCNeA&#x2B;OemI0AQ9XClCkOccuawTBWXgr5qMlC8FCKI65qRgZ34BJUZDyP8jwPDliIYougJJXXl8YYLKQOPMJzWH21xObKQk8kVIeEMkUYlICU5cf/wAS8QiYRzU6tK76qStif/tJ5z4MKIYocRb3JF2Xzt3Zf6uTdKlkyRbKoBzwDWWu31Lw0PI6Q6opnvQJ8ceFngxmTmIJ9uK8tinPpBBIK0526HIWuttgcGg/T/x6zOAJTJrqToTiojjj&#x2B;1Amw&#x2B;C5OuduqXxKpu62lWts22XQAJO2bAGhQhJaKE/DCIRcsIsOQ&#x2B;bKEyD0mUyP&#x2B;I/gql7lZLIeLJtkkEFr5e2rE2LQUIJoiVWMMUsOO3TD4Ba&#x2B;7lFBKT&#x2B;J/etnoe6N8oJZZQ/26jaXFzpdLZrVSHqIVzz6NEzrehzKnnhhCQ&#x2B;gAeAQ8SXIJPiT8ysu3vHvDpHRcWy2thClogUAUDrFMpKwxoGY1Y/FIx4zaslB7xb06gBeJzQQrkp6NU4BzaclBrxxCWRqFBx4rSuPFR/5i3eXJ/dkUwIp6NelIlGyQc8Y&#x2B;5kc1V9mLdWiJveXebFS6BQpAfS0jvqMA76pDsyeONCUwHBR9vERSg/FWNN3g3jSz6qobd5s6dUACc2dKlzpbQ0qBJlzWvkyh/6UxsGd5G6wIY9QQeSv3d7t5g/VXymBAWuFHRBxIIh/2elI&#x2B;WM/cyg8vBbOPGA9SfFL/wDNW80PVcGtK5fs7eUGelPx1zxn7uQl7S8FgY8b1Cr/AM07ucU/uEt5AVBR0DUQHJKcmOq4erKb6&#x2B;CTGEfpHvXNPu87311H2E3izdl/t1s2/e/2O26yrrrJ/cpIm3mYaaibLpbZLkV768VrmOkOY9jGTADMd0B2PCepBGfZ8uLP0nHPyl3b8GL8F9a/QvB3Sf6ndvzdiGY932wnuMf25xxyicQ6pSMsglDoEXE4kHqBIiHZfnKsvZ6Zti6Vs/ftX3JuVr3LbbwKGyd079RbY2rtOrk1C0V83TubYlbeWzNu7hkODaKVIeLjJcR1SHCOPlI7Rs9uRlGKLCNA3Sx0JJdvEXX9HNz&#x2B;pnqHvu1ni2m7xSy48wM5baBzZc8ZDz4cWLNDF58ZrMzH2mtkCz7ju/s/b967H2z6tt2nUUVH3D7eWMbln3mbJ3Fabc6be7harxcay1fsrHNM9okOq2vr57IGnCrjw88WTDlkIOBOXUKva9be9l5/tveNv6k2G17nvZRnv8Iltc8xiEHx5JeSGSEIzEsgZ5CEhjifzlfe3sF3M3HL7IdqpVRda6bP/wCDWF86Yaic2c&#x2B;bOopcyb6jJhlEPD3Z9Mce&#x2B;bKWY7HGxNIe3tqv57et54D637oTEAHfZdBTzELz/wB0uwv/ANZbtbd&#x2B;2t53hujbEuuqKaqpr9ZLrXU1ZRup5rTOZOpZFdJk3ClqJSsfJngy0K48P3PHl3UWMiJRLh7PzGvvXtv6ces8nobvke7bfBiz45Y5QnCQAMoyH5ZmJljINeqFVf8AYjb&#x2B;1fbpsK09ue2FNMs1ktrJRqp/rPn3O&#x2B;3INDZ93vVa5sybXV04qnU4&#x2B;m1GtAAx1tpKeyiIYjLrJeRe5/dwAsj1b37uHrPuc&#x2B;697kMmRmxwbyYoXEMY0GpN5GpK6Ckd3L45oD7lWFvSfq/cTg5OAI9Bg8I88ewbbuM5/WSvnO77TiEnjCPT4f5uvmh78u9m65PcTsrbqbcFbQ2edZd9jcX/AM&#x2B;pppFRb7pb5VokumT5dLXTZUyXV1jC306V7yF6SDHHi&#x2B;&#x2B;7ieXpiASwNXsDQ34&#x2B;C/SX9umw2&#x2B;Pt3eshgDn&#x2B;5tvtHpEiJ45GdAZRuAbyA40Xy8sGy3z7H3EuUut37trZr59dZL3eLjTUl3o&#x2B;2NRY6dpqd7SL3uPcW1bnKoNyVBH7eRS0NyndL&#x2B;ghrlA8Pte37D7bTxAyIqZDqbi9RThRfoHvPrLv&#x2B;x79tNts91GXcpNlxYoZTilujkLDCIY8WaJlAfXKWTFChIoXPgtp2d7u9g0k&#x2B;87K70zaVbptqffLNsvelbT7sdY77cpNPt&#x2B;vrKWkpWUst90pJjZhpGzamoa1x&#x2B;nqEDH2eGPL93AZwnZ4z42cD8HqF7Nuv1Q2nc4jZd42eLNhbLXdbTHlxdeGJOUYpZOojpIMZTAjE8V&#x2B;yjt33Y3fZdjbPs9XMDa617astsr51bQ0VRXVVbSUMiRUVdTUvlPfUzamaxzjNeep6qQCuPumx&#x2B;5i2uLHMvMQi73Ja6/jh6j3G13/AKh32924jHb5t5lnERpGMZzMhGIsBEFgLCwW7HvhuZsP3FEW5dJttES3xSRmeGeO392ZpSvJeGOLFRikHvruRmTrasE//R9E0FDEg&#x2B;gYpxOM/dm7cFj7cLl3OiY7vpuglr1tBY6ABtVIUHNJagrrri&#x2B;5kH1UCJY4mgdvFCO&#x2B;&#x2B;5g6MuznpVXG0Uha9dAehQcEskxUKGOB8penBC7vzucO6mU9ncSoDXWilJOQJBRE4YYyla8mR0RehPi6gd99yqS&#x2B;hsb1cR9VnpWmOoIJ&#x2B;eM/cloNE9EbEkjxRO77X8n6rdYSjP0ttFL9ZKrEshz44z15BVgs/ajcEureZ3lr6pq1Nm23NWBbMs1MAIkg59IKcDHB1ngD7luMALO68du9j7N33dM7fF07D9naves5ol1G8f8AhtBSboq2dJYGVV3oH09VXy2sKAVBmIIDHDLFiyUnCJr8fcuxDc7nHD7cMuQY&#x2B;D0Hhw9yXMs/aaa1zZnZrtw8OcC8vsIcXOBQO63TXTAnI44/5HZzk0sUHfgt/wA3vAP&#x2B;tM&#x2B;9Cyx9rJMx0yV2h7bsSLf/APX1eD/&#x2B;bcyoa8BfsMa/ktn1EDFGnJH83uummSdOay1PI7eSWEN7XbGl9YISRaqiQ0wJBd6dUXNcOSY4zs9o3lxgFQz7gmuSTDmvRdibvdYnvtu0rJadvtmOYOqgZVmY0zXhpBfU1U17gBloOGO3gxxxFsYPTy0XUyvkc5C/ivpFbHTf7ZbTPeZs91DSvnvchLpjpYLiS2EScedj9IbgvGuAFkhEeWX2yxr5LH5gDxRg5alM84cSqxwPVa6qsja4iGFaRlwRVK6CEM&#x2B;RwrNjSykug2K6IoXzwdR1spg6AnJSVPmBoExoEPWyuq6EuQkwT7AROmEyJ8FdL3QNKLCC5&#x2B;Yh5YBHVBGuquQ5AhMBn94wEV4pHK6AlSc0ggMIfFCuNAOWCukIXH9XKCZQ01gDhlTgsi/JLX/&#x2B;Xjoq/HGOooWMHjnrrDKMcNHdZP4oCSqpzjqukYJgBuFEMjCwCIddNYJkmWIOkNqnGGev5&#x2B;eElqaJi5smtIOfH5fhgcmpWbIwmUIZpHyjjVPp0SZOm5Bc4JwEY5IOOD8rLKpU10yOWiYybpCoocsvDPPPgFGN6U4KcpZKHlpmo5YxoyRyuoVIpw&#x2B;ZxA6qLIHRGnM6Rz56YqOhASi8&#x2B;C6ZZxxtnuFVUcVKjSPHj8MZ6QdVK3ngGnqmlpJNNOzH/wCbcOMcUn&#x2B;nRQXzQ7htS5ToAOa5/wBRyLRNcHAAIpGhx42Yl1&#x2B;1F5LET0DiF5sJgJcpiBCMCYkeX54wC5IFGW21SOoK4HMogACAiLlAwAtGvtwWqvRG2a8hoJTJvSEQHIRQQ&#x2B;K4zKIav1LVBrVEyYGl3U5QAeKuOqoiH7saBDtyWK0KuBPLWtLR1KfpBgFJOoXJMYIADmoWwQ1VPquf&#x2B;kOaoEcwEzRAFHDE4dgmJINLIHug4uEU/UcyqfVmmOMQBcEVUD8FazKr0W&#x2B;oQ57AEf0M63AlQwgAhxK4yxA6TqEgkWZOE9xlh7Cn0qhH1RAKaoQccsCXaVIMp2YaOl&#x2B;oS1pcQU&#x2B;kJHMiJQ6a8cblDHIdRcBZ6g9E6WpLiYhoAIgmgJ4nGGq4t8UA8LuluVYH0xxBzPHVAcUMYvIkPZJNKLlH3udzNrdq&#x2B;xtXuHd9dU2yz1t&#x2B;tVhmV1HQf3C4U8yvZOEybZh&#x2B;5pH2y7tp2O9CtZMD6d8QDlj171buI7TtJlMEgzFg593Pmvtn9vnp3feqf1Ihse3yxQ3GHZ5Mz5ZnHi8piwysD1wJbqxkETFCvzIXr3e2mls9229JprjdbHS01db9sStw3u4V9nlz5VwfV2zfNXYQZtMO4Mh6GZc2dEyZk8uGPkuTe7rJH7MMZ6NHP4kcfBf0vw&#x2B;kO1w30e87ndiG/MgcssGKMeoGPTPbwmB1DaysMZLAWZT2p7u9w&#x2B;4W5rZIqtnU1u2Xcqi73fcG7aLbFNT2bcl4k2ibLq7pV1tRIfS11dMplLw1plOeheIY6GfFMDr6omRNRquzlj2TaTO32Uc8dxCMYwfLKQhHrDRAfqjHQVdrL9OnYiomT&#x2B;z/AG8fUesJztrWsCZNSW/0myAJBmtlCXLY50oCDYJlj3ztde34nesa&#x2B;5fzi/UeGLF657pDC32BvMjMaXqQfFen11OWyOuYRTBSf3FVNEloYh6vTfUvltcNfpdjk3G264dZDDmvV9h3ADP9uEjPIB9MQZEeIi/4rBvlyJ7SZE2VPDekh0mfIqHPUH6g6VMcTEL&#x2B;o48Tm2whEyDdK9n2&#x2B;/byz6o/8QIrzcKyE/peC0gGUgJaEew8HIeog/8AqTHU6jEvE&#x2B;9eQ&#x2B;3HKJdNQfai&#x2B;Q3&#x2B;TLeNbYdw265UE6ZT1dr7e04p5smYS50y9b2sNC6W1jZbhLM&#x2B;V1DqRxQnHFvZGU4sx8i/SX6AYBt9lmlOHVHJv6hv9ODJfwJdch7l70bc7fdzbZtTeVXdrXb6W0HfNNXWqtvl1r7BfdwWynktsNba33eQbjtGtaz1q&#x2B;ip50llQ5yFvTDHWjnO1IhLq&#x2B;27uHJrof8Abx4r6/DseTvXbcm67bkwT7jKIwSjlEMcMmPHMn7kJjGencR&#x2B;nFklGRgBxXuPbjvXtPuRuTbW4Ka5Ue5dv7O3Htah2htm1y7R2pue3t1S5/Vc97bfkTnVkq37PfLf0Ms5/dTamav1MVceQ2e&#x2B;22feQiJyEgQ0QBFuYBcdPHVejeoPR3qDsnZt1ixQic&#x2B;&#x2B;2&#x2B;c7nPOWTexyYm8uDKfIZ7iLOMw6IxDXX6N&#x2B;s&#x2B;nShoa0GmkGDS0O6pbH9XRH0yeqLVgVx9rEXgOn6gAV/LPqEpSkH&#x2B;o87EhT6kRwTMoDkVac8ar1ElgVh6pbyv1EExDSQogiNOuR8cQkB5ibhaBDUUGYXKgcCvEplBuaLxwRhCLgXSa2ulB6uDnABU&#x2B;pqxTkVbphMR0kAVPyQ7V1TQ9wQqhJ5HNVQGLmwzXHCIwcsSGCmFlHW3pBJILSYQIBEVRF6TjQiWrSP4rNyyguVEa7iWgE&#x2B;ZUrnwxkVk8n6VUtVR1uUgsJHgOGaoqnPTDMUAifKtdXBF6jUHUqxQIjjmh1hjiFyPZ1AhqmqBXIIkAk/T4HUgKcLnpJPFavVMYUcpJyH9UC0IpQQzwEh/KKIbVMDnjqc0AeS5HJASCi4yOaRSy9A7eSXTLrLe6P&#x2B;7TygpEXGaxsWgE647WE9QNGAPsy4MxIFOC&#x2B;p1M0MkUstuUulp2EIRlKbppjyzlqrxoJVx5Q&#x2B;CEr5RxAqcvT6kbXQzidc1T8MaAcrVDVNBgqDPmufAmCJ88Sq6IstU04czpg8EuHYXQ/1ExTx1&#x2B;Rxaq5aqVEIHPxKBNeWGjLJjUtwQOiU0iQgPlHhiIGhUSOmqFcwIBCn55jE50VRrpoKxIJSH5nTA/xSHaiIly&#x2B;OXBE1HPC8mqsig96UToPtywOtkteyhBxHD/3fDLG&#x2B;ofghY8iCDRSdFIz&#x2B;AOMmlQuN3ulnPIHRM/MBNAcRoKXQfwTBHPKC/cM/HEGfmpMbl9uK40wtqkXTWpyjprzHGOAgC1AinuRjpGXlnnqcVB4pD2CaORBjrlpx&#x2B;0MZoz6oVGGYB4nPih5wwG6lRQERTVFCZpxiI4TSikDkzMIrn9jiPJSWSVMYco6pgUgPFCc8sgpH5Y2QAykCqYqM04/LPE8rEhDBkJICHh8c/gR&#x2B;OEAN71KHDrDxAgsmDycxwGGTsxsyl83e5sj07nVFGudLqKthBKKPVJBOWQx4zIHm&#x2B;i8liJMXuF43EkqrukQDYDKAA4axx1yGd1y6oQQQQSQU&#x2B;rIcY/PAZAeJ1WhxZUDBEUrmTBBBAOOWGLkMUfJUCqfQ5Coa6ITmVgmIdLc/a6Wo6c2ZkwlACTyHMDSOeAmQFKjXxQGF05pDwAJhyRGlMofUsCnliLh24JF&#x2B;kXUdJLkJcWgoUKqEggzQkRhjQjIGgcsgklKJ6BALGMQFUlSY5Y4ZgvyWgQPFCSShHUghlFDBeBaMb6SHELEoJDoHFzSgBRUcQPBCdFjjRd3fxQia/pi0mISCo5SoHFDx1xlnsrmdUIdH9TmnPphFeCmH3Y11kWUQZMLLj/33W&#x2B;Xduycm01u0rXvPbtTum3t3bbL3&#x2B;3lWu17eFNUPqtz1dyqp9PSW1lgn9E1xmTZYns6pTXBzhj1z1cx7WPL1D7sX5cS&#x2B;jc192/t1lHH6&#x2B;yZYbmW03w2GT7EogyllymUQMEcYBOSWUOAAD0nzMwK&#x2B;Mth7c7A7YPorjYavalNZd&#x2B;UVDb901Payz09Zfaq51Ve6Ztquse3N5UVezY21aihRldV3V9LTV8XU0x4IX55P7O1j92J8kqPEdUn5PYcyw4L9oZNx3T1FLP23dYs39U2U5ZIR3czDDDHGLZY5J4CDucwlXHjwCc8dskRVYms21XGp3FaKC&#x2B;TrTb7tcrm7b0&#x2B;12aqpLNty01E6XSPtW1bVKlzW3a5bqqaWYJ8iXK9R7yXSv8Aajj1rcxlLcvjsD8fHmV73td5tdn2rHPdRE88MUBMSnHrySYy6skiR0QwggiRLAMJeZdE9wfetedu0du2tt2or7G&#x2B;z2ujtk2ybNfa6y6S30tO2RKfube1XOO39qVM70iTRUTa2ql/UHsaQRjzUd/lhDoxzMYiIDCpfmTQeF18n7T&#x2B;jfad5uZ9w7pjhnhmnLJ97c9ccUhIktg20R93OBpkyHFA0MSRVcgbn707&#x2B;3XUS7jc32ybKcZkdx3LdO7atrnEOmB9ZJuVgpGOmqA3pp80CAEHHHk3O4nikJ&#x2B;aZ1JJ/cF9M7X6S7T2gDFsZTx7THTpw48GAEc/JlmQOBmtbou7u8LDNkejQbcWT0vpJdId0WqUyUZgeWGrlbhrplPJc1rwH&#x2B;i8hwEE6k6U555ER/KOZHydeay9m7bucOQdeciQAHUMGQWuYnDHqI4dQp7l05sj3tbv2qXOvt3/AGVNJqZEqRbt83gXzZlfTT5jZUltL3ApaSkvWz5syafTZ/c6FtI2ajXzhnjtdU5xeAImBqaH/wCLT3hfMO//AKW9o3sRuNtGEcp&#x2B;qW2gceWB/wBR2pMsefiRiyGZFRBZTvnu&#x2B;d3O3m7fjLNWUtqtm1ttbdvu1qkSqvdUvcFxvTay1UtBaxJqqe82W4uDXyK2SfQrJbUkvLsunvDkjKMwD1FgRq/D2uvJfp32zD6b7fPtGXNDJuJ582XHnAIwSxRh0zlKRYwyQH1Ql58ZPmDVXgu8uw2yLxRV9z3nt3Z&#x2B;9O5O8aGudMse0L1crtvypvrLj&#x2B;yl7k2hU0U6daqHa&#x2B;1KPpmV1rYZtwa9jmGUBjzeLpOGEpN95qgFz4s1QPwXa/qncM&#x2B;5nHteXdbf09gnADPmgMe2gOjq&#x2B;1l6&#x2B;nIc2Y0x5iBiIIIkVbdo/ZLs7bHe3s1YhujfbNyT92y7wbDvii20&#x2B;RuXblophca/dFhpLZeamda6SkqGBkqTXejWTf6ZZdDHb2&#x2B;w22bf4ceV&#x2B;vqBsBIgVcVsvDd59f8Ae9t6J7v3Xbjbz7fi2ksc8kMmYjFmyHoGGfVACUyC/Xj6oR1ky/Ui/wCmXKb1E/7clrjE9RbLltUwBK9McsfYPLINqAv5eQsSdST8TZUUanS36S79Jio/1eWCdRZ/mkkPdQC8tRsFSJMVBKII/kmMA182ot7ap5sGQEIoLlJKlSi5DyITwxolmkSxt7kghtVGQ6Sv&#x2B;nREhrGGEzh1NqEEgHkmh5XIwajQIiH0x5dOOL85dZ&#x2B;oV1QOcYOTqLkbA8IpkjofDHLGngkVF1AJWClyKkTyWBMMZ1fVZfVOOpAJTNF0y/SsAfhgk2qUAfGACQUxKJqnA44i3U4v7WTZFmQCOY0MclyiueNGhJZ3CXBDFSIORyBo&#x2B;9AQoCnHGGqWqtV0smBz29JUEOVA0rwIVIZj4YmDODVQ53XsXaShFTeaCX0Fzqi6UjOoqSnqNc6PBG47W3AJA4ldfcHykL6aFvSemP0Na3ya0CJyyGPK1Xjw5FGUqYax1VRFFEMQUPNREIjy&#x2B;yglRhWpEiqaAAnn9658cSQXFUS5a4kMHdSSVGUc9F011GFqIHSB0hCqxgBkE/mY4DzVS1yEJJgBEjUaePhhF3YKPIXQZuXlnp5ccHggcExuSAonP89MXitAsHUrHNU81zXGnrRTPaxQomuaHqEPzzXFd7Os&#x2B;YNxSk5aprjK31/v/wAFZdWsT4xPCMNcQquIB6KCAoWKa6cF88bkBYoR6L&#x2B;anjHXLCIgVHBRZEyHn93HALuUJgTOC/ZI4TUKomNyyPy&#x2B;GOPRaN6pgyIRf5iHLAhST8UCryzHNMLKQlefL55QyxMmjc0KBVT7cc8I4i6EswJ4Q&#x2B;wjgo6SqJzRQiwjCPxywkkkoSuH46acoDAI6KVGJPOCpqFJyTTHJVmNkIpQCgHUpHkE/wDcMZcseKl87u8Eky7zc5bU6mXCpBBDekNMzqUNCwI5Ljx&#x2B;VwSy7&#x2B;H6WozLweYUcAAvUp4BfGKrzx15MJV/BdkcRZIcS0gNavUXD6QUgIro1w4rjIB/NbRIAubqlVqR4oOpVSCc/wAsDBCodQILSjS2K5ZxWJHUnHCCXd7hZLuKhk9HPDR0EghxVzWoSMy3KEcIYeCaoWq17S0ERPDMpzSK4RwFygEEeb9yuOt7iQW9Th0jrAzAOSlVIwv5qBgOa0WP0qQFJCgf&#x2B;pIFNVyXwXF0gycCjpcAOLoXEkxcHIADEIo5BEK&#x2B;PlhAINHqsl76qAGgxbxTqHUVWGblT78RIGhJUFD3BC5xAcEBYIwy/pahMOWKZYauoXSw9XN6ohpABQjwXQnnjjixqk87rg7/ACMb&#x2B;vfbfsnatz2OzSdwy5u6ZdguNgqaG53Y3aivNHPlGmprHa3Nn3aaXSz1SndTPTU9Jyx6j63z7jb9thk24iZfcZpE9JBHK55L9Mf2q9n7H339QNzsu/ZcuDFDYSy48mMwiYTxzBczmCMYY0kKvqF&#x2B;bXat&#x2B;7&#x2B;915t92vaLPcdsbImTG2Lfu8p&#x2B;0bHZ7/t/bdLO/cybBeb1c6Ol3hcJMqT9NNRufN6AWt6Q2OPlu3xb7LAiUurQhgAH4m9OC/ffde5&#x2B;lO15477BhEe4Vy7d8mSUZZPp&#x2B;5CAlLBEyNZ5BEPUu66gvN5n0goe3OzJdTRTpdFS2q4TqZJNxtVuuVMyQ3btvqJcipnS91bppZgnXquY81EmRPZSyE&#x2B;pju3ucWPC2LbjzgMT48OZ4l1692bFm7hGffe95I5NuJmcQawyTgXOWQJH8HEaYcf0GQOST0Ixkjs9fZNJb6W22O40EiQJtMGzRMfSMkOmOdJJdLmS3SmtLCXAue57P9zqc4PdjihgnEfSREjh&#x2B;3/ALzEu97TPknPJuIHJI8deDEVFdLHy0DBYSv7e7qt8mZMfte8vpZk51I8PoQ&#x2B;lbUSGPc4S3&#x2B;lOa&#x2B;W9h6mFXFzHEtBHUx&#x2B;zjmIuQW&#x2B;K7Me4bEz6ce425kz0kAS9HYc6Hgb8RrNwttXQTpRraatt3rvEqSyp/cSXfS1zpjWPbNPrylLSQOoEuiqgzcAyiKjylc5njnHyyjIf7WIP4EPdnZyKMxEb632qnnFkuuLZcpwqJU5jpVHcKetkVMtJMtkmpp6Zr5IYR64dNmynyyiMQOxkxnXp&#x2B;nh&#x2B;9cWU&#x2B;V6gmoIeMg2tDQg2YAvqbLNba3fUbcqrJtarZTvoZtW6zbVvE6onut23rhXu9OXs&#x2B;7VUye97O327anopgZjQy210yVNaJbm9U5xgGP2psYGxOh4PzsOBXQ7pjgMOTux6vvQaWeMQBLLGI/60QzfzOIVLH&#x2B;Li64FwWj5Fvjvdu3sjvmso79aXX7Zm6rDTVvbq4WGh/wCCXTYVObnP/vtkor5sGgsjtubppLvTPpLhOlNbU1bJKmYjkx3encbaETi6DnALAlqaGJa/&#x2B;pdPYYuw9/2phvY7nDGGYHOH/mYZ59LROaG56xlw9JE8MSTGD0i4XX3sp9w23t7d6u3dlpXi27s35vo3i8W1&#x2B;2ZO6dv3CfT04pqav2jdLnuOVW7Hu0mmYTcK6XQ1FwrHq6bNIJGO12HcSl3TFjlDpzzyeYEdUQeMToSNWuvVf1n9Jw2/6fdy7jtc&#x2B;LJ2PZdsMcB&#x2B;&#x2B;cG4MSXMM0IYm3MOotjxynDFjFIwF1&#x2B;l2pc8TXsPT9L0zDx1A9KhxaFEEWC4&#x2B;0SA6dF/K&#x2B;H/AEwTchCQCelAEGXUEKRMDy4QwBhLViFpm/4SkhoLiQAADk7LgQn0qumMyj5n5qI10ZSOlSOl5gA2KABInXzjjIFKAMPBD9IdHMc0dMOkgEwUfSFJKoUygpTlhkD1LL8UmQ&#x2B;XNDXy3tmNc36XsQggKgDhAlVhocA4mibFMLPqVqhyIEcOkcVVUJ5HE5JcoAo9FHV0dRLg2ABLsjEIri2Bw38VIBUygz6iGqSA5ytHUDFo6inUvxxGoCdWTWgj6SMyC0oDmFBjqT8cYMSOa0A/gpd0tPSFQpHNCBHighhY8wghGo6mpHipTPNVMPHHHIMHIooaDVMYOoOKOZ0kgAopCaGOei4wzLd10X2FphP3PYvpzuBmkE5NkyieoFIhxx39sKxXS3HHgvoU9Ot6r9RJRMipSOUMeRXTc6Mqhr481gcs88Seo3ARr5cdU&#x2B;emELQreyMLAICPkmapiBS4dM4Dn&#x2B;WFySynq5UJmsYwURHnAHErwVIPMLE6qfxwPxusdR5oChEB9SkmMYa4qc1EkFAojmmkPNMsXjdABfmjGUAMocYcsxjTrQpQlHlBAPghPAcAMZY3FleJcICuZESDzHwGJRbjVB5u46/lnirxWHVkIn7LlEQ1ONCqFGvAKfERhDwxEa6oRlfHih&#x2B;aagjE5IcpopEYiAEMs/yGKt&#x2B;CaOmgJEFEEPGGnDEZcqqJBHNNAhE&#x2B;AI5/hgJLMVac0QEYnP8AI66YK3USNAq&#x2B;owOfDyXXEzqLaKoFVMF6QM10XwKZYSKPohLBPPmUgi/FfwwAsXCkJ/qWPksDkeCQxsgC4/yQgPgvLjgFK6KQ6xz5QiAVA8FwmIBpdXiqRQNUTksIn54nMuSlLYOEB&#x2B;oEk5A5lF5Y1cOpcC975IZuO8j9IdWPIb0qvU1pSHE48VuD5yK9QXkNuB9tyKrm2aEAygQE/pByMfKHDHXMqcf2rnADoShJB6TEfpOQI4aGGJg/D2skk&#x2B;5US1T0kI0np4gJr4cMa/MzKZ6e3gilAIT9LwVipc4ACBdohOmIEC/ghmDaBCCSR0qAHOV3Vk5CILm0jGb2Sjludmen6Viq9WXmDjfUQekKZXQmdLA4N&#x2B;olUVczxERlgN39vBTpRcXElAGrpFEHOOkeeLgOCDzUE9Ko1CP6k&#x2B;QTjjbk/wDCpqMoMePUXIBFSAh8FAGBia3&#x2B;aqqAVJADVWBLteSQUccB6mJKgGqlgv8AU6nBAoALkKhYkgZ8sZDxL6q8FxL78pV4p9gbWvVsvl4tciwXu41t1s23qT9xf982yfaJ8qp2tZp85kyjstU5rDPdcJqOpJcoulnqx6n6xnKOzxzc&#x2B;WZoA5lT6RoDq5sv0h/bRDt&#x2B;49T7/t2/xYZ/zW1hCGbLLpxbWYyAxz5ACJZIuREYo/WSBIMvk/d7ntz9rV7wstyvtZSjbVCy&#x2B;vuV4p7/ALeqqDa9J/cqWmodwhxrN3XF1wmtk1NwrAJzTL9Nv0jHpMsmAfxIggdFQajjQj6uZK/WOPZ7zpj2PcjB947qQh9uBxZOrLLoJnhPlwQ6AZQxY/KX6jVeHdr6irn7s27VTamfNuFbc59/udSOmpqa2tuH/wA24ic6WQ&#x2B;ex0ucZJb&#x2B;gyWhhgieIxTMsglInivond8eDF2rLtMQj/L48QxQFmjDyx8C46gf9VV3vT3kiXPmTJbemZOlubJp5ZEiRTz4OMAXuFPMZFxiZLAP1iPlusVJ1Lj/AB5/sXyc7cGUcQPn6WJN5EVHg4Nv9Z/0lZacKCtW3ifTVrqSopqibKbNbN9Kqa9s6jmGUHElx/7ktyIgh9SjDLpJ6AQeP7KrghLPibcQjKEckZRBIZ42kH0GhF/cueu51ftBlyqpt9t9wuU2VVEUNJb3UTKCmmOAn11POkzJYDHzBN65RBLQOpv6HNTp7joxmRkDIk0Zmf2svdvT&#x2B;37hl2mKO3yY8WJmmZ9RMtIkF9GaRNbG4K0mzze395q/&#x2B;OU9DWWa6VhYKCpuZkupZ75imWP3VOepjJjz1AwIP05rjq45YcpMA4J4/Irz&#x2B;6j3TBjO6nKGTBAeboLyIF2B1HDW6563ZYaqiq7taaoulVIq62jbO/b9TnNYXy/3kqRVIJjWhzXo5Wq1oyLSGEBC9ga/vHvXltvl/mMcZ4zHokImppVi0gLHmK1PAv7ZZ7fL7gbSsdvut329J2tver2lX75s&#x2B;7JNVQUW521MqotN4o6F4lTqy132v3bt&#x2B;ZVSWQE713yiVeuPLSl1QgYsRIh3LeNfxb3L53nGbZbzcwhjzz32yhmG3liiJTgYEShKUXAnjGHJGMpH6RES0XRvsl7K9uaf3JbZ3fsjZtkn27ZFNuelqO5O19rS9v7au256iY6ids6s2/NP7rbG4dqUh6jPndU&#x2B;tKkHpKY8p6fwxy91xyxMccXcgFieBf6SPxXzT9cO8dw7Z&#x2B;mG82PdZyw9x35wSjtcmb7ubHhHm&#x2B;/HIPLnx5zTpg0cYuHC&#x2B;703pc8qWuPWWkR1AQk5GOPqEjc3o6/AESWbRks/qABJQ5lqgjMxzGFiWlr8lsjhQKSpLgekhQgIUt6XKE0jhZgxshhEMpDghLkJ5L/AlMYkGoOKzKLWs6U5n1dcWmLSSgDhwc0aKcZFmWVLJbWANls&#x2B;kLANDWgkkkhozcVXFSNHRyCMuBEIIAgc2MYK3kcZZVBZKdmAVewop6V6kiEGhAGeHnYqZ00MYWhoaHdWjkQ804ocVPcoM3JC1jZKeiAwtSBP0tOcBERxmQr1CkVokkM6cwOd9LgGPMYFWrEn4n78BnMBpWPxW/qohIHUP6ehqkgqTHLzxHzhj9IWW1o6a3qJAUiWQgEIkw8Q0g4wIxdiU9Wq659utuDtx0MzpcBR0VVP6iB&#x2B;pzQ0dXKOO/tYtQfiujuTVtPxXbDj1FRrmnzOO/pzXVAABCMaRCAZ5fYwwVTVnFymAZAFeBw/JPMmiMHTU5QiBkpxeCSdCmc18k/HyxKd6NRRHq5EHTXEqTMygqpyVTEZKsAvLFU&#x2B;CyzMTZkBUlT4omXEeOHSoQwA8UCgIqxWKfeMQLeKgS6bLjrBCseH8MCTS1EWcDr5rwI&#x2B;0MXgf8EMQfBKcYROQAUZaj7/AJYTeqtXQoeXDIZr92JuaveFaQCaKApRfhHjiAqslAkV&#x2B;3GGORgaaoRwiB4cc/FIjGZUHJ080YCADjnppn8sR0bVLgGibkEihiUif4A6YwaFV0wc89cGqOSNYmBQCHLz8/PG&#x2B;D2SQ1aKj5iGoTTLTF5SH1QhKJ94xkl/BLk3UEp9&#x2B;v4Z4WLVshAc1y5fdAiI44Yk6ISyoCwT5p8UjjbKUZmIhlBViFT4YK6hSgFVz1hloNdMAqa0ClIgQYICsIxWHggxpw6lxB3/AJAl7kuxH09Qp5yCJR8sBVUkBRjx2dxIyoy722rBudFyzMa1HBQoiihFQO4oBjrlmpouwS1SrdrWOl&#x2B;rLeHS3EhswODmkqjgC0kQPPGSSWAp8Eg0a4UhiFqkRVQIiA1UkouAEgMbLT/JJLUBUFoU9QQoCciIgnE5voVl/ipY1CUCtaCHRCKcioUZeeEXcAMlwpV2bWlsVK8CUSITzxEmpFlOnBWlCSFU9ICgiOpxACj3WXCMIsNVRIwRYgrEJHhjVqG3ggR1BopcSE6FIBCx6gvFDz1wOTQB1pqMlE9JAe8NJ6iA8o0kCIGR81xEl2J0UluDnNAIKnVOkEA8iFz4rjLkxrYqejIQQVh&#x2B;mKR4oHBT1QwDpFkEAn/dovmp/lA253D3V2y2XQ9t94O21faS93GsudpdfWbbpdx7cm24UVwbWXL9zLqXyrcZzXmTJkz3TOqPS1Tj031tgy7jaYRjmccozJLFnDalfqv&#x2B;1Lvfaux&#x2B;ou6Z&#x2B;87HHu8Gba44QmcX3jhy9ZlHoBiRGU6tImLNRyvjLsvZF57ce37eezd1Wu30G6aKRerk02a8Wiss9wsNXVyawXibOpBMpayprKVyteZzOkQcQcek7XAMG1yQJJLEj36DRvf7l&#x2B;te792n3v1XsO6iMobAZceLzRkJ9UXDEGoY3DE8Fme1dIJm8bLOt5IYDOnS3NaS1jRThwdJYKetMouD2kxd&#x2B;rJyhs7pxgDkiLE/iF7D3bL9rt&#x2B;YklgOkigueZiT/hozx613TtqfuiVTzaS73ezutykSrXUsles2Z09b5rpFU189rpbW/T9TFaD1RbMf3Z4vuRHQTED24r0Ptu/hsJyOTHDKZkVkHMWsCDGgcngatoYx1vY/by&#x2B;bWvd2u8y/VdZKulK&#x2B;nZLlTfTqp9MZ0t8kVD6iROLXU88BwYHOId&#x2B;kFTLfw4sMsUyJSPTbmF5fu/etpvthi2kcAE8WTrL/AEgsQekRlqKOdLt9Q8z7o11ROvBnTpXXTOfWzZbJL6iqL6inbTSqkTJUqquUthnyXAgMaxzXOLWhwmtdPzuZSetfx96816ewQhs/IZDIG0A8pcg1Efps5dwHcdBjDQts7aqrpc6CqtFOJvoVlPX1BEibMFPLLxUOlVpdJmftZs0IXS3MfMARgY7LHTEep5RuW8PYaheT3W7G0HRuJGJIIDm4s4qHHAuBr1LZe9FRRVm5rbMkTxPrJdLLZcgx7vTpDMmO6JDx&#x2B;2nmnmPc8/SKfrHUQ6WfrkTe3mrIMWo/t&#x2B;/8F4zsUZfyuQS&#x2B;mU2jqTxIIkH/AObQESPllHDy7Pv2r7G2i19tbpPsvcC92i00&#x2B;0KmmqqShu1ROuW5t5bhFvs1ZcDcKeTcpliIdThs18HD0XtVuO1OMzsowwkRzkBvxNL1bkvET3nbcXrLc7vveMZ&#x2B;z4M2Q5hIGUemOLb4hKbdPkGT6nYU8wK91/xr9zN/3j3QbQ2B3I2ddNsV&#x2B;2tn3q0U12r9v71sjrvUPk1FRNo7tTVddR7Ymbir3sdNnV8&#x2B;jqKmp6fom648j6QybqPeo48rDGYlxUEkVBIs/O5Xzz&#x2B;5nYdi/wDaze9x7NmjnnPd4chMcmHJERJEf4chA5RCIoMUckccOC/QwC76lZ0H1XFoVQ5mbHwi1zuGYx9ZJHSzMCv506VsmFp1JDSoCKOrTpPP4YyJFjP4AcEGb&#x2B;KgtAZ0tEVCEZwgVH9RjnjMiZFZJc1U5IAUKhVCqpyUojgRnjXUWpZ/xQ5B5KiUi7iQkSvLTjhMyRookmhuiBcf6Eb0lYgEHNUCxU5Qxmr0ug1olOirgE6iAFGiIW9TiCsMsueB2QjCtBJB01IhoVEYkYreKCSB1CyWQwuh1AlXPJJASCDMDKGQwCYBrULQqATZQWJ9csuCDpH1BwV0dS5x/DDGo4FaHBqoGumFwQt6lHUYgEg/Ajw&#x2B;7HHKP5Yg&#x2B;3vXISrgh7nJ&#x2B;khnUod9JyH0wgMcZBjdDcbp0rqL5ct0EewAa9KqhgDEY5BIMOLrFiV3L7caPoq7nPBUSbVKZlAOnTSnH&#x2B;lox5Hb1cro7mkhVl1aCkAfJcoajHaXWf4qQYJmuXn8sSXYjkmAgHJY8&#x2B;GnHEqraIl1GagKPmiYVoPaSYHZ5cQnIDEoU4lSvUmafFIaGOZxWKC4rQpakKMljDxguGwZJqA6gk6FAVBXUHgcR4lDAeCWVgp5hNE0xkMhxZNYQFOkYGGXFCEw3Cb3KJQc1KnT5JAZHCwZUnfy6oCR55&#x2B;WZweCC54sh6hx1/gnxwOUdJVoShz4AeMP4405ZlNVQUGR5c1wg8UeCoCJ5cdP5piJa9lWqnBT8TDz88TEihU7BNSI8iugAHHPLExdyHVojyjpnjLG6kY/LxOkFxDhx/BSo/BVA0xoEHxUgKZQ&#x2B;3JUTGaOylGmaBFUKIKvgMaBLMeLIQuTXNCeC5R5Yg1jZ080s6HL7jxXGn4VCFClCeCny5xwuPepADmvBBxhnFM8FJUUibCGnhqv5fDFGLA8XUuOPcPIDL8&#x2B;cS5JlFTzCggC1Wr1CKgfLHRz3cLubc/lXIk89byB9SqECdIHBeBGOpN6RHBdkMa6K3a2W0FjSGkKAxoDR0rwAIBxlv8AUastqQBFy9REDkpJSCZ4T7fBZL6IC5QPUIRsenJYZkJEjTBpWyzGTg8QqJHUS2AMMhqgJKqmE0LBMZCWlEJeVaC8EBpMU1AgGgIR4rliJJLGyTSXuVB6agZ/WApMOIzKYgS&#x2B;jkupuQACL6IFryijq6nRJQceH4YQdXTqo62uH0NIDSD1dRHVxBHA4pEEUogNrdQ5zw5UCDIlfMALDPGWKX0UdTVAiQ4IXAkdJEMioBRBDEBwUkscAVaFIOSEcgYEZk4SCDWhS/Cy&#x2B;b/&#x2B;Rvde09pWbt7uO4XLbFo39t&#x2B;Vua9durvuKoE&#x2B;daKimopBvFXt7b0&#x2B;kq6C6bhqKNvoUtROA/ZTHiYA6IPp3rHNiwYsUpSEc7npJ46tGxPB7L9Xf2t9s7r3Tfd12WDDnz9hzRww3ePE0RkiTLoGXM8ZwxRl58kYVyxBjRfKcd79k9z7dOqxui2MvN9nV9xpLM7Z7Nqb4r9u1lE23bhu&#x2B;6K2muFbRbyvVNOImiqLKZz5QhK6YY9GhvsW8lKOGmUBpOGelydSv1XuvSfdfSmHFizRnk2sTH7chn&#x2B;7ghKMurHjwY5RjLb42p0PNj&#x2B;Z15X2/wB30Gz9yOp70twuO0KqbY7qJFNRU9Q&#x2B;aKZbXWmjEmZJ9C82&#x2B;eybJmykkzWTCgP1sx1fNCY62LcPbVey7nLi7xs5Z9sTDHuIvEzdgX80TY&#x2B;WQI/1RI8Cun7Z382pV&#x2B;s&#x2B;ULxKEZk9j5Ti0k&#x2B;m9zpb3Tp/1F0/qIIVTMj1Fxm9iOWP1AsF6hP07vYS6JHDKQDAg0PvAGgbm0aMB05CX332NTvluNRX07JrngPZQ&#x2B;j0VD5cxD1MmykfOa0scHNRyhVH6WW4xR8pJpq1F2R6X7tPH1x&#x2B;1KQGsqtziQaDkeLNrqO4&#x2B;8W231omWqzVt9lu&#x2B;upnV1VNopP7hzpjzKoZE1k/0i1zy4qrXF7ggV/XwZM0BYEzPuXktj2Hffb&#x2B;1kyjC3&#x2B;gO1rkEUt8OUWw07ukykpnO27b6K1Xi6SHya6oq2mpcyncrpSlTKY6U4rUzXMmOmzChD/1Y4zljKkR01rr/nzXfj2PrmMm&#x2B;ySzYcZHTGLxD&#x2B;L/APKAQw4WXPs&#x2B;iuW4rzLskqrkS79uKfPlOr6r0jKpqNrG1F73Fcg6RLLbbYLTInVE15Bly2ypbQ1SxsvET9zKIEeeRuLNqfcKnwXks&#x2B;WPb9pPfzB/lNuBLpD1kS2PHCrmeSZEIgVJkSaO/U1LuPYW2DRVV0qZU2osFO&#x2B;tLqre0nb1NsyxN25S2nZVHvCzyWncd9rr1Z6OkmGnt82mq6epqnP9Vh6ge/mnt8VMk5CUBTzCLPbqbz1DfSQQTdei4O0eoO5bT7mzwDId3lEZfwDm&#x2B;5L7plnnhnL&#x2B;DAY8hyVzRlCcIAdJoV9IPY1c63cG5901G4auRQX6VabJdmbAmUs&#x2B;fO7eUVXI6ZEul3FJp6Wx3ykvMpzaj1GNm3SUXBtVUTY49w9ImeTcZMmU9MugEQIrD32IPH6uJX5k/uMx7bZ9q2m37bCUtl/M5MZ3fUIx3sonzE4iTlxyxl4dMmwMHxY4r6QOIYXI5QpaxFjGBav&#x2B;n4Y95Lk8V&#x2B;SnlIMgDViVURa9AYahCmYwGoY2CFKhCSOoRgCVyQFf0jC3GyOWqNepSAciMwemK5xUgYgSAwspR/X9QCAHpKKETMIRmThenJVWZR1dJYSQ1WkI2HELzTAbgIDEOyguRqhAS5An6i0RXOAwFiWFnWtFRLA4L0xK/T9JJgEICE5&#x2B;ODwshCpUGAJ&#x2B;gtggGgP&#x2B;rqGAhwKMVdVKaJhbANch4Iq8YFQYDAzCt3Ta90PQRkPq/wBIKeeAxETx5JJFgjQgtzKogEYgLAwT44WLW83txUGAZX1I0zKyQ2LuqYwvMFRrgS1YxI&#x2B;OGEZA6IkQeK&#x2B;hPYKj9G2Xys6A1r5lLTNKI4hjC5Twzyx5PCAz6rx2Wpc/UvfVAOinXLL445iuFFwIKcILHzxBKIE/UDHkuv3xTEj5I1Q55x&#x2B;UREcMXNJYJgIOYzEY5D8cI5rQ6iKKRwXIZZQ4nkMRaqTaoqg&#x2B;BKaa&#x2B;GJBBZ6sqC6pr8s88TFBAABCS4qDDL7fFcVUl7hMaRGMNTlE88SiHRZExHllyxclGVv9Sg/H&#x2B;fHAS6nJNaKNcv6l/wDyU&#x2B;/EsvzVqIApAx4eWfHG5AAc3RXVCYAKIErxRBHniTZUCCM8/imnkuIk1dCa37fZcQoKJ0bR0xoVYmKZZR8zCOEjRBLp4hz0&#x2B;WgxAdNvxQp4fmn4YDD5J&#x2B;SGJMeesOOM6c1KEXT7cMMRWynZCVieR8M4Q0OIitLqQErBeMRzzPGONgVc1KEpxQfd4gx&#x2B;/EX1spQp5qoCHXxyXCbqURKKdSOPDh44bKRcuQUDLw8V&#x2B;OM69Q4KXKvuFldVZIc49IfbpaOSC9bguSExx1NwKrtbdmK4umy2te4L1NiSQURSSRDL8MdQxiSy7kXZWjiWtLgpiiwC8VPED44yRpxCDIuwSc1BCuKHkSdRwKt44wzjV3S7h0Ll/UQqI2P1RPhnh5CpWGDdUgz3UEt0BXQrk4agDMHBe11ugYAUZD1KSQUKJAJHipC9KYS7l9FmIAN3JQK4NRyAKnU2DnHIFoCkfjibq8FtxbVSXADigKlOpRlkgIVcFPesmxDsi6nFAxFCFwIiF4JmDioFksC4anFF09SKT1I7q6iqtKJFUEMFRZckZOHCBxaobEOzAVfmNSsccrCPGyHUB4L0RyAgFEXWPPXHG4ZN&#x2B;QXyH/yf9qNod3NydrNv7lpt5VNzt&#x2B;3N11&#x2B;2HbeuNFtva8mdNnUEi5S99b3uINFtCgnU5H7afUdEibOaWOeCRj0z1bjxZNxgxzBMhGXSGDO4qSWEfEr9c/20917t2n093rddvy4MW2lusAzdQlPNIdM&#x2B;kYMMfNmL/XCLyAqBdfN3bXti2FsPcFJarva9u0O7tvTrpf8Aa26N&#x2B;Xyppd47z25Lov8A41VQPts2baNhbPtNS400y7XZsu3XSX9UuaS4DHpv2MOGUsR6YZKmpYy5gaD/AHFhwK/Sm59Ud07727H3OGTNvO1fw8OaO3h1Ytrlkfok7ZNzuJjzfy&#x2B;ASy4rSiGVturY9FcqG03q0z7PT3CZb50i110icW0tHIpKg&#x2B;tsvdd0mNa2ft8XN7v7HuGNJL9QSXzGAM6vEzziTZC3USw4cADp4G2i9j2sN123Ll2&#x2B;bHlnsurrkCPNUP8AfwwuJ9Lff2x/iU6xG7edU7K22yXUN5oq3bd9p5gkXCw7gly6G70k4NLhJcSWU08TZTvUkTpbnyaiTND2Oc1HN0TKM3m4PA8efA/Nea2n8vusQzbKePLtpP0zh5onhzHAxLSiQQWNDeSmqDMa3pHUGdM1v&#x2B;1MlgsBmtmPlzJYnx&#x2B;l6k9bWtRXNa/Tk0H7/itSBgOjIDa/D8RT8GPIkWXqS5jnO9NzC6aGPAnS3emWulmXNkzKebOax01jkUdQ6SwgkFpdxmUTSX1e2q5cRlBpiXTMCj21cF2px5vzbL2s3K&#x2B;3mRa7JQPvt0ZSVQn0lOJTAyXLldUmuvFTPdIt9DZ6KWOqfUTZ0qWE6wV&#x2B;nGowJIAHmIpz/c3Oit1vdnstv97uExiwmTCT6vWMAHM8kj9MYiRNm1XrWzNpVtifapcmnm7kv295tHLq7la7SbpNr7VRXCQ2ombdtc1wraztjtup9KpuVU0MduCbKayWDStmzDYcv25iMK5JUJuPdxHE6&#x2B;C9V7vu8m&#x2B;GTc7mUdvsNrGRhCcugQnKJb70vpju8sXjigabYSMpfxDGK5/7we1R1feLkaHuDuOw73rp1ZvfuDV7wlUG9jItlddP2FovNknduG7jdeqm/wBVLLjbKXqmW2X0CZ0KBjlz7CGXcjJLp&#x2B;/GLy6hZ9QYu78NF5bsfrru/wDSBtdnCI7VLIMG2OCR2464Q6skMkd39oQhCLD7k2GUv0kr6vf4mu129tl3PvDV723NQ7qqrSLZtW1XmhrrxV2&#x2B;rop8plwqP21NdOg2ufI9OW2oppjGVdPMIa8NBx7v6L2c8O53OUy6sXSIipLam/8AmF&#x2B;Wf7tPVWz712P0/wBuwYJYN2cmXPlEoY4ks8IkmAeQNTGQJhMOYkr7KIApJ6gFA0AJJQgKUB/HHvpoea/FNVByLToQhIIz4kKExyB5X9vctjqLOGVNgC1UaUUA84lSc/lgkANHWZBkboFHCED9IIiILCCuOuMCyzqyIkshmqqCVGUUAUjC&#x2B;nFTVdC5HFp6XB4GoIGUXAZQTywUUSBUmilYjqQkA9MPIBAEJwXpopSGghSQSHFYEEDkqcojCVKelqlCDmCFgIAkAZgpniBIoFKh4hAIdMXN&#x2B;&#x2B;IAjjHUQGSyWXEEdDoBCSDnxKnU4JdL9QpJNNFcMcvnEGIidAgOMxc0eqisvZZZmV8kdJcQ5qKUSP64/qQHHLEF2JWJlokr6Rdl6YSNlmbrVXKpc4kIXCWAxqEnIAY8lhforxXjcn1L1hsOarE688zjlWEQgvP5eGJSMEAeHl5goq4kjmjavURmv5jLgMS15Si/q1XNUy&#x2B;eFqOLJLEMKAIiM&#x2B;KCGZMCvnidVGBCAQjrplnyXFqiUiaaKIk5EcDrx8lxH8VkNxSjmToDispmLImnzyhomvniFloCrIxGBy&#x2B;0PDFeiZMKi6p0AQIQ/CMOYwLBNQUiPE5J5fliWurlqkDPn4L/AAhjbhZ&#x2B;ShxgoiYZ8TgJNEeKkLxUcOeIua8lJrIA6rr4gHGqCPikngmganUKCCUj4flhDPVHgm6A6wXjnHFTSyq6ox8Tpr8sDSdCFEHH7sBpZJLofEJ8/MRhgcaiikDs/H8NckxsDmhAdfP7cMUToFICiFU/p&#x2B;fHmmNKQmB0GvFOWWJSgeJ4fH464lIiB9Ka&#x2B;f54vBS5u9wlP1U1tmwHVST5RXq&#x2B;oscCAsQkcdPc1kOK5cV1wrU/7UzpQAu1JKFEUgooGOqAGJXbiSOYSUJgCjSqw4RXOJxiTWFgtwrVIcCCpKEEAOBDDFRBocQDxQxxlmdcjAl9ULgAoLiEPUUAB8XErn4LgoKn6lxkgltEDmtRQ7QqkF5K46E4A7OESJd4ghkv0yc2iK5lAqZlIOVca6iQrGSTyAUFoRHdRLTmSpI0UKSRzywflZlyERN1HU4ggiBA&#x2B;pdNEJciEcvDESepRZnRKiQKn/TmFy&#x2B;wzxk8FkyDB7FUASFHSIkRKEHMCBzJyXCRwV1xAvVEcj1NDhyEHc1IyCYnLMDRUtOJKV1gooDXLo4w4ANJGuOTpJIa/tdAPQP9v7V8jv8ALPvuZsDZGy6ut2vcr1bqmqNdaLwy50bLFtXdtsnSp1pvd2s0&#x2B;11dXcqujILpDBMZSzSSJweABj0H11knh&#x2B;xAQMozdpOwjIakar9rf2f9u2W&#x2B;n3fcS3kNvusERHJi&#x2B;3I5s&#x2B;2yxMZwx5BMCMSaTaMpxDGJjUr4dTO7Pf7cFks18sexb5a9q0t3ra4772Z283E&#x2B;2btrb8WyamTebzdJt8tkygratw66aX&#x2B;1tjX5S24&#x2B;ebjJvc&#x2B;OoA0cA31eUnBHKy/Ye02nobte&#x2B;nsp5Iz3U8cWw7jcQkYxx1gcOGIx5ISj/wDeHqykfnXZHtAtO75nczYFB3lprRWbwtW&#x2B;r5YLhaHXvb9/DLLvPbVe&#x2B;Xa5lrs9dOtNtlMbLaK62iQwBWunF30jG9pjI3kMe4Dl2IcEFxwBYcxRej/qHv57n0H3TedpOXFjO2hlhkjDJjBODPBpicoiZOkMhlJ2IiRUr6Xdx/ZFsncTKeZtasl7ZkU3W&#x2B;n2rd7PRbv7ey1fMe1tptVXVW3cuxPTM13QbBeLZLlqUYQoPkdz2z7M5HGT0yvGXmiPC0o&#x2B;4tyX549N/rJ3LbCOHuuL7&#x2B;Z3/mMU5YN0aXySAng3P/7nb5TT6lyzI9gl&#x2B;tm4qV1NRUrtumsltqqK09yrs&#x2B;2zpJeXVDxS7x2lum&#x2B;y&#x2B;pzv0f3h7&#x2B;k9AmdKg&#x2B;LO3zYiR0k1DNN/xMXb/J19Y/8Aebt&#x2B;42QlmzTG6ET5sm0iZPo5w7jFA&#x2B;IwxGvSFe7c/wAem5X3l5un/GnWwVkz0zu/eG8d3SBLfMd0uNk2fa&#x2B;2U2cTKEWTLm5nUSST1PLuzttnuckhHJGHQOMjX/lET/4vevGd6/W/s&#x2B;DbEbLJvJZumn8vttvgJOo&#x2B;5uMm8ERzGF7MAwbry2&#x2B;0jtxsHa9/vV1qJ&#x2B;7qyzbcu9xobY6gtO2dgWqro6CfNk1Nv2TYKemo7pUyZjQWz9wVN8rQQomh0cexR7bijgMsp62i7AdMA1qCp/8AilJfFsv6s&#x2B;o&#x2B;8d4wbLt8I7HBn3GOEpmc8&#x2B;7nGUgDGW5yk/bBFDHaY9tDQhqL4f3HeO9ptm7jbxn2253Kb2/p9qbz21NutFe6Kz11VOfMk1lzn7goZlrrLpa6AsliZLbcKSmY8Na9kyDR6TljkwzicYebvrd7uDYciv3PtMnbc5j2/JKOPDljlwTjE4wREAERjGfVATlU9X25zIcgxusHsT3l2KmsFFa7DP3ps677gm1tfu6t2U&#x2B;xSbBK3LerrKqr33PtFydQjdtnqaaXLeJVhttwobbPH0VDJzVDvKR7hPbYDj6DAmVSGPmJcyGof/QGHF14Xc&#x2B;htl3Xukd7nltt7tNvjAx4tyMtcGKBGPa5B1/ZyRe&#x2B;6zQyZokPjMTUfej/ABx3rZ&#x2B;5Nhb&#x2B;r9j0FGNsndHqUe6bdIu9NTb0raqnDrpuGtoaq2Wfa9q3DW1beu4U9hppVEJhBf1zFefovovJt82zzTwRIaYcnqAkdSHAAPERDcV&#x2B;Hf7oMHedr6i7ZDvm4GTeS2ZMcJOKR2&#x2B;MH&#x2B;HiE4zyZsmKMaYp7qcsrBgRHyj6FnMIiRBK5KuQUhXFCce3SNXsvzEK3uiVXNAlgEHqWB0iogUONB68WWgwChznEvCoioADBUQZKq4nLNzQCh6noAUgINVESDo5n5nEQHAFeKfLo6MkEKChEAiRA4xGuCwZZLgVZSSQA7IhFLlJcIIVAJCnIa4m4XWavWo9tFQPWYoQoWBiVzSBBwMiMnL6FMe94V0uUZjxADrDWlckeV6S3muGi34pUuaD6nqyptOn6jNLelCquY&#x2B;X6oc3mS08sMhECik0Fsz9LelpH&#x2B;pC4IMkzBA44xc1sUpTmtaC581kqVLBc98wtlsAhEue5rJeeZKYyX6WDM/vVU0TZZBR7S1zSnT0kFrgsI6gjUKuNCNVXW3bWlCbc2OUD02Ochi0qYh2WSQxqLyNNFxZSwbUr6Wdtab9nsiyMQkzZc6pcVKuM2a45DQ48nj&#x2B;gLx8rregEUnIxgMoRgn5Y2sosSkwFYoOC5BOXDEpHw5omnxQpiS90yAGXBPAR8ymEMxBU5JqaKhmqQAjkddE1xGodaeLHigjnxXlrgQSCFBhHXmqfJcSOQZKIinAEeWfHFVTsibzzEfvONMtPV0zPjjNigjpKFIQCeJhzxKsGNkvyOafiuefLEhgkaE6lQvIR&#x2B;JxskVBQhcMwqjgiwgcQFHTeihqkcRkOCDLLhjLsXQnt/McoJHxOOQcRWiExEA1MI/hyK4gBqa/sS5ZhZMENSc&#x2B;eX4nBV1IwOKpD7R8Ma5FCo8ox4xAxmuikBzgf4QxSBvRSAtJKr/A6KNBhkKUZToDkeWnHALtYKQlFQr4nL566YYly50UhKlwhw55wVdfHGteSqKjp8CTxOvni&#x2B;alKADxPiQRoP8AqODkVLwXv3JMyzW17WxH7pgI/UD0grGHjwx19w/S&#x2B;jrlwkCVVwVWMLZkxjwEUrAdQAyJROpRjqac2XbDWNlaem2A6g4BdPqBTKGhwPRbDMJGyT0B5HTmQIcUKqNYYywB9qLjMpGoLB0p7GpDgpKJFdeBwfbDLkMxTpSXNQEZ9RCOBgSpgfhgOMiLk2XEeKWxuZ&#x2B;oFURxUEjgFhzxxlgK3Woj8wLN7VQPJBiWqUQdTUJyVohE4SwANwy5JSDa14IQXISAUSPVmI/aGICoKOvqDAOGTmhqAByQPUumiE6jGzGQOj6oiz9X4cElw6SWqCWmI6RERKg64yIsWPxULARY1UOHSSArdFBgFWCctcDseC1IgX1KSSHNIiCCCCVh0mITNcckXFeIXESD9ILrWN97L2z3EsD7DuagbV0onCoppzXMFVSVLWFhfKfMY9pY5qhzCOlwzx1u4bLa77B/L7mJI0IuPArz3pr1D3f0v3OPduz5ejOAxBcxmDpKPLQ6Liab/j&#x2B;7fhu4Wf8AJb9W0l2F0k2SmmVlTa6rZdqvUblt7aE&#x2B;1vl0Nms1bMUzAGGcSSQRj1SXpLEccoDOTBiwIYjlSn7V94j/AHH966tvnydvwR3uLpOScWlHNOH05c0ZvKeSIoK9PJZLtv7LqbtpuTbu56LdNNdjZ53qT7TMtku109R&#x2B;1t822WP1p0hodXVVjpJrv/lzSaipeVeScdXbejDg3A3QzRlGJ&#x2B;kjUBveu16j/uM3PqX0/ufT2XYSwQzgRGWMzOTGYnlofpGQgeSPliAwXWVTY7pOc0S5drEvqHqTp8&#x2B;q9R0kr1iXLlnp/cNEQXfQVx5Lcdgy5/JjnjA4l/2ar45t/VO029ZQzSIsA3zOisJu1qxr2ehIfNlNlT5wc6pksDqiV9UikYwjpDqkhA930tOeOjl9H5ZSBjliOLj4D3ry239d4oxl93EXcAXsbknlwF06k29cnypVTUU37OdMksmTqJ1TIn1FPNe0OfSerJAkTpkgwLmDpccsZxelt1i80pwqbfuTm9Z7DI8I45ltWYHmxqx&#x2B;KsN57Out/wBnbp29QVAlV9&#x2B;29c7TSVU0AS6afcKd1PLmVMtpQsldSnoR2O6exbgYJwhMGUokBx&#x2B;B/eut2n1X2/Z952vcNzin/LYdxCcgC5IiXPSePIr5lWH/ABzb9oaOpobze9kilqZlro7nPt0mbX3C72e104dLrHtujnSaO/CuKypYb&#x2B;zMtiTQVOPWcXovuxkJZZ4hjB4uQOAexdfqrf8A903ovLjbZ7LuEtz0SbraMI5JFgGjWWMR&#x2B;o/X1Hy2WM3B/jFrN/7pZP3pae1ldYbJKt237Ddamff7dfr7tMyzMvt33XQ7TfTUs7ftRVTHMpyR/b5EgN6BDHf/AO0t5lmfvHCIRIY1cjWRA/NpwXr8f7luxdt7V9ntA7sN/mjknmhGOIYceYn&#x2B;Hjwyyuf5VqzA/iSkS6&#x2B;p3ZXtVtDsR232/wBrNi0rqLbe3JD5NtlSgyUyXLmvMwy3p9c&#x2B;ap&#x2B;qY765hzjj3bYbPH2/bR2uKsQ7nnxX5Y9Yeq&#x2B;4&#x2B;tfUGb1H3bpG9zCIIFgIhg3AchRemlxJ&#x2B;kkRKnNCAUy0zx216yzFSSW9buhS0ICQFii/UMvxw8hRAJdQCpJanTDii6FM1GKtkfTU2dE4FwTqACqYBVBihEQuI1uFoHVQemAIRVjw4c&#x2B;r8MTMXughwxspCoOogpEIfqAiFcvI/DGXaqBEh&#x2B;CZqD&#x2B;lFOucVEIYg5A4rXMhV9cUI&#x2B;pA7PLKHD6gmB&#x2B;F0pkSAqn&#x2B;kwagJzhwX441UxvRD1RAKoT6R&#x2B;l4CBRoG/6YYDVKU&#x2B;XLe0smMZOaXfW2Yjpb4dQgYFHRAxku3lupGGOc9hMFgGgAtCDlBBwwCjE2Q4bkt&#x2B;2ZLLqslzyCAXNIObxBpT/Ty1OO1jLyJFlxZqNT96&#x2B;nG2pP7Xb1kkH6fStdI1UEXOlNe5yCBVxx3wGiF48s9FnBlE5J8BlnxIzwoRNy5/LifniUiBIyQ/CB0TmMSdEwLCKquiQgnzxKD6JqrqmflEfliSQqI8QNSQiqRHicNEAoUAGuWfGPzwaqcu&#x2B;qEhSoOSqOP8sCakMKpTjHQjLnDj540pqN&#x2B;ZU0qYcSPiIfywlrBTSTyiwBzRSmM&#x2B;CvegKEpGHxjCB8cSmavFK8x/DL4Y0wWWPBWwPJE1jpkM0xE1ccFIjERWMEjlmI&#x2B;eNCgdJYUUsGgCfD8RiaJFkUTm5Jnp/DxxtCMDP9XMAffgarpKYuq6GGRyhyxl6uFU9yNIZef56Rxo3fVCEAKM1jr9oDFe3FSg5kqVHwVNfjgLGhNFIDwHAJ4chHPGeph0pQGConn8lTDG1EISh5&#x2B;EcUg1aulQv5ZKT4pwxsW5oUHMmKIhzjAKMiQI4lIUPFAsQi55IQVTE&#x2B;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&#x2B;lyogKpEqEUiJ8kxxmIFSFsVFaqDJY0NACoqkKqlAo&#x2B;o5DFZAIFBopag&#x2B;nojxLkUnkQCvwxUFEXrFnKMOLXRaECgpEoQiISsT9hhqeNEgalMzaSqAoFAyUwEU&#x2B;r7hhv4IIeoZ9FCNDXRICH6hHgqopxNbiVpqupBDTkIAEarzh1HLjiYi9kqXI4tMCVB6Q5AANVAIC&#x2B;OABDh21VANyaVQEhCpEdQQAq4FIQ8CAJB0AUhTxzWGWJi9EEAeYpjACekROZIUjQI4EiCGOJvigPpWLJ7FUqDDUR01BIT78NWopo9Vboop0glEiWokdCi/hiei0GsEst6ioJQAgMhFRmuYTLGb&#x2B;CCA76opTXBoRUWEC7pOsAYtTUpgAIJ5&#x2B;3sU1I0deqdvqA1NwkgkK98tjYBCHPDSB9RJJBzGOzji3EEldfLLpNLtdfTOnlft6WlkBQJNNIlI6JPRKaNR/DHkSaNouj81cZ5pED5nJVIhgUibl/LP8AFfHEpMGf06cl/PPF81Jg0KD7DRMwcSQ&#x2B;l0ajVFROKfkmFaqfBSCpjnlmv8PzwLJs4VEwHxh9/jiQlrFB4ZfDyOBLIHaZARgmShFxq9EltHdQzMnnHz4cMvDEKVCL3Vw7Pn&#x2B;OmgxnRSXpmF&#x2B;H2TCkMbhLQLm3PnwVc8sPvT5uBVo0wTmFzifPiuF&#x2B;NlhGUCAoM8&#x2B;MBHkoxtuVEKmmCLnqPwxkaDRSa3yCQ5c8bAIpopOaAsRFSQOHnngBB&#x2B;KkQQrksFh4csV3iEvRFr4fhh8UKiAcxzQ/aOLwUgK5Ap9w5ZYxctqSlC6AJhD4qctFCfPBIV5KCAxiOHhEQ&#x2B;EMaFqIIrVBmpMYkHPkOcAmNc&#x2B;ClQ&#x2B;MY8CkRHy54n0UocFjqBp9/wAcNrKUaeC&#x2B;IGpQpn4&#x2B;WFS8r7xSuvaXWUAlVJKkKvVJc1IjVcdfO/S3Nbxk9QXz2rJRM97epxHW&#x2B;EW/UFgMmlWomOkblrLucGuVj3yCQHdQUKR0w&#x2B;pNekcMTpMJAc1bmWCSXkdK5pDT9SRiT54HiPEoobJE0BiBQrTkCUDTwQwXzwgj3rOqpQ4wahDUJahGseATB0h2VVImAKAGkxgmblA4IiYulywoUh2Y3SHMmAAENAcHQEEAUDxJxdIu7cHV4JI9QOaodAwROlsMlVShxk4iC4KLWTMyrihP0h3Hj1AQKJjYAAdywTolPBBb0uD0IBH0kD/U1QhJOISiDyUeBuga3qDiSVjHhwC6JHNcRk9GVTRKcPoc0dH0gEqikKpLYQyxdNQNEuQKWQtIRSEcirEkrkHRgohg6WqKlk9b2AogYhBMCSplhVYBxTPEfpoQDqyhUnqqU0dXSesgoUABOSHKGSg4wQxEhdcsfpqzIOklAQWucChXKKDqEUEMaFQx0QXDaEomqGKoVM/9KGKkaJi15rQoK/ilOeP0hyuyAOQJBzCoY4CDcupwpAPQHFOpAFSPjGBxkyexoEGLl9UHU8FwT6UGZ&#x2B;k5qhEUhHGDXkmxERZG15T6YfSeqKFqmKRIJjywNVjZaS2hoP6vqcpL3KXcC0EqgKYiC7LjAkZWHSj5iKQQcAEA5LgsGSS3mNipBLukEFCEKg6CPVmiY5GADGzOtEKWppFoijkGSJmE1wRrQLjlJixdkwBxa0hC1yJFXLkYwiePLASQWDssxkHrbRVFAgQhyAnQanxOLp14rfUCOqNygMt3UkSeRECQCgIT&#x2B;kQ44qe9Tl2LuNNEbfTCsa1vUUWJX/1EKgOJiKFJvX6VUtwKEEFDmdQhBGi5RwGngFmdA4PBPyBQoOC6HkeJwDhotOCel6so5HIIRnBpyEEjHXFVn1WgC1UxrQ4tc/q1VCE0&#x2B;ooAo6RyxMCjqYtqmN6GKSXfUUAMfBMszjQj1UiuOZkG&#x2B;a927QUgqb3amAEmbcKJhECGkzg5yxKHpGOzAeYAXXXySozVZfReafrcUgXFMuMPhjvF/ALrUQBw5jTiPHj5YypEpiP4ELH44RbVlJggIgxiTAw4JlngUmAgrmFKfEaYlI2jNfFBy&#x2B;GJLlSpzVNE1EM9cXyT7lBXIxPj54tH0ReuiBxVUghTmOKcMVVMboCgCQ4pEw8xzwg1SSSH0VNzIXJEh5nXjhs7IbVXBKkJyQYyyEohOa5ZLx55DFTRaFSq/NfJMvHEya8dVaM8yTHgdeXPGukGouse9Q4LmsR&#x2B;OnLHIKB0IhlH48fzRMLOAVJjVSAivjp/DA5NqFSY1VC&#x2B;P5czgALPqrkmjTw&#x2B;H34daKU4o1D6qVEpxOnNM4YSAVITmPn9&#x2B;XNMDgUKkB0RD5BC3nEw8cD1opDH4L/HEHeqkJTJcyn55csIataKQKmSFMkMApKfLGYKQqeeSDhwxvVSpeeSHzASBjwxWoFLQe6Er1tm1wEXMnyntCKAHdbSdSM/wxxZh5CSmNZAar513dr21M9hKFriQjelrokQHCGOk5NF3I0AA8Vi&#x2B;otaFUaCCEE/06eWAhloyl0sLK2ciloBjAng2EAiq0mGMhjfirqB0cBkiawnoBbBkBCLi0cuHPCWsEJBHSVCx&#x2B;ZRC2GS4iSallPRC95LgYkHOBHKA54yKhxdXgkoFMOZU8iiE4CzEj/BBSHAtb1BUHArmeBgkVwmZpq9tPep2S3PRDm0f0tQEk6KuYGGdYlhVVz1WUAtQOGZKoYKSoKwiRjOMsGNUFIcA0uA6oqoIzJiEBOmmEmQbi5&#x2B;HinVQQDAwCDIZmBRToTjLkOGLnmh2HNKVzQSS0QIaQVVCkQgKgHHKAmqhhDSv6iUiOBzPAFcaIDMOKYlj1BS&#x2B;a1EaTEjUlRnHgMY6D1dRNEyIJdH1M1cpEASVUaiCElcBkA7BRLVf3JTnLyDlhqo4gaYnAPgoyJLkIXZhWhCSOoBpUaFVX&#x2B;rASWHDVQLVdqonElij&#x2B;giCKCBAglUCfPHFINJhwWxMEHqsl9THuLRFpRCGkAEcDFWpgDn3KB6Q8RQ/gmNADUQgrArFMl8/jiNKixWoMNfMUSA9LSSFBDSEBcRmTFCmCpHJa6Q5PFMDAArv6iiqD9Q5qiE5YoiI4glBJEg3txUBjshBEJLgSEJ0IOIv7loEEURlua5HpQiIKfMwMeGN9QajOuEg9VbqepqBpBDki1EaNVJGQ4Y0ACQTqUSAiBEiqkfUHOKgAQPSfqQ6f6hzGHIIuASUCTBuKFpcRBECA9Ii7kpiAB8ccch&#x2B;aP0p66HiqcjXRP1H6QURIa8YYCGYiy5IEGLC/xUgPIT6Q0FsQEKJHwJxrqcHgszPlf8qMAgBwQqGORUDQDAqTAYwS4Yoxu/EomKocXg9ClAgH/4sjiFKtRcnWPzMC6Y1OpQAFKdRJCNKKP9JMMIA1usSmD5o/UriW1pc3M5AE5uQgfSNQAMbiz9LVuiRkQ4qWXT/Y23CfuSy9IIliqdUPaAB/2ZZcHH/UmfLHawgdYuurkdn0Xc71JJjEnOBic&#x2B;WO24vKwXAh4QGeoz1jEYyQHLJTUA1Oq8CM15njirbRSlq5FYjQrEaJqEwKTRlz4LzTXlDEpMGevNNBFUOJSkDlrCGcUz88SbHkoRMh5J54monVkDgT4fM&#x2B;fAYkG3NA7NU&#x2B;yeUeWJQ4IWZ5fbMGGWEfimx8tk&#x2B;H2OIt70VYoU0MePhzMEywKLaOgU8NUy5InxxMFeXmrdsAeP2zJxscOOqyhQEp9vPPGqji6QauiQQX5feRhIe90JzUGmRyHiifDAwdLFMCqEUpy&#x2B;P2zwuhMacvDh/GBXAGfm6lOENYKUFMysP4R44rKQnNeWo4oF8QcDvYVUoMVyQeGZySASOBpUs6kvjwP254QA3BSAiKAQGUE58UwN&#x2B;XRShFUcyfNMtcjjYAFlISuXw8MtE&#x2B;xxXUoJyHD7cUxO9lLTt/s9XaV4ai9MmW9SFQMmN0B4HGMgBgeSQWkCvnPfGdNXOKoS8hoI/UP&#x2B;loKI3HQei7cS4WAMFUqqGIzGRcOoNy&#x2B;xwEuaJ5JRcB1dI4ZDkACh6jH4YrVNVMLoJgI6QSr&#x2B;rrcAQcwgDivT8sXMJ1VsQo6VQkmJjlBARkeCYx81k8Chc1Gt&#x2B;l3JwgM89QCfuxqpcUTUVKUQQSHRHLqKnJEMEC4CzVspwBVW7wsMzovBVjpnxxn6S4qh/gliUBnmp&#x2B;psVhloiYZVdrEanVQL0ZJc39P1xAMEikQdGwCccEROFD9Ki7Ii5x&#x2B;l3SC3KDyTkQoBQFOeNTDipo6H6iwslKSUycIqv6o82rHVTjJjKVImntdOtEp0sKMowKEtEYwOqAph6jC7c1qipzBxc0kknIqv&#x2B;gIrWpzxyAlrVUyVMaBErBOkKCCf9SlDjN5UFU1iW/FQGlxBgAIIYDlDqiHDnjiMYsSQblFQE1ocQ7/bUr/QSSdIOgi&#x2B;ONN5QHf4KFByVIf0kRMUe5SxqK5XFR0tapJJQALkMEmqBoty6ukk2WKt92tF6pn1dmu9mvlC2pm0b6&#x2B;yXe2XqiZVyITqKZV2uqraaVWSD&#x2B;uU5wmN1aMaERShCx1AjpWRDQA1AdAqH4EKqDPnjIjfQMtMBUVRp0npIEIHNqDQqUKkHhjM3&#x2B;mi28upqI29ILwRHRoJROIP9WMOkgsZA3UhnV0lOIEUP05osARjT8Q5XH1VDFw6lMlBQ8c1OUIgOOIUiSaLkj1Al7t7kauCqB0tAAEFBzJ4gw0xlcR8paj8Vasq6WfV1duZXUb6&#x2B;il00&#x2B;4W6TV00640EmraTRzq&#x2B;3y5r6uip6xrSZL5stjJo/SXY7IHTEZOk9J1aj8jZwtSxzjGOacZDHMkCRBESRdiaEjUAkjVldOBYQhAB10XI6KDzxxGsfeqUAIuLqAD0g9TkMYfVHUkLko4YYgO4ZkCLF5WUH6iAUOsR9UMgkAB4Yi4Gi5IszoQOlxJ&#x2B;knXqALk0iMhoMTFi/0lcRYitap7UJMtqlwzXNDFFCjLnjBHTHq4rUdeo1ZG1quyiQFzDUGRiAAo0xmzMqQ6o9ZDVTkcHAEIYEtIIIa5OkoYlpRRxxr6jXh7FAAMHFaq7p2DrCuABc0IA4uJJ/pyPyONiLNImoWG4LsP2/Uo/wCSMmkO/wDjWurngkfVFglNPxfHxx3MIrVcOU0ZdeOzWECD8eanQY59SAFwKEBMeOnEmPiMBB1CUUGkACBy8VI54FJghofGKgHLhE4rKRt8TnlGHwxKTAM1&#x2B;3Lh&#x2B;OJSOCDkueQj9tcKSOCghI58eXnrg&#x2B;SvwSyvDyVD8cSi1whdFIQHzQKEzxXsqnvQgEH8RxCRiMIFUi7gJ2fOH2J1waI1qhIHJV/gfLTFdBLoekfNPPP4J/PDVStWiHMD&#x2B;SeeORmshRqeUE8hn54RU0UiaCfDhDTOOeuJScMock8DmpOeeEqCYqgQiEgpjBQiQU4mpVSNogNfuTEwUp/HFZSpMvPwOX3YL&#x2B;KrITx&#x2B;3P5YvzMpDn9&#x2B;WRSJTVcTKQlE55Jw/LGRUvqpKOYIyhzy&#x2B;3yxqgqpQhOaxWBWEc&#x2B;cMQfVSBY5FEKE&#x2B;PwguFSorxHIDRdCdcWnNS17dsozdsX1iBP2D3HKAaWuOMT&#x2B;kqq6&#x2B;cm4JfVUvCFRMcAqdJB1J4D8MePq5a67cKeC1h7CxxLowQpECGYA0440B5lE1ZLcpLCg6oGCIYkRIygMXNadA5vUBFSpBAzyyJOi58MZk7sVFtUibLICPQoA/KAcf0qYhSMRY3o6K2N0kuVv6ulSkT1AFEQA8RrgAYtcLABezpZY8guVU1hDIAA8MUQ5J0T&#x2B;YBilOAagc2EIROaHzwBjQXWiEp3Q1WhqL9QIaT9SRBWGE8TXio2deR97&#x2B;61r7HdqN892btaLhuC37Gs4us&#x2B;y2wsbXXF86spLdSyJcx46aeR&#x2B;6rGGdMMJckOdpjy/p3smX1D3rb9k2s4Y8m5n0icnaLAyJbUsKcSwXNtsEt1nht4FpTkz8PbRei2mtl3Wz2q7MAly7pa7ddGMH&#x2B;41jLhRyatrGnNwltmgKceOy4vtZ54ZVMJyj/ykhcBHRIxrQn8CrohqAkDqjEtcevLQfphjADHmkNpdeZ94u6m3ex/bDdvdrd1De7jtnZFNRV16pNuUTrhe/wBlWXOmt0yrpKIA&#x2B;tJtwqfXnaCVLOpGPI9k7Nu/UPd8HY9jLHDebiRjA5D0wcAlieJZhzK59tt8m7zx22PpGWZo5YWOq5yoP8gntQvu7to7H2l3Jl743JvinpH7bodoW2vvArrpXzmMkbYmTpVN6NHuRsp/rPp5j2&#x2B;lKaXOx7Tl/TL1rs9jn7jvtr/L7TakjJ9yUYkAXyAEvLHoCLldw9r38YSnPEYiH1E0YDXw5rtOaz05j5ZV5lktJBLwrT0kh4ggdAnIwx6HGsH4rxruXN0LXB3UURF&#x2B;kkIOXBccco5HPBbBBPAMoY5xan0oFJaVbzU8TgJF9XCwPLfgsJuixSd07X3FtmdX1Ntl7gtFXbDX0Zaami/csAbPZLd9FRLa9oE2U76ZspzmGDsaY9RPNbDEMbLn72y&#x2B;2y3e2nb24bBbt23Ldj9w3J1bUVdxlei2nY&#x2B;tmV7mNBJmVE0T5hZKfM&#x2B;qTTpKaekDGoiUSxJk6wxuF7ZuzuNsHYc/bVJvve&#x2B;1dnVu8Lo2y7Vpdx3iltU3cd0cQGUVqlT3B1ROc9zQSUYHOALo43g2253JyS2&#x2B;PJkGOPVJg/SObLynbe0927rHNPte13G4x7eHXlOOBmMcP9U2sPxW4PY6WUIId1EODj9TXf1N1UhIHHAWnEN9IC8eZV6okMUxoahSDhAKV6uGUY/fjBpYPFYNJVqEQ6XH6icnMCgwXQnWPzw9MwXp1LYALxHuVEOCABwLgrGlR1BpQkcG88jjJlVpVSJghotRYPdlVuqk2zuGp2TarRfd5U9mrp&#x2B;1LRfbh/abJcr/AC5Dzaqa73Eg/taB9WG&#x2B;oUi0Jrjk2/2/vR&#x2B;&#x2B;ZDD1DqIqQNWHFc&#x2B;yw7TJvsUO6Tnj2BnH7soR6pRg/mMY6yay&#x2B;Ju0&#x2B;3fvg7f9xtve5S39lu0Vg9y/dzez9o93dqbg7lTn1269jyJ8mmm7lsPbSruIo9q2KZTy3TnVNtl&#x2B;q1sprpQDZjsfQMub0/m20u3ff3Eu1YodWOQhSM60MryL8ffZfpfuHd/0t7p2LN6Kzd038/R3b9sM20zQ2wbHnIJGOe4EXyzcsI5C1WkaBfdL9IY13pPmtlSP3Bkuc&#x2B;lbV&#x2B;kz91LpHv8A9x9NKn9TZbnfU5jQTE49C6AJE1Y/LnzX5g&#x2B;4T9NnLE3bRwNWqWoh6epXZ9IDnj6i1FTMQAWAXXGJO4iG6b/tSCLnUrmT3W7T90u79iWC2&#x2B;07uFtDt7vGRuq31256/dMoS6i5bakzmGdbrRdJzX0VFK6ep1TJe0vqmfQ0jHlOz7jtOHczyd4xTy7foIEYm0uJGvLgvdvQu99C7HumbL&#x2B;oOz3O77YcEhijhP05WpKcRU/7SKRuVpXaPt975bR3&#x2B;3DubvR3n7abu7ET9tUFNQ2HaW2ZNpq6zcTJEuUZFtsM9jqrZ/o1XXOn1jnFtYwBrAFOOzvNz2LLsI4tlt8uLfCZPUZdQ6eZ18LBd71J3P8AS/del8O09K9u3229UxzSM558nUBjf80x5crhhGIDwqSgr6D3r2r3PzN4bm7m9ltre0STRU1udagyTMdOZPm/t7Ta2094cLpR9xbtWTA2dcDM9AgdMsImES7JLtf2MeHPPvRL9T05ml4gaXWsc/01zehhsdns&#x2B;45v1D6iepywaspeXynDEWgzvUrqnuRuup2B267gb6pKCXX1uy9oX/clFbal/TJqqu2UE6qpKepfl6Ie1peRmPHHh9tgG53OPCS2Oc4xfViWJXpXZO3R733bZ9rnMwjudzjxykOEpAEjnwXKH&#x2B;Nrfu8u63tS233L7g3yq3Hu7eu9&#x2B;4F8ulzq3lziypvZfT0lIwIyntdBTuEmnktRsuWwAY856p2&#x2B;22feJbPax6cOPHAAe655m5Xvn6xdo2Hp717uOy9qxjFsNvt8EIxHKFZHjKRqTxK77pZSzGkNXpcIwEIEoDw5Y9fqJ01H4r5bQLt/2/UYM&#x2B;6VYYQ2TapUoKkDPnt6gmanpx3MIu9rLgzEOBqulMivCPiqBPEY7EhSmi4VIGvDiYEnMngcBJLPYqVa8xpqCoUg5omOO1ClMEDxghA&#x2B;7xwgcVJgCQX4xUJ8guBTE2TWoRyjHy&#x2B;eeJVR4oskWHwRFB88sSS5Lm6BEHKA5nn44lWUQgsSig8OMeOJwqrNoluCAkcE8NPGGJWqBpQjkqx5plrE4qq&#x2B;auCQQCkUjll5YrKDg0QEcBDivGB55HEo11qg8tE/UPjiU5Vl1EwH28uMccrLKKOo8OPPww1CWdOaDx5fw0XPE1XFkJrUUBDrwz8V0wE1CkzhzMTkU0zjhpopMaDn5cF88o4Q6kUAYIIxiiQ4oUxOpLzKwH2zhjOodmUoI4jJMvDMZccT1pZSArr/ABEUBTiDiYu&#x2B;itEDgEMeP8I4QGDC6kCQTPwCn&#x2B;eM61PvUoKQgfPy8SsMbH4KQGKc4eeS&#x2B;eFSiKcjpgKljL3L9ayXiUE&#x2B;q21UTkrZZePCIxiQ8pUCxXzm3NJLa2YIBCVIaR1FwBa1QCDA5646Bqu3F2YrTi1zevKJIAWHNSTDlHEK1NktR7JBaIEE5lVisSYZanETzSKXQOClOkAJGOfEhMx44gWQSHpcpLmiPWWMYpLpjiWtlS2AumPeRBrGAEkxQDAXvEOfn/mlwA5qvj17gfen3xrq3aVP28/4t7YOx3cXdN&#x2B;2ZtT3Wd4LTcNy01Xc7I1zKe&#x2B;0&#x2B;0bNIqKTau2dwVzRIoK&#x2B;9TpQqGkzBKDB1Y&#x2B;4el/QPpuGHOe6/e7t6j22KGXJ23bSGMgTvH7smOTJjFZwxAkGjrzG12e2l1Sz9eXNCIJxQoWOhlqQKkRqupewHvT7L717Y2Gr7i95e1u0&#x2B;4tm/d7a31a9wb025ZjU7isVQ6jqL/a21FdKpayxbklNbWUs6mc&#x2B;QWTOkO&#x2B;k49O9Rfp/6j7b3bLi7b2/e5u15CJ4ZQxZJAQlUQkenyzh9MhJi4XU3Ww3MMx&#x2B;zjySwXDRJLGwNLiyrvn7krNN2pTS&#x2B;wXuY9nlh3GambU3fdvdPuxtS6bdsVpo5fqmUNuWbctFdLrX3KYegET5DaZrS49ZIbjPp70nuIb/AK/U3aO&#x2B;ZNiAwx7fbzjklI6/clAxgI&#x2B;B6rUunbbWQyNu8O56GoIQLn3kMBxXGvbX/IR7iLluao2nuTtd2N39bKCrtgnd09t946HtFtC/Wa5zmypW6tq2vu9TWS87ksLJauNRQMqqZ5CS5z88e&#x2B;d6/TD0ri2Me4bPedx2&#x2B;bIJNtp7Y7nLCUQ/28ktsZRhM2aZEhqAvI5uy7WGP7wyZYA2hKBnIEfll0OInkWK7o9xm5u1XcD2/d6doU3dTtbWzL/2v3fRUwou4&#x2B;ynPm3H&#x2B;wVNTRtpGuvTZ0xzrhJY2WjetxAIapAHzf0t2/vXb/U/b94dlvI/b3eMl8OUU6wC/lZmJf4OvFbT72PdYshjMCOSJ&#x2B;mXHwW69lu4ey7x2c7P3Cp35siTU1fbHY9RX&#x2B;rvHbbH0lQNuUJrW3CV/czUUsymMtxmNmNa9qFQuOj37tHcsHfN9i/ldyRHd5QGxZGI6y3Seli&#x2B;jU5rO5hMbnIOmdMktDxppquHtv8A&#x2B;Qd&#x2B;&#x2B;/cXtrbu0twdopXZCZ3Pb2kvdlrLvXze/d1r6977fa&#x2B;4Vs2&#x2B;9tJbKft7PvZZLlzKR1xnOlLMmiU1MfQt1&#x2B;lx7d6Wz7rdw3p9RQ2f80JiMf5OMRU4JTDy&#x2B;901PV0AGgdeUn2aOHZGeUZhvDAzFP4Y4xkb9Te5fUS62a23ajuW3r/Q01ws13pK2w3621UsPpa603GS&#x2B;gulFPlu6uuVPpprh1ZtcjghAI&#x2B;OY82XDOG628jHcQInCQoYyFYkcwWXgOogieMtOJceNwuKfY1sGzdvu2m8&#x2B;23/ABPb1DcOynfHuJsez3yTty0011utjk1syq29ep93lUTKytuzbRNbIm1hf60xrUcUhj3v1/3TP3fuuHupzZZje7HDknEzkYxmwEoiJLCPUHEWYLy/dM88&#x2B;aOcTn05cUZEOWB1DOzPYfgvWu/2xe/e76bYFV2B7wWLtZdtsbwo71uug3Jtj/kFq3zt4dNPUWStmS5v7mRS0sibMmGnltluq5haP3EktC&#x2B;H9O9w9P7Ce5j6i2M97gzbeUcfRPoniyaTjoS7CthoV1dnl2UZTjvccpgxYEFuk8W9m5r3wyj6cwSnSWTn081jJ76d06nl1TpLmS6t9KJzZsyRKqCJno&#x2B;qHFo6OtY49Z6hrUPZ6kcH8KO3Nl1BTwXPPtv2l7jdnWDelp9xXc3bfde5/wDOrtUbA3NZLH/Zbi7YtU98&#x2B;iotySZUqmo/3dE97ZVPLly&#x2B;uVKYfUmTCerHsXqXc&#x2B;md9ucGX01tMuywjbxGWEp9cfvD6pQJqxuXNTYBdvdz2mTKJbOMoQ6A4JdpasdXXRXSAgAVGmKglckLRFAOePWyKEn8F1gSC4Qn01D5jgySwPfPdwlSWGbOeGop6ZbCQBHFEGIq9bK8PqJp4mw&#x2B;K/Jv7ru7vYL3OVXuA7nb1353Mt/fXbu&#x2B;a3aXYXZrrFMuHa2X2x2pWttbqWlr6Zk6ZY9wXq6SKqrn1M51KWPZJCTBFv2Hse17j23FttrtIYTsJQ6s0iWyGZq/OIDADxX9A/087B6v9E4O09l7XtNjP0juNqM2/wA/WI7o7jKOp5RLdePHExhGIEgXlbX6&#x2B;&#x2B;3D/JJ7ap3YbtLK7u94qayd0Lfsyz2ffNBVbc3pc6ll6tEn&#x2B;2irqa22WCupqibX01KydMmMmvBe8lxVceodz9Kd1/qOb&#x2B;SwiWylMmHmgKGtiQwqvzh61/RX1ti9Wdy/7c7ZPL2SW5nPDKM8IBhM9TRiZggRJMQCBQL3Jn&#x2B;Rj2P9Pqf/AKxm12gBwSftruDTOBygJ&#x2B;0GNcRqWlwHHHjJelu/9Qj/ACxpwnD59S9UH6Pfqf8A/wBNua8J4T8sh/YVmZH&#x2B;QL2VzKZ9W33FdvqiTKpJ9eZLZ13lz5jZEibPZIMmZbGVEudUvlem0ODSrwqYz/2x30Fjtpg2qQ1Td30XB/7S/qUJCB7PvI9UhFzGLByzv1aCq5D9kf8AkG7QXrt/3G3B7ju/Vo273R3N3d3LeDb92UV4oLXQbIDnUmy7bs8Wy3XC1SbJJtkthfLbME0TFdNVxXHmO/8ApXeY9zih23AZ7OGGIJiYuZ3l1OXJe2jL6N&#x2B;pf6R9/wBp3fabb0Z2nJn7Jh7fij14jGUpZr5ZZXkJGZk9WZqBb/7of8lHZvYOw7O3sX3T7e9wt7bx3FSba/utlq5m6KPtdaKuFz7g7l21SCRdbxIstMS&#x2B;noJfpuq6hrWFzQq9XtXpPf59xKW9w5MWCMeoOw6zpEF2D8dF4b0N&#x2B;jPqbvPdsg9UbLebLYbfEcnROP25bmY&#x2B;nBjnLyw6yGlM/TFyvlp3d2P2Nke4n2zdzdpe&#x2B;5/efd163xQ7j7p9ze45qLRK7fUe259Pc3Xe1/25k6Rtu2Xim66KRY5UptSx0HsLSSPcthue4w7Xutpue3DFhjjbHCABMyXDF7kXM19z7B3H1OfRXe&#x2B;zb70n/IbKG2OLbbbA0znlkBj0kGs54z55ZSek6F196P8A9ev2YVtTUule5rtFL9SeXiXXXqss8wl5g9jbrbaFhE3pLiWq1qxOPnn/AG930DzbTOQOAB&#x2B;LEr8qQ/S39SceOIn2PuRYaY&#x2B;r/wCiS3Cq44unv87X3H3wbU2y7vptSg9uO1O191uMvcdouAq9p7r7tX9pkyKHcm4aGVPlzaOwWdTTSSZciXVvJmOL&#x2B;ho81j9MbqXYMmYbecu6yzACJpKOMXIHEn8F9GxfpL3/AAfpfm38e1bmfrHcb&#x2B;MftyiRlxbWF5Y8Zas50kay6RQM5Xbcj3ie0mbLc9vuX7MSZYQOdXbzoLeA6EAa0yB0Lm5ennj16Xp7vkaS2mdjwi7fBfNT&#x2B;nv6gQp/Re5EAflwyJ/Bz7lyRtT3zdttx&#x2B;9ruLYL37hNgWrsJsjtHQ0nbOYy/wBsodhb87h3qtp526LxUbxmTTbL3d7DamelRyfXlyZZmTOhsyb&#x2B;nzM/Tm7xdix5se2yS388xM6eeMBYCPAm&#x2B;vgF733H9Lu87P8ATbY9w2vad3k9U7rfzO4HRI5sOCIIxxGIeaMZyrI9JNA7Bedf5Q&#x2B;5HaDu/wC1mdM7ce4bYV1vuwt4WXd0jY&#x2B;2N8WKvm71mMnMkUz3W&#x2B;hqZtdcK3btWGT6dss9DQ57nNUAjvek9pvdj3kfzW3yRhkiY9Uony&#x2B;9qPaq8/8AoX2b1B2D1yP6z2jdQ2e72uTEc2XDOIw0ctKUekCYeMnrQMV9Cr1Ov1/9m1RX7s6Ruu8e2sVO4lKepcZm05nW9wKpOm07GOcOJjj1YDFj72Y4P&#x2B;lHdeXw6l8p7cNrtP1EhDYH/wBHj7y2P/hGW3xdeU/4ydsXDafsd7F0Nypn0k&#x2B;72y&#x2B;bnlSZzXsni33y8T3UDyyYGuDZ9PIExpRC1wIx5L1ZmGf1BnnBiI9MS1niKrzf61dww9x/VHu2fAeqEckMb/7oQAkPcXC&#x2B;glGwTJstnS&#x2B;DgSUUgKAFAj4pj133r5aTSn1LvvsVSiRYLtUFjh6k6jkB5I&#x2B;oMY6YTohU5Y7mCrk3ddXIXkvbCIoOKfHIeGOzRcanKDdYjVPHMRxxkMwuVKQQVB8/xTzwFxQpTUJgM45wCarnFcZUjGikRh5/hiZaYtR0xqxzOkFzPwhi0bRQcmirQDQFFH8eeHVLVbVUQCV1MYeATxxLVvBAUCqF0&#x2B;HAccSyX4oShBMUIX5HIQwLCWM04wP340K14LQjTmnrAQ8Tnn4YCkR5qIx4LD8wNcCzRDD/AE6cDxRMsvwxIWLbGHjp4DiMcokSWUQyuGt1RVzjqi66YTodEJw4ZQTTMx4aYiWspOaIaJmBrDUYaGqkxNc018cAoXUjb&#x2B;cPLTPI4VKY6fE/CBPAYtKqQExKJrACKDjEhDg0rZShxgDkgVPmnwxjmPpUl5nVM0OpPyjzOIeY1qpCTDMk5w4hTjYIduCkCqkPOEMZMgaXUhOeYKcPgfOOGLkVspCQTAIqx04p8sL1HAqQnPNeK6p5jCpW9dL9W3XGWM3UNS3xPovPywS&#x2B;kupfOXdjQy4T2gtOoUuBagRQSgBB5KMeMGr3XZjIs2i0gtdGKoCilWlSqlSc8aJDNouWity1GlQSXEjqBT&#x2B;r6TAqTguHozI&#x2B;SEM6VcUciIoJLU1cCSGwOAFkMAlekyDZgL5Uz6JjXCBkzQWTmhCT/uS3EEhCmFyA4&#x2B;ofPRJFG1XF/ta2vJl9s&#x2B;6/t67hWi27otfafuzvTZP9p3Jbaa8Wm&#x2B;bGv9Y/dGz31lvuMifS1cmXarw2S0uDi3o0OPePV27lLvO09Sdsnkw5d5s8WXqxyMZQzQj0ZWlEgh5RfS67&#x2B;/m&#x2B;fFu8MjE5MUZOCxEgGl&#x2B;IdbbaPZb7R7HQstlD7ZuzUynbPqaiU&#x2B;57KtN5rJT6uZ6k&#x2B;VLuV1kVVwl0Yf8A9qQ2YJUofSxrRDHTy&#x2B;vPW&#x2B;4y/ey937h9wgAtmnEUt5YkRdrlnNzVcUu59xJf&#x2B;YyU0BI&#x2B;VP3rKN9o3tTZOlzJftv7MU75c1rpLpWw7Geh7CC2YxjqQtXqaCiEQxwz9a&#x2B;spQMR3XuBEgxH3518aqPdO5fT/MZv&#x2B;YrTLb2T2p3ykVV991XtX7LSd7bTulw2bsv16S19waS4duKCYRt6422vuNul1VlpZ0lrVt5JZJf&#x2B;lAExzy79vewSG29J92338hkjHJkYywkZiPOCIyaTH8&#x2B;uq5ju8u18nbtxkOOQEpXj5jcc/HVXsv2U&#x2B;z6XUy6lnth7Ly58p8uYx8vZlAyWJ0p7XMeadktsl3S7QtTAfX/rcjpPd&#x2B;4Gh/8ANlret1g927qf/wBRk6TzWDq/YN7KK6e6pqvbD2jmzf3H7pxdtqS4Gb6nr9Z6iVJm/UkW6EJjsx/Uf17jHRHu&#x2B;&#x2B;ESG/6hszN8FyDvfdow6RuJv4g/Ar3ut7Yds7hdNq32v7ebGrb3sU0jtk3uo2rZpl42iaGWyno3bcuf7T95aRTSGhjRJe0ADLHrMO6dzx4su2xbrPHBuH&#x2B;7AZJdOR6nri7Sc8V0IZ9wBLGck&#x2B;iR8wcsfFb21HOernF7j1FxcrlOblcpUuMcdHlouHp0FVjaO10NuFYKCjkUf9xuFRdbgZEsS3Vl0qI1NfUn/wDuKmaM3FcbllnlbrkZdI6Q&#x2B;gFgOS5DIm9fayvOgHpSJRepAECkCI4c8cbsfNcIIJPtVL6EJVUGfGGqZ6jGGAL0tZAfRQGviU6R0kqgReSDXAJkOJaJS3NcSYEEIjuoIRqYRA5YSdePsVfMLmruj7tewXZLcVRt3vDvK6dsauRK/d0V23LsvdB2xfpPpiZ17f3TZ6G52uvmAHpMqY6RN6odOuPKbLs/cO4w69lAZTYxEoiQ90mXufY/0/8AV3qfbR3fpvax3sCWMcebF9yB/wB&#x2B;OUoyiOYBDVdfEX3G7l9tfvP7q2vtN7KfbzZ9w9zN/XyVV7x9wk&#x2B;03XadHQUrny33e/0&#x2B;1rbcGWsUdvpGOnVlzust0yd09EqUJjw7Hvna8Hc/T&#x2B;0lve&#x2B;7k49rAeTB1CRkdI&#x2B;86DxdfqL0Zg9c/pn2GffP1M7vPD2Pa4yMOw645pSkx6MZySiZAyNI48RAFzJgvqBa/wDFh7MqSy2q2XHt/d7xcKC10FDcb1P3fuSnqLxX09PKl1t2m08i4S6alfX1LXTfTltaxnUjQAMeqZPVXfZ5ZZBmEIuSAAKA6Wei&#x2B;I5/18/UvJuMmbDu8eLDOcjGAxYyIxdxEExJPSGDlydUUz/Fb7JmjoHbfcjV/wD3HcPeUokZ9JAvHTE6ouCPq3v5PV94f8kf3LP/AL8fqdE//O4XNf8A5fEf/qrm7dXZ/wDxK&#x2B;33u8Njb1NzsfcvYlmo&#x2B;6Ey233cO/b9Zpf9pe27Wq0zyyrq6O6bkqm08uoZbZ0v9tOkul&#x2B;rOaXFo8ni33q/uW0ObBIS285dB6RCMnNOALc/gF7jtPU39wPq/wBOf1Lt/Rl7Husp2vXDHghN5jplIUEowDmJyA9USC0Sy9V7a&#x2B;0z/HR7t7LU9/O1&#x2B;yq64WHdt3uoqn0FbujZsq33sTC28W1u2xWsorU&#x2B;VPBWXSOmUzD&#x2B;h&#x2B;Ojue8&#x2B;qOzz/pu5y9OTGBRoyppVnPvqvBd2/Ub9ZP073Q9J973EMe922OLdccWYmBHkl9xnk41k0uIW8v8A8VXsmPWT2&#x2B;3U1rwGkSO427gGIilvqXN4eX6gqMccfVvf5XyilnhH9y8X/wC/f6mEud1tv/4&#x2B;L9kVbzf8U3swmN6Zezd4gOeCHP35fZj2NEOnrNUXBsMaPqzvkixyx6v&#x2B;CP7lv/38/UlmO42pD3&#x2B;xD9zLxrvF7Ef8a3YOzWXcfea8bs2Jatx3mTtuzVdTv/dU6bcLlUkKJFFSVMyebfQs/wBypnhpbIlguIJhjvbTv/qfuEzg2QGScY9RaMbcyfwC9k9Ofqt&#x2B;tnq3d5Nn6bxbfd7jDiOSYGDEBGA1JIA6jaMfzGiutr&#x2B;3X/Fh7g7xbOyfbDcFFft6dprHUS5rdlXzctFeL9ZJ9Wa2pvN03HVUjKLfbae4VrmOrJrmz5Lnek0GW1pxjJ3D1b2yEu4bjrhgzEB5dJAIsBH8tBpdce79bfrr6MxT9S9/xSh23uGUMNxDHKEJswjDGC&#x2B;AmIfoFDc1XpE3/El7RnS3y2y&#x2B;5Elk6UWdMretdJI6whc10oAmY3&#x2B;knHAPWneSGJx/8oJXh4f3CfqFHzk7Iy//AAYmngtu3t/i99pu&#x2B;/8AjHrbe3Ptl21dq0O0aU7R3DNtYutDb5k2ZLuF&#x2B;Y5s1lxvtRMnvdOq3D1ZvV9RIATgxequ8YjkInGQnLqPUHry4DkvF9p/W/8AUDtP3jDPh3H3s0sp&#x2B;9j6&#x2B;gyvGH&#x2B;mFA0LDRaxbv8AEj7SKGuoatw7lVn7GtoK5tLW7qbMpJ7rfUyayVTVDZdNKfNpJkySBMYo62EjG5&#x2B;r&#x2B;8yjICWMOGfprWjjmvKbj&#x2B;4L9Q91iniJ2cYzgY9UcTECQYkVuAaHQr6VXWzWy82O47buNKx9nutombfq6KS50mW60zaNtA6jlmWQZLBSNDAQVA1x6wDKEhkh/wBQFxzN3&#x2B;K&#x2B;L4M&#x2B;fbbiG7wybcY8gyRlc9QLvzL1qriz2q3WW12qx2qklUNqsVqoLLaqGQ0NpqG1WqklUNBRyhFJdPSyGt1y4nG5SnkkZTLykXJ5lZz5su4zz3OeRlnyzlOUjcykXkT4krarSwuqGFpa0BwRAV6VATIxGmAg2DLie6&#x2B;hvaCmdJ2c2aFSpr5jgeIlSmMBKqpUnHewfQxXUnd16eVyQHMqCupVMcv0&#x2B;CyqBgOERDPNfPLA5PgpGgHIa5Yy1QlHnp9MCCseSczgIupN&#x2B;GM&#x2B;KQ3vUhfFQhA5pnhK0wuyNI8vBR&#x2B;ajE9FAsAOKE6DLySKKcCi93og18lHnhoL3Qx0sUJJRFA8eZ8xgQWSokmCEJFftDDo&#x2B;i0GZ1ctOevx&#x2B;GRhjRDeKgXpzQHiFQJHz54wj6gwui&#x2B;2f2hiR0lYxkEy&#x2B;ar5DIDG2IJOiLp4EDBfyjjYL0QmAQCxKJrlhDi6mTgvNIKE1yh5YyWIYlSa0BEU5xjn5apjVHQjARc4n4gaQywVSVRRQE8eCxKISM8TmikBQclGS5RyxMNbqQ&#x2B;WsMHJqKS3BSfBUio/DAZNZwpUQ1EQJEeGSxzP34iY&#x2B;9SVzygF4a4gNSpCFHVHXkh&#x2B;PH8MaAAJaylBcipAcSkUhnwhhCkCj7cofHFV20UjLOuVOZmJkicw6EdUpwGvPFeirL5ybykmXdq2Wp/2581WEAoA8gnl448bKLEsuxFiXWgPc39J/SVENIqCNFODVtVyl3QH9DfqQMKnURKpAHLFUcFaq2mgvDmte&#x2B;WXwL2Rc1DBFHSHYK1U7HRkmnksp2uYDNc57nTHvc4vmPeQikuAEOQAwxpx9v2olIkkm/wHuWNorNQUNbdbhR0smnrb7USay71MsBk2vn00htNTzqgj9cyXTsDAdAMblkyZBGEyTCFIjQA1Ye&#x2B;qOokAPQC3BXbi9w6kd0NPQV/pMemIgCeGOM8Bd1AvVktxcoJ4KOkRJUR4w5YLhtdEMDYsEkNPWCTDmUJ4Fw0ON1IY1okSDKDKIcOoggjqRrlidHQUZ4yQalJr9KEMRwQqoKAmAU5HFSglVAsWolPa4uJAAAJCJHp1GmuIAkNK7vyUAGpqiDQQOOoSJX6vEsX4YgX8Ss9TCl0v6jm5ek5AqgPEDgcaqL2UJcVJBSAKKG&#x2B;JUpkkMZL3ZHUWQmX1DqVwKEgQXin88ZvRnAWywqhaSBFAQqjTX/8ACU4YauxqoESvdQQ8KQEUjJE/TDwinjg6XLnjqtD4qxu1qte4LZMsm4rTadw2WoUzLPfrdR3i2ud/rbSV8qdLkPP&#x2B;qX0O543AyhPqgTGQ1BIPxXLttxutnm/mdllyYNzH8&#x2B;ORhL4xIfwLhajs/tl237ci5/8Aj3YO0dlPvDjMu83bVmprdUXEOc1xlVVTLD6l0kFocZfUGKP045s2fcZyPv5JzEbOXZd7uPe&#x2B;894MP6vu9xuvt/T9yZkI8wLPzZ&#x2B;a3PoJXpIRxVq5pBP/AFIOGOEEgObNqvG2oLISDH6SpB/qiEgC7XnywghqIJ1Wo3Dt92&#x2B;u24P&#x2B;U3fY&#x2B;0btuWZZ6rb02/XPblsr7nPs1wA/d22dU1MiZ68maGAK8GY1oRrgIY5Y5s0I9MJzjAF2BIqLFeSw947xttoNjtt3uMeyGQZBCOSQiJi0gAaEX4cQsptva23NoWK37X2ht&#x2B;0bY29aZZk22x2Sil0FsopT3l7xT08oQLnuJc5xLiTE44JZ8mbIcuWcp5JXJqSuvvN9ve57qe/7lmyZ95M&#x2B;aeSRlKXiTw&#x2B;C2EAhGwQN6UOmYhrkscNj1XkurZE0NKB45gwKhYKQRA4TQuNU6OtU3t257e9zLfR2juJsnbO9bbba6Rc7fR7ltsq4S6C407xMlVlE93TPpnhzR1BrgyYIPBGN4c2520uvbTlAkVILOOHNeQ7b3fuvZcss/Z9zn2uacTGRxyMeqJ0lx/Zolbc7Y9utn3q&#x2B;7m2h2/2jte/7jbTSb5drBYqG21VwlUbCyRIcaeWxlNJltMWSGy2PMXAkY1Pc7nNCOLLlnLFGoBLhzfxWd53vvPcdtj2Xct3uM&#x2B;0wkmEcmSUhEmpNbnmXK3uJQhA4KAOOin8McA8tfw4Lx9I0dE0KCEAcI6IrRmRBc8Mr0sok6JpYHIDCHUenpzQRMUCHjjL6ikuK0/FOaVaMgQE6kyRUOaFV8MLOXNSjV0SJkACYFRmeKBRAHCC97K8bLY9vSw6sa5f1OCwJEFLQRHPGQ6yaBfSDt9S/tNk2KWkZkiZPOn/dmO8jljyOJ4wA0ZdUuStvyQ6Q80&#x2B;CpjZ4oRnPigQ&#x2B;BiuWcMZZmOilTU0jBPvjnxwSNaKRqVSK/aGAcNXUU0RMcyqafphD44qyLapCIZxygv8ALAuQfTzRZD6eRVEhooOuJgq17e1kBKpD8/smKwWrAMhIiIRSCafkmIBjRcZqqIgRxiMonl4YquxuiwcXSh&#x2B;oDROUEK/ecQeyQ48U/SHAa/yTEzBlqnvQnMjTMfaPDBdYLKU5a/jl48ssLBNVjmpD7ZKV5ROOVzcWWE5pP45fwJyOK9BZJBF04HVB5/gQQY4maqE4IR45&#x2B;X3YlItQMAYFksSH0TUj4qF1zy8YY0zURyUFdM1McvnoUGK4Ulnxz8V&#x2B;eBuFFKDDAXdSXzIhwhAnLw&#x2B;/GCeouNFKCDlqSPuP4nCATUKSiSqCB0hnxzGmNBrKUZ8ViD4kRCqn5YVISchyBWMc/wCEcIJ4MpCikeOcPvjDEpNlj6gFVdIhQVEBnHEOCCvnt3DZ0X65BhJ6auoYChIIExwIUELjx8wOo1XZgeS8dul3tdlbQOulfIonXO50tmtQnNmPfW3eud0UlupxJY90yfUOy/SGiJIxk0D6rkJAsudqXvfuTdXfS49se3dg7eXzZPburdau&#x2B;G77v3Ss1t3jtbcNTZpV5t9m2p2woZFy3BdJVHT1Uh1dX3F9tpGtnD0TO6HOwSH5WPUWNqMeB48lhy76L1qt3bXUvevZHZZ21b06u7jdub93D2nuZjWOtl8G2691JdNvWmjAmV11uVPTAVBm04fJEpwjFcaINGBY8qUUZGVAvOKn3EduqXtBunvfU0&#x2B;&#x2B;n7K2RuO&#x2B;bY3db6XZF5qN8WCv21uaVtfcVRW7KbKF7bb7HVTv3lRMDCWW0OqULBhI83S4DP8AgPnwQbLPW3vN27vvee1&#x2B;3mzXa9XTuVubY9bumyTLTte9XLaxk1dn/d2uklbypqR&#x2B;3pm8ZNNcKO4/2UzHVgo50ua5ga5MAiQxP5jQe3sUAkWXDHti3v31uO6/ajS93u5d63vW3i1&#x2B;6zaHcJlwsts2sy4712ZuCoG1RerJaqempptbYLLTmXJe5rXkFS1Y4xJhEkVkMje5LsWsSPZl9IL4a3/j&#x2B;4Da3iTdTtfdM2z1JYJ37W8U23LpOtVWJD0E4U1zlS3Brvoc5qGCjGogdQBskkAUC8B9uvcyrvvtH7Vd7O5d9mMkz&#x2B;3s2&#x2B;7&#x2B;33fJMymt/wC4tdxn0N0vNwnyKVlPTy/VYGkMb0tgADijdhxRL6qMy9Nu/dLtlYr7252vfu4ez7Hu3vAZbe020rpepVNuzuWZ1CLlKO0NvFr7rcqc2/8A3TOdKlyA0gep1ENwS4i2q0JNSV14vefe/wCzvavcq&#x2B;do94&#x2B;5jtRsruNtepZQ7hsO9Ltcto2y117gHPtjt9bjtNq7b1V3pmOSbTS7y6bKf9DwHgtGpBmehkKW9grqAoON9Fa3Tun3ukbp3fSN2v2Uo&#x2B;1972duq59g&#x2B;6Vu7xu3Hurf&#x2B;4aHbNXedvSGdqnbZoaS90FVVUyzX269z5QpgZnUW4B1WZ1gniaLx/tD3&#x2B;75b77n&#x2B;yO23Gv7eO7c98/arvHuP3QD7DXUu7a/uztg2WVN/wCGVtJcpdus1rlTqqoM2hmU9RL9Ifq6gHYg4A6hXX9y5B0ydvpZdp7svW67Xde31Pt6wbeu9jv&#x2B;7qex77u9/wB40e0J&#x2B;0LHWSiKW92Klr7fVSN43aZV/wC2LWJ9HNmiMt7j9OEkjRYJagNCuGtke4/vF7hPcr3M7MbA3b249uFj7Ab5FHvHaHc3YW5N0&#x2B;5LvvsW0mjmXXePaix7n/4t232/2xq6uo/Yz7zRO3VX0LiZkxlIejqwxlb209vish76L6LTZtP6s0B9PIcj57aY1Ep0&#x2B;XS9fSZwkzZn7t9LLcekzy3oDoFwMMIDOHquSJoy1P8A57sX/nTu1g3vtR3dBu237zd24l3&#x2B;1u33J2cx/pP3XUbVZUPu9Lt8TCgqZspkt&#x2B;bS7PGZBhRyUdTlhRWPc/c9fsTtX3W39aLZLvt27f8AbHfe/LZYp9Q&#x2B;jk3uu2ftu4X&#x2B;Va59XJlT5lLJq/2Ja57WPe1oPSFTCSXBNIha6qvovPPbp3oHdftD7e959yKbavbLuF322fa9z23tkd5Wu43Orqainl1d2odltrTbbpvNtlpniZUmkpphpmlZobnhIEogvVRIvwWB7Pd/bfufZXcveHd&#x2B;/duO0lNsn3B9wezVLcNz7ys2z9uTJG26u2SNssqNwbyu9so6jcm4ZFd6noS3tJMGM6WudiEXaMa8gs9YdzZl0u2X10tLX006jrbdX9H9vuNrrqG72u5B4BY&#x2B;33O01Vbb6&#x2B;W8OHS6TNe1yoDjfTKNJAg8w3zWgRLVlYU9wtldU3Ogt93s1yrbNUiivdDa71a7nW2Kuez1G0F9pKCrn1Nir3y/qEirbJnFselI4G9xSJP4rWKruHsWg3vP7Y1O5LW7uU3truPurbNgvnzKa93nZ&#x2B;3pFzkzb3Ql8n0ai3y73QClqDKe&#x2B;fTh4c5gaWkjg01ZHV5ukarzn2x9zb93j9uvbHu9vCXbKG&#x2B;by2xcdy3yXa5TqWz2yRRV1W2b6DXzHPl0tuoqfqmPe4l3SXEaYxQ2pJlEgFhYLeq3ur2ptOwaTu3ee6Xb3b/ai4tpnW/uZuneFj2tsWs/d1k230Ypdx7iq7Xb58&#x2B;tr5T5UqSHetNe0hrCi41E9MNEguGFCuffcf7nt4e3TfXZu7VXZW/9xPa9vClmS&#x2B;8nfLYVe29XfsbOq7hTSLJue67JpZFRP3F24qqKsl1FRcqOa59NLcZnS9gwkh/MWA1/Z7U5oL3FQFvHtz7rb67sXb3Fzd1W7ZI2b2671Tdi9od27GvFbdbfv7YosFPeZG4bi&#x2B;qlupxcB&#x2B;5YHOpphlfUGulscDgHUbhiCsO7gcVnrz3e3pZO&#x2B;G1O1n/ha71ext2SQ&#x2B;i7zM7i9uKC1itpqCsrr5QU3bi6Xai7iX6Zt9kiT&#x2B;6mWumq2ypdS2ZM6GAqsTaw1Vccl0FMpJwfJYJT3OnoaaWGrNmtd9csiQx3rMM2Uepoe1rnMiFEcDH3qDAuE3&#x2B;310tr5z6OqbTtKTKj9tOdJYBl1z2gyWhYRKLDGRqVoAO5sldBRhAej1DSQjShIPSSEVWphowkLrfgnMklwe4AhslvqTSYS5LFAD5z3lrJTS6CuQE5Z4uQdQP4I2tDiqkmCL9KZHKKD5nAz6KNS5utu2zJe6sBIa1stSVaCHFw6Wglch5DGg2gZYmQvpRtuR&#x2B;125YJBI/2rVTKmSzGGZkFierHkIAiIHJdUmpWYKHMw&#x2B;PPT/1Y1X3qVDicig1JOeh1wOOKahEBmdPu5ZBBjBLlSMKuceZhgLMrlomDIHT8&#x2B;fIYHKRx1RAc9BHTCVqjURNgvAHyUcMTlaHUQ9EMPDP78SiQ7ahQcs08YBfvywLjkSShIgpAUeA8FKIcSWGhQw4IU8vHzXGgxUBVMRPDKGXguIrdy6oouX3p/GGCmoXGWsphy456LniS6xwybD&#x2B;SRJ8cctNLLCcMswp1Kny5nAG1UjCon2/nhoSWSW0T2hGhF/M84LHEaeCLo4oIg/f58sZJeTB3UmLCMEQfeCUOQjjQZSFxMPEqmgzCjmcRJ0spDgcuA6kJEc/tkoGB3vZSE8ocuXPkmBzevSluKAwMVQpAZ58OAGEFmDoQHh92YCfnjTDqUh5J8FjFE5Z&#x2B;WFSXHXLT4BfPEpEE1Ufb7sEeXFSbJP8AuSzHMQXQGHhDCApcDd0qdlPuW5yyn011W4oDDrmuICDPHQm/XLg67EOrodckd7e1Fb3b2ZIsFk3/ALl7VbssO47PvLZHcLasihuFz2tumxT2z6Gqn2e5smW2/WioAMuqo54LJ0pxGMhrrTgrwbtt7M7RYu6tw7694N7W/vL3kuO2L/s&#x2B;buezds9p9pbabBuq2y7RuJl8o9oSqaq3dcbjapLaaXPuBmGjlKJJBJwGUyQSfpLgC3jzQemIIuT7MvIt9/4uPaR/493Hau1fZGxU/cL05U7ZV/7h9y&#x2B;613p9t18maZjaShvFDe2bisG25zHOE&#x2B;joJkuXOUdQKYZdUo&#x2B;YkvzQ1qMOKu7R7Yfc9s/sLt/2/dqN/dhuzmzKxl3oe4FRY7Nvrde77bZL/VVE/dNJ243Puqsq51Td95UE79o&#x2B;vu5nTbd6jnyjBuIhxRgSgij6LRLr7FbV3y9xVD3D7tdlabtDszYez6KxUe4&#x2B;2ffrdcnud3Z3BbLRQbc2vUXC4bRqqOm2pY9n7ftktnrBv9wr5pAmOLGNGAEvEBx02L&#x2B;1lsEVsSRqF3d277G9rO022dmbR2JtmopbT28mXudtCpv95uO6dyWyr3KZn/IrjV7lu8ybdLtdLyJzxPnz3OmOaeWABzUkycmqyHLEgW&#x2B;C577gUXvU2F3p3ruzsRsDsH3X2L3KtmzZcup7n74vuyNwdsrltmzGzVdvq6K3v9Hdu0bnUPfcGMpw2obNnzWOJUYm6R1B5S4J6XDl2XK&#x2B;&#x2B;/8AHFfrD2h27tftjvvvHvXcd2rLmzux28vHul7mduew9fbr/ONyvNBs3aFoqRJt1glXOc4SqGYOlzGNLok4IiQiOJ&#x2B;HuR5QbPSj3W67m/xQ9lN6ydk7iu/eb3Y0PdHbI2oZ/cz/AM43q/bzZZdriRW2TtzQXa4lzKDaezrqzqtM6m9OfJDQSSpGNmUybsfc3wSL1Wzbn/xf9je4Ft/b9yu7fue7lbjorrIumzu4G&#x2B;e5rdy7u7ZzxMdMuA2GyvpHWygnX9ziK6pnNmVE1oAXGRGUh5iTIK6YAOBUrapvsHts647Nvk73he9msv8A21bdKTtxe7p3NtldVbIoL3bZlnvdFYaaZSimkSbrapz6aYrVbKcQ1MbjOcD0g35BleWQZg623sl7MNsdkt47R3ezvT3w7nSu3e29x7W7abX7o3&#x2B;iuu2u3lv3hUNn7iq9vU1FKlz21dcGlpDyWNa4oMYkZEdNGHAMltFoXux2/wB0/cfaZPtMtXYDdln2dv8A3JaLlvD3O3TdNrotn9o9v7UuUq6Uu7&#x2B;3xtbpW4qzu&#x2B;&#x2B;dIH9npwfTp5h6pqthgLkMQVGI6gfyrKSvZvfqPul2w7zb99zvf33I3jsPdbpuPtxtXfFp7e2W&#x2B;XGuqLHW7fbQ1&#x2B;87PRU90rnXe2VfTXyJ73U1xqAHTmkxxFxwu6yQb1HFeX7w2F3h93XuE23vjaVp77&#x2B;xSi9s1j3Ptjb3f&#x2B;92S0UvdXu7ed6uo5902DZ&#x2B;2l4m1u3bj2Q29MpPXqau4se&#x2B;4V0wGR0saRgeUpeV4jn&#x2B;5TMF6f2p9geyO1Xf2xe5l3ervj3B7pypW5ajflTvi&#x2B;UFXt/uRufdllm7eum6p9op5QO1KZtsndDLNQObbAGghgMcIgep3JN&#x2B;SnpQeYLCbl7x&#x2B;4TbV/8Acf2vuns99xnd&#x2B;t3tdN2bf7K7r2g7bMnsRX9s929vabalrnXfd1xnB2zH2C51tdVXqVNluqKqcP8AaMW4SzHqN9G5J6n8FxXuX24b77l93fZjsrsnvfvXsXuD7ZNobctncnupvLsraR2d7W0uzBMq6O47Ku&#x2B;7xOr9wb93hcZpo59tthbR1tEwTKtQQMYawF4jgsg8F0/cPYB3L3DT7lse&#x2B;vcrsTuDtDfG&#x2B;L33E3Zat2&#x2B;1ztvdqtm6N1UNFa9z3LaEqtpn2vblVdLZb5cuWWsSQ9XtQnCx41vZcjQIcu60rsZ/i/vntXve7q322e4qi7a0W&#x2B;JVZZL/AHm59q7du7uO/ZlbUVcz&#x2B;x23cl1n1FJYrrbqetmMoq6klsfTzS2YIsGOaeXNlk8y9KPoEdI0suj/AGh&#x2B;x3aXs93N3avW1O5&#x2B;&#x2B;u4Vr7qytuy6y172oLPS3unqrFPqKp9&#x2B;3LuO1j9zvjd1yn1Tw&#x2B;6VZNSZB6HFAMcQiYkyd/ckUBui2n7bu&#x2B;0/3EWLvZ3p9wG0e4&#x2B;3tgyu5dN2v2Ht3s/ZNn3PbFF3Hs87b822XTfVPLF7vlrobTMb61NMcZVXUy2zXBQuJnk5NP3q6Q54ply7De5DtxsXtJ2z9qveTtTs7Y&#x2B;ytp7m2lvi197O3lx31N3U3clXVTTfLG6zzJRtVZbaatmS5ciatPMQdQxF6RFWDJIJDn6nXHY/xve6u3V3aK1UXuv7N727Ydh7ZvSy9u&#x2B;2PdbsFT7m2dc7b3Cq5twv1TvTbLy601G5bRWVlRKs9xp2CfR0Uz0wQpOEAg1AIZlx0sAWXQ3dqV3K2d2W7Re01/uS7fdnO/8A3mrrvs/aG7dl9nrpcdk1Hbi0U06Vetmbf24G1DdlU/8AbqhlI241DiWElspChE7Dpo/DktgkDzWW/UXbzuF7OfYtR9tex2239z&#x2B;4PaHa1VT2a2bGscuTddzVdwvRrr9eNubfr5nVddxUtLOmzZUqoeZtXOaATEYnLMARp/isxi1NCCuQe4192p3q9zXt89xVFbvc72q2B2b3FtSmvW//AHBdlqDtJs6xTLBKu1feGM3ndpVy3s&#x2B;59w5Va&#x2B;kutotsuXQVL5MubPcZclrcHUIZOp3jx09j&#x2B;xEnMW5&#x2B;3tzWmdhOzffju7evdruzsN3Z7V7m7Cd9dzm03vuD3a7dd0LR/wCertQ3GfWXO/bdmU9bRXSbZtvU7xZJt2p2U9LdKeQBJaGHGuqH2&#x2B;kCJJL9Tm3BJi8usUBWzbI/xhd9vb/3Tt/dP259&#x2B;NkWeW6jo6&#x2B;4drtxze5tp7NUO7W09ZSV4sWwbHdnUF02jLp6hr6WVcuupbUMExxyxRnN2k0g1OI5KZw7VC92l9kf8nrqTd1I/wB2HYmnrd0bzmbzk3mXsTd1TOsVI6hm0FL2127TzqgybHsK2h8ue1kkConT5Qc8nrdjBiS7N&#x2B;5XnrfpWl9yvYj7yPcF292LsnvV7ue3tPN7Z19DVbfp9p9vr/V2bfNylXAV79/9ya&#x2B;6VYu9Tv6yu&#x2B;mzmncKOk6WlzCmGNCCWYezrYBIAP0svrtLExsumlTZz58&#x2B;VTUsidWTGATq2pp6aXInVs1rQGMfVTGOmECALkxoVNFqlODMvQdm075tbTyypdOnSJSAFXF05gBAyAAz44h9TGzrhN/FfSmXL9GRT0&#x2B;XoU1PKMOkKySxqQ4Y8iGdguvopUePIZHRScgDi1Uo81HBAoiMhx&#x2B;/BQO91IiuQhmQqxBzy544yUo8yAAfy8eEcRJKkxqkDggz4kqYZQwElaDjgyIHXj5jywiy0ACHTFBKACATNRx&#x2B;CjEtOBe6E8BlDWOsRiWeaopBCueWXDyK4FhLdEDRT58geeJ0htEOn0xC&#x2B;CAaw8cIOigK1TQYNK8QeITIeeJQFC6jOEE18&#x2B;GBGr6oopl/R/05qqZY0xS5WNYQ4gDIeCffDG3c0uywnhuRME4fcschivyAKkwCMPDj&#x2B;OeNUuNVMRdNaiCPwOuSHADVSYApw81JiQTQeHmcjjIHC6kJgvOIguqKSdEyxANQOpQBAkw4QReCeeAgsSpCYcOOElgFXSzqDHMpy56DxxxvRKFwivAZajTWMRjYLnwQgTl56/euNDUqQEoM9U5KuXjhcWUgOgPDTngNRWylQgAmmX5IsAPDFEMGUmS3APaV/qEeQjknLCKqXD3d5glboubCCDMrKh5gA8o7P6kJHhjoZnGQ&#x2B;K58dgPwXikxgOhAEQRBzTFCRmSvCGMxLhwzrmJYUugh0AlqObAhSFXMkBpgc&#x2B;eMk8LrJPSDxKtXN6lLUhqBBNQTm5y8Fw1uVCRNTdLcAgKqoRCCrVTMfqQJwXCE/wC0iqSA4OQDIRchaPEuhEJyOKiyIj3KiAihHCJOTRwVRA4eeq0GAfVWpHS5wAAUiAXLgkXNhipdSU5HBwMEByiT8ASPPGQQ7qIc1QtQhQ7MhpGgKQHUT0n44jyugyDsj6SyPS5SCB0qInMxLSvKOKlzdcfPRIJIRoJPEIAvVBSFJUaxwVNAtAgVUFn0lqlpDgcgpTMJ&#x2B;pAnMLh18wC5NXVASSr1jEMdwI06SP0u8UGIuL2RKoqg6C4IgK5gAIpGTuoAwHkMBZmookUVDqILCXO6fp/3CSAz&#x2B;lrSXH6QDAADBBnsskh30RJ9TQSEJRSCg5AZp5Y01yLqiAQoOT2/qZ1KWxawuCo4tKNc4JzOEcCkM3NFNmz50uXLmz586XJP&#x2B;zKmTpj5Upc/SY8uZLBGZaATrjLEF3okUNbq3c36uIahThnoEiuvPGo1DqAohQKDACLcwo1GQ6iUxAUpxSyJiIqDqOQhllpEGGIjxQQRZUjz9UULlz8ioWPI4KX4oLoi1pAICZJHPlomIVo7skBT0gwDRmOCqNYrpliFLPdL6JTqGmm1FPWzaKjn1lKHSqWsqLfR1NbQsnRnCgrZ8h9VbxUED1PRez1E&#x2B;pQmKVaaoNfFXLmAdKkNI&#x2B;pWqrHhygKMjrAqMFXWB1HwT5lTWVAmOqaqfViZJNM9tbNm18udSu6S6lqJdb&#x2B;4k1FM8gLKe10s6jC3F215pjFqGyJ82ZOMsvIIly2SJUtrJcmTKp5bQ2XIp6eUyXJkSZY/SyW1rW6DGKCungtsPchDQ57QTxUkH6cyYLjQs6UbJaGDnEdQLepEHhoOOagYqm11XCcWc3NQxy1j5NOkVwA8aq&#x2B;ae0HqEIxRynhHCHPgiuq9b7a07qm72ljWuPqXKlYpK9QbNDnAIDGHjjUIvMDmuPIwD6r6Fz19SYAAgcWqpOUADHjjyDcF1kmCDPOPh8dcR5qVBc&#x2B;Coo0XUrFB4Y4ikIg4cT8I/Y4FIsLFnUmNP9Occ8ueBaBARiMFTP4cIxwhMah0QRfjqhPDEUyFH4qNMsj58UjgVf4KIBdE5aYkGz3QkhPNQoy5iGWJAKEKNEiOEMIVdNC55/bwRMTukmigklfAQB4ZgaxwIZvBMQcf6OByyxr961X2ZY1oAEIR4xU/njl0fkuJOWGuug1Kj5YmBukc7JihoCoBELBfvzxgkaaqNa2TGgpnzhoP540/C6E5rQY6eSfeuEuLKRjXx&#x2B;yeGApLMwUBIeIGo0PjiBFgUIXfJU8PLAWdjqpLjjJd2CUJzzQqqc8shgY3DKSzDSKcVX5DGg7l6IQIq5kcFKeWFg1FKHZBVBGScficaupLh/OA8&#x2B;WIu1FKDmmZ5ZfKGmJ6VspGM0BiYD5fniClxX3rllm7rpmS&#x2B;e2Z1EENZ1ymO6Wp&#x2B;oKc8dPMB1lcmJ6Nd14aWdPUgC/1Q1K5kISmOGgpouy5uaBW8whxKiCEdRyQ5BRERMcTVpZBFaFkD2j6OpWgtVvQS4NhAkqFB8MLN4oaX1PX8EotCkF6qPpBACOAUnwXF43QwoLFJcoDWhOCdRJcSqkqFhiA1UQLj/BBOADgwEkDpzAJUjNpABB8sTgaJALUuVbvVznDpDUAKdILQfHMwxPoliL3QAEZA9SBAmY/6UzPArgA4odr2Sy0PRQ5ACiqEIVRpGPxws9Asyj/AKVJajQQAAOlqgOQCOauWJ1xLJug6WE/UoJJBgPpGhzRVxgB/gkANzQOiChgCMkRwB&#x2B;kmCqDjYDlzwXIzBQ1rmOKNcjmngjnZ5kIQcRtydZ0coWkoS4fVyAEYwAWLY4mN&#x2B;a0RTkqaquDQX9RIIAKoApI5c8ZDdVLrjFKqWuEOgt9NR0kOBBzVCCmYgRjQB95XJXW&#x2B;q5791fuI2/7Uexu5u&#x2B;O6LHc9y0Nivex9s0G37S&#x2B;XJqLled/brtu1rYamsd1NoLfQzrg6oqZhaXtZK6QFcCCrUrVcZ6Yjmvfqab&#x2B;5kUtSOlzaugoqwFsWf8Ay6WVU5uERL9RATmmNWvdbBDPqmy5L3zAySx7pkxzWsawdTnvJ6QxjGAue5xyQLi05JcDwVVUmfTzXyp7PTewgPE1GvBaSvWG/pLTD/VxxAhT0ooMl7DKZMlTJBeA&#x2B;WJoczqaSgcFDT6anPFXRK5w2b7k7Hvb3Edz/bbQ9sO9Nlvva3b9q3FcO525tlttvaDdkq6hjhbdn7rFZMmV1dJEwdPUwip6JnSJfp/Xx0kek3B9isuDZdFgOa0kh4MAoT6Q5FBCHimuFq&#x2B;5a15MmMY8uBDSes&#x2B;mxznIHPUAMDijViF5Y2gyAC4q7b/5Bvbd3M90fdD2h2jctdau73be7Os1tob3b7hT0vc6qt9HKqN0T9jkUBLKfaVZMdS1Lqx0sTXS/Ulu6HNGIgmH3Pyuy4zliJ9Bd2XbYZODfV9CZ6TXdD5oCy2vKnpe9oLWOKZKuMMXW2iVDQEcUCNbNmkuTplypct06ZMeXnoly5TGFziU6WhTDG7hlr9ixdhv9i3XZrduPbF1t1/2/dJT51uvlrqWVlsukiXMdJmTaGqlnoqJbJzC3qaU6hjDmyvqCzIarmFIAIqpqgJjgajCmqrVWsb63FW7N2Zu3dls2juXuBc9s2C53e27G2ZKo6jdG666ikPmU9mssq4TqaidWT3gOPqzGsbLa4nhhLtSpWDK3H2ouOvYj7lO83fizdyrH3z2FPsW&#x2B;O3e45Aqd5Wq37JsuzrjQbja&#x2B;us2w5Ni2jundE6k3lsqib6N0n1EyW2omAkNBPSKIceb/DwV1dR8rN&#x2B;K78aIglhI6lVAV0TUq5dcXhVchvWy9&#x2B;7LUbqvc1kYjuhtYah3Aek0u6QP6elYwxy426wAuHKWC7ieR1uOhJjFFJPFAcd5&#x2B;K66AmAyOjiuUYJ8PDB1BrqQCGaouhgOfjjjK1RGEdnBUHPgI8VHPAGetkIlCQPnniLe5QBKMHWPkfmcCkz8ctRp&#x2B;OK625IRNVfL&#x2B;eYw6Lbs2ik&#x2B;afPwHnidBLWQnPjp4Zr44tFljbRAcyi6eXgiHLFyQCRwUN&#x2B;9fuxOpnTRk37xnDiNExcloNUKI5A/bUZYFk1Dm6Z1c9Ey5pwz&#x2B;yY35ed1N81jASUhDXPG6EOFhOaDkePhAiPkuA0HFaFTVNDQ4AIjQsP44mBFdESuWT2oIKg1/AnChMGWsDBEC&#x2B;K6jE5fkkBF1KUWIUroNPDxxPXpW6iLsqgo5/Aw/BBikOK43q&#x2B;qUU8wU&#x2B;3njJZmqpkJCKPuxhglLMIoCVMTnCC4QHKkBiDyBJ8NRDEA1DRSBAgyjGK5axhyxsGjk0QocVEMvnHhHXCGNrBSWkOSQHLLjxxpSgKCqxQaJ5&#x2B;eIFwhMB0BiSsYBfJTHAlcjd&#x2B;qf0tzTpxLQydSUr3FU6umWh0gMdPOGnyZc2KsaUXOUx6/U1CXAmESYhEjl444GF1ztTzJZIJPQrtS0IS9wEfpGhxac0E6aJBcUVyCBDGAEKwID9WQThiFSCLqNKCiW4NcUBCQSMEzPhE/PGqCpupwPEoD&#x2B;mDWlxAMYokS7OMYYH6RU0QWAayUSSPqahzaUzETnw/DDa6gwHJLdm0lS0kxUFQ7&#x2B;kxyMUOIM2jqlUMLpZLmK9gIyLCUd0BUgdFxBYPMoCS4I5Gw9SJAURVY5wxkNpotdJB8UJbAKAjkBJLgo/0gJFTjXIXWTw1QOl9JKAmKQH6VCgcPDAIsG4of4KC36emALUBRqKP&#x2B;o59Qxqt1oSrWygtICOfAJ0KCAFP3fLA2hWuoE9KgtDYgxc79RQhy/wBIHjliNiE1qDZcje&#x2B;&#x2B;V3oqPaP3rp/b1Y6/cvdh9itk6w7esz6iVe7zbKa&#x2B;W&#x2B;q3PbbK6jBrDca&#x2B;xSZ0lrZAM4smOLAXDBKoZYMje5XzjtP&#x2B;Vz3YUtuskqR/iI9yMqTabRZqCdTz6y6iilf2m309E70ah9tdVmRMdTl4M9rZwc76wuOUDGI9UieTBcRlM0YuvCP/AAx7p9&#x2B;/4tvf1uTuVYO6o3h30790nffsz2c37MrNwdyNn2az7421cJtLPlSJRrA26Vlummnp5UpgbSyGTWsAfjEZREnFIErT0DsvbrJ/mM7gWbb23rXuT/Gb7zae6Wrb9ltdwq6Ch2xcLfW1Nut8ilqKujmOuMupbJqXSS8Caxr2goQuNTEY6ghDg1DutO7r&#x2B;/f3ue83tzurtL7FvZ57juz/AHHpqCTfe4m&#x2B;d6/8cs9/oO2jJnoXOydtnurJrv8Ame4JjxIa6QybVsklzpLHOGMR&#x2B;3I&#x2B;Ynp5fsUSSD03/avS/wDGAz3h9k/8d/uGvG&#x2B;O32&#x2B;L73P25vTuhub2&#x2B;7J7j1F4vHci&#x2B;VDKZra6lvFNei&#x2B;9VEuhvonPoJc9ssVT5QQBhxqZi5Mfp/YrH1CDTusN/hP7md/d/V3vAsndq/d3t07ctm7dl7qtr&#x2B;&#x2B;tPaKTuftXuPu0zJm8Np1dv29X3Wy2OzspvWdS2&#x2B;VPcZNPIY97WOVuNTEegSjcUKQS9baLPd8P8pncT2te9rux2m7qbNrO9Pt1lbO2Rddh0nt6pKTcncLtTdqqTWsqGb&#x2B;p6yop6esrty1sqeJtDMe11JKlSJlP1tfMShDqBcgAWRKfSwZ3ugnf51exbYSfar71pkpnU&#x2B;ZOm9s7Sw&#x2B;iz6phAk3GYqNBRUIOmL7chQkUWxKR4rzLaf8AmQrdk93O9N378e3z3Vytlb1Gxbx7c9l0Xbyjo6vaXbNlqnOrKm90VbPkF993Pdp5qnVIe9kySxjAhCEjjkQ5uS3h4qJkTZgvbP8AHNuTZfud96/vn9321u1m49i7W3mO0eytoXjuhtWisW&#x2B;rVXyLBIbvKXbpTPVkUNFW1IbNnTZDg&#x2B;cU63aYyLEPR1RA6urVl4fN93Puw3d/l/7X9r6V/cTZfa2n7oXjsvP7OXLaTrd223J23p7c&#x2B;fWdyaLc89Kveu5K2YDUTJrWS5VtlsADnAnGcbTBnK4JpwHNU/LJhV1693c/y5dh6O8&#x2B;5j22b47d&#x2B;4GRuaTfu4nYval57V7Hr9y0l5prraBt/b99lXWT6VRJvFwvFY9sxkkOEqWG9JJJTBfLExib0WnlGTkhqFcu&#x2B;xT/ACy9hPa57Vu2vt17&#x2B;7R7/wBt7i9m5m4tqVTtv9od2brs0&#x2B;xi81NVZp067W2gqGSbpKp5gbVU03pmypgMMdnJGNJRIMukBcWKXRHpNQ67Ep/87PsYqHtE1vfmllsb1znzeyu8JTpcoELMcydbWENQkjVccQgRUkdJ9iuQzADMVxB31/yn3Pfnbn3g9rrtvrvF2K31v7ednpfb4Z3Y/flVbtu9gqa20T32e8zNsWqs3PtXc/cT6p9fVzpbXiXOIYWsK419qR1DCQccv3rjlkl19EQQ4oVaf4L6WvHud78XHZN8lV&#x2B;wLr2Zsdx7lW6zbJ3/ALA2ZZt/i6yJNio7Fae4lNR3e/3J9O18ypuTA9k1z3DrOOXJ0iMoS&#x2B;sGiIQImOn6Wqv1J08CHfUo/Rw4IQeBjjrF6LteFl1H2Ckde4aaaWdQk0VbNLxo5OnqMUEccuJ35rrZJOV1p1GKlfHTnjtig5riVKfEKmRzj&#x2B;eANfVSiOXPwHniPC5T8kQOiaGP58sZLX1VojBRVyXPXzhAjFbxWqCgKYCADA&#x2B;WvLlgRfVE12hQJrxHPTEy2R0xTGoCscj9vjiQeErBUU8tM9I89cKjWuvghJGS5DMcslhgQz3dASmeZz4H&#x2B;GJAD0ChqrwQr8sV1oUHimjLXn4fxw&#x2B;CH0UZePIfbNMCCR7037046J9yYlUWNaE8fny80xurVuipqrgDIJ468viRjQoFBtUeQQLoI6Dgco/LC5IpdWqbl5wEEhHwVcDgVuVU1RAkHIodPwGQw9QNBZbp0sjgFIhllnn8cQYlgqRfy6KCoCGPnrzH3YmuDQLBbRB4fM/yxkt0oQrFOXjyxnpIKUAIzPBDn/KOJiFICicYn&#x2B;APDGj1XQllMukx/H80xAamwUhPDgecViiwiE5YTHRSEmKQ5D488a5KVcfCB0XhmDitdSlvPxXI8tQMKGXLvf2T6l2kvHUjqKQjgiuIZkOpXFSInHTzsZOOC58dAuXndRyJCRPSEJzUNJCFByx1wVqhpZA9OotcHxVwcPpLSIgFywJ0w2Do&#x2B;SQ79OQcODiVXxICYmGi5W5VSg1SgBB6V/UURYgRBIC4npxCz1UqzqCACQWgtLVQkakxMR9JzjHEz3VKo9qJPSCEByJAAiOKIVgMJa5us3YJTgkU4IWkFVBzBAHzGJq0SJV5JaN6CfqaBABqu6nkwLS5yAJgaqObUQBHNJDSXQBHVE6ouXwwXpolyC2ilB0hIdRDwFjwcEBgQcicNqLLIEcgc0iEAQ4GCwUZBx8MKmKWvW4lyEtJQZOJOSIoPnDEm1kskkBSSFQrpxBUZLiUaHkoLQqgtVrifqDXQ06R0xEeeJytiT&#x2B;3zRGADg1wIcHB7Sjw5qkIVUPHywl0HgWXMncXsJ3C3z7jOzHfa0e6jvt25212qoblS33sbs&#x2B;6W9vb7uaa8fTM3JMrZc&#x2B;poRNb9Fa0yqx1RJ&#x2B;mQ&#x2B;kekzGWL3IisLqB9RUTKp9YZs91U&#x2B;Z6nribNM5rjAdE6Y&#x2B;ZOd0NQBXKBBUw1SS48Fctut1lv6mXO5y0j9Nwq5YBEOn6ZwITlA4vmjVJra64XGXLlVlbXVjJUxsyXJq6upqWS5gVHyv3E14YQMiI4tXUxXKXuD9vXcfvlMu0qz&#x2B;8L3KdlLFe7TJtNftbtXM7X0dvY2VLMmdWW7dN12BXdyrXUVsokThLvplr&#x2B;hksfTgIJ1ICmYcVz7t//GX2s7f9lh2j7Md4/cf2ZutZ/dKveHdnYXc2bK393Jvl5ctff&#x2B;4Ei&#x2B;W&#x2B;8bY3BeXAlsuoFBJqZUoljZwDit00YE/Fb6G8F7J7OPZT2e9kmxNw7P7Zv3LuW772vrd0dw&#x2B;4/cGsodwb837f5cn9vJq79XyrfQ0cqmomFwp6WRIlypLnvd9Uxznu1VukpEXHNew99u2N87x9sLz28213W392Ou90uVkuVP3I7WTbXb96Wplor2Vs23UdTcrfV0suiujW&#x2B;nPDWse5p/UWq0hcUFCskA1iFr3t17Lby7F0PcWi3N7hO8HuDG&#x2B;t4f8AKrXW956rb94r9iUjqOXTz9t7bm2qzW2Qy11dQwz5g9NjOpAyW1C52iZG5t7e3yWuivJbr3Z2n3O3pYKe3dre9FR2Mv0mfOmTr/Q9r&#x2B;3fcimusuawBtLcNv71oXU9MyS8dQnUk6ROcSjy4ImC7eUsUAMXC5c9tvslunafu7u73Gd8O/29/dX3/vVnn7S213B37bqTb9r7XbIrVFx2z262Va62qse2v7s09E&#x2B;fS&#x2B;ksr6Gtaq4tG19vb9iOlzWy7obQW98xk&#x2B;ZabK6olvZOlVb7LZ5lbJnyXgy5wrJlCasVMpwBbM6&#x2B;prgCCDHB1NVaIB0qEqZt&#x2B;wT5pqZ&#x2B;3duVFROeZk&#x2B;qn7csk2fPmuPU6bUzZlBMmzZhdm5xJcYk43XQ0V0Bnai8N9wPYq&#x2B;d39qbf2/287mTOwN0tO8rNuW67q2Z2z7Y7oum4LRa5rps/alVR7u2/XW6RQ16g&#x2B;p0vaHAepKnMVhNfKWYqYEMh7B9htwdsdoXOz94e69d7o93XDc94vNL3G7nbA2Jbtw2qxV1Q59p2hSstFunzJ1vslORLa&#x2B;fUzAT/wBqVTyg2U21c3R0lqFdB2&#x2B;z2i1Am2WW02lk1PV/tVst9sM4iA9dtvkSBNEvTrBTTFWqRQlZuUHdQC/UXI2DtFCEERhqYY4xfktkgWsuvewNL0zbjUKvo21ktEKtfPmfVyRMvvx2NvqV1cjPRdKQByWMfsMc640JUJAg/aBVYpjTkORQKUQK5hM8l/gDjLpR/MDPXTimWBXijEdRDn&#x2B;WmJapUaKRCCpl/Lz0xKFn/wAkwJxieKacNcSuSaMsyYfAccziU9XKgnMRVPtyGJTfmQakKEOfgNc1xIqaqCVgIcs4nM4lB6cEIKfHPlzOJaobUTgQkM/trkMJQDoUIKkeOWmXywaqc2VxHic/mmWJFFjGFUj4kQOir4Y5QQbfUspzUiMjw/LxGM0a56U80wQCZhdYEwX5Y0xaqhdMzQhMsjp/LAXJpZbfQ3R8EUnkFHlywAsiJNQiVCOOv3GONdQdgiTuxQk/VmPzI1GMdTjk6EJPmc088NGa4QhOqZwTjwXzwBqPolLWKkfb7zjYa5uhLJOUP0qf4YGYqUGBOuflFPDCCLaBSAq5ImAKfBMaUgVFC&#x2B;BPzjywAupSI5j48dPNMAFzopGOZhw1P2OGvvUua&#x2B;/Ugvn0b0cT/bw5vSOkq17mn6hkjcdTcBmJW4XZcpTQ5rFDOohQGscGuccw0uMAHZLpjrtrquz/ALVayzNc0&#x2B;s1jJxiWS3OfLYA5Ojqd&#x2B;pzVCu10w1aqQBaL9PzUzZfU0EIdCHZA5grnFMLlBIsUt4&#x2B;kOIQjUECCRU8TgoywR5qIP1lzFauTjAtCBG9SxQLjVXT1HqVu8vaOkEOUIelqBARpzw&#x2B;CyeIQn1HNJ6UCBvSUDvhzGBADlKILSrlUEggnoaqI3kEwCzlLAWshHUEJADwCpzgTFIZlMQOuqKtyUNeWlzm/U0tAaHhqN4hrSgTnhZ7XSIk2uhIc3qIAGrSfpBGWWXTwxBmWwALlQXEf6Qpb1AAgjLhksMKwKJbjB5T6jFoQgjpKKuSkYvBLNUcFCHoH0q5VAWMQvUEjnpgWQhCNIUK3pVwIQL/AFFvFDwzwlylyQykNLlAcA4o5rjkvLRExfvSAH4hUF6lP6kKoE6UJinEouLkokv06JZLlzBcFUpkM1LtThW&#x2B;kPRMaSEdA/T9UVTTwTAVkhyVT0KkkdBAJ6QpRxzOkRi&#x2B;agGD6qvT6&#x2B;ktQBrfpMAEAMeUPniSz6qnFrC4ENc4BSFiCUiggXBfDCtMwUBh6QCga76gRENPAiCLi1dDtdGR0gFUESq/UgTQ5eGBIIIoo6xmCB1HqUsUgng3JDiQOl0TxByBqJ1OLkiYfpOoOIBaKlrAXl3EggkBIJkucD5YroP4K76YQAbkR9UAgU5ZAjBa60CQNFQI6lJzRAERYIDyC58cAqOazfxU9DHhE1DkKxzJHHGlAfFMDIQYgBLmkfUmUXLFQmWAke5SvKdr&#x2B;uACCLSgHUUOQOf4YyWZTsKLtfsTTCXZLpVIjps2nkkjJGMUjxXHYwReBazrqzvVe5E68dR/COOYDVZQuceOS58tPP8ADEST4KUDLNDmgh5IYZnGb3Uj8kh8ofDGywHNkKj1CAQ8efCPhjCUaoBrwGhUpni5LY8w6dUxp5faEPDEqQ5pocB&#x2B;AiI6hfxxLLSFWVFwQ8chqCOeJR4oCY6L4L8cVdFrpINEJIURisPhiWmqhDgSfL&#x2B;J8MLE2WC9jZGHooJXgMgNV5iGKiiQaBGDH4eP2hiHFQCavMY0phzWOaeOY&#x2B;nTVIQwggjmspzCipqn3cNcQNSq6aHED8FgdMbYKYlkxvHSMdE4Yz0jW6TfmjBOh1P8EgMABJ5ofipA1UrH7vHBatUn8FBTTl/FcQDMdVMGeqBxTLWMOPPLNcDeZkIFip4aZ5Ecs8aDAjiqjJZP1ac4xgeUSvDDrS6EsrqY5w55jLEdHu6kJ4DM68P44magspBzVc8iYaEr4Hhgq3gVKikSEThxyX5Y0AHUpVVMOAhzivMYKSHgqyIQA8IEZQxqhqpeB99mf/Gtk0NMaWYwuVMnnWIT5nHX3Gi5MRaTrkScAS0HpJAJ&#x2B;kny6vpamOoFz2rdWznEqrfqAiPpAKQMc1TDookPRAjkOQbwKxCr/wC0A&#x2B;OBqu6h1FKcxpgQsAf0kAFP05ph5LFT4pRajQehA4/U4gAkJCJcDg/2kpI5hLd9MWhxcT9AIXLMEqQD5Y0LclPRizJbg7rBLTp1NQEqhagEUgBniHEJpoEL2ucfrCtH1FQoTQdRAa7454hdliylwCfS5VAUgH6WrAnIQOC9Qlqsbq3mNKkk5GBgQ0A6tCEY0XHILkiAKC6BxLmlpOfSQhAVDk1UhHniN0N0yfRE4ABGjqisDHpg3pJyKZ4qJoH0dKIJJZ1FqfV0/SCp1JHUqLgXEKeKYGOTp&#x2B;nqyQlPj0xiuuHRaYdPUhDCWuXqgUiiBM8kIJxPwspq1oClmEMgMgDpAhcwvVzxWWm/Kfio6CpCAuKkkfUCekwBOq88LrVAOQVNlgABFKFXfpWEF4kA&#x2B;GDwWOqTEqGhEQNKL&#x2B;oxj4FAIZYkguzqGtLZrySSwtAc0Bqh8YxKEEaYvkkuaCiJCOkGHghIgYIiKBxOIHRAABsVJDAXHPNXNADkJJIUwLVxJBdSAHI4N6XCJA/TBUDgCuueKlk8ioQqXIBmXZgEiOQEQn88SRVRqS4fqcioRl4wAJhEjBKyyzeCXWVMiioqq5Vk&#x2B;nordbKadXXGuq5jZFHbqGQ0mdVVlU8tkSKeWIue8ho44teqqjal1pu4O5G2Ns3ztzty5Ov06491bvPs2zqix7W3BuGyTayTb/7q19/vljt1datpW&#x2B;ro0MiruU6mppz0a2YSQMDiJArVDkHlzWK2h3t7Vb&#x2B;3puft9s3edsv28dlmqG7NvUgq5dxsb6GqfRVX7qXVU1OHy5VSwt6pRex2YJbHB1guAardLcF6ywDqBcACOaARGcIlMasELSt2dx9n7Fvnbvbu6ry22XbutuGv2psSTMpqx8m8bgtlAy51lBMqpMmbS29zaN4dLNQ9gmuUNUgjAToblRPwW&#x2B;sH6h1EEO9ODUPUCjgVAIAcEOeDRtEEPdXdNLLprZYSLg1FKgE5MgiuXGWN9Qklo0su9Oz1L&#x2B;32gZhBb&#x2B;5rZhaP&#x2B;mW0NXxUY7uD/p8iupL6l6aSSYfD4D445HZZVFQqknLjwjygcZlelkoVRusT9jmPPPApSCp5fwSCJ8saMiQpFrkqaf8AuzHFMZV4JnEHx&#x2B;3imJIujaVgdVTw4eWJa8oD6Ojach5BSv5ZYVosB1cVOn25/emJTA10UFyKv24RisNMTqcFAXa6J5qf54CiXHVLJ8h9uWGtkENW5UFxAjkqc/jmhxM11k8lAm8T4fhyONAGVQpwLI/WPEZcf45Y23zUhCCKqqDxOOKroomNCkeIXj9&#x2B;NRBu7JofBXLdSoOXGPMZYeqrBm4pNgjC6oM/ipxoEkOhy7BTr8vtomMm7BI&#x2B;lHovLOCDPIcEGIAe6yHejBCYmEc4/ZcZr9Kn42QOzHgfLKJ5LjQbq8Cg/glOSMEVBA&#x2B;A&#x2B;eH5qSwgC/FV0yAOjsLc0JZ&#x2B;/wCAC4DERDhSAnNESAVFU8tMRiGcfUpRFNSVPgPgdcDECtlPR0PLIqVOHSl1Kc8oHSCE&#x2B;eQwV6mUmjjqeMD4eEMbtZS8S73yuuzW6aQT0OqQE0IDXAkERRcscGcAgE2C3jAckrjucGh6oCHFeoI5VgSdRjpk6BcxJPuCtC2ORQCETpERgf44iR4FLeUA3QuajGkgArHn/pKj6geODm6iSCluY4n6m9JEAYmBaqAcIfHEDoLoFqJT2kEENB/1cVKZFE1wmzi6mDaOluYxoBaCOohUJUkEoc2hFzXCK&#x2B;CyoJ14L/ShzMQEK6HAzkOnR0onqai9JBKOeTmkYlACNAMaI1C0Q8m5JPT9LWjqIUkkfTqArxEFpK4gs3qVTw1Ogt/SqEAF0SSIE4CQElnfVKd1OLukAqC0Ko0QA4WeqS4GiBuSEocoEkwJBBJhphqoF71ClCSQT0gFHEgoG&#x2B;C6/DBV0DpHMoOkF8NHICEJIAgoUZ4VuRYclTVjAj9RUhCUWOsSPuxfNB87FCga0K2KIYDI6kHqIxAFTAUqqDiHfSVbmAAifSAMonAgAkEUoq6j9Tl6lKAIhBzSIUIOGFgoRooB6SYqSE6SYAEff5YkgVtRUAJgSJdEaKoi3mBH5YklwChDerq&#x2B;oNPIn9QQKAEQr54qaWWGL8kYb0pmTD6k8yQFBLcTLYDONFITpLU&#x2B;k8ChBMQhDUTF4JIBoj6QjGwCLmOolGlSYkR5jFRlac0RICqWgZBAQFgQ7KI8lwq8VwV74vbB3o9z1p2rt7tz3mtGxtlWm33wbw7c7jsd1rbB3Bu9ZJcLPcbnd7HeLNcpBtc5o9KTUisoJZ/3DTvcBjjlAyNbN&#x2B;KJCRDRRzq//IEnZqTJ7AdjaKxduxbJW/ds7Z931&#x2B;oX93Ka07ZFgtdBU3Cv7ST22ay09ylsuM&#x2B;neyf67gJQLQOrB56AD8f2rPTR3Jl8F5JS2n/J7X733Vunem0rXJtm7dnXHasvaXb73XUVg29sqqmXaZUWbcPb0z&#x2B;0tbW7TuNstDmU0&#x2B;Yx8ydVzGmYXBUxppa28f8ABUg9QvePbTs730bDupsvf3un2o7r9tp82vqrdVVlvvtd302lKe1rrVt&#x2B;49wKOttW29/yZEyE&#x2B;urLQypc39LhgAk9wY/iqL&#x2B;5e7d7O1UzuxbO3dEyok0VVsPu9tLuZT17/wD7ilbt&#x2B;VUyaxlGjHJPr6eoEotCAtzwTi4ABsXTISNl7pUPE2omzGgtZOnTZzVgWiY9zwBouFhd3ktVdirm3S3OqZKH6jMRwKoYggxJIU/DAUEtRfQbt1I/b7MsjXZzZMychKlZjyhjBMd7F0jGGsurL6iAtyKw8PHx8CuFyhV1Q/I/PxOuM1topRDTzisfwwspV/DApEDx4R0ITRVGJSYDlFdOXkgzxJBZEmh&#x2B;EdOSLiWxWxRtJMI8l8CIcsK0WHij8T9tYccSL&#x2B;1EJOYOiJx5ZInywfNYLgkiyDVAp5p8UwpAYcmQu/H7aQjgSGNBZKMeOsYeMDlBMSzIAFtEjUrwgvHX5DGwx5JN2jQo156cTmiL4phccfwUxTwNR5fwHgMYAWWonsjH&#x2B;GQgOcMJkNAqNPemtVcss&#x2B;HicaYWNkyBCOPgv35QyyGAkilws1d9UapprnnnniiSJcz8EhG4n9Phpw0&#x2B;GGrmKOaAECPLLPL8lxNxuykHNST4ZL&#x2B;XnhA8tUJTkBReKGCZiOfLE/8AqUlkcMhGJieZGpU4iANWZSVoB&#x2B;OYTXjDEWFNFIEimi5YWIiwupVAKgKHj&#x2B;HKGM1IZ1IV&#x2B;Z&#x2B;3yxsX5KUgohySART8eC4DdSZ&#x2B;qCiCHPPkY54S91LyHvPJ69t00wgwqXsgQFLmCBWCQxwZ/o5rUDU&#x2B;C4vndIf0hAiEgRiYAOdlAx4Y6ldVyq2MT1NJ&#x2B;kIhUAJoRzGMit1t9AwSnNXMkK5W/wDq4dOuE1pqqRBZAQ5oCkuQmJKnKACmBU&#x2B;eGr0CAQBo1lXT0wQ6KhGcYhUyOI3dZJculuAGWYHSTnmVCiJ88INbK&#x2B;SAtdADq&#x2B;k9RLopAgAJEjXEyqcElzOuDwHSw4O1VxQwB0/HFa5qtW8UoNdkwlpB&#x2B;kFVQEFCoHPFV0NQ8EJUlw6ctUj0nRuqLiYGiekAAlKVzR&#x2B;kq1wUBCYmC6lMPyS1aqCPqVSCSSQkCCQhPBIDEkBzT6WSvTaHGCGY4BxeSEGQWKJw44mqStBG5oEAhcpa5FBhAoBEkYtEHnRCIK4AhIwUodFBiQRidY6iZaFQS2I1KEgHjkQkSscV6rf1ClEIDgUAi0NAcQTDKKZx44uaGr4o3ZMOpJDiGw6jm4If0t44vmksKFLcC5XlwUkdSNCwRAUUKRiLrHVI8bqAwFQWEOJJgDFykKDAmIxfsWpWZG6WAGwcHNcA0n6S4lczFpdyxDmqIMfBQGHrPW0kD6I8CVJRYqTi5rQr4o&#x2B;ktBQomUIkkwIWAAyThhUCDZA55JDQhdEdQECq55c4YGCCOARAhqBQeowPD6UiYiI8sXjdQfW6uCGsEQOpELg7hEGMY4qnwSi6QoDmhSWgE5BI5IpCZHFdBLBCRFpDQEgCB&#x2B;kgrEARTGau1HUbVsidLao6SCqqhILl5jjHC7eKgjaIgNURRVJKH56eeM1ukvonZgMIIQqsTHjxEB5YSPcFaLN2loNVLXU6alIAlderAKrEmPiy&#x2B;iG2ZIpduWSR0p0W6QozQub1HLmcd4RYRezLqrNKqQIz1VfgsMai7l7KURyGQjlmucdRhvRSgealRDIH&#x2B;OMVFkoyYqnD5DGWIUpBVdFWKLA6eGJSNpHJYcIQ4QyxKCnPXwMVxaLYLB9XRhBkg04&#x2B;arhW3cUuiz1KZc&#x2B;KrxxLIBYISclCqOMUz5wjiWvGyEGHPnkkMToLXQugFAWMY5YCstE&#x2B;XRJOqQGfHTLTEsmoAKW6ATh8DDTyxsOzhaZq6/JVHgf0r5Ln44kv81eCKE8PgcY&#x2B;awGZkwGI4rnrzjlphsahBsmtKGC6opK&#x2B;TscjOXTcVVCZ9RaYBPGP3KmAlRiwcXTAuipnrHjGIzxjWiq21RFxiqrn8o88a1Y1KECofHLIQzidMsQIF9Vph0uoJCoPMxTy5YX8rCizolOOnz8DlzI&#x2B;7Gq2CEsu01OfHz5YGDOLqSyTHh4pr45YCzDipDnl8oEomWgwGRI6VIFMePxB80zxW/4gpQSV0/j5LDjjXVVzZSLh81Pzyxq4UiA6YqAo/IxMUxIXmvd6X6mzJrh/9KqaWosC9vEeHhjhzxfGTwK1EjrC4deT6hZ/&#x2B;UAqujo5S0&#x2B;EFx0ojjZdh48KrWt1bt2nsax1e5t87mtGzttUM6RKr9x7iqJtJaKJ9VM9Kl/eVUiRVOp2z5xDGvLejqIBIzxEgVNkPWiO6X&#x2B;z2rbNw3nU1sudtW12SZuSpvVvD7jSOsbJLaj&#x2B;40Zpw81cmbJcHS&#x2B;gj1AYYW1CDzV1a6&#x2B;mvlDa7jbnmoob3brfdrXNLCx9VRXSQyqoJvpk9Uoz5E0HpJPSsTiejq&#x2B;axO3N0be3fbXXnbF3pb5aW3C5Wl1xo/UdSm5WWtnW67UYdMlscZtDXyHynkBOppQkRxDiPBJduSzTg4FHKCQCvTkCYIR9I5ccQohAgILWlXBGrr1LE6Q8MQql9UkuUkEfUwh2UGgZ/qP1LqcNw4T1SArZY2VdLbW3GutUi40U&#x2B;62htLMu9tp6mVPrrVLr2zH291xpZTzOoWVzJL3SfUT1Q1xCgYBweqH&#x2B;KvyUB6VUwdkcsi1YAkZprjS0DxZkgMQgljQn6j0lgAUJ1BwCOwO5ZQI6mNkTmFiF7Hs9RvqSw4O/3G5dbXZFpPDLCtoOkMaZjkLU/wCnoMSOqCgkeWJLq0l19tmV863MuNum3KikSKu4WeVcqGdebfRVZcykrblZpNQ650FBWvYWyZ86UyTOc0hjnEEYFxkdRPAK6P1OJL29I8VQDwgnBRyxOshrVQtB/Q09RdAANPUer9IAHUSp0EcaXIwKIhFD80AeCYoBkQfqBCeIwBBieNUB6HKxzkEHAfpAGgzCDDzWC3wQuDukAFQSiIDmfpOakcuWWCxqExvVUroAEqMoFAkESEeeJLgjkia4dP1jp&#x2B;o9Z&#x2B;oFwJ4Kq&#x2B;Aw0XIOOip2bmqfpAQu1BCgKkIDXAuMFvBRMPT9RIIEACQB9UEB0TTPEgBw6FAEKqDm0pBFWCgoF5Yua2WLkGyNrAQGlVJcCFQ6oMjA8/LEocdExYvagDmjqI4BoirssxhSC4dGwIQW6jpzDhxBCZALxwfNVvFG46tzygpWKK4OaQnxxc1ClUWSNQRiQ5cwVSBzhjJdQL2TEWLiDmoXqUqMwFIh8MGhZKIAtUlGtOYhwhFc08saDs1ysvWi2rbMgzqyWip6kpidJKl72NCDgScAeUgsyDs9F9E6eV6VHSSoAy6WQ2BQDpltHCEMeRAoAbBdVH5&#x2B;QPErlxxHipUFXPMLp5&#x2B;BgmMxNa2KlBMCc10KwSOXA40YnRSIZqFyGf5YxIMK3UiBKEJqmX3YxzSiGUPuA/8AbispEDygBDjz8cSRxRhc8/MJzjiXJQUN1JMeUM4fcM8SGYPqoXnz8&#x2B;fPCtVQlwCCByHCHKHPAs/VxCAugnzIT7LiIQaHxQHKHCEUwhAANSUolQmqxJ4&#x2B;HLGn00CCxqo6imf9C&#x2B;S5YqpYK8CIBzGUcufnHGQspiR8l8tU1OIGvNLlNaV1gBrr&#x2B;IxsEsyKuiQZ/bzxPqU9R&#x2B;CYCAEGZOWn8jjLGhoyjVyqL1hqh8M8lyKjG3LOVlQRAEiMNVQxz&#x2B;GMtY3iVp2BAslkxSBzVBl4LzxpgCArwQuK5RgufyTJcT8LLPJKJiUEEKflicCp&#x2B;pSW6K8RpkIRJHjivX8oUggOAByQEpBYDjjId3UoGSj5jx0wihYVClBQFeEfCKfdi6SXUiBGqlMo/GGeNWaOqqKRzCj7CGHxspaN3MlNm7IuwJIEt0mYugIcW56Ljjz/APSpxVD6wdVwjPa0Pec0c4oM8j&#x2B;lIKox0KnkufkvHO/Gze4/cLtPunZnabdlk2Hve/yaSiot1X&#x2B;TXTqG12x1TLN49F9sIuFDdp9B1tpaqSQ&#x2B;RNIcI4ZAkMCxQvDb32U9wN7vfaqw1u/9jV3bnY/bq&#x2B;bL3nvapum5aXun3Rqdy7amWe9Ue4dk085uy6mxzLo5tRIqZso1cgM6wesnF5xISNh8SsmJk7sxDe3NeZ7H7c&#x2B;/bZ26O1Uu8X7Y1b257U7Q2ntO27a7ed4bttui3NXbeqnU1y3L3IsdSx9Fv233rbjZcuVQ1QL7fUSy6SQTjPTKIFaBaK6c2rs/ePZzt7vuTsLblp7i7mqd9bv35s3YNTeWbVt1zbuu&#x2B;zLxP2tN3BVtfT2ydJNVN6Jz2mWXIDnh4kVJLpejDgy4&#x2B;vNf/lBttPIOw&#x2B;1nbuhM3uye4V7pN9dxNub5rJnaWsbI/vPYi2TZVNLbad1UTpMx9DdJKSmMegjg6ZmxA14vyQHBrULpPs73J7v757R7v7kXjYlpuG5qzdu6KztZsC3Xqit06v2RSXWnt9psF73A&#x2B;RKopW4KB8qulTKp8v8A3jTMLlL1xsWJ&#x2B;CRW1lrO5PcD3i7fblrNtby9se&#x2B;dwU&#x2B;69xOtHaDdXbncG3rvZt0Sqi3CqlWCuoa0Nr6Xd1pqiWVUt5Eqa1pcwoRjjJmCKUJ0UWXlVlvHuf2P3F3n3Cqvb5dt67t7x9oNpUr6Lb9wt9j2vtnudsy&#x2B;7nprRZ96TaiY6dYqSdtu6UrqubL6gx8uZ0lSMbIN4jRZcqm9/fdZtKk9qVv7ldvO2tp3/wBwe7N92p3w27RXds6Xbdt0n7mbZ63Ztp9eZXyWvopUqonz6n/ZEuZ0vKnA8wK/U6XDsLpe7veNZeze8u92yrZsfuV3VpLFvOkdsTuFbdzy949tty7tvtL69T2ym7rqJ37fYlysXR9NplPfIaD9JBKYjIB2qAVPVlqv/mzuB2h7cXHudsHs5ui8v71e7qxybltDuheTt/dW3ttbpsm2LJfbnarBVV0y5NZKrqOZ/aaeTLNNN6XzHAArgsHAufwUPFbnfffhtPbu9rnW3PYXee39lqXZ1XbJu6Lz2hvlnn2rvhRXCe2Rsm61VZUS6X&#x2B;0X6gY0U1a1KcTXROmHrq1WSZE0K8r7Gd6t896PfSd323tRX7U7V7h7JizVN8uX/IKG&#x2B;MvNvom3NtRuKnqALNU0VuuMx9FIksLw8kVEkqTiDEiQsRXissXcii22Z/kGn2vvfK2FvP2/wDc7anZy/2PcNT287301prN12/fdzsgnNlPZabBJmzLDZamrp3yZj6gidJcWkgg4R1E1Hl4petV5vdffruvd&#x2B;1O8Hbbf3YzuR2Ivl07Yboq&#x2B;13ebbs&#x2B;v3HtTdFxn0FS7bLdrNoaR24LbfK2fKEpzpxl&#x2B;hOdEAYSCHekeKhLpLVXv/Z33j0W/N9dku1Fg7Xd0L9a91duaaqv3eu7berLTsy17523YLdNvG06&#x2B;VcZTK2uqZlU2aypqj0s9c9IUlcHUAekWXL1ACpW&#x2B;7I2R3ele5Pu/c9zd9e6dw7RWCdZ9y9q&#x2B;1s237cl7Gqpe66D075tzcG5hTDd11kbVubTMoqUTvQkSyiYPN1Fyelcci9V6LLvfuIHaW4XV/bPtnWd9KS&#x2B;XCVa9gSt/wA&#x2B;n2FfNsStwSZNruz94zWmdbLxW7UfMqH0rgWy62WJZ&#x2B;l2HzNzV4L1SputDSVFqo6yb6Fzu1NV1Mi2yWvq6j0rVSsqb1UD9u1zzQ2xhIfO6ekpxhjSRSpuuDe7vvj7E7Q3n2m3Ptz3BbX3N24sV431L7ybc2I6u3Fcrgy3WGsNlttZRybZ&#x2B;5k1tJeZbWtkgtPqfqCYyZBuofSglnAsvce1PuWsXdDtTurufT7enMmbTsVTuWftHaV5kb5vt5sJtLbzZX2z9lSUTRuC9U3XK/tr2&#x2B;tT1Ut7HGGIE6iqn42XMm3fflsjffa7fm4N5b0r/bPumx94rJYNtbTn2j913Qqtk1Fxlm3G9WLcNpq7ULZuGheW3Ssl/wD2ctTKIIxE0eoJPwSJkGt&#x2B;dlaf/wDQftttTuf3wpZvcGf3t2ft62W66bCsHb7alttE6bUtr2Um4NubT3FOo5VTvuts8pxmu9f65rAkrEJEuRUBDklzRdp9ofcN2l747Ed3G7fXy4z9syDJkXRm49v3Xa98sNyniS0Wq9WW6yJVVIuEuZObLLGBwc8/ScEZ9QcWS5Zcee7T3J9zOzHeCr2naN82Paey6vZ&#x2B;wLve5ldS2Ss7h7K21eKmfJ3Jv7tfsncdO&#x2B;h7g7gkzTKE2nnAmmlK5g6hhL1qwUZl2AoV3jS7j2/tHabJ933duLdtNtvt4/fl23TdaMVm8r9tGhpm1VRu&#x2B;7Wy2yg1tbXNmhZMqWGte4MAQYupg5ct8UiTMNVzJbve32/Fh7eXje952Hsdneu/3i2dnb3b93S927RNhog&#x2B;TRbr7iXinkSZG35smvaJVfbWls6ncC3PGROlQz2SSPpIIKxJ99/azYHb0bm7pb4213Mr7bvC8bW3NfPbjZ7xuGyWqXbqiTIl3kbVr5lRuubbCZwDpsoPa9HOZ9IxkziB5i/gsg6i69R2N312J3b7k7BvHavvkd37L3rsu7Xi39v7NtSgNBLdZp0umq7rui919NK3XtS7OnO/26GcWseQYQwggt0mihIEu1V1WyYEJcxwUqBFCTmHDQg5nCHArdcrOSvRdg05qLxb5IAAnXCkYWiK/wC81xBOghjcKy5rjyVBH5l3/Mb0kNCENAbGGQEBquPIPULreKSSoguv3r9wxgt1cFKV8igOfz45YtaCqlSr4AJ98eONAsG1UqyQ6hPBBr4QXGDdzZKY0E/qIBzP244ypUqeY&#x2B;3niUiasCDnmEyiB8cS0xsBVM0/NF/LECWrdaBYVuyofj88Oi04KhDyA&#x2B;7lgdHVR0CjgqpCKAZQwpIpdC4gxgMj8ky8cSyzRrdKQEEl2R88icjpi0WH0CFVyCEnXw15JHCC3vUwF0H8vmqYqrkeKvhpw8NFRFGYXGdFxJw4rlHwj4ZHE50ULpgJOqQ/njYI8KLTsGF0TeanmIeJy5YKjmFlSF6gQuoAXQ4ajzalRGqlABmuvAlV8cQFEIV&#x2B;388RYlylLLgpOuiarnx4YiXFLqQrrlEHksdMIL&#x2B;CFbtM3rcXEdJP0hIqMyuYHzxNUKUuTzj/ABXx&#x2B;WFw1LKQH4jXP&#x2B;eGuilC6/bUQiR8MFqKQjOB1igTPROEMLUqpGCCOJ468tcV66qU4UNV1qHcOX17JvgKgCVKdnD9afVyxx5a4zwSH6g13XBlX1GY8ANABiGglDFCqA/DHRqVzq2YAj0VSMlJIRUzRD88LoSHFRmQFKIEaDEZpmeGKr8k3KSQYL/7RAKFUxICn4nhiKEovBVHMmfUWOR7HhswQdLcW9QbMGoMQdBg1SRR0pApJaAVyLWgxKwICEQy&#x2B;eEAPyUpLGOb9MuUwBT0ypcuU1R&#x2B;ohkoMaA4lcokk54lWVnPpKOofImVNJTVEymnmopZtTTyZ02jqA3pFTSPmSnPpqgNh6jC16QxKAcUuE4sY2WR1Egn9RcVKRPUQkSeK4Kqte61udszadTeTuOq2tt&#x2B;fuR9vqbY3cM6z0E69/2uvaP3dG25Tad9UymrmoJnQ9vqAAOJSCQCVqQAs6xdv7b9vrTt2n2bbtjbQptoU9xmXiTteXtyzmwMvU2b6028G0Ppn0j7s6ceo1Jb6xMQ7F0gU0WWk3IKrp252He932Tft52Zty8b42y17NvbpulA2uvVja6S6m67bNnvdJpahlM8y5U70zNlMcWse0E4aX1WumLObrP7usNo35YKvau&#x2B;LdT7r23c2SBcNv37ruFrrRSzDNp21dFPmGVMbTzfqZCDsjgoQrpB8Fk7exlqo7XbqFok2&#x2B;009FRWyiYOmloaO3MZLo6KllkuZLpaaUwMa3INCYVdOhutQ7Y7Qk9q9sP2nt653B9tbubce4qeXVzQDRTdx3mpvM&#x2B;ipulzw2jo6iqc2UB/QAvDAHFnWWJWWsu3rZt6bfH2mQ&#x2B;Q7cV6q9xXp0yqrK795ea1rWVVaz99UVQomzWMaDKkelJCQaDhvU6pbjZZpzpvSGj/ALX9UtiNYNepsthDcwp1OCwYIolhS1nSAQHlwa4gj/qIVULhi5aJaN9VDmgAEAHXoIACk5GLgU/DCjpLOvFO8HYnafembtCuv1/7i7P3BsWfcnbc3T2t3xXbF3HJob0Wm8WS4VVPTXClutjuTmrMkzpDi16ljm4DXVQPwWe7ddnu2XavbMnaOytkbetlpl1lXc6l9TZ7ZdbvdrvXuD669X29VtJNuN3u9bMAdNnzXqTkAIYSSUM55rfaG2Wy0PmvtFqtloM2Z603&#x2B;022htzZs1Ppmzf2EmSJjwpRxUgHEuSIi3NTUWmz10ybWXG0WO5VU6WZEyqudktVyqplO4dLqY1FdQz5zpBaU6S4tTTE5bkiYctosENi7E9amqGbE2JLqKSZLnUs8bM2zKnUs6UR6c&#x2B;TNlWpjmTZWbHBHA4hSgsqMQb6pe/Ni2DuPtPcGytytuDbPuankyLhV7erpu3r9Sz6aok1lBc7TebfL9aguturaaXNkTnCY0OajmuaSMBAZkmIai0HZXt27Z7Soy280d07v7hdNkvm7/77TLF3Q39MZSn/AOFSyL5c9v0lNaqOjzlyaKmpm9X1O6nRxCIiPFFGDK77n&#x2B;3/ALYd4a6wXHfNrv8AOuO2pFTQ22s2xvfeexKt1rq5jJtRY7lUbNvlkfebJUPlNL6WpMyWE&#x2B;npwSgJESNwnpotWZ7WO2r7vs03Fjbv257dOrazY/ZO47V2U7tvt&#x2B;9V/U2dfJ0ptjN4v9XLVZbKyaWdZL5pnPJdgA10GmiLG69mtPbvt5YbnJvVj7ddvLHeKdobT3WybH2vablIQIPSrKG1U85n0wg4FMbaIqtMAspbdpbUs9yr73ZtrbbtF7u567tdrPY7ZbLlcy53W411ZSU0mbVdTonrJU88DVdLVdbI0BwCt&#x2B;6H4kwxWryWtV7L2iozP3NaVa0j916i9MEkscVyJxrGHmOS4Mkl20&#x2B;LnBP6jyRD8Rjs9RquFJOaZx&#x2B;wHnjbg0vRChQuX&#x2B;pP9XnxTATEhmqplK8iv9XxHhlpjDp&#x2B;SkRMDnCJjlnn92NRsQhEoT5QWH3YEqQVzHhomgMRg8VI25FPH8khiTVHlBE14p/6s8SRJvBFCGJR4m6glIRJMMl/hiUGdLMOYGh8IccS2OlqWQkgAwiR9kyzwqHmHLmluaIn7L4csGiJUFLoF8YZDL541ehWT1O6GHH&#x2B;aLxyTGulTH8FegIQiwUcUhGOarjjRomL8BH89Di0UExWwSBORHPWEMao9LIY6Ik8l4GCwgvFBhY3sE6I4nlCMcMgHogFCSYJrl4nU8cZ0cKshOYPBfnwyGM/JTUdLUHwX7/lhqEs11A4ZY1dRbSyBf1R8BonLlgqSyEsn8suONFzaiFGhBjlnn4A4qxrqpRAHkEygBmv8cbJIHNSoFYxQj&#x2B;UQcD66KUgKYKBwAiU5cEw/JSL7fDFqpYPdbBN2vfGkQ/YzHCEUahVIYzN&#x2B;kqBHUA9VwBWlxmP6gGhpcIZlVIJI/UU45Y8e&#x2B;i59Oax7gOkn9JCqWwCZqIjFyClg77cam0W&#x2B;XWUVjuW5JxrqSkfbLVNppVYyTVzPSmXIvrSJH7W3j65wH1uZ&#x2B;mOIltHPJS5W3b7odx7Ot24rTV&#x2B;2j3G3DuLanbibtqm2lsnaO79hbtn297jYbha7uO5Ng3HOsNwYZTq2f8AsGOo&#x2B;pwIKBbqPCvzWXGvFeSN9wW/e0FH3xtVv9tXevuB3Tq90Vfc3YmxrDtxv/A9yU28LNQblvVEe5NRfKeRRN2vcq2ppailEtlS&#x2B;dKDJTj&#x2B;rASa08xV1AUXtmz&#x2B;/W896d3e2/aK79nNzbCkdy&#x2B;xk/ulM3jcquklzNr7pl07jW7Pp7Ma&#x2B;rrqk2aaD6k&#x2B;bKcyW/p6pzlIL1OdRT2C1SgcrzGy&#x2B;&#x2B;DszbLJL2burdm/Rv60bj3J2w3TWXrYm67xXMnWuVdaRvdim3RsHZ1z2PubbXqftiX22Y2ZT1T/AEZssPlvJz1jV3B4ftso0uzlRs33NSO2Fv8AbZ257r23uDdKPuJ2vv8Au7cPf7cVBd/QtP8AY6mdNlTL5ZpVimXK61Nwt5bNmCV0VVIxFp3Z4QWAeyvmsjb/AH8&#x2B;3qndvOdufd9Haqbbe87fZ9pVMjbXdCfQ7&#x2B;2hcKemm0/cO21tTsD9tKsVFWTXybg54l/tjLXpdrCQLu4/dxUWBYkOvLfY/wC4mVvLaHuT3Duus3PR7L2L3TuF625XX6pkbjnM2puabMqZFDaJ1tlior66puheKajJY50udJ6WSA/pbjGb/wCkFFQa3We2z/kz9rO7bD3KuNHXbo2/ubthe5douPaXuCdu7E7xbkkTnuEu&#x2B;bd2ZerpKcyjeZbumlmz31zgB0MeXAY0MoNLELbkDqdwVeWn349ku5jex&#x2B;5&#x2B;1/c/bNh2ruzu/U7D7i2nulddm7C3jSW92071X0z5&#x2B;3LtuervVooKK&#x2B;UDZc6rnyqR3qJLLB1NBXEmIIZ9VObXXvna7v8AduvcrY&#x2B;5kr2/76nzbjsu7VWzZ27Ljtqndb7VuOeC227gtlprqysG4NusmD6P3cqldUDOSGkOwxmJv06JEv8AUtP7Yd49/wBN2&#x2B;7nU3cGguHevu72U7pyu3u8bV2u2xYtoXe9W68S7VVWHc1v2pPnUVjt9vl2y4PqZvRN/wB2TImFpLwBgE5MeqpBQSC4ahXU06okSJkhk2op5T6hj5klk6fKpzMbLYJs0NbNe1z/ANswrNIUS0UkCONEgJ6uC587i9&#x2B;tt9u&#x2B;42yLVft5dv7V23vOyO5O5t1biqdz7amz7VW7OtjrlapEmZLu/UyTXtlvaGdCzpoDeoYJSANwyOonxXqHbzfll7o7Ytu79tUW46C3XN8yRS23c9rpLVfRMlv9Nk2bbqK6XimFNXtc2bTTZdTMZOlODgQYBBcOFhanuHunOoqnb1Zs6R293lsWr3NWbM3xvGo7js27U7I3VLM2npLDQ2d1rrf&#x2B;RX&#x2B;fXSxJmUE11JNDl6ZhEcVT9N3&#x2B;CWotF/8AP13p/br/AOVqqw2Ydx6jb/cS/Wnt6XV37W7DtzvSs23e/wBp6Dn1k2ltNrky6mqPqAsmTAFQ4ySREyI8yizLIWL3Dbetu3e5e8O9E&#x2B;zdqNubE7nSu3FBd7iy&#x2B;z5N5NdbbXX2aqFLIo7hcqm6XEXIGZLp5JlU0pHzCxiuwvR5WdVxRey71vk7beyN2bst8ikuVXYtqXLc9rpJs8y6G7iltpuFC19VJc5zaOtYWkzG/wBLuOElgTqEh9FzV2A9x27e/e6rhb6baG3e39g2bZrU/eti3dI3bTd277drza6Svtm5dn2yvprTtqm7V1c2bNbSV0g3WZVtl/XNkuBZgcuRRvxqhy2q6B3d3CsGy5&#x2B;3KOste8dz3TdV1lW21WXt7txu7rjSynv9Op3FuEtudvoLBtC2n/7mvmznFiEMlPMMJKvMb2Vp/wCR7dXVtm/4hZKjuHtS57kuOzLz3G2fuSyHbGyt0WwgVFjv1FcaWTcbvWumkNEuimeoM&#x2B;lwBInp1CsbOtA0fgrzandXtdvmtrrTs7uTsfc95tEysk3Pb9pvck7koDbev97OqNt1raK&#x2B;upKRrCXz2U75AAXrIjicE0Z0vR21WduO5qel2tWbrsVI3eNJIt0&#x2B;4W&#x2B;ksl3ttJLvzaYubMlW6915daaY9TSDNnn02OCOTETTqFvmg3DVCzFLWS6qVZnemaOqvtslXWjt1VU07qp9Kaanqat8mbLcaaup7d&#x2B;5a2dUyXOp1IcHdLm4Xaq5AX8PktAm97OzFFSWu43buz28sNvvt1r7HYbhufckjbNBfLtbZpkXGgttZfmUNJMm0c9pa50yZLkkj6XnHESHDlh7WWA2l1hd394p&#x2B;3ZW8ptp7b7k3JSba2Ncd67d3pSXvbE3tx3DfbZBmu25t69WuvrbqK4ZTKptPOpGNj16YSS5LUb3JEgLVKzna/uFWb/but9xscnb87bd7pLL&#x2B;zl1hrjMmT7JbbrPc6rLZbZ4kT650prmsYHBnV0hcbiSXozJBJLL1hrQnPwBQHJVyXBXhRQNPNQroLsjTh9&#x2B;pn/UsuRVTC4r0hJfSCDoSSmObDWdLLgyeC60d/GBSHhAEY5jwXGlqvyXgPNFwu9EKPmddYY0PMQFKohIAjwEY&#x2B;GMEMaJ&#x2B;ak/M8gi8I5JiB4KRggoEU5cDDmoOBSpI/Pn9oYkumhWqeKQ4qqYlA8bIxwMYKQnH5YlrQnVVmPkRAZ5FdMSybqIADX7ZxxM6QbtZRqdDz/GKYloktolkqpIJ&#x2B;RxLNRSyAwB4LAQCLl44SkyJLFLJA8Rqvw0OIXQ5KBR818uOWWKqy6vwT4L4FTw88CatyTAM01KkcSVwxuhEGxiIDWKchHQHCS5W3HTzTAnFcvvz88TghmqsOfcobLILnkrogyVSfjHGyAS7URqyI9MDkhUfKGMxiGcrYFKe3NC4oFOi8F0gRwOMklmWblghUqCTxcBALywkNTVVNLJRRRnDh4a/bXCKGoUhMYDwhE&#x2B;ENBi1opAgVViUH2&#x2B;ONlgX1QodoRBAnnqfPA4lXgpQoRUQRVeOURwxp&#x2B;KlSEBBl9lguvLAX0UpBXiCoiqLDLwwhSIAa5eKfYYlKwvLPVst1lJ&#x2B;ugng6lAwkpzCYpfSfBFAXK&#x2B;e1e0irmkqWiY8NJQIjiOXwx47pDrtdNCVjnkRQZrEBA1IaosMHuWWIS1yACEqXE6pkUKJh5qYq1dS0gqae4mnk/3GilVEmhrukitpJVU0NqaalqWlsyVT1bQPUaIPTFVQAeqaJ9SGNYJ85ssO9T0mz5nptmAuPV6fV0B/UeGeKqiI6LyO59huzdxrN33ap7e2qXft/W9tp3juOiuW4KTcN3tbXF7bdIu/wDdps6y0heSXS6Jshs0xcHQwAAhDB3V7Rdmu19sb23lWvZNpt8rs9SPou2UmgnXOll7Lop/W&#x2B;qp7dTya9lLXNrJsx02oNWyodOnPc9x6iuEAAAaBNL/AJkNH2l7f0fcKr7pMs9fX79qrdU2eRer3uC53u32a1100z7hSbY21W//AKF28bnMK1EyWyZMmj6eoNhhBDuahRssnubYG193V&#x2B;1rnuCgmVFdsirm1u2X0dRLttJQzalobUSau3SaV9DdbfUNH1U05nonNMHg91oRBqrXf&#x2B;x6Heuxd4bMp5dt26d12ybSsuFls9ttBoLn60iporwJFopKOVMqqKppmPa4tL0CAhMBsrpLOrSf222Xc6Lqvu09l3PdVVYLbZ7zvp2ydozt31VwoLbKt8vclPfbjZau4Sb5Tul&#x2B;tTz3Oc&#x2B;VMQxTDVq8FRi4c0WJldkOzrqKlp712u7bbvrqakkUtVund/bzaN03VfJ0kNL7pf7xKtUibcbxWvYJk&#x2B;eQDMmDqOEDpDBJjE1C9DttnstofVutFisdlNeZT682KzWyzmtdTSxJpptYLZS0zaubIktDWumBzmtCA4FgxaquJVLSSaioqZFJSyKmtLTX1cimkyau4eiwsp3XCoksZPrnU7fpYZrnljSjUGIpI1FV413T7S3/AH9f9p7p2z3Xv/a68bZs&#x2B;4ds1su37Usm&#x2B;Nubr2xujoF2tt7sF9uNrZS3BnpJIrJE31GtJaQhxkxMjUkHkyWIK8l2d7APZ7tHaUvaNV2G2Bv2R&#x2B;&#x2B;rbpcb13CtVxvF4u9zus81NfVTmC&#x2B;vp6ClfNcRKoZT3SJTYK7FDHGIaIoskdR5r2mxdm9p9stp3nbft&#x2B;sm1&#x2B;yFXdZra&#x2B;XXWOy3K/2anu0qR&#x2B;3pa&#x2B;ssd9vtc6oZTMDeiTImypY6AA3D0tSFEs/ivFrf7FvbtV0tXX9ytk0ndrf&#x2B;4Lib93A7h7hqLxZKrfe65jxMfuSr27YLvR2O0VFI/wCmk9CUJshgCzHOU4Y&#x2B;WPSWfUolF5MXBai1V/8Ajn9sx35M3DP2LYqjYUyz1dFJ7Xh29aR9su1x/wD8te6De0reEysFLelWst/7dsqocjnFxxM5dqoAPNekSfY/7RpNPWU07sja7lSVc6RWvpb7u7e19pmXGlbLZJutPJrr2lPdmypLJTp4Jc&#x2B;SwS3K0Jg6QzABlqtlne4XafuzuTcU&#x2B;d297xbS2HsC&#x2B;7Godgbu2fuPt9V7vudNaaAftm13b&#x2B;5yKiXQ22rq7YXU82VWBrGu6ZgcS1DEE604Ji9jZZvtn7c&#x2B;zfZ2rn3DYu3dw090qtoydjVF2v8Ava&#x2B;bquLNs08qcyVbbVMuzniyUsufUvntlSS6Wya76QAMaAADMFdLAuT4Lxej9qG5aHdWy9/XDvBU9wN29o5N5ou1FDerZW7As7bTefX9Tbncu67UudfUb1s8iXOIa2dSEF31lwOMdOprILItVapsH/HT2PtFiqm70p94Td1Xjedd3AurO2ndfeO09kWDc9bUzaiQ/ZVrmUkyZJ/tzJr2/u57DOnGa9R09OIR8rKDtwV9vr/Hx2cmU9w3D2dduztf3hqrZS2Y9yKfuFeJdZfLY2Y/963e1ZQbeq7peayfSzHShMkiS0tQOYRHB9sXFOa3F20Ze&#x2B;Xbtx3As3arbfartNV9vLLbqXbknaW4blviRdrtKoLbVsMq&#x2B;3axW6RStZfLhVsmzHS5NUZHXNcC5MbY2izKAPUK1XLd9/x5002nuW39q94&#x2B;5e3dtW7YlZtbtfXTe6G8Z&#x2B;5dmXK6NpGX2jr6P&#x2B;yTbXO7f7iZS&#x2B;nNoKepfPp5ZYJbv9sLkQaxQRkd3eJ0WQ29/jz2Dbuy&#x2B;0uz&#x2B;8L3uDu7baSZLp94WXuDu&#x2B;pumyJlsmzjUVkzY9rn7YmXi1XelnHqpZk6ewHOYScak5GjD2osiL11XtNu9l/Zi2S7DTUN27wyLftqhnWew2tncyqlWy32CodKdVbcbbpFqFMbLXek315AT1Ao6guMSrda6DcErpS1bds&#x2B;321htNFKo/7nVtrq90ppWorfSlyBUvBP6zKlNbwAAxoMCtCJAb8VsDApLolzmoYZEZfTpiY3NnRJyBxXUHY2nWrq572lvo0fREqhmvBPLJuOfGKlcM7toulSMs0ick1Uqox2tLLjS&#x2B;rgAn48ccQJBfVKEeP254Q5NFKR1AJFPz1hgNb3Sqj88/FI8cXzT08bogqroSfnmfDAVERZtUQICoY6uTUgqoOQxIZEqlV8fv8AxxKt4oyDz0hBI8I5QxaIDCmqIlBr8hyUeJxK&#x2B;SEkrDURPH8IYWWhzuhP5g6rgWrDy1ZQYA/YBIx5Ylmtkpx0GWnCOvPEGWgKEG6WY8uY5E4vBZq3&#x2B;1D8PhBPj&#x2B;n8cSGPAq/GWg5pHPPniQ6aCUX7L&#x2B;YxMWfRSIEpqIx1Q8fPGgCbWWnGqMBCnJYGA&#x2B;WeLpLoBY0R6J5wPwgMbHCiXDl1BH38fsQMRDB1oEM34IHRIio1Ty&#x2B;cccZYGiw9KXQuEOBWI&#x2B;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&#x2B;RB&#x2B;OIkjwWkr6iC79agR0iUyjl8cKKJhDmwBB0AyzGaZgj54zpS6hxUtcrelAIHLQn9QcgGfPD43WZR11UBpSPSAAqPB6s4AIjcGrIi7eJVAgdbeoRTRCPvXLPCtG9QgBMFJ6QSjslKxKgAQ554kGilXErkAhUlVB8kCngcSxQ6KOkAFB1DNEUtWJXUovCGLUJ6SFIUI1Q1SgQovTFqFIYDWyQAXdOLnKQ4hwKdIBbknDPzQZYKqFuATMoDJNDn5RTC7rbOq8kUkCC6rBBmmuKrKAZUOkRASGpVCQkFCheC4iDb2&#x2B;CueqYD9MB1n&#x2B;oNhn5hTGGAhT66KcyCnVxECiZCP0qMALVKhxCuJDC5w0XMoIjkQREYRJVl1/2TphLtlxqC0AudJkqQVPS0uCnIqOGOXDYldadTRe4khF/UnGHz547Y8wbVlgByyAmPkkFgmWaLEY4ykxIUfbTAqioHPTxiv5YUENdV9uWIkkuUkvdVy4HjA/CJwB35JFm1RggLyh8Y4kgG6IIv2AxJNAGumAkwz&#x2B;MB&#x2B;AxLBp4qVgBz4fCPAfLEkB0OX3rqNIZFMK5CAXHNQpATUc/tngXGwdhUKCTpmUHyOJa&#x2B;m6SclhxVM4ovzwrRdDyP8fKGBZJJshhyz&#x2B;aouWFLH24q/Ccc9OJ8dI4FxIxHVD8f55Yk8PBGpbzASKoF1hhtZCMFASc08EEABhFBzKquiBgmunhocPUAOaiC7KSeGWp5HULyxqRDVSTVwl6Qy&#x2B;3yBhjBIsFBQU0&#x2B;ONhjVBJN0qGmuoC/FcYJibBLH3oCdEjFeR4DkMF7IcpeYiPLMoPuOEB/EKUlEMT5eUPE40R8VIVgCqprqOK8cxhkWZCpY5&#x2B;aDiqDnjVCpEviYp9uQxl68lKR&#x2B;f3w&#x2B;GNBSqb9Uie3IOkzQUj&#x2B;qWRlwKYCHRouBtzyWSrvXtCANqHkAqSR1uyGgJx0GBcaOu3Cl9Vq0xqoitOcCsXJ0oeAAU4ndLPeoSun9TnqmgzCgZQzxNwUYuQBZCXKoIhFOOgAKxAB&#x2B;GBcaFwUdKnKBP9JPyicTISHhpAarlQkjh48QfjgqRzUgAcCRDOBBGSKeaJhW4iP1HTRLJIUgKAURsfCHJMJrSqqSDC6WQqdTSSfqaFgYJHlgoFguPFRxaEhEBVB5j/AKUwA8Qk1QOaDGCIMuOoHEHDqkFr3QvLwGEBFKOaQUQtQOXQj8cAYrUal5WKt5tbQyJ1PST7hQyaqtnehS0r6qR&#x2B;6qp7WeoZEuma90/1fT&#x2B;oBzWqIhcLh2o6OpqCyGZX26TNpaadX22XVVz50uipH3Ck/eVs2nYHVEqkpvVM2om0soh82W0dbGHqITF81OWepK12k3nZq3cu6NqTGVtBUbQlWebdb1cmSKHbM6ZfZZm0NFQ3idPbJfXJB8t4YriA1cD1bVUiepwtjL5M0F8ufLmy0/XKc2ZKeRAta&#x2B;WXNLmnNCcbXIBRtUc3/YUznNkOlsa97p0xkqXLluA6XvmzXCW1hDlBJxgglFwyNsmbNAmNY97D19cxjS5rnAAmLQQAkeeEg6XWSWoQ6pC4FP1DpJJCNgiAOihHzxWCBVholua1pQgHqBMIg8WlFEDh9y2LNqqIaoIcQACXNA5RETlitdYMn8FRLegIp/0kaqYBM1aRHFqtxDCiliFvSUiBEcQsOYwVUXAcXRdJe5rQASoawED6ig/SRAEqmHxUWZiVRLT9RACI14U5qkTyxli7rMWt&#x2B;UJoJcqNgYAtDkgIkpCGJmYhaePFSA49bwOqW3p65gChoMGuJiGgnFUhhwWCa0qoBaSGqDFQEgQfyxl/ikBnJTWKSwNHFQ0OVBmUHxPIYg5vdbBAFbqQAXOiiL/1Z/pI4phNEBirymaXvY3Pqc1qEoXREQIpEYr1CSQPgu0&#x2B;08gU&#x2B;3HOAP8AvVIicy1jOkfBxx2MTdFF1i4rqy9VDoFDzPE/jjmFK6rIFX0QdS6qvEiHHywa8kyDU0U6hDwXlHOHFMCyqUfDhyMV8jiSWsFP88Sh7lKwiqax8EGEDVaYioqFIT5p4nQchg8LJJBiyNuSBOI5/wAjidANa1Ugqvz&#x2B;3HCtEJgJ4ZQ5ZleeBZPlQ/MjjzjDE78VPRvxQNMIkqEin2VMRTIUUFBxTLNOJVeWGqh8kLomBhmDxTP78GiuoJZTXwX7c8IUBR0P1c/1fLB8Frqjf24K/ECuZBjrDXTEuFEDmTwH2VExLRZkzQeRj8&#x2B;WNFrBFQUYQqMuAMRHOPhiAJD1UXFdUcAsY&#x2B;SoiA&#x2B;XLGwwDH8VAveyCIWEM1TmueMmR1simigkk5ZR1xk0LKo3NAf4/PLmuEk2KkokjI5/YcTljPJToclX&#x2B;Aw2LlSA5nn4whDLHKBqLqq9buoMBBYHw4ZYrXuovqh8fEYNWKFPVBIr8Bx&#x2B;OCRegUpBh4nkg1yyA&#x2B;y4hLT8wUiB5eJ11/EZY0HIcqRLB3AtcCqZFp/HCARSKlwtviU2Tf7hLaD/APdTMuDnE5qCQuOgbkrsx&#x2B;lhdaQ4glwIMQQmQgRoqjhHAuQACyAOAz6iqoVCkaNTKGIssS&#x2B;pxdLHShJUFQfqiCCIhIEnAssdUl2aMgiE/wBXUo4cIYjULKhwDoA5QH2zKYBQeKn4IHMc1S0jqEQSAVVFEdMI5rT8bJRALQUQrFUBJjAAaDmYYVC7BLchEelsU1WMECgoBDzxkqLihuq&#x2B;ldQI/piR4wJTliZ0WACUmQiQBllmViEzwsVoSHBa1va/Ve1tnbl3PR2W47jrNv2uddJdhtMqZV3S5y6Ys/dy7fSSWTZ9XPkU5fN9KW102YGEMaSgwVALB1UNNFw7SUW7u4O9r17kexuy/wDlH7vePb64Udm39cLt2irdxUNgs39t3NT0J3zbaRtCKKbCU91LKZUFpHWTjLH64ivw&#x2B;axV6sy8/q9h&#x2B;9mp3bZt9O7R9npO57Fv/du7NtPlb1sUyi2Xbt47c/49cDLlS73PO&#x2B;L7LlU8mYHzZtokvJew9IAc56SK0d/h7e5HURYLct5&#x2B;3/u1v&#x2B;9dm907l2fYRvzdkuxWL3dbl2v3DkWzY&#x2B;4th7TrX1&#x2B;3rFK7YXu6TJN83JSVbJc2TdbWTUUZDpfqVDEIumzgObpDhgV0PK3ptn227V2PYu492k2myXvd25LTI3VUPqKix2WXVfurnaZN3r3yHOkz6qmlNkSmvA9SeQ0FSMQeID8VsuK/mXJNr3D3ar9r2DsTsGmse9rbu3Z3enc&#x2B;56i77lrH9xLbPqNwTLv2265N3nyZu3bLfA5smVNuJlSgHNa302txxy6pAwFvx5IcnzFbluu9&#x2B;4G83mj3FJ9p/uO29X23au1pUuZtfun2olOvu4bLUy23Kz7ktdJ3IvVjdthtGwvkzqamZVV8whj5rBloxLuBVuKwZWuy9rsfezuVZKXuzvXvh2jb2i7V7PtNovWzbxdNx2O4Xu80tS9sm7yt2yLNdrnR7cqLfNeHPZMcwU7P1PcPqGnIfqFFolaHuv3Db&#x2B;2/O/4f2f2jun3YXuftqk3R/wA97eu2NfqTac2&#x2B;3Wb&#x2B;3sW87XZdw2uibLstneybQmVNE25yWx6XlTdRP0sT4gIoD5nXsFzbv/uD2r2fPn2e&#x2B;7Z3pJ3Zti6bitlwtVZsm4TKS0XKVUXJ39lraqorLfRVlOw/7EyfNa8Q6nA4tBxdNPcvOd8&#x2B;6G87Ov8AeLjW9ou4rdiTaGbbdtVFftOfYLlcO47bq&#x2B;QLAZ14qaSnfarrbh10U9jTLmTB0tcS4DEZHhRa6g1arFbX9yfd&#x2B;875rtpXr2q929oWyv3TZKPYO5r/AGmolWbcW0Kmllztw7gv9TTSZ0nZl1sNQS1tFVuBqGgOa4Lg65u3TTTnzVLIGYar0ruJvXfG4rz3T7R7V7fb2tsq17IZcLB3cMqZR7VvV/q5zemwWS4iUaUV0mQrnv8A3HqtIQygPqxS6i8QPesv8VrdT7jquw7137su79st71Nm2Pt/aTbTvPaNnuXcF25dx3yzmYaOrsG0qO6XO1W&#x2B;lrpbWPqpgLR1EzOjB1nqIItqirstesO7O5/di92i9220d09ittjtn0G8Nobm2pfdmWaVWyLyJt6rrN/yK0UM7cFHUWwAzKmknzafpPSQDDA8jWos/wDgl2LarE&#x2B;4rvjuOwb723Z9qbP77S7ltfcO4JFWNm7Fvdft28yLnZQNt3q5Xb&#x2B;01e3azbEqqmPa4tmTZsiaFMtQmGZJlR78FdRAdvgsRR&#x2B;8Ddt2d2wmf&#x2B;B/cHt64zplxl9wqGf243XUWG3Tpcl0miZcLjbdpXd19t1TUNExs23ulek1yu6k6caqSB8U9R40XqNl7odze7uzptNO7Od2uy277TvPbf7h24LTOptubn2xJvtNMrbrs3c75cj&#x2B;52urt0t37mnqZFJXSGOIfJAjjJ6pRoDEukVJa49qLrlpX9TekkgjpBAHNq5AHGtVtw76ALK22WHVUoBP1gDpTqXnBY64QTY2VItFdu7Al&#x2B;jtiggjnh71UqS5xAcRoeRx2YBogLqyvyW8Aj8Pj9&#x2B;NIdSsMiEB0OsPKGK60ZHVV19IAz1hEx11xNpqgVKkHNEGRgq&#x2B;YJyxJAa&#x2B;iMOVdB5eYCpmcSiwo1Uen5fyxKfQqgdT4cvscTLWrFmRApDmhh92v44tUs0nRgxIjDKPzyGFaFEQdpngWJNbVVn&#x2B;X4QxWSI1cqDHXT7ZJHFopnQEIBFUwqEWtdAVdry0HHTjgsoAjmlldfLI5chh5qNY1UKeea6/lngoj4WV&#x2B;CIqPtH78SwA5ZGCDAaosTwjFVEMKW10dEDnGCDwHniUxJfiiBRRnFV0EBAc4RxuJahUYsHRdYIhGCKDAJ&#x2B;eEyj70gUULAhSsfBPwOMAGR5rB5IXLp9vPOGIuD/uUOSAkiBhw4Q1EMFTdMUvTP8AKH54gCdElgWZC7wIAGYOvH7Qxro0WdEslMisfLMFB4Y0aamivcyjq11zh9hHGSbOqltFHUvEKck&#x2B;8YzQ&#x2B;KlAcVWACCKa5QXDIMeSkYMNY5QUFOMMaA6g6FLTxgpSBSEcbUiBJLQIKUAGeSKUgMVnUCuKO4bS3cFa8NMKic3pROn6ipWH6jljoH6j4rtY/pXm8CijpBESQToVjkPDLB4LZKAxUtUkIilAWpHSBxXus/7TVA7p5F3SQdEKRyzTPEK2Uz0ZLBDohSBl/pcNFXIfdjNjzXG2qEAaBChgg&#x2B;lRELy54VMb6LzKZ3QsP/lVnZy309TdN3U20ZW/NwmVMZLpNs7aq611stNRWvIc6fXXevlvbJktAPQwuJyGAy83SLqWw0e89q3DcG6tqUe4bVV7k2NJt1RvK1SK2S6ZtuReJP7i2uus1j3SKZ1RIPWWuIMsfqTC4qNQpleXG82y22St3LUVVPU2K3WutvkystlRS3J1bbbfTzKiqqbPIpZ75t5DJUs//bCYC5GkjBzuqrNosVsrdtn37tKx7026bg7b24bfT3W2m90E6x3ZtLVM9SQyvtVwcyqoKwt/&#x2B;g8epwGIEEPFJNaWWVud2ttulUc66V9FaJdyudLZrdOuM9kiXcLxWuDKO00omJ&#x2B;4uFW6DJTfqdwxEsKoqaLLvpaymksqZ1NVyJL3j0ql1POlyHPYSEkTyxspzmuGjoJhY6qCS9k&#x2B;fNa&#x2B;a2bNm1AAlzZrndc4tMWMmTPpeRwXEQdbLfTd9FY1lXS26RPqbnVSLVSUoP7uquk&#x2B;VQ01Ixz2S2/vKioLJdO106Y1quIVzgNcVGd6LBDcyrlrRAlpVAWgZua8fS5jY9bXAhDqMQVe61iXvLZtVX1dkot27XrL7QT6qluW3aK9W&#x2B;u3DR1FDTmsqqassMua&#x2B;6SZ9JSt9VwdKQNiDpicOwTIG5V7Zr3ZNxWynvdhuFuvNruJmGVc6FwmNq308x8idLqJj2S6htRRzmFjpU0B8tw/SMVLhHistOlOlACcDLfLDQWzy2U8mYFYGMm9D5ji0wABURyxEhaJHC6TOpaSqpJ1PWU1JXUtTLm09XR1smTU0lTTzmulzqarpJ7ZlPU089ji18t7Sx7SQQcGrqIDtote2js/Yu07XV2vt1trYu1rPIq5r6617CtO37La6e5hDUNuVv29Kp5FNc2tcFE5gmoiBMJIlwJf2dXSIs1Ebd2bOG4Kzap3dtZm6qJ9HJrNrVF5paO/yJ1wlmZQU8q3Vjqd1XVV0tpdLl07pswtCkDF1B2cOs3YarJV1ptl3pxS3e12u8UQmy537G826kulKyfJmAypoprhJnypdRTvALHhvUwhQhxBitDpArcq5dbqafOp6&#x2B;dQyXzbYXS6OrfTsfNoPUb0EUc8t6qcTWwcGEdQzxFraLLAlNLTOb6YLntJLPSTq6iYuAZEEvECNcXgtkB3NljLBtKw7WkVX/Fdu2nb1LXVs6quTdvWyjtkutuU0LOqbg2hZKdMrJjArnTfrcOWAAAeWyx7lnpQnTQZcvqmoIMfMADQSpDPUcArv9LYnTCXtohOP7wOlSUns9TpdKkO65Zc1xUOax3SkV5QxaVWqNW6ozZoJSdMY5p6Sj3K0jNpiF8BgBIPJALF1Qa8te8hyA/7j0JCu&#x2B;lvUYhpccJJW4kaog0OB1IUHmnEjRcYWgQVnbNL/wDlSiREvBaRBCkQdSPDC4ROocLuLbEk09htcsiIpJZKkmJaseGO2KgMuubNwWxAiAyTInTz4YUE1dEp1h8UiFKkkRxIQnWJj4p8YmCYluIFDqFAKKkeUFXXLE624snA8VSPxGQ8sTLHSTwRtdlBT&#x2B;C&#x2B;IyxIMS6MOh&#x2B;ZSJ5YkuSKol8R4eOmJLsW4IiVT7/wOJacI1HHQeJgY4VUvooiPiiZBNEIGJVG5KSeaZ&#x2B;PwxK5lLP5w8&#x2B;GJRFKKD98R4aeeJNUskZHOHkQpXywLPSCbqlHLPp8skz4a4mV0xV8Cmoj4fiRkmJcSNogCgXT8SmJ1rq/LKyJB4JmnxRPHF4KFC7KSddYfdjQoCLFWpoqa1B4xON0Pm1UTJ2KlV/jCEPzxPWiwgcdAFK/ch4ROMMTwZaDapZKGKgRPnrA88aDxLFTG4QEoo5r8dIYjLQJfW5QkkEKvmAnNOYOI/Uz0QS/FL4/b7LiDihspAq&#x2B;C58eXxxxq5qYwGWapFCePLG2LEFCoDPjBTz88AZuKkS6DRPAfzxvqjYWWgxFUXIRy5/MaYfMCxWbqR&#x2B;puSQEQo1UniuGgbxRU&#x2B;K457myem/VrCkaiYevQRUZZg8cdCbjISBVdnFbmF5cWhogQQCh1KpHPOOBch4JPQquUt4E5OWCEYCQFk8I/UhKAwaqdWXF0fkuIcVgseQSXNiAAQDBUyX9WfE4ks1dUtAC4DKIGaaBDyBxaclEACt14nO7Qy6XvhW97rBc2Ud23T25l9r9826oL&#x2B;iustuq6iv29fbDUSmv/ZbistVVzGgvHpvluBzaFGr1asy49XF1wDK/x4bk9ulJ3B3Z7R&#x2B;/3uJpd791ZtbbO5Fl3LujZu8Ze8rVd5k&#x2B;ZOqaq4b/AJlrpKH&#x2B;0MqXNlMlzHTHMQBEwCERYkPdRJsFp1r9knuhl9zvbVX7C7rbh7I7a9ufbC/7WbvG7XfbPceZum67jqa6urKah2BTXd1LJmVlVcHS651YtM2QxokPJAGNCEIgGNJi2rIHW&#x2B;vTzXoV4/x3d4t4nZdPvr35957pae3/AHZld3Nu2mx7Zs235dwulRcv7rfrNu&#x2B;dR3Azb5ba2pc6XRCDaCmSW1jscZxveRu63fkeS9Q92Xs77se4Tu5sPvDsv3O3vtm3tYyhvGwe1NdtKmv/AG4p&#x2B;4Nsnyqik3jenSaqTcq6bVPldFRLMskS3ODEXDIRk3US/wCCzV3C582t7Vve3T&#x2B;5nce&#x2B;twe7PuntetuVotG7L7U9tdkU0z21789CumMuGxJVt3hcBPsm9J9NL6Q2mYyTJkPY7qJwmAJFZidzIWPJlpyC4AI5v&#x2B;C9q3zt33Md99z&#x2B;4a1bBtN07Zdutzdv9u9uGbf9ysm&#x2B;2fbV13JSlb1vftPTbNl1G57FPlSwD&#x2B;//AOxUzQC0pjPQDKRL9JDVt4qEjbRet7v9uW5&#x2B;53ty7c&#x2B;3budv2bebTI2vQ7b7y7otc2vkbi3zT2KgnjbrrHdHCTV0j6O8y6KdOqJ/TNqGUTQ4K92NGAMRA1gA3ihiQ&#x2B;q3Tadp9xWz9vdjdpTrl2x3/T2C2/2DvXvbcM6&#x2B;WLdFfbLVKFLYrr2/tdFTVFBVXqbSS5YrG1s2SwvBc0knEBOIEQx4&#x2B;GngtMWY3WEsHtq2VtX3ZdwPdZbrVbZd8332ys207vMlU9Q68yb3ZK3rn3qlpWE0xqL1ZuqRUOY0zZrukGGFg5I11RW&#x2B;irsxtXuDsuwd&#x2B;dwixyJt13/3S3b3C7bdv75VstFFbqSpt8ijs9ru1TLWXYZe4aynNRUEAGn6&#x2B;pwVcZiSIktVLPVc09v&#x2B;3vuR2nYNh769ym5W2Kj7X9/t39yKi10G95vdSfbu1O4bWWSdrXHcFlpw&#x2B;9U1nr&#x2B;o0vrSwaWSjTEYyIyDGZqCpyKLDv8Adb7s912XuHuftZ2x7ZVHbHc&#x2B;95e3PbL3k7j7upe0lZVvJl07bRe&#x2B;326f212v025XUOk26vYwMqC4EBAuIHNIkjp6NCaHwZXVEQsTJ/aqvO1ftr70yZ&#x2B;&#x2B;O4d325J7M9we6Huo2f3j3ptS39wn7qt03Ze39sust3tTq6inz7ZPbdLk41LaaUGRd9YUYo4gHIDSMnPNRJIZeCf5Erf3Ql&#x2B;6fsN3Jr&#x2B;zEmu7FdqL5I3Ba9y7f7nbI2tvXuju6kc2rkMdb7xcrfX2p&#x2B;3nsDZcyoc71JZLWtIONmPVLqkA0bLD&#x2B;LruXuL3&#x2B;9zsz2&#x2B;7j7ndvvand6fvTcb5b6XZParce6ds7jm3O13stqG7xmT9uV9TaptBTSp3V&#x2B;1mzZbnAK5BjL5TGg8z8fxS78WV5Ju3dymunYzvZ3dqbT2rs&#x2B;2&#x2B;1G86bu5sq7bjt1Ftpvce50rplhlOmU9TOoAP3ADQ8PeynbBYYfM4JowL8HSuZ9he5T3v9xewVyuMz2zbj3Xuvfdd3OsuzO4HbO/7UtNDsmhpXvoNkX26U92uEiRd7VMmkzZddSumCfKYTnDAPuiHmDvqCrqegs6jtlsD3P8AcCV3p7o7l2F3J7Gd1t1Wnsns6ksG594UNfarydkPkM35umx0Vtram12&#x2B;g3CyU5wmu6KiavSmM/bkOqR&#x2B;strwQSSa2Xpfvqf7hd17eqe23av24dye59vbM2Ju/bu&#x2B;&#x2B;3277Xt&#x2B;llX7b1zoqy87W3Wx9fS3u3sqmU7hLmypb5cxpIMMMuuc&#x2B;kDyULu3uS7BeC2LuT767RaO9e0N4eyzunujZ/cm2zazaU&#x2B;XV0Ft3DtHct8a2VuC1XidKvM19XtmhltEygmUsxkx8wFrg1VxqcJEyjeB/BBbW6udod4f8pVPsftptLafto29N3dtWZOod4zu7lJQbL2jubbFLNLLPTWXdDLpVzrNeKe3hstzniY6dO&#x2B;pxTGD9yIAgHbio8rrvi0Dv7unfnY3dO6dtSu21loNsbw/8ubAt26aPdFmpt0V0mTJ27Lk3ujJl3noLXPa9islgxjil1mUZWDVC1EHq5rpsNQhwVcgmhHHQkjG6HxXIYxNCtn23JM24yGOJKzJZDdGnqA6x5YtaLM6Lueia2VS00oQDKaUwQQQlt&#x2B;AVcd4UZcFZK9DkiW/khyPMYysqVh&#x2B;eWRj44U3uq/BIePKETiSCbKOOgUJxVOcUXEthxFijB&#x2B;Hhkh48MTBZOjnREq5HPKHyxckN&#x2B;UFMaQAVKDwU5wGJIBEq3RZleGSjJdcWtVfVKt0wEx1&#x2B;/KPhhWnAoCjBAXmiZL4DmMSQpVQEiAgHI5&#x2B;SDEhiTeigppmmaqn8TiSwe9VAI4x0OkBzjHESkqDpH8xiRo6BAIj7ZxA88DIoUPSeWfzXPx&#x2B;WF1OPwV/0/LwKeWSLgXGCxqmNag5k5eHguWJTOiBQwH5w/njYceCjwKJqH4Q4RTljUWKvBUUVCdft44i3wUXIdqIXZQUoo&#x2B;2pjgJFg3ijmkdRMFSOUSh&#x2B;4JjIJBotAN5lBXWOf2icchJbzMyjJ/BA52aQj5HOA&#x2B;OONwKvVZSyeOImjKQ6jh8/D4iOMqUaeZPBPMcBi0SGeqpvlkYiMdAghlpjTlkKVdGPIQReWNNIWIQqVChVTH7Q0xVbpN1qIB5IlWIPMff441UhypqsVIMWnw5a58UxrnVTU5rk3uvILL5PehLXzn9RcidRAjr9Jx0cv1kOubH&#x2B;xePPagigbBAMiYxJzxh9NVyuSvNb13Y7b7ZqN30e4d8bctVRsSgpLrvCnqrjJlz9tUFwc1tFVXaWXddLKqy8dHUEK4wZRqC1FgkEqtwd0NkbdorfdqrdW1XWyt/tz6irG6LJ10VBdaSZW0FxdRsqptZVy6inl9TJclj5pCkNQFEkDULA4LTXd7bVUb0s&#x2B;27Rb5W4LBfavb0q0b4tN3oqyzXCk3BQPrZdZSyZBmTvTpJksyXdZaXPWEMZEi7XBUJEAgL1ll2on32r28XTZVbRypU/qnsMikq3z5pkSaOgqXHoq7i93/0GLMAimNPUhR4rC7l3fZdvbf3de2VdHeJuzKR1RfrTbq2nnXC2PZ6bn0lxlNf1W&#x2B;q9J/X0TQD06YJEAPdkJV93lYNuW613G9VE&#x2B;S270dHW0FHTUVTcLpPpa5rCypkW6mlPqptHKMwCZNawy2ZkphcAObqUV27Lbbd0bR2pO9R9dvWkvlVZ58vpdIaLHb/AO41cisHV6kidNpj/ttQKcT1AOoVZbeJE7rlyfSd6zw4skQ9d7Wjq/25SiZOIBX6QSMKVja64261/sxcqyTQGvr5FroTVOMv93cahwbIoJP0xqpzijWHM4y3Gz/irksZZ9x2vcFy3XZ7aZ77hs2&#x2B;S9vX&#x2B;lnSXy5lNdJlvprkyWwGM1n7Sra7qbBSRphcEsLgoWRm1NPRvpJNRVypc6vniioZc9yPrqx0W01OwAmZO6RBojjXJID&#x2B;Cs5N4tE&#x2B;/XHasmup5m5LPRUdfdbG3r/uFBRXCa&#x2B;VQ1M6T09TZdZNkva3UlphjIMSW1SToLLKtDHqJbmP6Hlj/Re2akxpR8t3QXETGOCFuYMDjVdVOq9MuIlj6phcG9PSRMLtB0gEryxKFS5YBYE7l24ZRqXXy208kXp&#x2B;3RUVNSyTLmbhluDTZmPcAHXFSgl5uOAEH5LUWDngrqtvtjtM5si4X61W6tf6IZS1NfJlV7hVPMmndLpOsVJlVE76WuA6S6GIyALEocM5smVlBQ14ZLutDQ3NkqcyfKZdbdR3Fsmrk/VKqpLa&#x2B;RUNkVlO9DLms6ZksxaRniCAxNVetzTrLur6UULE5BQSerlrjJKSJHwVi&#x2B;ptlRObTGptdXP6pg/bCbR1c8GQFnNdIb6r5bpIP1ggFuuNaLLaBOd6MiW4vMmnkoOpznskyWNDka2Y9zmy5bFIACgYloAx8Ck1tpt91pX0F3tttvFLNe0uoLvbaS60cx4&#x2B;ppNDXyKinmFoiCWkjGC9zZZprZNkSKaU1tJJZTSmyJTZbaWnFNIl0skK2XKFLJ9NtJKDWoxvS1qCGNMCWCSxNKJwYGD6ECCDYdKAxgqQ46YW4WUGKkiWHiW98j1yBNEpsyVNnBmQmFrXOd6buOWmMm&#x2B;hWgYmosjY0EPMosPQjZvpvY8yi5S1sxoJdKe/MB3TyxkMaOiVS4unGUQ2UXN&#x2B;pwQEAAkA55aY2G1VFqvZUA1Shb1tBcWhzesD/X0qXdOikIcHI3WgWoU5ohmUzUkHLTisVw1stXDBb9sWlFRdqdgBcHzZRckVSYIjgB4Yo/Uy4ZFx&#x2B;9dogdPSNAAAmSCHiFx21w&#x2B;CYCE&#x2B;8fcvPmcSuSIEwXP&#x2B;SiI1xJHFSSp/CA&#x2B;OJLFQp&#x2B;4pqB54tUO1lQJ1hDimvyUDEkN70Spz5Zj5YWdap7k0FT9o/dgRW2iMOA55krEHRCBDXEEit0fVAHnpp9vLD8lAaaol0/Aw188S0DqVKr4fHLLElUDryH2UKFwOsk1bRViKnNrKkPlriS4UDM5aw5/kuFRNFEeWfHyTLjrgQw4GyvhoVivxAQ4ariTBll/DkvIYFoRUw4ef4rhpfVDc1K5/9Ixtw3BIFW0VElFzOD8tVk0KWX&#x2B;cRy88VGLhN7pRJJ4Q5kDkF1xmvxUHFRolvKcVjD7cxjRkSKrQe5bxQHTSBgqxhjI1SCKgfghSP3csVwggM&#x2B;qEg/bUnQLxOeJYVKqtyyjn4rouJw3NLUdQc0KQjzKKnJUwgAiiiA3NEqICRwMI6j4LjkFRzQ&#x2B;gsiTX/wBo4jmnPA8X5qF62RL5nQ8M8IqW1TrWyjhz&#x2B;0PPC5TD8AuYu78n/wDSbyB1AljiUGZA84a46OckZHK5cZJLtReIuaiD&#x2B;kEEngoHKIH44wWXIHXi/cDsrszfdBvKlNvt1pre4VFJtO&#x2B;77ItVHV3Xc1olIxlvuE6pY4vlSpbemWTGXmI4OgMw1WDEmXitOPtB9tXoWVju0W3HzrBQ0VBbLg81RrpLaCmNJLqHzDNPqVQkPeOogoHkCGD7cNAoRNVuvb3sZ2n7Uy5tPsPZdusVLMrKavmUsp06dKbOpOr0DT&#x2B;s94pWSw53S1iAE4RCIss9PTVeXbl7Gdxt5XK5bd3R3MpKrtHXb0p9701FR2n&#x2B;39xLfUU0&#x2B;VWUllpN2UxZPkUdLVSQWzQfU9MlqocZ6CQxPld1Gy3rant67U7Koe5VBtmw1NHL7tyJ8nuFOq7pWV1ZuF8&#x2B;nfTTqufUVUx72VkyW8rMaQeqOGMIxdqE3T0vegK5vk&#x2B;x&#x2B;bSd6J3caX3z7qN2WO3jdgWXZknclaLvZKAM9OZSyb697nPsx/U2X/3A7VMZGMdT1ZmWS&#x2B;mi3za/tputDb6Kde&#x2B;5m9G7y29uuqvO2942u9VNReJNmNpNhpLJWza50wPkf2h3ROaIPcOrPD0jiQXVwPBadTeyaQ211NiuvuG7&#x2B;3W1DdtVvOziZvKopbtt&#x2B;41UwTplLbrzIe2rFAJquEtx6SCmQxk43DF6/Fa8F7Xviy916IbUt&#x2B;zKLbu/7HK27WWK/wA3f12rqW/0V1mSvRt&#x2B;8qeupHNFfcqZhPWXfV1IQVxo9QIEK01WV5Q32ydx6La&#x2B;57Jtn3Fb02lXb1s&#x2B;2GXy726ioq27SdybZof2Um9UF1qmPq&#x2B;mupmSpNQxzj60uUFiTiMOodJLONPmkdQDxNVkN0diO/27rfR2q5&#x2B;6q6UdBKl2011FSbB2801s&#x2B;30jaUVEqrZTiqoX1Dx6swy3BzpkcUYNSUiR81OQQdVsvbjsf3A2tb91s3r3muO9N237aFHse3dxKCx0O3t1W6yW&#x2B;fXT7ZV1lRSy2sud8tpuBZKqJiu9NjQca6a&#x2B;WzNzQvJLH2U9y3bSis3ajYXdenuuwjctyXyfvrcdkttduCW2&#x2B;PnVE6x7imPYbhWThVzjMp6mS4GW6BgMZ6Z2ifKiunyW/bctPuJ2Z21uFh3JvLcndvdF1mPt20b6&#x2B;32Dau4&#x2B;3rzUEMrbvdKGS03u10zEdJJWcJYQlTgPWIliSfknkta3F2U9xlZSX6wbV7ubR2hQ3ffVL3Bot1Ue3X3LcFBdn2&#x2B;il3OluNsrfUtNwpqm40r5rVaoEzjjJxzIaJYO/wC9IpzWcpexndPdlykX7u9u3Y913TaqCxWqj3VtGwTbPPvNFY7y66tqLvbi40tLVVAPSklrWgxxoQlJxNv8kXpKysO&#x2B;0/3NWW&#x2B;713V293lJo6Cp2oyx9rdj2mw1l2kVu56mpp3Pv&#x2B;7al0z0rVV0hDmSp0pGmW8l4KYZCRl1cAw9uKi/JYW833307ht1VbtlSuzux922SVtL93db/bL3cbRPu1GJNXuZtt66h0u52rcMpxliawNdSvBDcsI6y9QPb9q05NCV6X227Y7r21f63uJummsVLuSvfuu9Xrbe1quuq7VMuF7tzZfp2upuUx9Q5sydLJDXmBcAMIDeJuhjdajd&#x2B;9O/e5FFN2f217OXK8C/7YvEm&#x2B;bh3g&#x2B;r2hQbJ3DJmPk09BOt9aXuvT2TAHyns&#x2B;guYuSYwZSJYD3rRMuoPRY3/hHvBd7cdu7QoO5O15HeikuM4bj3HfaedUi67dZVCdRWOjudL0TaGuEhvompH9OeWDpyGAD&#x2B;ZZabVDSKxW/bT7nt0Wbc9JQdie39Dc79YtsW9tym9z5k6ok3WxEvqLjUtISt6p46qdpgGuIdHA0y56Rzqmjc1s0jcHvXttzstVTbC7S3LZdNaLZRXzZ99u76Xdra6VSinuFbtbc1qEqRPkzpg62yqwPQFBjRGS/l6eH7XUCwLXK3ntj293hsqZX3&#x2B;ZT0ba&#x2B;p2nV01Jt2sudRVy5V7m3GbcmUk&#x2B;4vc4eg/rEv1R&#x2B;kxyxQh0CnCxU4HNeJzne7ay9wbxvja/Yfbcm23y/2q43uz3LuRb7nPvNvZbpVsutNTz/R6LXPpfQE2jmSgAS4iYuMtMEyAFS5r7e5AtRZmTuz3r/vdzVFh7J9urBOuu45VztdPujdAuVsNlAa2rt1xqaAS66nuc0AllRJIjngEsolQBikGtDQrpvats3TP3NVbu3LRUtmqbptS12yrsNvr51fRW6701S&#x2B;dVtpKia4un0pCBsx31kZ5Y5GeT2oy0RUr05oPMomsSqDSCYW0UxNV6x2tphMvNM5wd9L&#x2B;pCoXpP9XLww4/rAXHNyKrrMGCFIgRiseHGGO2uIO6MFIg6a8OOJIFK6owYArDkT9x4YvFaDD6rolYhiQdCirwEYriWahQpTPUqY88uP4YFaKjAk&#x2B;JIyCfYrhU5CMJ/Pl&#x2B;WLXkmt0YIRFhy44lsgCnFGDodPsvni8KhLHQow4JAwSCaHhxBxfNGqNsYhFSPHWIxa8kkh2RgcddVX4LjL6i6H4JeXI&#x2B;aa5&#x2B;WNDwWteSkRjGAyhHxGi4TZZqIuUZKrHh5lfvjiCgxqEskRGvHnpHhDA7GqCCDyS&#x2B;p/BmXA58fHCtPX3rJgLkSCggEic05A4FxN8Ea/SuZXj92G3itfTLkp0hmQYEa/E/dgWbl1LSdfL7JjcbsnpJ8VJivhBVTyxohiearB0oiEPsuipzxhXlfkgJ/L7DEQVNwo6AhCuXjCI/AYCkkuxSSSMox&#x2B;3LElnoLKidOPgnl4eeIhmWC1kLkMOfhy/HFyog0ugGo&#x2B;Gv2OJuCfLRSqEgA5jMZfCGIMzG6mqoUlV/qCjkmiwxp2HmslteaMJki6ZaAQIMYYvqDG7p6S7iyMJlp8U1wjyyQQblQTx45IuRMV4YSaIqBSy5y7wtMuuYUi5jHhOORRAV88dTOPPapC5oceS8HcjoAEfqgIEGCqueeSY4aWK5eStSxSGxAKj6UUeYPUTjRYBZMaPqh4NhARdqeJKKAF8MVHVVuaAlys6YCJIUFUygn1IPhgf4IAcoEUOd9JiCSTqDkYQwu6ne6W5oeEgpRIkKI5FEXFY80ktIJbw4HIBEHAA8GxETiXGbpafUoVTmpgE4FShOMllBLeioiuXhErkvIYqs603lBdSC5q9UeooTqhhkhAGCLvRDfFA9riFaYKv0gougIyEcafUWU4F7so/SpI&#x2B;oADTJc4oFxkXd0uHdTqVMACpBKwT4Z40Co/Sgyj/T/1NiecAf44QR709IdgiIYR1QV3/Uc4RjFPkMV7LAHwUBGtgYELFCHRHzXBdOjC6AJE9R&#x2B;qK9OQ46ovzwoUgt6S0rlo4dJCiCIcSR&#x2B;CExHSAC39SZ84ERAXEX0ZlskCrIfpUBwJ6YnqHwIKQJ8cFywWYgGThNeSSYAq6BTNdSYZ&#x2B;eLVJFaoPqPFP0wzXILBPuw3pRkuAW0KJkCn0kn&#x2B;okOA8yghgtZDvUBSW9Ti0tJAIOcP/aRkUwflZZpeyJrWtgINMVLlJ55FI8sV72XIAL6qgBKPWir9PjkUEIoTphJcLFNLowrtYZhYn8xjBclypiz6OiDQmgJgQi9XMxKRxpchbXimtDdW&#x2B;HT&#x2B;kEQEEJgVzwEgBzZPJe39opK3QzHNVstjz1EOAUiHSPqJjjkxDzOuvMldLKUVCpWGozESumOyuLVGHfHgNOWJN0YTWGuseEMSnrVECmSQyWBI8TiQhXXxPML4Yk6c1IPFDExy1Ug64jwC02oupBiRDgCsOKeGLxQPLVMGmcft8cFkjijaUUZwy5YarQNEQzVEMfPxwrWiME6HTlzxIbimBQhzXM5pyxKarqlBCQyiAmv5Yk1fkoBI55c4LiqillKDiTp5Z65nwwKYu4shzCDkM&#x2B;XnhVe6BD&#x2B;HniVRZIRP3&#x2B;A8coDAuO1QaJn4grlxTPLTGomrGxUWZzdRDMEAQHH5JywFnpZI&#x2B;lyHCPWERqvjp5Y1Fh5hoEOWqocn5ZZ5iJ5YZs4Ky3BBrArmY/f44yA5opLOSeI&#x2B;/Exatlq5eSW75qnHwTADowQKHkgAzy8f440A60ZNyCDxXgpy46a/DGSXWXJLoYleA5xJH54vmol/FDxAh&#x2B;Az4YgfikNc3VKo&#x2B;XInTLGgz1SRWikDWA/IrxI4YBdIBNDZFx4koCdAiQzRDjQLktdat4IxoYZ/zxjwWTqCqWOSRjAIpUfPGg7M9Vgijrn7vHJLp1M//wDNNJISPS5EiFTHVzfXSy5IVuue3QJVSCHZA5DWPLHHquYBB0kscqNI05f1QaAmJtU9Ll7pBa2LjrEAKQDyVdMOlGWSeCXBP0jqQLGJUxzIRFxMyD1CqWXNH0rBSIjIgcRxxc1mNSlkEEuAUdQQ/wBLiREZklMT/FL6m6rq/SoCFVKCLuHEnBR6rJvSyUVJROSnw6YeGG5UgewNeYIkUGfhjNFsyHTUJbnI0kwUhOXmOIxUBZYAcqW/pQ/eYjTgpxH4slqsELmgEDxhBRz88IAI5pABLFeKd6u5m6&#x2B;3VmtrO3fb2d3U7g3mbOfYNj090prI67Ult9Opu5bdKxJEmpkUZc6W0/qdnDGJkhox&#x2B;o/IXWiX8vBalUb231sWz763FX7I3pfbjvC50122Nta3yJd7mWCpmWmldUbdu5kTZcu3UrK4TJfqtVjnhcjgj1Rc1qaarAkTqwXlFb7l&#x2B;6NLuq2yv/1ee7Z2ZuqmpLVcN10cqknz&#x2B;299lUjjVV1TtOfTGbX0hqFRzJ0yXNDQCI4SZm0Xjr/lqsdQsKhb9Yvce&#x2B;02mRSbl7f96dxXmjbVMnXWR25dQtvhk1zZNNNNDQvFJRun07xMRiN6AdcAk13otu45LSb1c&#x2B;9P/lCv2TYNy7wuVjuNmuPc2z3eu27Jt3/EairkNNH2uq7rLlfstxUrlLpRcG1NM76XPcmHzdRiX6Wd&#x2B;fDwWTJhRe77937/AMb7c39su/2&#x2B;0dw7P28pdxPoamdTf3FtYKWW2ZMpbZPeZtymzKtrmBktriXuARcakWBr5wHSKLnHeXu2mm89s5HbiwdwNxVlVuGw2bdtpm7Nq7dY620XiTKNde23Ost0yokTLXOeR0S5spC09Qxg5CGZzxop61XsW9fcpbdg92Zuwtz7N3RYtmU1mqK5nc6vts&#x2B;dt29XY037qls1nn0jHymzXMBY504tWYgAwym02ZokXUS0msV5n3L94vb6m27arhs/ce5rVWy7vtm6XOZ/wO73R8/b1VXOprvZ2076Oolsr2tT1HjpdLYetpTGJTYeV38Pisk6hXI90kjuk&#x2B;RT9mX3CkuloqL5Tbn25uPblcy5vk0jJRt11t0&#x2B;bLZTzrbVFxLHgknItBGN9ZIHStVpwXvVV3gtVs7hbC7UT7JuC57o3bt0XiuuNsols&#x2B;2WyqET3Tb5VTehsqXWT2mWzoJLXkAjEZgSGMAmR10HioWdafvL3I7DprBWO2jvPbsrdVLcqimm23cVNdGU8mXZqoyb5Rz301LNBqnymONM5hc16KIYwcnlPQQJhLrXb97mNvXJ9BI7b7w2tdrpe7Hb6y02WtoLjMqHXGZWSaWrpxUH9u181rHP6ZBa14A6icJkBJgXcIEuK224XHde6NkbNul2oJ8i&#x2B;Su5VMKimon1dF6NvkVdTIbNdKp5jHT5BkhqtmLLcqkE4pBwH/1KIagWH78e5jafZ/1Jcq&#x2B;W6v3Jt7cNloNzbD/ZT6jclXQ3h8psufaw2dTy5DWSpnV6iTQsC0YJZYRJArIXHiptTZe29utz3Dd1muN3r6X9ow3uolWqS6Q&#x2B;nn/2h0tk6kNRKmR9drJiOdkXA41EuDLgtaMt/Y1pBcQSugMBnnBQmF1RBowC6J7PyDLbPmkdSMg5It6oAAarjnw3KxNe8RiEiuup0B1Q451xIinSQCQcliI/BFTEhEDEAhNCc/COpxJ5JkB9l0&#x2B;eJIfS6Hy&#x2B;IxAkJsaqV8yNPn8MXNaiKMCqVYp4rkeeJQLUKYEVdPu8OJ8sCy8VLSSoy0GWUfLFR&#x2B;agddE1RDmq8RxPADDQUXLRMEQIrz/PnioEOAjiOOgCceWcMISOIRAa8dNM9OSYkEP4KjwyUfIc054PFVVBVM00hwQx88KUJzyzRUC65QGDRDUQ/H&#x2B;PxzXEh1kQEQQIz4oVxBvesXDvVkSoVIhmmiZpzBOGgHEqBAB4ogmkYR1z4&#x2B;eDV1CoJPwRBenUlfPP7eWHy8FSLlwoQ5Q880&#x2B;OeK45LJu6AlF5w1IQ/qjyw8OLrV/FLiFJPKAhw&#x2B;JwxYCpQ54OgJ6QREnnoqL4rjNGqAkB72CSTxgFWMV&#x2B;HHFfwVK6FQQYGIz/ADGkc8Tk8FlAdTwUoPuxLVkIBDurMmC/PRYYgUGtDZTkPkvDU8MJBBBK0GJIOiIQXwgvkvywVFldRARByDNfKOSZ6HCDRhdaYFiUQihBRFULr44iRog1BVKV6iVTMZNjkhwWZkGNW4rxHvBL6qejmAq8AtUQUA5IM0OODM4IIWxECy5umFCnShKkDiFiEzCa44HK5GIDukqvXGDQnAFRrxU6YSSfFRLFgwCQ5CWiPSilOShE0GKL&#x2B;9QBuLoQ1iEhwSMCCSBCHFca6jcBaL2CtnEEAgCP0qIHiPp5fdibQp0ZU1Q0EuU5CGXgNS38cC4yGsFTgrQOnMfA8f8ApOIu3NYJ6i5VuhQhscyYxKEFORKYnYVV80bgoUBE&#x2B;qAj0&#x2B;PPEailmS/wSXBwQoSBksA4OzXUmOMtZ0U96Euyh0xXxz10OE3SalkCEEwKuVEMSBw88asFDQ6BYussttuNxtV2rKZs242N9S&#x2B;1VBhMo5lXINNUulkRPq07y08RjJDkP9S0QGBF1lJcyYzq6Zj5ZcCrmPc1Qcw4tP1Bclw2UYgB0Xq1EVnTi9EDvUeCgiASscTAWU0blG&#x2B;qqEAl1VQIo4NnzEVCFQOBBC4nqPBBoeSQXEtDHPJDSH9JXpa4xLwF/UdTh0c3SWMXstSvOw9j7ivdr3Lf9qWO87jssr07Pfa&#x2B;lM2422V6jZplSJomNY6V6jQ4Ne14DgoxUNmdZLCyz1uttDaWVEq3UsumlVlVNraqW1ocyZWVBLqie0TA8y3TXFSGEBchjI&#x2B;CA2t0F3str3BaqiyX230t3s9UP/kW6vlfuKOa1VT0nfoc1wBBb0nGneNVEOrO0bV29YZtXMtNpoqM1jaZlQz9tInS5gpJXoU5bLnypgl&#x2B;lI&#x2B;iGYzU4CWtdP2wKrNMp6ZkxrpdFQSZjA4NmyaChppoaf8A6fqyJEuYWciSMT9RL6qMWD6LC7i2xZN026ptl4ppkymrZT5FRPoZ7rdcRId&#x2B;qXLuVO0VUuWTm0OTlgMQzGxT0ups209sWO3UVpt&#x2B;37Oyht8qXIpGTrXQ1MxkqUOlvqT59PMnzpnTm5xLjqcAoKIAc1dX39gsAmsnM2/YGzpTjMlTpVltcidJmkxfJmyaZjpczm0g4ueq30AV1V1UUUipkT6Z7XMZPY4OdKPpTZa5PkvA&#x2B;iYzQjXE5/NZRDBytRsnbHY1hlzWyNuW661NRVTK6feNx0tNe73UVc13W6dOudbKfUPId&#x2B;kKGsSAGCMYwfpA9uaQC1WW&#x2B;slslj/alsY0hreljQ1EEAA0Bpw/NZMRpcp0oOcQGj6iUIMBFerSIIxlurzahaiCAXXUna2nY231ExoAHTLa1IAOQEpxXHZw2K65cF&#x2B;C9aKlDAxUxRNI8zjmWLeKOKgFSMgsFJyDvDEpSEHSsVOaRP8AEYlIhD7ckyxWWolqgoVOSJ92UI6g4vFDtUqV/EJ&#x2B;fji&#x2B;SfwqpVT93BMTrRpF9UwQyiQSc1GWnFcRr4LNCbaKmk6nP7JiIWzyoU5rfIZnSH4k4lBwK3Tghhl4csVRdTcURUBOcIxPidMKQA/NFEINIeS/hiVT3oihHA8eCw&#x2B;OBlAMeSEiAidIpry8MXggmrC6AIChVEVVGfDji&#x2B;abhtVH/wDUnyxfFY/cr/XOHikNIY108TVAHltVGAogmn2RCuCwZZ1RZ5qEy8tVgqE&#x2B;WBLD3qQuueWfLmqE8sXyQoiVEANP5eOuNORUJanNC4fHhEQ&#x2B;emIVKgUs5w1EUP3aA4CGLFT0SnA/n9hiYrcRxQQB0A88sxyzOIxZcaAqCeCCK8AFXFR6LTRtV0GhEBp5/Y42GLrRqRd1BJyXmD98IquAmjKEaKBnw11/HM4AHDnRRYCt2UjPz5/E5YmJA4IZwOCkw&#x2B;J&#x2B;xxMPctBjQomZkkJEDMxQHXwwOr8tLqQkYjmNBHOIKZYEmLhl4/3clddup5gzlqdcgRo3L5Y4stQFQYkcFzJMB6lK9RP9XiOBMMcFFzctElzF6hBpgVAAIhwOmCllkmIoyT6SKDHqIJgSdOpI54QXstBA0Io/pQgHXw4J540OFEScChqlOY4KoBRM&#x2B;kJyQQIIMMFECQNLBAZfJRAgQ8UgECDnguqRcUsgfHJepPqCxz0Konhi5BcYBKU4uAEUKgGCrlBcoYBU0spHoc0QoBqTxgF8saoaKH4pTvqBTIkA8QRzWLVwVNlatqvAO5vfKm7Z762PtS5bS3LU2PdE15vXcKRb6mp2jtOmDHiWbrU0DKmopql05oBMyWJIaVLhgMiCAzufgou1brT&#x2B;4Xui2NbdmVN52huRboKtrqOpm7Xv14oplFQ3AU91Y5lBbqj1JlRTgup&#x2B;n9QQg4jMAPomJETVbnZfcP283L263P3O27T7tvG39qVDqGvo5G17vLvVbWskSpgFqtM2lZcaulmTJsXtlEsC/SSMRyR6DIA05LXVTn&#x2B;xafa/dv2duFR2&#x2B;lVO8rJZZ&#x2B;9rRXXGtstwl1zLrt6dStLv2l1nTZdN/a6lnQQ6VNkPmOcEQYxHNE9JkWcOxQ0iHW70fuO7H3TcVFtW0dx7Leb5cqeqqqWis37m4vEmgpplXU/uPRkGZTOZIlOdFpEEVcbGSHV06&#x2B;Ca9NWZbHQ9zdrX7t5P7l7RuNHfdvS7ZdbrSTqidMtbKqTZXzZVxM8TJc&#x2B;opJdM&#x2B;Q4OeZbgMXVGUeoFwQsvoq2h3V2NvWz011tW4rPUiZt2RuiuZbLjLutLbrROJaaqbW07Gh0uU4Hq6pbHtAUtxdQah0TcPotZt3fbt/N3luDad13hseg/aVW36fa8&#x2B;l3NQ3Cq3F/f5Mx1M&#x2B;bS0k&#x2B;o/aB9Q0S5ZKBzihAOMjICasBRjd1PLhReq124KC210qir3NoZLpHrTbxV1FJT2qkm9Yly6GsqJ01hkVc9VYo6CNVxolj5vilgznVWG3t77R3ZUXak2zuO2XuZYpxp7obdPE&#x2B;RTTR&#x2B;tKwD9rUMlmDnS3Oaw5nCD1DysyyXJVhWb&#x2B;stPe9vWymq7dX0F8lXqZMvtHdKWpttuFilNnVjaibJdMlAsa49X1KxI4DS/wDgl3o7rNf8lsUy2UF2oLvR3SgvAqjY6q3VDaqlvc&#x2B;llOnPpbfVS2vlPe5rCApCHPDGseqjG3NZ1Wi7e7t23cVn3TeWWS4UDNr2ll2qqKpmyXVMyU41TTIa&#x2B;W1rGzR&#x2B;0MUSOMjJ5TI/lFlomq3y13&#x2B;Xcptpb&#x2B;yqqWXfrPKu9pqJw6pNawyWz6mnkFjIzqGWVmKQCMsUSZHkRT9qurnRO2zuvau86Koumz9w2vc1upK2qtVXXWeoM&#x2B;TSXSif6dZbqtjmsnU1XIdBzXtauijEJRl9Jcg1SZF0O5r8zas3bsuvtV0nStxXU2yVWS5QkUNsAp51S&#x2B;43GpqQySy3y2SSC8OUEjCT0s&#x2B;tEdXmfVZ4TZL2yZkmqopsuolmbSzZNbSzWVsho&#x2B;uoofTnH95TM/qmS&#x2B;tjf6iMQAKRKLF1cSiyY1sxjmPZEsmS3NmNI0c17C5jw7iM8ZJAlzWn1Cu5DC6YBlEA8UPAKFTXEZChFQggAc11j25kmVZCdXTGhQMyGwI0iNMdnCxj1LiPGVivRBnFIqseCxSHDHMuIqkBhBTqdI8OOJARmCcivDjDyxLTEh1RJTTQR0HAkeOIpFAoHnmeOR0h9&#x2B;JREmcqIjSHmeXHLEjWqkCOunOA0CROK5ouQhxS6YCM/H&#x2B;GJRP/ACox5Zefji1QCxqmA8joBH74jPEtAg0Txp4r8/lhT80yBIJy04Dn44PkgkhSqKv8hxxKetLKNU8uAMPPDzU1XUaR0Vo1UZ/LAHChwUEBFHh/AYlVfklpopzXLTPjhSsiIOI8Pn&#x2B;OJYr08mRgkaR0hHw8cVEABiyLTzKclwIIH5XTAOPy46JjQDh&#x2B;CC4KFC2KwXIc8h44OosgB0lxJKAGIEdFGfxxeKqISACECeOUYFRqmICrp0c2SyCFJSEOeIFiFs0YBKIMD4QyVOPOGGRdYNyUJBAVeonXgIx5Hjg&#x2B;S5AWozJX1Kmma8&#x2B;ei4nZT&#x2B;bkqXLC73UG6jxVJEFYfLA&#x2B;gQTVmqpjx4fb4Y3F9E2YMpBVoiuinmfKGMnxR&#x2B;aiPMggkghE0HInBZabSyrPQEaHMDhnir71MCA68s7qS&#x2B;u1SSoCdQXMBcyBljhy6cVqJHUxXLs5n1kRhA9QHTA/SYcRjg05rkoKJbmgErFACiKSCNOaYzrVaIAHgrdwBQHqaozBRYIA5MaZrWQEDgnSAAgMMiFTRMjiBDOVxaVQOBJiIEFFRfpzBzKr8sJZ1oR8qV0E5EwMCq&#x2B;EDmumIFRZ2LJcwugcyEA1I4KOGA18UMQ7JRAIVM4KCv8AOOEXZYAd20UFoBBKBqlsW9StyGqgJhfhZIsXDoCOlf6hpDNQinmMQc&#x2B;C5OkNS6s66ho7lS1NDXU8mro6uRNpaqlntEyVPkzmFsxk2W4FrmOaUTEa/FZaj6rTLH2x2JtydLqbLte00LpNCbdKZLpZfpMovUMwyvTeHM/7hUFFGACL8EdH&#x2B;pblTW&#x2B;io2OlUtFTSJLyHOlSZMuTLc9cy1jQChTTGtaoaFnWuVOxtlVk51RU7U2/PqJjnPfPnWqjdMe4klzi/wBLqVxKk8cYIi9RVBBsVhq/thsqpp6mVR2GhsVVUypkn&#x2B;67fppFru0mXNaWTBIr5Etk&#x2B;SZstxaUMQcNPBaEGqVrFf2Q2dU2Hb&#x2B;27e&#x2B;62C17co6&#x2B;gkSbLXz6FtfQXYH&#x2B;6UV0EtwbXSK95Jmh4PUXE4OkMwcBBBBWp7b9rvb3ZVpvlj2TVbh2pZtxOlNvNss90nU9NV0DD1TLSyWv/wAa2VJJMySxGuU4yIwHlAoipW90HY3tFbayhuNL292vLuVu/auorgbbIdWU7qRBTPZNLesPkkK0rAnE0RYB0iIPiVhr/wBmJu5K7c1Pdd6bjrNi7sr5FwvOwZ81jrNMnSAz/akTun93Jo5kyWHOkhwauKWOMqyJY6LZFG9gtk2R2a7b9t33B&#x2B;x9rW7bwutPOpa9lva6Sypk1DA2cyYxSD6gzdnjUYiAoFhiPekt7P7Ts&#x2B;0KjaOyrXQbSoZougkmmo5VQySL6x4vTxLqA9vVXtmH1HHMnliMR09IYBPSCtKova12nkWay2aos9TNp7JTS5VCyVcq2mp6edKcXCoppEqa1kidMcSrmgEgpljAxwAAFwseLr2S2bL23ZrfPtdHbaYUNZRyrdVyOgH91SSmljJE8n6pjQHmJVSTjbB3WgOqh0WkX7sXsDclYytuVJePVp3JQy6W&#x2B;3GllW3qlft5jaGVJnNZTNnyW9L2sQOGeMHFGX1WBpySIHitdsPYGz9tNr3mydjKik7fV953DI3LXVNwpH3&#x2B;13GvY4GpbdKKe5zqmXVtUOI&#x2B;oZjD9sRHk8pdPSQOK1&#x2B;q9rVl3eytn9z95b03RX1V8/5BIk23cdzsVksdZ6fptpduW2knMbRUEtXENKl3V9S4DjE6SdZAkSy1mv8AZRsClZaa/aG6O4Ng3HtuZVjbN0rd43q5yrTR3R/Vd7fJpKiodJ/Y3JpIewghSoxk4YCTxcEc/imrsaldcbcssvb1itNkpi50m2UcillkzHvLjKakx7nvVzupykLxxoREQuQBbVQywZ0uCjqGWYCxyzJxGEQGRQnp4hde7Mk&#x2B;jYKRoPSHh0wIIkFBFcjjt4/oXUN2K28KQqhF1RDjkUGVAQyGiHggUqQhxKRBTnzTPLKOBbZhzdUgKg/emvHlh1SSSPghgMuH0xJMAnhHFaii5LGwUgqFUZxTTinPAbsEMPyqtV1&#x2B;CaIeAxGyiD7fsRta4ElyIUgvKBXE2oukMaBOaPDROAP2yw6VU3FNAQrzih1GRhxxfNPlAujGSwUqD8cKdaWTw5VBB45Anl8sTcESHBVErCAA8/jpidIsq0XXXmmnniQ59yGHDPPXL&#x2B;eJJoHQuii5Kq/emuAvpdAJu1EKf9WiacMPt/gtLJJqiLxy&#x2B;7LEHXG8mbRGIfVly8fvgMVHRdgEZHUF8wTDwQYNUv00VRGFQIN7qipSEEidY/bgMCwlGJUJrDj4LrhfitDpat0sqvA/YjE3BPS5bRChICwh5cj5YtFoMfDmhAPjyz58I4iCsSlVkHllyxaVTqAbXSykTlr4plFNMS2AzcEsgjROEDD7lxKDMwNVHUQCo&#x2B;5FhxKRxCymY0sqiYnUAHjz&#x2B;/ElV5/b8sSB4VRDxAz5aZriSmFOUOBHPiEGJZEWXnXciUtmYQ3qR7wGkBwQtMSqeMMcOYtF&#x2B;a1Gh4c1yrPaWzHIiFEII6T4KhIBx1iBquVtNVau6ipgEjDPL4x8sR6Xc3U7f8JS3AuCCCwIGZAGozxVuovpdKKiEYBFbmNM8giY0Dpoh&#x2B;SBAIiOWUVjyGRxEk3ugh5OCklsf6gORUhdQoOXjHDSy0R1XSntyGiwVM/9S6lcZQ5FG0QI5pb0gucInpaobziRhr4II8XUdIX6lWESqhCUBSAJCQwil1BwKWSSrjCKKSCUiNCDlDC61U&#x2B;CghoJQFIAk/1Hl0lR04HChbmocgA6Sqpy5KVyAwOR4qsKpfUWpHNURXISgEQsFGEcTosFmeP&#x2B;aklpB&#x2B;lDmCDDKJ5qnHCWNQtMbEpa5giJCqQvhFY4NADZRi5d0ROqaAoOEV&#x2B;RwWWSPLzSswTo1xHDpB0zUxxWKXkLVopBQtVD0qOlIcD9WgwMhibo1BiCEXREBXxVGgjCtgUqqXLP9JgYAAZrx6kwihfVZIYhH9aHMqQRqPBv/SuIF6kIo6iKqCQikBfjHPpGDkbLJuyKJc0oGwMQc0WGpw1skPFSFJ6R49Qz4GJUIExLbgVTG9QdwGYEctUOnwxcjZUn0smRMFU5poOlU88Tn3KDI2xEdMiQCAgjrBcsDUSQDRPa3OGYHUkQgKhefPGTS6yAbPRZW1yXOrpAaCEdBeCRAEAYYeS2SQHXYNgliVaaFoaQPQaoJBRRxHHHbiGgF0pVvdZwCGhyPHyXxzxoqc6qYgkog5wAXI&#x2B;XyxK8LqdAdUIXLKOJcgFWKgOa4pqNOKiOekMVdFkmriygiPIEpkETTFz1S5uVLSeHMny1JxPRNCKokQromWS/jieqXTAFOa8B4CA5Yvmsklm1CcBkgTwHDAahIci6MH6QQFKEEfdBI4VpnponNGeapDksV44rp8EwZA8YjJE4YXCC2t3VKp8Mx&#x2B;XhgUWFOKhFVIHwJRNUyC4jZRoq6TqgMETkuawwoJi1bKCgWCIi5/YYkiyCH4/&#x2B;3h4piqpysogPEpzisIeGJZL21Ux0TXw&#x2B;7hios80ScfgFTnywJPmFLKvCPGHny44h&#x2B;CBUuVXHhp9gBiQb1ShBTAnMDSBzh44loMQGQJqTrpmnH44fBbqfFC4GMcxnA5p8UGHxqUGQCWVGQy1BVfHAhnvYoftCH8MWiToBdCW/ep/H5YFOKugcEIJivE/niCIkHxSnIhUc&#x2B;HNNSkMIqtB1WkCEHn8ExJVA/HxC&#x2B;KQxKRjMR5/HyzxKR5wyKmGuqEHifPEpaNv5ofZS0J/3CF0QtKjUgfLHFmfpopcoTgkxzQNSVLlHPQJDhjrEOuZwa6K0LQTlECCQATRMsTVWSQeKUUKCIQRzK6g8MVgtHldkpwBGeaFCdIkk5xxODayPNEdRZkqIisSIRKp4RVMAZ&#x2B;amCQ8E/pIJJULFsCepcsIWiCKaIHOjoE0zQDNpCQBGRxM6LJQcSSqdIJgY84QVAuFtFEyPgq6gWopJ6igUordNMa1ZZN&#x2B;at3kxQJqkE6tV4w1wjgqLvyXlndfu/sjs3tp&#x2B;5t8X2gtFKWubSSaqplSJtbOH/wBKmkuWbNIOZDXAY8T3Xuuz7Rg/mN3IRctEayPAL2z0h6N75627oO29lxSn0h8k2JjAcZGwfQPVcas9/W3byKus2xKs1bRNJpLe51ypptTWV3T1ukupGTqaolMaDmZTg7QjHqWb1nkGM5dvjgcYGpqT&#x2B;wL7rsv7eZ5JY9rv9zkjuiHl0xaMY8SS7n3r2nsj7lz3guV2th2zLtJs9BKq51VKq5lTKqnmYJL2ymPDTL&#x2B;s6qRxOO12r1dl38pQy4BAQgDQu70XqP6hfo1D0TgwZ4b2WYZ8hixgA1Hel6arop&#x2B;4pDJjWuY5gc3qKgOQjRUyJOPJz9RRx/VjbwK&#x2B;cY/SmXLJseYE&#x2B;DBWbt1A1TJbKZhkFpLnOe4TGzCQAWhEDUjjiHqSJkIxhTnddo&#x2B;jpxxkyy/xRwFG&#x2B;ayb71KbJNR0sEqU175x6y3oly2F7nqQQQjSox5Ed3xyh1xHi/ABeKl2DKJmBJ6iQAwckksudbd7uO2Fyu9RY5TbrTV0mdVyumrZIkypgpHObNmSpj5glulktVSWwx4jH6x7dkyfa6Muugamrv8ABfTNx&#x2B;gnrPbbGPcZS2xxzjEgCRcdVWIajar0zZXejt5v6aKSwXyW65B82W631MuZKnvdJT1fTcGmVMDAn9SEH6Vx5fYd77f3E9O3n/E4SoaL0b1J6A9U&#x2B;lsX8x3Pbk7NgfuQ80WNuf4L1bJC0/qz&#x2B;/Lwx5e1F6XWheiMlAgTRBqXLyhriooVGrououTMQHx/FMRtRHS1lUGqoUoekEBF4grkmKwbRIAI4FECHjOMfiFiBwTEXNUlG1GgagIEhqAqqIDC2uqBfgm9QWHhFY&#x2B;OmuMslqNojAVwKJ9XBqgLlxwup78k1oa52hQqUU/UmoKwGB0hyOpqJrYHNAsQgQgwMEUKp4QwAlvNRA4lbFYpYfXSSEJDgFyMSF5ofnioaj5rMzRl1/bmdNFSA5tkSxAZQ0x3IuwXWJV&#x2B;Ich8dNMyCDjSmOiIkJ/pKJoCBqNfhiUXF1QKZ6aFPlxxLT0DXKohTCK5/Y4FnRCRFCTEqsCc4eWFaibDQIwILBPtDywNxU9HaqloWB8Y/dhPFIaITQ0hy8YYLrBIvqmggJDxWI464Vt7tdN4r9ly&#x2B;WJIITG/qQHw8o&#x2B;ZOFJpUpnkPy8MDPVQrXRUQinUfgsPniWS&#x2B;vFUCSR9tMs4fPCtctFRBPxTh&#x2B;amGBAAFFOWenI64U0&#x2B;kJfT9/DX8sSq/isiQSERF14gHVMSwSRxJTAETLI5p8CmCizQ0qykiKKU4oP5YdG1SQAiigTRNI6/dg5aIIrVCc4n&#x2B;WnwGJLsLUQoghqp8PDliQEuACj5Z80IXDVchu9UtxJTLQ/DFy0UwKA5aqFzHx&#x2B;IxJNwQgOQI8PHAs0EqoRAcuEcuPniUDW1UD465JFOcPHCpqnilnX7c/LFZaFkJCQGR4J9lwJQGEREtReJ/LDooI2u&#x2B;lqpxQ6R&#x2B;rPOOJTIlz8M&#x2B;GX4YtVLTt&#x2B;MDrHNzBD2omsCPLHHk&#x2B;l1O17LlWsaPVc0ACOmhzQwVSq46djquw/XQFYx7U1RXJoo5qsAcRaVDYqIIjzdJcgRM8tUhl8ScaAAposq3HLyB08RgIo9gChvglknNiOBj1cAIHp4BcOvUgya/wDilzAWjxiToM/lHGrWuluJoVbOLnOgYFFyC8uYGIKog1CO1PUPujquAljSyQDc&#x2B;5SWgI4KSNVMeR/HF1aCyumUjRW7&#x2B;pwKgDjAgAZoPHCQW5rLOF81v8gszZDaHZErek6wSpE99fSSXX6pksky2VEsMnTRSz3NbPDBk5Whjtceg&#x2B;tYbef8tjzCJJMmfTmBqv1D/bge44j3TNsPuGIEDIRDu1gSLftXysZ2a7STqmg3J29uLqcWGa6uoK2lrnTJd5rpUXSRT0xmibRNJQKjhrDHo&#x2B;42eIYuvBItHieGi/U2z9QdxyZhg7hjAnOjMzROpJ1XTfY7u5Re3n/kdZc3OvF03LKE&#x2B;moiXFlCZs4T3h3T1ObKMyAH6QcPad9LYTyTlDqlOLCttV6r689FT9ejbYNvM4dvtZkykz9VGYE0WQ3L76O41fVLZKKnpKNJjiTKlSnhpJ6A1HPcejVUJxrdd23e6BjjaEH0C6HZf0V9Pdvj1b2UsuQinmJbxWq0Xvc7q01UHVIpqkS3Nc9jXKJrTk1onMZLKatLguOtDd7yMwZTJ5H5rzO4/SX0rmwGEImMy7X&#x2B;L3XQOyffjZtwUNVYt7Wp9oq6&#x2B;jraGVVUhEkTp0ynfLYshxMhkwucrRLcS7Hltr3yUIHHug8CCAReo1C&#x2B;c93/AEL3OLc4972TcCYhkhIwmKUkCfN7tV8&#x2B;N4bZ7p7yvdTV7T3LOsdn&#x2B;q408uipXzZ5ny5xbUVBrGsmOmzJ0j/6H6Vzx4OGPe5HhiHmv7v2nkv0DKXadtto/wA&#x2B;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&#x2B;PiRgP4Iq7cExAP56afAYloWrZECqDxAA&#x2B;2Yw2CQAPFkwBCvy48zzwrTumtKRAC/DPgYpiRe6Njg7qClQi6eQXEiQLUsmJnHU&#x2B;XArkcVjzTzF1CH7D78SiaWUDIrnD7/iowKNCFRPH81woari6X6jf&#x2B;rh&#x2B;n54K8FpZUDTI/bU5nD42XGWPFkcTBPhpl8YDAssNVIVpC/wAvHl54WGq0QDF4oxGI8PsmKyGERzZARHz5RHHjgNExNGSzFCeJ4GMFjERxIIINEBAWPjko18/LEteYB9EsiJRBqNBp8DhW6aoOR1wLNGNaJfkkYDP&#x2B;OeFUh5WCCGX8s8CyAbpZHDMkZx&#x2B;/XCuT5IHCPx5fliUoAzPDEpQnMx00HnzxKtXRA5wECPtA4rqv4IQ5wCrDQgIeeaHPEpche&#x2B;LeO5Nhe3u/bz2nWzaC97fu1rqqeol/1yxUN65MwI5r5UxsHAggjHq/rHebnYdklvNpLpzwyRb42PEL7N/b/wCmuzesv1P2vpf1Dj&#x2B;72zeYMsZR1B6SxidCNDovhTO/yedybfOnsuez9vV0yWSJs&#x2B;WKiQZr2QfM6JU0y2Y&#x2B;cj9RO5wiTkwYZECpciy/bm4/sf8AReab7LuO9xRmaR8kmHByK&#x2B;K&#x2B;pPb/ALmVe9tibU3g&#x2B;jkU53HaJFwdIZ6j5Ml80AmUHGKAnH17tch3DtuDfS8ssuMSbQPzX87/AFp6dx&#x2B;lPV3cvTMZyyQ2W5ljEjQkA0JHFbPP3TUSl6aWWSGq0fW3qgpEOr9OPIDawNHK9YOMHxWKdvicxxD6GUMgoe6OpBWAGOb&#x2B;nxP5i/4KGN1aP7gTWk//AKPlFrQQjZzwQuQ/SjvjjY7dHSR&#x2B;CjhDkA1Cx87uY1oP/wCjxkrUnxckChcxpAPBI4j2uTfV&#x2B;CvskxdwrV3dKllA9VsmhgYrnCaF6uCFABHD/SMn&#x2B;sfio4aCo6ljz3ftrD//AIupIVrS6XPYnEucHMajRwXG/wCi7g2lH3rZ2z/TIN4Jc3vRZJQJm2&#x2B;raj&#x2B;kNbNlGMTD6QNMaHp/dG0o/j&#x2B;ChtyWANPBWzu&#x2B;m22NcH0FcAiwfJ/TqQACuNn09uyHE4E&#x2B;/wDckbbKT0ghfNT3z9xO0O&#x2B;rxs6y7mZS0la62XCVTVF8n07aaRQVDm/up3oTCxj5oMGJNlOBiFyx819d9o&#x2B;xu9tg3Mo/zE8ciC9Ixdviv1D/AG9Z&#x2B;49o7f3Hc4CTtZ5IiUQPqkBQP/gVwtJoe2nbC31F/wBpsm1MyopxQ2yodPfMo6kTIMm07XVdVKf0uiXhwJ1aMei/0gbLFLNA9T0c/wCa&#x2B;/y9Sbnv2fFtNzAYjD6gL&#x2B;BLD5LA2YVF69W6T6kFjuudPrqqZ1tLR9T/AE3P9SZMDRBoH0hMePxdu3mZ8kQ0f9RIb3C69wl3nt21hDBGb0pGIt4rMttlhvNVLH/LbbKkv&#x2B;id0SprqiWAVBbLPpiYSc4wxyHt0nDyHUOC6eb1FtsMPufbm&#x2B;lmK2gdsbL1S3s3KJrZjFZNfSvazJWPJlTgxw5Z47f9CzD6JMZVquh/3xt4uBgLuxL/ACcLWrn27pmlzZe4KeaXtmh3XTzmtJa0vBALw9jQmYUZZ44s3ZtzECQrEaruYPVOxzfSZRyuKFlgNo7qqaiVcdpndRtV0liZ/b7vKbKnpLlu6XB7aiW5k70QIq3qLczh2u03ZeMARP8AKaftWO677YY549zNsm2JacCW&#x2B;S9n9s9jrtpd87JfO4XeA0O2JddLuNFIdUShZb1VNX1JNZKlvJp5joPYGMLeJx5n0/2Lu&#x2B;579gxT6yTkEgwfqPDk/wAF6F&#x2B;pvqP0/k9C9wx9i24nvJ4TjILiUAfzBxXhd2X3Wb307PzJhls7jbU6yFb13KXKCJr6jZZQ88fa5enO/QHUdnn6f&#x2B;Elfz8O03URXHK3BX9P3h7V1IHpdxdnkugr79QSyXDILMmt6o5Y4Z9j7xjj1z2u4b/gkfkFxnBuLdEurwWTHcft6/6pW/dlPUBenc9mOgP6TWMIAHGGOI9r7pH6ttuP/wAqf/2Vg4swDGEn8CryTv7ZE9w/bbx2pOBUdLNw2mYqCI&#x2B;mrIenLGD2/uEaZMGaJHGEh8wFs48gvGVORWXkbh29VAGm3BYpoUAulXi2uA5Efuk6uWeOGe3z4/rx5B4xP7lgiYD9JI8FftraNUFZRTDBTLrKWYQAIfomuCcscYjMixEfAorwPwV3KcJg6mljhEjoe14ATVHHMYy7itggctFeCTNIaRInoQ0t/wBp/Ty&#x2B;pHA5YBkiTRnCOoCTapoaSjS15&#x2B;qAAcSHa9QRQnPGgQGkbpBGpCuGS5pRnpTODSWuyEToVXF1wu4V1Czr0PY9M511pGulvUz2r1Atg0KSQ4AFuKDGTRKwZCwsuo5ZVoUCEIck0OO2y4TdOHPmvPjFcXzWgHFXdT&#x2B;nzMOB0yxMoRB8QhIJK5EHIL4qETEguC10QBzQ6ZmPnit4LQcAMm9Locftx0xKAHUXRAQIBT5rDOOX4YC11kgmxdFLByJjGKJHyERiPFapR7ow0nyz0w296bJjRwyj4/zxINRRMDDDiM/M6qDE4lANRODcuRMeHLhlhS7XsiDQQoz5DXSOJIRZ/wAjyU6KEXEpSGlM/DTzRdcSy4JpZV0DVVyGJKHo4xXILDyJggxI1ZQg4jPn&#x2B;lFXPFRaWTI0Q&#x2B;WcPxxRZ6rijS6IADx8NB92HmFySdqXUkKUTnn&#x2B;AwOT4rNegh6og0AIMgIeUPimEVTQnzCqhQg55fngN1ggA19ihLcgAM8/zGq4LrTiVSlFoQExHL5L5g4VCQal0BYCkCmfJOWKyQ4uyWQB8B4xzhrgVW6S4IeoIeKjI8cKfqCAiAiI5ePNMSrBih&#x2B;SR5iGY5jAiRFBqUtwAjmsAgGaQ&#x2B;OFaQKU8cSlJgAF5nzy55YlMkOzJPFOKkQAOscGqmordzlCEkR/SmeQ8ILh&#x2B;alx3785Aqvar3Na4A&#x2B;jT0U4CP8ATUsBK6GMOePVPW46vTWfkYn8V93/ALZchxfrh2Ui8pzH/hK/ILuWUBV14apPVOIY9AYtJagEApz0OPz5MDzDkV/bDF5Y45BwzL9C/tkqf3nt67XTyQ6YNvsYXNH/AO7d09PSdRlj9Lek5jL6Y2U9ftMv4ifr7tv5T9ZvUGJiH3hk3ivXJ/U1XuJcPqgv6RABp8MezwZwCKhfImWu1TekODST1klxRGiKp88dmIEVqLP1XWFqQS1QAUya1V6gEQrDnjcWdzQIqarX6lgBh1EgfSYoY5AZkjLHai5HAJhfkyws5pcJgzLlCwLVy8ymOaLEpdYN8lzXEJpHQkaIQsCcdmAq&#x2B;i5CWAIWozvUdJeZzBLd1v8Apb9Qa3qRjupIE48hBupgKkKEgTS6wFSHF7yAVI6XEquQUjMAHljkoJESquaJaLgUJ8V8/fdlY&#x2B;3G4NwWCi3WyjlXqdbaynpqm4VMuQyRb2vb6k&#x2B;lJImGplxTpIhj5H&#x2B;pGLa7nf7fHlb&#x2B;Y&#x2B;0QDwi6/SP6L5u4bbs&#x2B;6z4QZbMZg4a82sToGZcsbks9BSbGtlt25Um42CyVYFPWvImOqqUEtMyU5jnGY2U7Uxx8/wBxhbYDb4j1DGb8RqvsPbd2f60dzmHR92BiRoJaN4q5s1wZd9tssjZ0q3VVsc2Y2ZMe5smsZMP6CVCK0&#x2B;Ax18WWWTB9iLBqe5ec3OL7OaW5AJMqHxQWzbtQ64ShPmUqCZLd/sVADwjka0dP1PadUw4NsPuj7hBC6G7zkYTQg8eC9pvm1dwVjLc2zX022XIANYwSTPbNa5itY4Aq0qPhjyuTDObGJaIXrWHe4McpjNDqexdm/wA1iZlHeKCgq/7hPdVzpFJPmdT5bW9DQxwQFuZTJSqHHMMcvsy66rkhngc0TECMTIMLrmTaDKh&#x2B;7pdZIDSyjFZPnvmgO9L1yWy2OB&#x2B;n/cJ1x1e2xJzsQwDuvOeocgPbOl2nKUQG/FZiisG9LdfrpVbg3NVst8yeaizWVoDqKfRznh7Wy3vMwmZKJVGFoAOPqH6QbHPk9fYBnm&#x2B;GBnIRNQQB8xovmvr3fbDH6OnHbYv/AFUgITnqJPqOBGqyVwq6gfqnTuqYJnSGvcjSCVT/AEoueP3DjwQIAAHwX5uAJBHw4laLW1lc1rh&#x2B;7qm9I6wk6Yx5AzeAHBAfnjvxxwm0JRiRayxGEBPqckP7MtJuN6uEln&#x2B;zV1rOqZ&#x2B;oVk9haDmS0TFI&#x2B;7HksW0xEgSjE01Ar7cV2BAmouy16Zua&#x2B;yH9ci93SQ8xPTWVDT1f6mlr4Ox2v5Ha5AYyxQMv&#x2B;EGiyXgXo6tKnuBvCS1zmbtv0lyID/c6wBwH6oNmxP345Ydl7WIiA2&#x2B;Jh/sH7lx1loDF1jJXd7uTTOP7XfO5pLWoWeld61iuX6en/eUALlpjnl2Dssz05NthlLnEH9lVuUMZIIiAPitjt/uK710jDLldzd5MmGLXi&#x2B;1oLEh1N/3Ua7Hj8nov01ln1HZ7cH/gix/BZ&#x2B;1iIIlCJfks/T&#x2B;6j3CyHozvNv8AAYGva1u4LgyKH9fTNAKIqCCeOMf9g&#x2B;jpBpdv2p8YR/cj&#x2B;W24i5hEg8gVsVH7yvcxIlgM7v7ymNc53U2beasuQf1sWYcvvx1p/px6JmfN2/AOYiFwfym1if8ApwPAMtot/vq901O0ypXd/drRFrS&#x2B;4TS4ByAuRVUaHPHTyfpZ6Ey37dhFXoGWv5Hb9AMoQe9mPgvv3/hW7m90&#x2B;8jO7W6&#x2B;5m7b5ut9uututlrm3mrnVTaZsqQHzxTeo4sltLnRTM4/Of63en&#x2B;x&#x2B;nO47DYdl2&#x2B;PBGWOUp9IAdzR16/3mOOEscMcQJsXAX6BmPzggJ5cssfE30K8IARe6aHAZ5Z&#x2B;KD7kwrXUw5qVLsjAfV4xiIanEH961QGiaxq6&#x2B;A8Vz8Bg5LEhVGBHPI&#x2B;UDD4xwpHVZMAJ&#x2B;Py0xOz8EyoQ2qkNUA55x4Zrio6nILGyaG8UTjmpVflg56qFSCOCINX4KVJTDX3pA51TABmkPAclOGyQGCa1PlxX4YFMyJMo&#x2B;EOfHRDh8VeKcGgZiHHXhDkoxBQp4KEXElEhxIcaqA2IHEKDpHQkxXEqvJQeS56a6ZHEoBktDwH&#x2B;nXgnwxJWRAcB9ocU0zxLA8xcfSEwCHFPu4nmMQbWyXjZQSAQMw4gAgZ/xxNVQi3gjRc4R/LNYgJliSzF1CcPj/HFzWTeuihEPxOJIFKIS1QYpw4D4csTfBDAFglkEQHBT5eZxKLPWiWWRHD78S0Q3gk9JUxUcIDXEh2FUJGg0&#x2B;0OeLxWm4paFTDyUeXyxIYaIUSCfDTiPLEnmgLBwOf2CYlJbhErmPt4lMSkhyfUusIfekFRMHgpWb1BMSQPLjmSuKgHJK5H98E0/wD6sHdNhZ19dqllwKFvSycx0VQFsPLHrPrEg&#x2B;md0dOkfML7V/bn/wD7X2Euw/mT&#x2B;MSvyF31oFZUno62lxcF5yyOkOMSmmPz3KIkxibj29y/tvizB6l6/Bfeb2b1f7r23dvnOILpMiqkAZBobOcg6hmQPjj9Feh5dfpjasWABHKhX8Z/7n9udv8Arl3rqZpzhIe&#x2B;K6Dqm9Ae79RcT0wQAHPWJAEMe4RINea&#x2B;C3WAqXB3UAUIKBILyOhHjjsigrZItZYSoALHENKgEAKAepeEAcacs2iytendZJ6sv0jREj4qmOzAwLH8zLT/ABWIqA0NeSCFVUEckUwJB8MdrHfxVG/Fa5PIaCF6VVrACSrs/AA8eWO1Eh1uX4OtYrySzpCqXBrioR3JVROOOxioX&#x2B;CIgPQhlrVQ4y/qa9c2lIHqyAIioaueO0GazldiNTShZfPf3aWnt1uDcVkte6nW&#x2B;nucy11Tf3dfUindIt/qtV9AXmW2ZND4wcS3gVx8e/UWG3y90wxnIRzfZ&#x2B;Adfpj9F9z3Ha9g3X2R1bQ536WfzNr/AJVXL9h7eWjZsufcNr7jqKra1XJFPMoKqYK2nukSDOp5Je4UDmr&#x2B;qWSHf1Jj570Q2xOTFPyEMzu/Nl9aOU7yUMWSAGYF3FOlKru399/t3992pR1dzsPVMp6iY1jiKOe4hxp2T3AdLZZOUwhqfpccdaUOuAz4gTE6DQryB7vtNvuY7Pf5Y49x00c/UNKfuXn8ytuttqZc2bLraKdTzXtd1S58roSLwx3SkwLwUc8cJnPHUkxJ&#x2B;K8jjODNExjOEwwor&#x2B;X3I3VS&#x2B;qaS71b/AFyC5oL5jiWEFoY1rXvf9IiMdiG73IHX1fw7Lrz7T22YeUA/F6c&#x2B;S2ej3H3GvtG4Tnz5VDUsc2oq6mR&#x2B;3lskTWIeiS8NnKQiFyAnXHeO43RDSP8ABZeOz7ftG1MftNLOTQA9Rpw0Za1V22/Wy2NoNkOpZdVWz3su24LhLdUtkzJ30iU&#x2B;QJbmNMxUDnIxmhx2MOfIYdG2&#x2B;okOT8l43d48c8v3d85gB5Yg1f3Ktp2HfFn/AHlLvDczbo5j0kWl0qSktjR1Sqilm9DZ72M6kcjg1MoY&#x2B;2/obst5L1dPJuJxljxYCWA1OoPzXzr9Tdz2v/t6P8likMuTIAZu/uKu7o6aCWkOaA13WIoqq1qhv0lM8fszC3S3Gy/PsSIEkCpWh3R0svLfVBcGgdMV&#x2B;rLIdJCmGuPI4Yz6XFHWYGQoAtDrZhExz3ZAkdBljMEgq5UBx5THF4&#x2B;XguWrPEEBqrUKqYyUyY93UInoiHEOJRwc4iDcd/DjmNakhcMiJFlptynuJDg8&#x2B;mIHoAahziFJLQuPIYokUP1LkIFo09tFhmfW1w6nZqwoCjQc2kwHUfFcdpiGNAVKmOmBwbA&#x2B;p9Q6ihBEAiwzzyxShEk8Vrp1Ku2zXdbSSnSIJkQiQgesKvLwwdD1IFRZFWfRXjZjCG9LSjfpA6dCUCEgBHa8MUgzB1ohiyv5TXdbHtRzmOEELkLSoi0ECHIDGTdtFoAxuxf2uv1zf4MtrC0e3C835zHNm7h3TcKr6g8P6JTvSHWXMAKpBFCY/FP68bsbn11LA7jDghGlvcvTu8k/zxjqwHuX3NZEIV4pknEBI4&#x2B;N814shg40VyB1fDLTLTEKJYAvontaSYQQKQOENThohmsmtEEQjMjLTwTBrzUzmiZ0nPXMjUcteGIp1RBoWMBHP&#x2B;ofwxeCiKWTA1Of2zw&#x2B;CgzuLow0rEJDyI8UBxK6QQwsmhv8DrkBwPxxJf4ow3ksP5Rz1xIcmyPpAAReJ1AIjl5YFoPqiaOoBwyUn8Iw4eeFTBMDVHFU4BB4&#x2B;GJSLoRVyJgERMvvxIerKuniV&#x2B;KeeJRVFsfCI4Q&#x2B;7Eq4fVCRBQirnCPPL8sSuRQIfkv254ksFkEhnlmn2442Ygny2ZALo&#x2B;j&#x2B;oHPkI8Ia4JR6fFQOmqIAZiJ1ziYaQxlDkHkihDz/ABgfDAoCpdD0xyy05H4RwocRQInDTQ6Jroq4lp3FdUCA/FcSrBxdCQmWixK5RUa4FkvcpeWesV8IZ4VHzBglFzOot/qAEBmnFBi0WiKICNdInyHjwxJUEJ5Rhkh1&#x2B;eJVCoT7DEpL6SqjJTr5HOKnEpQ9gJ0iPhiUrV0rMgROoU5BAueaYlKymSnI4ovPPWA4nPAQ6Rx1XlXdnYlm7jbD3Hsjc1O&#x2B;psm4bfPoquVJmPkzw17CGzZM5qPZOlui0giOOn3DZ4e4bPJstyCcGSLFrjn7l5/0t6m7r6P9Q7T1N2OYh3XZ5ROBIEg40kDQg2K/PP3Z9gFg2xXVcu3b03GZbnzm08h9BSVE30QXiW2ZM9AF5aCASVVMfK8v6dzxucO5JD0eIJ5Bfuvtf98/cI4we7dl2uTOw6pQyTj5tT0uR8F792LulH2e7bWzYFbTXq8zLXNqHMr/ANnLp3zhOeXBhlMYGMcxcxnj3709in2XteLtud5mBPmAZ3PDRfk79XPXu3/U311uPWODB/Kx3EYg4&#x2B;oyAMQ1CakcivR6vvNt9stxmWi&#x2B;/SA0tbJClymB/wBtIHHsH9QxxP8A05khfM5SEZclqU3vrtsvMs2C/BxJAeGt6OrwMkEdOscc39TgaGMhFkDKJBrDgrV/ejb836Ta7vL6iT1GQrIDV7W/q8sco7rtuEn8E/cjE3urKZ3X23NV/wC1u4jBKdACpBDfpCokccmPvW1A&#x2B;mbalgkZIgMSx/BYyf3Q23MaW/trs4gKFpgIk5h0CHDhHHZj3zZAkNIjkFo5ICVLcViJ3cSwPId6FzBUsK0bodSNiQoKqsBjsx75sQG8zeCycsJ0dqrBV29bNNKiXcWoekPNGWtY5xSLVCeeOzj7926NT1v4OtieMeWLdXvWq1&#x2B;9bPTdbzKuU1rE&#x2B;ltI/qJP9X6&#x2B;kBPjjkPqPtgF5v4LuYWkwcMuDPcxI7e79u9rrLlabrMfLo3U02uNPOZOpkmhwNJ0ODpLnAfqBGSY&#x2B;V&#x2B;ss&#x2B;17r3SOfG7DGIufE25r77&#x2B;mHqfF2DtefZ5T5Dk6gANW4rlSRt/athqq2btuu3HKlGjmW&#x2B;npa2jqKgS3zASK2T1vcZbw7nEY9Ey7TokftkkaDVfYsfrbtWbEDuZCOSjsBTleq&#x2B;gHtr3NtGz9thY77VVP9xNwmvnmZQTnipa5qeoVUI8j6iiY8v2zpwbT7ectkMnXyb133GfcO/8A8zspCW1GMAF2Lr1G603Ym4zv3V6oLXNcQrpr7O4GP0hzSxnqdQ/1Axx2JDY5SJTjEnmF6/g7z3/ZuNjucsC1Wl&#x2B;9WVu297bfVdLopVkfMc5FnUtR0EmPS4PaWgcgNMd3AO2gN9vG/MD5FdTc&#x2B;oPWOSst1nMTwlX25rRu/wDU7Bou2lTbts1FlZOdVyQKajlGS4S2NeWEMbKl/S1yeOOHvJxS2Bx7YRE3FtQvN/pzv88vVIn3jLPoECxnJ/NyPNfMCj/8gTK6rpm7q2/aaC4y5jeiVSSugTZS9BcyZLLpNQ5pjMBDoY9e2p38Y9OPojzK&#x2B;&#x2B;brf&#x2B;nchMtzklIxNACzePFej7Pte5ZVsnMvu6XbiqZc7ok0ZdLeaSQwf7cymn9Dpkxk7g95I0x9/wD0O3I7f3jc5&#x2B;7ZoiUsQEXoBXivjv6r9y7Zudjgwdr6BiM3LcuI4qK&#x2B;115bNBpKkPd1EuEp5HTEnrc1kepMssfr3b917XliOjcYCG/1x/evhJNDLVl5jdqGtcer9nPbLaHBH005vWg/pRjg&#x2B;Ix7Dt9ztYwERmxSnynE/tVjlIxIDFtV59cZM5xDOmfKK9Ja&#x2B;XNlgFq/qBaXoDlkDjzOOUAGiYyJFKg&#x2B;&#x2B;67IiQW4jVahcy9kstml7Ah&#x2B;ktUdOWZR0M8eU20JSDwi7e2l1iMOmXnDxdaZWlr2uDQ17A1oVelz8gHNaCCOOO90mIEphj&#x2B;1c/THosQAarFOYxog5vSxoL&#x2B;qYpBKkAElF5ZY2OoydiuuC5IAKFpe/qXrI1LQpIGUSAAWjFSJYnzLbOKFiNE5jnODD1AuloE&#x2B;kKCoRA0CJzgI4nMD0yust0lrrISyS1GMALSgIcXdTs3dQd1EJ8Bil5SDxVFgADdZmh6nzGuBDSwh7olri5CnTFCPzwM9&#x2B;K0Azz&#x2B;C/bD/AIjLCLH7O9hzCzodcxXVz1CdRnVU2IguQ1x&#x2B;CP1b3H8x&#x2B;oO&#x2B;/wBshH4AL03upE9/OUa2&#x2B;S&#x2B;qEpqhVgcickKRCHTHzqq8eHAY3WRlszhpEoijhyxHikilU9rDBFXlA8xyywp&#x2B;Sa2VkilfhmmIrJYcKo&#x2B;hE4aa/HIRxJBdEJeR&#x2B;PLkvPElEGJoSIQ5jSECuJATAEOWUIRKeKquJTpnSqHhxTh5YkogPj9oYkfNGBmPBYIRriSaIwEEOKJEBE0jmMXJYJqwTGjiiaEp/LEt/NQR8sz5Q5ZYvmqgKIN8vhHwzxIJAuhITPyzPHwxeCuY4KCAfJM/w1xKHFB0ffwH5fLE6VeAiKGMPHMHI6404ZmWYg3KYIAk6CGa&#x2B;BPjiBjqgnpPMqWnMK1OAKkLxTAOST5g4ReCc0h92INrdEQTUuqTXIL8&#x2B;OCxdRHSKISIICij4nM4uaRX3JbmgDiQV8ohfPEkcUDlAGsF8sSWBug8SSCPEodTiVz1SvTCucgXIlIkJkuJXhdC6WMlgdQfLJMSkIYQiFEEfhiU6EiHgTHjiUhLRDl8tfCOJSpOWifwxKSukp4cAVP54lJTmQyj84lfPEllj6yW18p4c0HqaYOAIzT4nAapDOvF9x7Ls9ynumVVDTvcF6XmSwkNyABIMTrjj6RIvokxBLm60ub2w2rPTqtVIrTFxkMBPgjVQYftxeqagclj53Z7ZswuD7XSnqCqJMs&#x2B;JH0ouL7cQ3B7rJkTRYmZ2O2MVJstGVXqPpMinAkKCTni&#x2B;1DXisgkalI/8G7CIT&#x2B;x0oPVH/aYVCRT6UIKYvtR0FHVV6mqp3YzYB6VsdGWg6SWAtX9RMP6vzxn7AJI/Kitnoku7Fdvuon&#x2B;xUROrjIYjm8CEg6GGODHEfSlyI8ks9j9gy2qyw0AAGQp2Q&#x2B;IzhDGzgxirOURlVgaK2f2U2EAR/YaF2ruqmYV1jCJGNfZh1UFBokE8SsZU9lthxA27byEETSy1WChEiC3AccHZgmMiC4JWhX329durh1ette0van0LRyCSrieghzCUGOtk2&#x2B;EkkxiQvI4dzuMYHROQrxK08e2DtaD1v2laeouQltFJCcCT0aDXHVOz2sq9EX8F5H&#x2B;q72IYZJGWtVsVv8Abt2xp2tZL2vbG9I6W9FLKYgJhEMAKnPF/JbZm6Ay4p9x3cj1HJIe8sr2q9vHbKp6fV2va3IHAJTy/pBzBPSig4yNltbGAf5LEO474P05Jiqw0v2u9o2EubtK2guV3UJDVcXRcXFAicsX9P2fV1dAcrl/qvcCGGWXxWJvftN7N3KUGVWz7ZOKADrk5gI5vKBOE9v2hvjFFrH3buOKfVjyyB4rzao9i/YaomGZM2PaWuB6lbJyJzMIEJjA7bsnrAFdqXqLvJDnPPqt7lnrX7L&#x2B;x9sAMjZ9vYCepWy/1FoQdR0TQDHe2uxw4yTj8r8F4ve9z327AhnyykBzWz//AKovZaZL6TtelAmMLSA0IAmQ1JJyx5KOAxHllINapXijnzn8xWHqvZN2Vq2Fn9mky2uaPpEthDSsOlxaueNxjnh9GXLEnUTl&#x2B;9Ay5gGEpAFahXf4&#x2B;exleS&#x2B;bbQAQwODZUpShP/SpRfPHbx7zu&#x2B;Ef&#x2B;n3m5gf&#x2B;OX4Von7&#x2B;cGk5W4rVK/8AxqdjKsP9OjDRNJDmzZElx6UTMtXp&#x2B;ePIY&#x2B;/eqMAAx9x3YMbNMrmjvt3jHT1Gq88uX&#x2B;KHsrXfW0CUkA1sqWOlqFQOkRAaEAx5DF629b4QBj7luCR/qLlMu5b8yBGQuNNF55dP8O3aGqkmRIqnAF5nKfpUuiGOAienTHkcf6mfqNhII7jkbwBXIO6b96yoFos//C/sRS6Tcpzmvd9XTUvlt6GugjVg5Ncd4frD&#x2B;peKQjDdYZx06sY&#x2B;K5h3rd9TkAx/asPcP8Le1XNcKGt/b/SB1OrJrnOKkk9AzAEV447eH9bf1IxF5ZdvkfQwC0e97kkkCNeS0G6f4V54luFt3JWSUCDoqS5xQ/qDXCId8seXxf3A&#x2B;uMXl3O12eSQ1Yj5Lnh3zJGsoRkVbWL/AAs7nfcaeTXb2r5Fv9eX6zWSGOmGW5yPYx2YdMYCF0x3z/cX384wJdswff6SOoSPS/Fly/14GDDHHqX6WPbH2cpey/aja3bm3CZ/b9u26noqZ04kzZrZQAdMmkgK6Y4knWOPg/de6b3vfc83dt&#x2B;Qd1nmZSAtXQLwObMc2WWSQaUjoum5VMgyCD58k0hjoh1x8zdXjJSZ6jzQBeEcSG&#x2B;CMMCwhBDwjxQa4lGyaBnBYafAffgUSdFBaoTLgR98ckwoLgUUu6mt&#x2B;gAlBBYHiYcMS1QqQpAJCFAq/ApzxLIiL6oxkNeMfhHVcSSdNVP3jz/kmJXjZS0Eg&#x2B;CcRxz8MSiBc3TEIPjmOCJlDF4oJfR3Rxh4/HElgmAEHKCcocxwxPVKgNPyTNI8fDEhgfFSUhm6OmsNNMSgGVAcdM&#x2B;Y5YvBTULaoHALDXy458MVwpqMb6oE5f8AVrmmJCvmhI5r8OP340we9Em3NEV0y&#x2B;PGGCxYKDs5uqly2tc4tCF0TrFM0OBkMGRIdU4c4Zri8Ek1ZQ5E4Eonni&#x2B;SyHetgqPPiM8s0/HEtADRA74JH58OZyxKajFAVWMPCI&#x2B;GJOiEhYJCMRnpiQCgKDKCxBT4AcMSUBiU0VIfI84YlKHDNM4QX5LlBcSj&#x2B;CWWlFA8PxUZHEpwUIBVD58oQyxKUFMgiFI5p&#x2B;IxKQFdMoqcoD88Skl6DRdEOsU&#x2B;GJSsqmDSQnVkRmU55quAh00BqtTr5PW5xIKlsQIxWEMssC3e9nWFfTMEUU5Q&#x2B;XInGgCUE0Vs6ShCFM4ERXnyWOL5LCtXS/kY8Dy4Fc/HEpLcwaAxg1YwMP8A8McIZmN1WQFmbQgT9RQiEF8VTCAWoC6LVSXS3IUBLRmSmsMs8bLgXqFltNVaFgYDDJDDNckAjhoA6aGytZko/Uf6XH6kSBIQf&#x2B;oHFqDp&#x2B;KeSsJkox&#x2B;mHE6oRjEwLhaAJosdOpA4KGRzDjFFJjyAxxsueB6YuCrF9va6LgrlC9KpCOkI44iKkiwXMSxYC6n9k0OB6QQFUtCARVB4GOMEuaonIhgLumOkENcC0AE5EA81XgmIBzRTg1ZKEglUBQH&#x2B;lpChEhnDD0k2utEsW1SJtN1DpDQSpg6CjOB0IIXCwdnQSburMUQRGjPM5jwUxION9DLTlnQmkABVQhK8VgUTgcdjGQ7aLqyJMq0JVftSUIUR&#x2B;nNDFSTqpx3g0vLYLgIApVA6UWvReaGJI1iDBDjmAjIPoFNTkpMsjyygogUhwTPCQR9KvBQJRRSIISpMfAwAJOIv7kN&#x2B;CESnJwMecFzMc8VqqufBF6Z6VKhyoFEUWOZzAxVdQuyJrCCG/UhJJLVj5EnCz1Nkl7hPEl51MM/DQRyEILjHl4MskHRXkuQ8N6mtmPQtB4x/0jTnijWsmWqAuVutnoyz03OY4kkHpd&#x2B;pCQnVzBx1chd3oCgUK9ftaslMDuowgFPUAQAicMdYxo2irgh1sTCMuMeQ5eWEAGLlKc0RMCoHHgTrjjZko4geGgzMYfLAq4UarHgUGaEfjiUahEQqpBcSlQCcPBEU8YccVqIL6KRAnMjhlArmRrEYkupb&#x2B;IiM0/DEgllIbqqf9Wi&#x2B;H44vBRfRGBx&#x2B;I8s0wfJQL8QmIkDxEDrnrhSiDfjoeeYTkmJSNUKIIr4DgnPFdCIDM&#x2B;Z1RcvjiQRStghIREHxxKBooyHD4nz44FoIXCIzRInT44VkOzfmCrpHA/A/ZcS0rvXX8PnDEFBF9tMbNtVKRmM9fHLGZXRxU/wBJ8ftyXji0WUBy01&#x2B;xWGJbF1R89Mk/GGBEbe9A7PT9Jz8RnonDniSg&#x2B;Gnh56riUhOYy14//k6piQbJbvPzyz05/hiSkDXPPVVzPmmJQsjxKVcfLgn54tVFDw/Vl&#x2B;GvPEpLd&#x2B;o&#x2B;X3DEpB&#x2B;YzRM9EjiUrZ36v6v&#x2B;2M/0/wBXCOJSsZ/6TnkMlXM4k6LD1Xl&#x2B;OfL7Lg0SLhYOait/Tk3Jeef4YdVG3vVnMzP6MtVXM5Jjk/KPBZVsdETKCLz4/JcZN1JLtMsh&#x2B;r9X6h5Jw54D9Xs6ybhJObcsj4ZjLXHL8fekXSZmWv8A7vw/6cB&#x2B;koj9StnaZZH9OfniGngjX3pb/wCnL9Ov/wCymvjrh0Hjqt6rFt/U/wDX&#x2B;s/r/wD2NU44p/R8fb/NbNlEzn0f&#x2B;1eB4Qx1ytR/b&#x2B;5WY1yVB&#x2B;jz/V/SmCVv3rsS&#x2B;hCE6R/2sjl1LnzguOOV9Lql7Oluyd/6efTl8UxnX9ywPo9/uSoKfA/p6lyGWiY3G49visG2t/Z0p/6H/wDbybmq5HhFfDCfqFnb25LkF0tqfT/2/wBOi8def442k2/Nf2/wStYenmcl4O/V1aY54/T7ezLhlc&#x2B;Crh&#x2B;nP&#x2B;nPXz8cc8foXHqVbzEj/wBrLXqXPRP6Pxx269Ivbkspbv1O/RkMl4arp&#x2B;GNCwRpoo0b/wBvMZrw5wxH9hUVB/8A4aefTnrquKNhf3o/ejaiH9H/ALlTLlFeOI&#x2B;5Q&#x2B;oexRBOgf8Aaz06kz11XBJaCyEpEmJ6a8&#x2B;pczmsEwG4dGqytIis/wC1&#x2B;sZ&#x2B;ouWui4xP9ijf3LcLf/3Jf6f0jJU1yX5eeOvK/uQvQ6D9LfsdM&#x2B;WOL43SFnZeR/Vr/wCrL4p8lwaKV2zX7fHGJfV7lIvBflx54wlThClWBSrErVM/pOSL5fmvDFquP86D4Z81&#x2B;UExLk0TRkPw8cAWIXPii0d&#x2B;KJkc9Uwreqnhll/SqZc9MSkwZDLM&#x2B;GZy58MSkenn/Sn8sCzFSMvhmv8ANcKTZV8fPAsj3KDkMvL9WRXzwrSEfpGenj5Jg1R&#x2B;b3Kfj8vsn44v3p1X/9k=" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>